0000912061-17-000012.txt : 20170310 0000912061-17-000012.hdr.sgml : 20170310 20170310144132 ACCESSION NUMBER: 0000912061-17-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170310 DATE AS OF CHANGE: 20170310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 17681607 BUSINESS ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 BUSINESS PHONE: 310-541-0888 MAIL ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 10-K 1 nhtc20161231_10k.htm 10-K Document
false--12-31FY20160000912061YesAccelerated FilerNoNo35350.50.52P3YP3YP3YP5YP1YP7YP1YP5YP7Y0.00150000000129794141297941400.00150000000.0000.000P7YP5YP5YP3YP3YP3Y8402021692218 0000912061 2016-01-01 2016-12-31 0000912061 2016-06-30 0000912061 2017-02-24 0000912061 2016-12-31 0000912061 2015-12-31 0000912061 2015-01-01 2015-12-31 0000912061 2014-01-01 2014-12-31 0000912061 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2014-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2013-12-31 0000912061 us-gaap:PreferredStockMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000912061 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0000912061 us-gaap:PreferredStockMember 2014-12-31 0000912061 us-gaap:TreasuryStockMember 2013-12-31 0000912061 us-gaap:CommonStockMember 2015-12-31 0000912061 us-gaap:CommonStockMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2013-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000912061 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2014-01-01 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000912061 2013-12-31 0000912061 2014-12-31 0000912061 us-gaap:TreasuryStockMember 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000912061 us-gaap:RetainedEarningsMember 2014-12-31 0000912061 us-gaap:CommonStockMember 2013-12-31 0000912061 us-gaap:PreferredStockMember 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2015-12-31 0000912061 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:CommonStockMember 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000912061 nhtc:DistributedMember 2014-01-01 2014-12-31 0000912061 nhtc:DistributedMember 2015-01-01 2015-12-31 0000912061 nhtc:DistributedMember 2016-01-01 2016-12-31 0000912061 country:CN 2016-12-31 0000912061 2015-06-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-12-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2015-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2015-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember 2015-12-31 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2015-12-31 0000912061 nhtc:AutoShipAdvancesMember 2015-12-31 0000912061 nhtc:AutoShipAdvancesMember 2016-12-31 0000912061 nhtc:UnshippedProductMember 2015-12-31 0000912061 nhtc:UnshippedProductMember 2016-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2016-12-31 0000912061 nhtc:MarketDevelopmentFeeMember 2015-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2015-12-31 0000912061 nhtc:MarketDevelopmentFeeMember 2016-12-31 0000912061 us-gaap:OtherNoncurrentAssetsMember nhtc:KoreanBusinessSegmentMember 2016-12-31 0000912061 2015-05-29 2015-05-29 0000912061 2015-11-20 2015-11-20 0000912061 2015-08-28 2015-08-28 0000912061 2015-03-27 2015-03-27 0000912061 2014-08-27 2014-08-27 0000912061 2014-06-04 2014-06-04 0000912061 2014-12-03 2014-12-03 0000912061 2014-04-08 2014-04-08 0000912061 2015-10-30 2015-10-30 0000912061 us-gaap:MinimumMember us-gaap:SeriesAPreferredStockMember 2007-05-04 0000912061 2015-08-01 2015-08-03 0000912061 us-gaap:MaximumMember 2014-12-31 0000912061 2007-10-19 0000912061 us-gaap:SeriesAPreferredStockMember 2007-05-04 0000912061 2015-08-04 2015-08-04 0000912061 2015-04-01 2015-04-30 0000912061 us-gaap:MinimumMember 2014-12-31 0000912061 2015-05-04 2015-05-04 0000912061 2014-11-04 0000912061 nhtc:GeorgeKBroadyMember 2015-01-22 2015-01-22 0000912061 nhtc:FiveYearWarrantsMember 2007-10-19 0000912061 2015-05-13 2015-05-13 0000912061 nhtc:SevenYearWarrantsMember 2007-10-19 0000912061 nhtc:GeorgeKBroadyMember 2014-11-04 2014-11-04 0000912061 nhtc:SevenYearWarrantsMember 2015-04-01 2015-04-30 0000912061 2012-08-13 0000912061 2015-05-04 0000912061 2016-01-12 0000912061 2014-11-05 2014-12-17 0000912061 nhtc:SevenYearWarrantsMember 2015-04-30 0000912061 nhtc:SevenYearWarrantsMember us-gaap:MinimumMember 2014-12-31 0000912061 2015-07-28 0000912061 nhtc:SevenYearWarrantsMember us-gaap:MaximumMember 2014-12-31 0000912061 us-gaap:SeriesAPreferredStockMember 2016-12-31 0000912061 nhtc:SevenYearWarrantsMember 2014-01-01 2014-12-31 0000912061 2016-11-25 2016-11-25 0000912061 2016-05-20 2016-05-20 0000912061 2016-03-24 2016-03-24 0000912061 2016-08-26 2016-08-26 0000912061 nhtc:FiveYearWarrantsMember 2007-10-01 2007-10-19 0000912061 nhtc:OneYearWarrantsMember 2009-04-01 2009-04-21 0000912061 nhtc:OneYearWarrantsMember 2007-10-01 2007-10-19 0000912061 nhtc:SevenYearWarrantsMember 2007-10-01 2007-10-19 0000912061 nhtc:FiveYearWarrantsMember 2013-04-01 2013-04-21 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2014-12-31 0000912061 us-gaap:RestrictedStockMember 2015-01-20 2015-01-20 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 us-gaap:RestrictedStockMember 2015-02-11 2015-02-11 0000912061 2016-01-01 2016-03-31 0000912061 2012-08-13 2012-08-13 0000912061 country:HK 2014-01-01 2014-12-31 0000912061 country:CN 2016-01-01 2016-12-31 0000912061 country:HK 2015-01-01 2015-12-31 0000912061 country:KY 2016-01-01 2016-12-31 0000912061 country:KY 2015-01-01 2015-12-31 0000912061 country:CN 2015-01-01 2015-12-31 0000912061 country:HK 2016-01-01 2016-12-31 0000912061 country:KY 2014-01-01 2014-12-31 0000912061 country:CN 2014-01-01 2014-12-31 0000912061 nhtc:GeorgeBroadyMember 2015-02-19 2015-02-19 0000912061 nhtc:GeorgeBroadyMember 2015-10-28 2015-10-28 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2014-11-14 2014-11-14 0000912061 2015-07-31 2015-07-31 0000912061 2015-05-07 2015-05-07 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 2013-02-01 2013-02-28 0000912061 nhtc:GeorgeBroadyMember 2015-07-31 2015-07-31 0000912061 nhtc:GeorgeBroadyMember 2015-05-07 2015-05-07 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2014-10-01 2014-12-31 0000912061 nhtc:GeorgeBroadyMember 2015-01-22 2015-01-22 0000912061 2015-10-28 2015-10-28 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2014-01-01 2014-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2014-01-01 2014-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 country:US 2015-12-31 0000912061 country:HK 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-12-31 0000912061 country:CN 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2015-12-31 0000912061 country:US 2016-12-31 0000912061 country:HK 2015-12-31 0000912061 country:US 2016-01-01 2016-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2015-01-01 2015-12-31 0000912061 us-gaap:EuropeMember 2014-01-01 2014-12-31 0000912061 country:KR 2015-01-01 2015-12-31 0000912061 country:CA 2014-01-01 2014-12-31 0000912061 country:TW 2015-01-01 2015-12-31 0000912061 country:TW 2016-01-01 2016-12-31 0000912061 country:CA 2015-01-01 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2014-01-01 2014-12-31 0000912061 country:US 2014-01-01 2014-12-31 0000912061 nhtc:OtherForeignCountriesMember 2015-01-01 2015-12-31 0000912061 country:KR 2016-01-01 2016-12-31 0000912061 country:CA 2016-01-01 2016-12-31 0000912061 country:TW 2014-01-01 2014-12-31 0000912061 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-01-01 2016-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2016-01-01 2016-12-31 0000912061 country:US 2015-01-01 2015-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2014-01-01 2014-12-31 0000912061 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000912061 country:KR 2014-01-01 2014-12-31 0000912061 us-gaap:SubsequentEventMember 2017-01-24 2017-01-24 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:SubsequentEventMember 2017-01-24 2017-01-24 xbrli:pure utreg:Rate nhtc:class xbrli:shares iso4217:USD iso4217:USD xbrli:shares nhtc:installment iso4217:KRW

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
FORM 10-K
 
(Mark One) 
þ
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2016
 
or
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from       to      
 
Commission file number: 001-36849
 
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter) 
 
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
 
609 Deep Valley Drive
Suite 395
Rolling Hills Estates, California 90274
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (310) 541-0888
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Name of each exchange on which registered
Common Stock, par value $0.001 per share
 
The NASDAQ Stock Market LLC
 
Securities registered pursuant to Section 12(g) of the Act:
None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No þ
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No þ
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ¨
Accelerated filer þ
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
Smaller reporting company ¨
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ
 
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the closing price of such common equity on June 30, 2016: $202,402,875
 
At March 7, 2017, the number of shares outstanding of the registrant’s common stock was 11,341,890 shares.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Portions of the registrant’s definitive proxy statement to be filed with the United States Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year end to which this report relates are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
 




NATURAL HEALTH TRENDS CORP.
Annual Report on Form 10-K
December 31, 2016
 
TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




FORWARD-LOOKING STATEMENTS
 
This Annual Report on Form 10-K, in particular “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Item 1. Business,” include “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in this report. Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes.
 
Unless otherwise noted, the terms “we,” “our,” “us,” and “Company,” refer to Natural Health Trends Corp. and its subsidiaries. References to “dollars” and “$” are to United States dollars.




Part I
 
Item 1. BUSINESS

Overview of Business
 
Natural Health Trends Corp. is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; South Korea; Singapore; Malaysia; Japan; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 10 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.
 
Most of our order volume, particularly in our Hong Kong subsidiary, is for personal consumption through existing members’ referrals. The exception is our Chinese entity, where we sell directly to consumers through an e-commerce retail platform. Our objectives are to enrich the lives of the users of our products and enable our members to benefit financially from the sale of our products.
 
We were originally incorporated as a Florida corporation in 1988. We re-incorporated in Delaware effective June 29, 2005.
 
Our common stock is currently traded on the NASDAQ Capital Market under the symbol “NHTC.”
 
Available Information
 
We maintain executive offices at 609 Deep Valley Drive, Suite 395, Rolling Hills Estates, California 90274 and our telephone number is (310) 541-0888. Our website is located at www.naturalhealthtrendscorp.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to such reports are available, free of charge, on our website as soon as reasonably practicable after we file electronically such material with, or furnish it to, the United States Securities and Exchange Commission, or SEC. The information provided on our website should not be considered part of this report. The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1–800–SEC–0330. The SEC maintains an internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
 
Our Principal Products
 
We offer a line of “NHT Global” branded products in five distinct categories: wellness, herbal, beauty, lifestyle, and home, our newest category. These product categories, along with the business opportunity we offer in most of our markets, provide our members a platform to further their goal of achieving and maintaining healthy, quality lifestyles complete with product supplementation and the opportunity for financial rewards.


1


The following table summarizes our product offering by category:
Product Category
 
Description
 
Products
 
 
 
 
 
Wellness
Products formulated and designed to meet specific wellness goals of our customers. Includes targeted nutrition such as joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health.
 
Liquid, encapsulated, tableted and powder dietary and nutritional supplements, vitamins, minerals
 
Premium Noni Juice, Triotein®, Cluster X2®, Children’s Chewable MultiVitamin, ReStor Silver®, ReStor Vital®, HerBalance®, Trifusion Max, Glucosamine 2200, FibeRich®, Energin, Enhanced Essential Probiotics®, Omega 3 Essential Fatty Acids, Memory Burst®, StemRenu®, OcuFocus, FE Enzyme Toothpaste
 
 
 
 
 
Herbal
Products formulated incorporating ingredients commonly found in traditional Chinese medicine
 
Herbal supplements
 
LivaPro®, Cordyceps Mycelia CS-4, Purus
 
 
 
 
 
Beauty
Products to help improve skin health and bring an appearance of youthful vibrancy. This product line includes anti-aging and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin.
 
Facial skin care and body care
 
Skindulgence® 30-Minute Non-Surgical Facelift System, Time Restore Eye Cream and Essence, BioCell Mask, 24K Renaissance Rejuvenation Serum, Valesce®, Soothe, Floraeda Hydrating Series, NHT Homme®, Complete Renewal 8 Shampoo, Conditioner and Hair Mask
 
 
 
 
 
Lifestyle
Products uniquely formulated to improve overall quality of life and to support active, physical and healthy lifestyles including weight management, intimacy support and energy enhancing supplements.
 
Supplements and topical gels for improved vitality
 
Alura® Lux by NHT Global, Valura Lux, LaVie Vibrant Energy drink, Twin Slim Diet Jelly®, NaturalGlo 
 
 
 
 
 
Home
Products designed to create a clean and natural living environment for the home
 
Home and car appliances
 
PurAir Air Purifier, AquaPur Water Purifier

We continuously source unique, proprietary and immediate impact products to offer to our members and customers. Our product development is an ongoing process that is fueled by marketplace trends, new scientific findings, members’ input, research and vendor proposals.
 
Working closely with raw material manufacturers and contract manufacturers, our mission is to co-develop and bring to market the highest quality products. Our manufacturers are primarily located in the United States, as well as a few in South Korea, Hong Kong and China. Our raw materials are sourced from reputable suppliers around the world. In addition, raw material Certificates of Analysis are reviewed in our effort to assure that the appropriate testing has been performed and are within ingredient specification requirements.
 
Operations of the Business
 
Operating Strategy
 
Our objective is to help our members succeed in achieving their life objectives; be it personal health, beauty, happiness or financial security. Our professionals focus on assisting our members in attaining their goals.


2


We believe we have a competitive business model applicable to the markets in which we operate based on six key competencies:
 
Our field leaders are experienced and culturally coherent. They work effectively with our management, implementing our strategies and providing continuous feedback to improve our services.

A discipline and capability has been established to continue launching high-quality consumer products that are designed to facilitate the accomplishment of our corporate objectives.

We have developed and rolled out a comprehensive training system that provides a complete career path appropriate for our members. Our training material covers the needs of our members, be they prospects, new recruits, product evangelists, sales leaders or dream builders.

We have developed a year-round, multi-faceted promotional plan that targets different segments of our membership and has proven most effective in the last few years.

We have implemented a commission structure that makes it as easy as possible to join our business, while giving existing members a chance to start making money as quickly as possible in multiple ways.

The continuously improving mentality and methodology in our customer services have not only distinguished us as an organization, but have also given us a constant flow of information as to how we can do better to service our members.

Sourcing of Products
 
Our corporate staff works with research and development personnel of our manufacturers and other prospective vendors to create product concepts and develop the product ideas into actual products. We then may enter into supply agreements with the vendors pursuant to which we obtain rights to sell the products under private labels (or trademarks) that are owned by us. In addition, some of our local markets introduce their own products from time to time and these products are sometimes adopted by our other markets.
 
We generally purchase finished goods from manufacturers and sell them to our members for personal consumption. We believe that in the event we are unable to source products from our current or alternate suppliers, our revenue, income and cash flow could be adversely and materially impacted. We have a contract with one of our suppliers through February 2019 with automatic renewal rights.
 
Marketing and Distribution
 
We distribute our products internationally primarily through a network marketing system, which is a form of person-to-person direct selling.  Under this system, members primarily refer our products to prospective consumers or they may buy at wholesale prices for personal consumption or for resale to consumers.  The concept of network marketing is based on the strength of personal recommendations that frequently come from friends, neighbors, relatives, and close acquaintances.  We believe that network marketing is an effective way to distribute our products because it allows person-to-person product education and testimonials as well as higher levels of customer service, all of which are not as readily available through other distribution channels. In this document, we generically use the term “member” to refer to members who purchase for their own consumption or for resale, or both, as well as to members who only sign up to consume our products.
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price.

Our members are independent full-time or part-time contractors who purchase products directly from our subsidiaries via the internet for their own personal consumption or for resale to retail consumers. Purchasers of our products in China and certain other markets may purchase only for their own personal consumption and not for resale.
 

3


The following table sets forth the number of active members by market as of the dates indicated. We consider a member “active” if they have placed at least one product order with us during the preceding year. Members may not necessarily reside in the market for which they sign up as a member.
 
December 31,
 
2016
 
2015
North America
3,720

 
2,870

Hong Kong (including those members residing in China)1
108,570

 
100,820

Taiwan
4,030

 
3,280

South Korea
290

 
420

Japan
100

 
100

Singapore
80

 

Russia, Kazakhstan and Ukraine2
940

 
1,460

Europe
1,230

 
410

Total
118,960

 
109,360

1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
2 We discontinued our Ukraine operations during the second quarter of 2015.

Members must agree to the terms and conditions of our member agreement posted on our website and generally pay an annual enrollment fee. The member agreement sets forth our policies and procedures, and we may elect to terminate a member for non-compliance.
 
We pay commissions to eligible members based on product purchases by such members’ down-line members during a given commission period. To be eligible to receive commissions, members in some countries may be required to make nominal monthly or other periodic purchases of products. See “Working with Members.
 
Members generally place orders through the internet and pay by credit card prior to shipment. Accordingly, we carry minimal accounts receivable and credit losses are historically negligible.
 
We sponsor promotional meetings and motivational training events for current and potential members. These events are designed to inform prospective and existing members about both existing and new product lines, our latest marketing and promotional plans, and new services improvements. These events also serve as a venue for recognition of member accomplishments. Members typically share their experiences in using our products and developing their business at these events. We are continually developing or updating our marketing strategies and programs to motivate our members.
 
Management Information Systems
 
Our business uses a proprietary web-based system to process orders and to communicate bonus volume activity and commissions to members. We have automated a substantial amount of our financial reporting processes through implementation of Oracle’s E-Business Suite, and have integrated other critical business processes such as inventory management in our most significant markets.
 
Employees
 
At December 31, 2016, we employed 143 total full-time employees worldwide, of which 25 were located in North America, 101 in Greater China (Hong Kong, China, and Taiwan), five in Russia, two in Singapore, two in Malaysia, four in South Korea, three in Europe, and one in Japan.
 

4


Seasonality
 
From quarter to quarter, we are somewhat impacted by seasonal factors and trends such as major cultural events and vacation patterns. For example, most Asian markets celebrate their respective local New Year in the first quarter. This generally has a significant impact on the services of our third-party providers, and can negatively impact our net sales. We believe that net sales can also be negatively impacted during the third quarter, when many of our members traditionally take time off for vacations. In addition, the national holidays in Hong Kong, China and Taiwan in early October tend to have an adverse effect on sales in those markets.
     
Our spending, as well as to some extent revenue, is affected by the major events planned at different times of the year. A major promotional event could significantly increase the reported expenses during the quarter in which the event actually takes place, while the revenue that might be generated by the event may not occur in the same reporting period.

Intellectual Property
 
Most of our products are packaged under a “private label” arrangement. We have obtained or applied for trademark registration for certain names, logos and various product names in several countries in which we are doing business or considering expanding. We also rely on common law trademark rights to protect our unregistered trademarks. These common law trademark rights do not provide us with the same level of protection as afforded by a United States federal trademark. Common law trademark rights are limited to the geographic area in which the trademark is actually utilized, while a United States federal registration of a trademark enables the registrant to discontinue the unauthorized use of the trademark by a third party anywhere in the United States even if the registrant has never used the trademark in the geographic area where the trademark is being used; provided, however, that the unauthorized third party user has not, prior to the registration date, perfected its common law rights in the trademark within that geographic area.
 
We have a foreign holding and operating company structure for our non-United States businesses, which involves the division of our United States and non-United States operations. Under this structure, some of our United States entities have granted an exclusive license to some of our non-United States subsidiaries to use outside of the United States all of their intangible property, including trademarks, trade secrets and other proprietary information.

Working with Members
 
Sponsorship
 
Enrolling new members creates multiple levels in our direct selling structure. The persons that a member enrolls within the network are referred to as “sponsored” members, who may purchase solely for their own personal consumption, for resale, or both. Persons newly enrolled are assigned into network positions that can be “under” other members, and thus they can be called “down-line” members. If down-line members also enroll new members, they create additional levels within the structure, but their down-line members remain in the same down-line network as the original member that introduced them to our business.
 
While we provide product samples, brochures and other sales materials, members are primarily responsible for enrolling and educating their new members with respect to products, the compensation plan and how to build a successful membership network.
 
Members are not required to enroll other members as their down-line, and we do not pay any commissions for enrolling new members. However, because of the financial incentives provided to those who succeed in building a member network that consumes and resells products, we believe that many of our members attempt, with varying degrees of effort and success, to enroll additional members. Because they are seeking new opportunities for income, people are often attracted to become members after using our products or after attending introductory seminars. Once a person becomes a member, he or she is able to purchase products directly from us at wholesale prices via the internet. The member is also entitled to enroll other members in order to build a network of members and product users.
 

5


Compensation Plans
 
We employ what is commonly referred to as a binary compensation plan, enhanced with certain unilevel features. Under our compensation plan, members are paid weekly commissions by our subsidiary, in which they are enrolled for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay any commissions. This “seamless” compensation plan enables a member located in one country to sponsor other members located in other countries. Currently, there are basically two ways in which members can earn income:

Through commissions paid on product purchases made by their down-line members; and

Through retail markups on sales of products purchased by members at wholesale prices (in some markets, sales are for personal consumption only and income may not be earned through retail mark-ups on sales in that market).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands, the member receives higher commissions from purchases made by an expanding down-line network. To be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, some of our commission payout may be limited to a hard cap dollar amount per week or a specific percentage of the total product sales. In some markets, commissions may be further limited.
 
In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to three generations of personally sponsored members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time.
 
Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into agreements for business or market development, which could result in additional compensation to specific members.
 
Member Support
 
We are committed to providing a high level of support services tailored to the needs of our members in each market we are serving. We attempt to meet the needs and build the loyalty of members by providing personalized member services and by maintaining a generous product return policy (see “Product Warranties and Returns”). We believe that maximizing a member’s efforts by providing effective member support has been, and could continue to be, important to our success.

Through product training meetings, regular conventions, web-based messages, member focus groups, regular telephone conference calls and other personal contacts with members, we seek to understand and satisfy the needs of our members. Via our websites, we provide product fulfillment and tracking services that result in user-friendly and timely product distribution.
 
To help maintain communication with our members, we offer the following support programs:

Teleconferences – we hold teleconferences with associate field leadership on various subjects such as technical product discussions, member organization building and management techniques.

Internet – we maintain a website at www.nhtglobal.com. On this website, the user can read company news, learn more about various products, sign up to be a member, place orders, and track the fulfillment and delivery of their orders.
 
Product Literature – we offer a variety of literature to members, including product catalogs, informational brochures, pamphlets and posters for individual products, which are both printed and available online.
 
Broadcast E-mail and Text Messages – we send announcements via e-mail and/or text messages to members who opt in to receive this form of communication.

Social Media Tools – in some countries we maintain country-specific social media sites to foster a community environment around our product offering and business opportunity.

6



Technology and Internet Initiatives
 
We believe that the internet is important to our business as more consumers communicate online and purchase products over the internet as opposed to traditional retail and direct sales channels. As a result, we have committed significant resources to our e-commerce capabilities and the abilities of our members to take advantage of the internet. Substantially all of our sales take place via the internet. We offer a global web page that allows a member to have a personalized replicating website through which he or she can sell products in all of the countries in which we do business. Links to these websites can be found at our main website for members at www.nhtglobal.com. The information provided on these websites should not be considered part of this report.
 
Rules Affecting Members
 
Our member policies and procedures establish the rules that members must follow in each market. We also monitor member activity in an attempt to provide our members with a “level playing field” so that one member may not be disadvantaged by the activities of another. We require our members to present products and business opportunities in an ethical and professional manner. Members further agree that their presentations to customers must be consistent with, and limited to, the product claims and representations made in our literature.
 
Our policies and procedures state that we produce or pre-approve all sales aids used by members such as presentations videotapes, audiotapes, brochures and promotional clothing. Further, members may not use any form of media advertising to promote products unless it is pre-approved by us. Members are not entitled to use our trademarks or other intellectual property without our prior consent.
 
Our compliance and member services department reviews reports of alleged member misbehavior. If we determine that a member has violated our member policies or procedures, we may terminate the member’s rights completely. Alternatively, we may impose sanctions, such as warnings, probation, withdrawal or denial of an award, suspension of privileges of the membership, fines, withholding commissions, until specified conditions are satisfied or other appropriate injunctive relief. Our members are independent contractors, not employees, and may act independently of us. Further, our members may resign or terminate their membership at any time without notice. See “Item 1A. Risk Factors.”

Government Regulations
 
Direct Selling Activities
 
Direct selling, or multi-level marketing, activities are regulated by various federal, state and local governmental agencies in the United States and other countries. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes. The laws and regulations in our current markets often:
 
impose cancellation/product return, inventory buy-backs and cooling-off rights for consumers and members;

require us or our members to obtain a license from, or register with, governmental agencies;

impose reporting requirements; and

impose upon us requirements, such as requiring members to maintain levels of retail sales to qualify to receive commissions, to ensure that members are being compensated for sales of products and not for recruiting new members.
 
The laws and regulations governing direct selling are modified from time to time, and, like other direct selling companies, we may be subject from time to time to government reviews, examinations or investigations in our various markets related to our direct selling activities. This can require us to make changes to our business model and aspects of our global compensation plan in the markets impacted by such changes and examinations.
 
Based on advice of our engaged outside professionals in existing markets, the nature and scope of inquiries from government regulatory authorities and our history of operations in those markets to date, we believe our method of distribution complies in all material respects with the laws and regulations related to direct selling of the countries in which we currently operate.
 

7


At the end of 2005, China adopted new direct selling and anti-pyramiding regulations that are restrictive and contain various limitations, including a restriction on the ability to pay multi-level compensation to independent members. We are not conducting direct selling in China. Rather, consumers and members purchase our products via our Hong Kong-based website or our e-commerce retail platform in China. The regulatory environment in China is complex, and our operations in China can receive regulatory and media attention.
 
The Chinese government scrutinizes activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations, and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense in the legality of their conduct. So far, no material changes to our business model have been required. We expect to receive continued guidance and direction as we work with regulators to address our business model and any changes that need to be made to comply with the direct selling regulations.
       
We believe that neither our Hong Kong-based website nor our e-commerce platform in China require a direct selling license in China, which we currently do not hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. Increased sales in China that could be derived from obtaining a direct selling license may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers and branch offices. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.
 
Regulation of Our Products
 
Our products and related promotional and marketing activities are subject to extensive governmental regulation by numerous governmental agencies and authorities in the United States, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission, the United States Department of Agriculture, State Attorneys General and other state regulatory agencies.  In our foreign markets, the products are generally regulated by similar government agencies.

Our personal care products are subject to various laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter (OTC) drug. In the United States, regulation of cosmetics is under the jurisdiction of the FDA.  The Food, Drug and Cosmetic Act defines cosmetics by their intended use, as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body . . . for cleansing, beautifying, promoting attractiveness, or altering the appearance.”  Among the products included in this definition are skin moisturizers, eye and facial makeup preparations, perfumes, lipsticks, fingernail polishes, shampoos, permanent waves, hair colors, toothpastes and deodorants, as well as any material intended for use as a component of a cosmetic product.  Conversely, a product will not be considered a cosmetic, but may be considered a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or any function of the body. A product’s intended use can be inferred from marketing or product claims.  The other markets in which we operate have similar regulations.  In Japan, the Ministry of Health, Labour and Welfare regulates the sale and distribution of cosmetics and requires us to have an import business license and to register each personal care product imported into Japan.  In Taiwan, all “medicated” cosmetic products require registration.  In China, personal care products are placed into one of two categories, “general” and “drug.”  Products in both categories require submission of formulas and other information with the health authorities, and drug products require human clinical studies.  The product registration process in China for these products can take from nine to more than 18 months or longer.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  The sale of cosmetic products is regulated in the European Union under the European Union Cosmetics Directive, which requires a uniform application for foreign companies making personal care product sales.
 

8


The markets in which we operate all have varied regulations that distinguish foods and nutritional health supplements from “drugs” or “pharmaceutical products.”  Because of the varied regulations, some products or ingredients that are recognized as a “food” in certain markets may be treated as a “pharmaceutical” in other markets.  These regulations may require us to either modify a product or refrain from selling the product in a given market. As a result, we must regularly modify the ingredients and/or the levels of ingredients in our products for certain markets.  In some circumstances, the regulations in foreign markets may require us to obtain regulatory approval prior to introduction of a new product or limit our uses of certain ingredients altogether. There has been an increased movement in the United States and other markets to expand the regulation of dietary supplements. This could impose additional restrictions or requirements in the future.  Because of this increased regulatory focus, our internal review efforts have been enhanced in order to comply with our understanding of current regulations.
 
FDA regulations require current good manufacturing practices (cGMP) for dietary supplements.  The regulations ensure that dietary supplements are produced in a quality manner, do not contain contaminants or impurities, and are accurately labeled. The regulations include requirements for establishing quality control procedures for us and our vendors and suppliers, designing and constructing manufacturing plants, and testing ingredients and finished products.  The regulations also include requirements for record keeping and handling consumer product complaints.  If dietary supplements contain contaminants or do not contain the type or quantity of dietary ingredient they are represented to contain, the FDA would consider those products to be adulterated or misbranded.  
 
Our business is subject to additional FDA regulations, such as those implementing an adverse event reporting system (“AER’s”), which requires us to document and track adverse events and report serious adverse events, which are events involving hospitalization or death, associated with consumers’ use of our products.  
 
Most of our major markets also regulate advertising and product claims regarding the efficacy of products. This is particularly true with respect to our dietary supplements because we typically market them as foods or health foods. For example, in the United States, we are unable to claim that any of our nutritional supplements will diagnose, cure, mitigate, treat or prevent disease. In the United States, the Dietary Supplement Health and Education Act, however, permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well-being resulting from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining a structure or a function of the body. Most of the other markets in which we operate have not adopted similar legislation, although we may be subject to more restrictive limitations on the claims we can make about our products in these markets.
 
Other Regulatory Issues
 
As a United States entity operating through subsidiaries in foreign jurisdictions, we are subject to foreign exchange control, transfer pricing and custom laws that regulate the flow of funds between our subsidiaries and us for product purchases, management services and contractual obligations, such as the payment of member commissions. As is the case with most companies that operate in our product categories, we might receive inquiries from time to time from government regulatory authorities regarding the nature of our business and other issues, such as compliance with local direct selling, transfer pricing, customs, taxation, foreign exchange control, securities and other laws.

Product Warranties and Returns
 
Our refund policies and procedures closely follow industry and country-specific standards, which vary greatly by country. For example, in the United States, the Direct Selling Association recommends that direct sellers permit returns during the twelve-month period following the sale, while in Hong Kong the standard return policy is 14 days following the sale. Our return policies typically conform to local laws or the recommendation of the local direct selling association. In most cases, members who timely return unopened product that is in resalable condition may receive a refund. The amount of the refund may be dependent on the country in which the sale occurred, the timeliness of the return, and any applicable re-stocking fee. NHT Global must be notified of the return in writing and such written requests would be considered a termination notice of the membership. We may alter our return policy in response to special circumstances.
 
Significant Customers

Sales are made to our members and no single customer accounted for 10% or more of our net sales. However, our business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on our net sales and financial results.

9



Our Industry
 
We are engaged in the direct selling industry, selling wellness, herbal, beauty, lifestyle and home products. More specifically, we are engaged in what is called network marketing or multi-level marketing. This type of organizational structure and approach to marketing and sales include companies selling lifestyle enhancement products, cosmetics and dietary supplements, or selling other types of consumer products. Generally, direct selling is based upon an organizational structure in which independent members purchasing a company’s products are compensated for sales made directly to consumers.
 
Our members are compensated based on sales generated by members they have enrolled and all subsequent members enrolled by their “down-line” network of members. The experience of the direct selling industry has been that once a sizeable network of members is established, new and alternative products and services can be offered to those members for sale to consumers and additional members.
 
Competition
 
The network marketing industry is very diverse, with giant multinational corporations as well as smaller, local operators. Big network marketing companies include Nu Skin Enterprises, Inc., USANA Health Sciences, Inc., and Herbalife, Ltd, which have much greater name recognition and financial resources than we do and also have many more members. They are publicly traded and therefore serve as informational benchmarks, but we don’t overlap with them in terms of marketplace or product range. On the other hand, many medium- and small-sized privately held Chinese, Taiwanese and Hong Kong companies are fierce competitors and are much closer to directly competing with us. Also, a number of our former employees and members now work for competitors, and sometimes try to use relationships and knowledge obtained to compete with us.
 
Our ability to compete with other network marketing companies depends, in significant part, on our success in attracting and retaining members.  There can be no assurance that our programs for attracting and retaining members will be successful.  The pool of individuals interested in network marketing is limited in each market and is reduced to the extent other network marketing companies successfully attract these individuals into their businesses.  Although we believe that we offer an attractive opportunity for our members, there can be no assurance that other network marketing companies will not be able to recruit our existing members or deplete the pool of potential members in a given market.
 
The direct selling channel tends to sell products at a higher price compared to traditional retailers, which poses a degree of competitive risk. There is no assurance that we would continue to compete effectively against retail stores, internet-based retailers or other direct sellers.
 
Item 1A. RISK FACTORS

We are exposed to a variety of risks that are present in our business and industry. The following are some of the more significant factors that could affect our business, results of operations and financial condition.
 
We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants.
 
We incur a low level of overhead and are run by a small number of executives, who rely on a small group of employees. Our future success depends to a significant degree on the skills, experience and efforts of our top management and directors.  We also depend on the ability of our executive officers and other members of senior management to work effectively as a team.  The loss of one or more of our executive officers, members of our senior management or directors could have a material adverse effect on our business, results of operations and financial condition.  Moreover, as our business evolves, we may require additional or different management members, directors or consultants, and there can be no assurance that we will be able to locate, attract and retain them if and when they are needed.


10


Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business.
 
In 2016, 2015 and 2014, approximately 92%, 93% and 89% of our revenue, respectively, was generated in Hong Kong. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. This geographic concentration in our business means that events or conditions that could negatively impact this geographic region or our operations in this region would have a greater adverse impact upon our overall business and financial results than would be the case with a company having greater geographic diversification.  

Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company.

In contrast to our operations in other parts of the world, we have not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which we are in the process of applying for, and has also adopted anti-multilevel marketing legislation. We operate an e-commerce direct selling model in Hong Kong and recognize the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties.  In addition, through a Chinese entity, we sell products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.
 
After consulting with outside professionals, we believe that our e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of our products by members in China. We also believe that our Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with our interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that our activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on our business, financial condition and results of operations.
 
The Chinese government scrutinizes the activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense of the legality of their conduct, and no material changes to our business model were required.
 
However, our business operations and the value of our company can be adversely affected by Chinese government scrutiny of our operations, even if that scrutiny does not result in investigations of our operations. For example, one or more parties encouraged the Beijing City governmental authorities to conduct an investigation of our business, which resulted in a meeting in January 2016 involving members of our Beijing office staff, Beijing City governmental officials, and two complainants. Even though the Beijing City governmental officials advised our staff and the complainants at that meeting that there was insufficient evidence to warrant an investigation of us, gross mischaracterizations of the meeting immediately appeared in several “news reports.” Similarly, a subsequent meeting between several Guangzhou City government officials and members of our Guangzhou office staff that resulted in our providing routine information about our operations to the government officials was also grossly mischaracterized in an online posting made immediately following the meeting. Although we remain in regular contact with Chinese government officials and take other steps to address the risks posed by these events, our business and the value of our company remain vulnerable to Chinese government scrutiny of our operations, whether or not initiated by third parties.

Various other factors could harm our business in Hong Kong and China, such as worsening economic conditions in Hong Kong or China, adverse local publicity or other events that may be out of our control.  For example, we were advised to voluntarily suspend marketing activities in China during the third quarter of 2007 when the Chinese government was expected to impose a more intense enforcement program against illegal chain sales activities.  We did not want to run the risk of being inadvertently entangled in the government enforcement actions and voluntarily withdrew all marketing activities from China during that period.  It may be necessary or advisable to repeat this or similar actions from time to time in the future, and such periods of reduced activity could have a material adverse effect on our business.


11


Although we attempt to work closely with both national and local Chinese governmental agencies in conducting our business, our efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding our strict policies prohibiting such activities. Any determination that our operations or activities, or the activities of our individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on our future ability to obtain business licenses or expand into new locations, changes to our business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm our business, financial condition and results of operations. 

Our failure to maintain and expand our member relationships could adversely affect our business.
 
We distribute our products through independent members, and we depend upon them directly for all of our sales in most of our markets. Accordingly, our success depends in significant part upon our ability to attract, retain and motivate a large base of members. Our direct selling organization is headed by a relatively small number of key members. The loss of a significant number of members, or the loss of one or more key members, could materially and adversely affect sales of our products and could impair our ability to attract new members. Moreover, the replacement of members could be difficult because, in our efforts to attract and retain members, we compete with other direct selling organizations, including but not limited to those in the personal care, cosmetic product and nutritional supplement industries. Our members may terminate their services with us at any time and, in fact, like most direct selling organizations, we have a high rate of attrition.

The number of active members or their productivity may not increase and could decline in the future.  We cannot accurately predict any fluctuation in the number and productivity of members because we primarily rely upon existing members to enroll and train new members and to motivate new and existing members. Operating results could be adversely affected if our existing and new business opportunities and products do not generate sufficient economic incentive or interest to retain existing members and to attract new members.
 
The number and productivity of our members could be harmed by several factors, including:

adverse publicity or negative perceptions regarding us, our products, our method of distribution or our competitors;

lack of interest in, or the technical failure of, existing or new products;

lack of interest in our existing compensation plan for members or in enhancements or other changes to that compensation plan;

our actions to enforce our policies and procedures;

regulatory actions or charges or private actions against us or others in our industry;

general economic and business conditions;

changes in management or the loss of one or more key member leaders;

entry of new competitors, or new products or compensation plan enhancements by existing competitors, in our markets; and

potential saturation or maturity levels in a given country or market which could negatively impact our ability to attract and retain members in such market.


12


We are currently being sued in three lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China.

We, together with our executive officers, have been named as defendants in three complaints (one of which also names our directors as defendants) relating to alleged materially false and misleading statements regarding the legality of our business operations in China, among other things. These complaints seek an indeterminate amount of damages, and one of the complaints also seeks various equitable remedies. Notwithstanding potentially applicable insurance coverage, these complaints, or others filed alleging similar facts, could result in monetary or other penalties that may adversely affect our operating results and financial condition. Moreover, the negative publicity stemming from these complaints and the allegations they make could harm our business and operations. Accordingly, any adverse determination against us in these suits, or even the allegations contained in the suits regardless of whether they are ultimately found to be without merit, could harm our business, operations and financial condition.

We are currently involved in, and may in the future face, litigation claims and governmental proceedings and inquiries that could harm our business.
 
We are currently, and have in the past, been a party to lawsuits, claims and governmental proceedings and inquiries.  Prosecuting and defending these matters may require significant expense and attention of our management.  There can be no assurance that we will be able to successfully defend or resolve any such litigation, claims or governmental proceedings or inquiries, or that the significant money, time and effort spent in defending these matters will not adversely affect our business, financial condition and results of operations.

Although our members are independent contractors, improper member actions that violate laws or regulations could harm our business.
 
Our members are independent contractors and, accordingly, we are not in a position to directly provide the same direction, motivation and oversight as we would if members were our own employees.  As a result, there can be no assurance that our members will participate in our marketing strategies or plans, accept our introduction of new products, or comply with our member policies and procedures.  Extensive federal, state, local and foreign laws regulate our business, our products and our network marketing program.  Because we have expanded into foreign countries, our policies and procedures for our members differ due to the different legal requirements of each country in which we do business.  While we have implemented member policies and procedures designed to govern member conduct and to protect the goodwill associated with our trademarks and trade names, it can be difficult to enforce these policies and procedures because of the large number of members and their independent status.  
 
Given the size and diversity of our member force, we experience problems with members from time to time, especially with respect to our members in foreign markets. For example, if our members engage in illegal activities in China, those actions could be attributed to us. Chinese laws regarding how and when members may assemble and the activities that they may conduct, or the conditions under which the activities may be conducted, are subject to interpretations and enforcement that sometimes vary from province to province, among different levels of government, and from time to time. Members can be accused of violating one or more of the laws regulating these activities, notwithstanding training that we attempt to provide. Enforcement measures regarding these violations, which can include arrests, raise the uncertainty and perceived risk associated with conducting this business, especially among those who are aware of the enforcement actions but not the specific activities leading to the enforcement action. We believe that this has led some existing members in China - who are signed up as members in Hong Kong - to leave the business or curtail their selling activities and has led some potential members to choose not to participate. Among other things, we are managing this risk with more training and public relations efforts that are designed, among other things, to distinguish our company from businesses that make no attempt to comply with the law. This environment creates uncertainty about the future of doing this type of business in China generally and under our business model, specifically.

In addition, members often desire to enter a market before we have received approval to do business in order to gain an advantage in the marketplace.  Improper member activity in new geographic markets could result in adverse publicity and can be particularly harmful to our ability to ultimately enter these markets.  Violations by our members of applicable law or of our policies and procedures in dealing with customers could reflect negatively on our products and operations, and harm our business reputation.  In addition, it is possible that a judicial or administrative body could hold us civilly or criminally accountable based on vicarious liability because of the actions of our members.  If any of the above or related events involving our members occur, our business, financial condition, or results of operations could be materially adversely affected.

13



Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business.
 
Our direct selling system is subject to extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints.  These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as “pyramid” schemes, which compensate participants for recruiting additional participants irrespective of product sales, use high pressure recruiting methods and/or do not involve legitimate products. They also seek to ensure that claims regarding the ability of participants to earn money are truthful and substantiated.
 
Complying with these widely varying and sometimes inconsistent rules and regulations can be difficult and may require the devotion of significant resources on our part.  There can be no assurance that we or our members are in compliance with all of these regulations.  Our failure or our members’ failure to comply with these regulations or new regulations could lead to the imposition of significant penalties or claims and could negatively impact our business.  If we are unable to continue business in existing markets or commence operations in new markets because of these laws, our revenue and profitability may decline.
 
We are also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which could require us to change or modify the way we conduct our business in certain markets.  This could be particularly detrimental to us if we have to change or modify the way we conduct business in markets that represent a significant percentage of our revenue.

The high level of competition in our industry could adversely affect our business.
 
The business of marketing personal care, cosmetic, nutritional supplements, and lifestyle enhancement products is highly competitive.  This market segment includes numerous manufacturers, members, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad.  The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.  Sales of similar products by competitors may materially and adversely affect our business, financial condition and results of operations.
 
We are subject to significant competition for the recruitment of members from other direct selling organizations, including those that market similar products.  Many of our competitors are substantially larger than we are, offer a wider array of products, have far greater financial resources and many more active members than we have.  Even more numerous are those medium- and small-sized, all privately held Chinese, Taiwanese and Hong Kong companies that are fierce competitors and are much closer to directly competing with us. Our ability to remain competitive depends, in significant part, on our success in recruiting and retaining members with our products, attractive compensation plan and other incentives.  We believe that we have an attractive product line and that our compensation and incentive programs provide our members with significant earning potential.  However, we cannot be sure that our programs for recruitment and retention of members will be successful.
 
Some of our competitors have employed or otherwise contracted for the services of our former officers, employees, consultants, and members, who may try to use information and contacts obtained while under contract with us for competitive advantage.  While we seek to protect our information through contractual and other means, there can be no assurance that we will timely learn of such activity, have the resources to attempt to stop it, or have adequate remedies available to us.
 
Challenges by third parties to the legality of our business operations could harm our business.

We are also subject to the risk of private party challenges to the legality of our operations, including our direct selling system.  The regulatory requirements concerning direct selling systems generally do not include “bright line” rules and are inherently fact-based and subject to judicial or administrative interpretation. An adverse judicial or administrative determination against us with respect to our direct selling system, or in proceedings not involving us directly but which challenge the legality of other direct selling marketing systems, could have a material adverse effect on our business.  There is also risk that challenges and settlements involving other parties could provide incentives for similar actions by members against us and other direct selling companies.  Moreover, challenges to our business system and operations in important markets may come from short sellers, hedge funds, other investors, bloggers and reporters.  Other companies in our industry have recently faced such challenges.  Any challenges regarding us or others in our industry could harm our business if such challenges result in the imposition of any fines or damages on our business, create adverse publicity, increase scrutiny or investigations of us or our industry, detrimentally affect our efforts to recruit or motivate members and attract customers, or interpret laws in a manner inconsistent with our current business practices.


14


An increase in the amount of compensation paid to members would reduce profitability.
 
A significant expense is the payment of compensation to our members, which represented approximately 44%, 48% and 46% of net sales during 2016, 2015 and 2014, respectively.  We compensate our members by paying commissions, bonuses, and certain awards and prizes.  Factors impacting the overall commission payout include the growth and depth of the member network, the member retention rate, the level of promotions, local promotional programs and business development agreements.  Any increase in compensation payments to members as a percentage of net sales will reduce our profitability.  

Our compensation plan includes a cap that may be enforced on member compensation paid out on a weekly dollar limit or as a percentage of product sales. There can be no assurance that enforcement of this cap will ensure profitability (which depends on many other factors).  Moreover, enforcement of this cap could cause key members affected by the cap to leave and join other companies.
 
Currency exchange rate fluctuations could lower our revenue and net income.
 
In 2016, 98% of our revenue was recorded by subsidiaries located outside of North America.  Revenue transactions and related commission payments, as well as other incurred expenses, are typically denominated in the local currency.  Accordingly, our international subsidiaries use the local currency as their functional currency.  The results of operations of our international subsidiaries are exposed to foreign currency exchange rate fluctuations during consolidation since we translate into U.S. dollars using the average exchanges rates for the period.  As exchange rates vary, revenue and other operating results may differ materially from our expectations.  Additionally, we may record significant gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of inter-company balances.  
 
Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar.  We also purchase a significant majority of inventories in U.S. dollars.  Our foreign currency exchange rate exposure to South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Canadian dollar and European euro represented approximately 7%, 6% and 10% of our revenue in 2016, 2015 and 2014, respectively.  Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, Canada, Central America, South America and Europe.  Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar.  Finally, we also experience indirect exchange rate exposure due to the concentration of our sales in China and the recent performance of the Chinese yuan. Following the 2015 devaluation of the Chinese yuan, the Chinese yuan experienced depreciation against the Hong Kong dollar of 7% for the year ended December 31, 2016, the cumulative effect of which has been to erode our Chinese members’ purchasing power and, we believe, to adversely affect our product sales.

Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition.  Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.
 
Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income.
 
In the course of doing business we may be subject to various taxes, such as sales and use, value-added, and franchise. We are also subject to income taxes in the United States and numerous foreign jurisdictions. We earn a substantial portion of our income in foreign jurisdictions. If our capital or financing needs in the United States (including the repurchase of our stock and payment of dividends in the United States) require us to repatriate earnings from foreign jurisdictions, our effective income tax rates for the affected periods could be negatively impacted. Economic and political conditions make tax rules in any jurisdiction, including the United States, subject to significant change. There have been proposals to reform U.S. and foreign tax laws that could significantly impact how U.S. multinational corporations are taxed on foreign earnings. Although we cannot predict whether or in what form these proposals will pass, several of the proposals considered, if enacted into law, could have an adverse impact on our income tax expense and cash flows.
 
Our principal domicile is the United States. Under tax treaties, we are eligible to receive foreign tax credits in the United States for taxes paid abroad. Taxes paid to foreign taxing authorities may exceed the credits available to us, resulting in the payment of a higher overall effective tax rate on our worldwide operations.
 
Our effective income tax rate in the future could be adversely affected by a number of factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, the outcome of income tax audits in various jurisdictions around the world, and any repatriation of non-U.S. earnings for which we have not previously provided for U.S. taxes.

15


 
We may also be subject to examinations of our tax returns and other tax matters by the Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes, which is subject to significant discretion. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase, particularly in the U.S., or if the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our financial results or operations could be adversely affected.
 
In addition, our operations are subject to regulations designed to ensure that appropriate levels of customs duties are assessed on the importation of our products. The failure to properly calculate, report and pay such duties when we are subject to them could have a material adverse effect on our financial condition and results of operations. Any change in the laws or regulations regarding such duties, or any interpretation thereof, could result in an increase in the cost of doing business.

Transfer pricing regulations affect our business and results of operations.
 
In many countries, including the United States, we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by our United States or local entities and are taxed accordingly. We have adopted transfer pricing agreements with our subsidiaries to regulate inter-company transfers, which agreements are subject to transfer pricing laws that regulate the flow of funds between the subsidiaries and the parent corporation for product purchases, management services, and contractual obligations, such as the payment of member compensation. We believe that we operate in compliance with all applicable transfer pricing laws, and we intend to continue to operate in compliance with such laws. However, there can be no assurance that we will continue to be found to be operating in compliance with transfer pricing laws, or that those laws would not be modified, which, as a result, may require changes in our operating procedures or otherwise may have a material adverse effect on our financial results or operations.

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets. 
 
The formulation, manufacturing, packaging, labeling, importation, advertising, distribution, sale and storage of certain of our products are subject to extensive regulation by various federal agencies, including the Food and Drug Administration (the “FDA”), the FTC, the Consumer Product Safety Commission and the United States Department of Agriculture and by various agencies of the states, localities and foreign countries in which our products are manufactured, distributed and sold.  For example, the FDA requires us and our suppliers to meet relevant current good manufacturing practice (cGMP) regulations for the preparation, packing and storage of foods and over-the-counter (OTC) drugs.  We are also now required to report serious adverse events associated with consumer use of certain of our products.  Other laws and regulations govern or restrict the claims that may be made about our products and the information that must be included and excluded on labels.
 
In markets outside the United States, prior to commencing operations or marketing new products, we may be required to obtain approvals, licenses, or certifications from a ministry of health or a comparable agency. Moreover, a foreign jurisdiction may pass laws that would prohibit the use of certain ingredients in their particular market.  Compliance with these regulations can create delays and added expense in introducing new products to certain markets.
 
Failure by our members or us to comply with those regulations could lead to the imposition of significant penalties or claims and could materially and adversely affect our business.  If we are not able to satisfy the various regulations, then we would have to cease sales of that product in that market.  In addition, the adoption of new regulations or changes in the interpretation of existing regulations may result in significant compliance costs or discontinuation of product sales and may adversely affect the marketing of our products, resulting in significant loss of revenues.
 
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional governmental regulations or administrative orders, when and if promulgated, could have on our business.  These potential effects could include, however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional recordkeeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or additional scientific substantiation.  Any or all of these requirements could have a material adverse effect on our business, financial condition, or results of operations.


16


Failure of new products to gain member and market acceptance could harm our business.
 
An important component of our business is our ability to develop new products that create enthusiasm among our member force.  If we fail to introduce new products on a timely basis, our member productivity could be harmed.  In addition, if any new products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, this would harm our results of operations.  Factors that could affect our ability to continue to introduce new products include, among others, limited capital and human resources, government regulations, proprietary protections of competitors that may limit our ability to offer comparable products and any failure to anticipate changes in consumer tastes and buying preferences.
 
New regulations governing the marketing and sale of nutritional supplements could harm our business.
 
There has been an increasing movement in the United States and other markets to increase the regulation of dietary supplements, which could impose additional restrictions or requirements in the future.  In the United States, for example, some legislators and industry critics continue to push for increased regulatory authority by the FDA over nutritional supplements.  Our business could be harmed if more restrictive legislation is successfully introduced and adopted in the future.  In particular, the adoption of legislation requiring FDA approval of supplements or ingredients could delay or inhibit our ability to introduce new supplements.  We face similar pressures in our other markets.  In the United States the FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising (“Guides”) require disclosure of material connections between an endorser and the company they are endorsing and require the disclosure of typical results when these are different from those reported by the endorser.  The requirements and restrictions of the Guides may diminish the impact of our marketing efforts and negatively impact our sales results.  If we or our members fail to comply with these Guides, the FTC could bring an enforcement action against us and we could be fined and/or forced to alter our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute nutritional supplements or impose additional burdens or requirements on nutritional supplement companies or require us to reformulate our products.
 
Regulations governing the production and marketing of our personal care products could harm our business.
 
Our personal care products are subject to various domestic and foreign laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter drug.  A determination that our cosmetic products impact the structure or function of the human body, or improper marketing claims by our members, may lead to a determination that such products require pre-market approval as a drug.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  Furthermore, if we fail to comply with these regulations, we could face enforcement action against us and we could be fined, forced to alter or stop selling our products and/or required to adjust our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute our personal care products or impose additional burdens or requirements on the contents of our personal care products or require us to reformulate our products.

If we are found not to be in compliance with good manufacturing practices our operations could be harmed.
 
Regulations on good manufacturing practices and adverse event reporting requirements for the nutritional supplement industry are in effect and require good manufacturing processes for us and our vendors, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.   We are also required to report serious adverse events associated with consumer use of our products.  Our operations could be harmed if regulatory authorities make determinations that we or our vendors are not in compliance with the regulations.  A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain of our products.  In addition, compliance with these regulations has increased and may further increase the cost of manufacturing certain of our products as we work with our vendors to assure they are qualified and in compliance.
 
Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business.
 
Our failure to comply with FTC or state regulations, or with regulations in foreign markets that cover our product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by members for which we may be held responsible, may result in enforcement actions and imposition of penalties or otherwise materially and adversely affect the distribution and sale of our products.  Member activities in our existing markets that violate applicable governmental laws or regulations could result in governmental or private actions against us in markets where we operate.  Given the size of our member force, we cannot ensure that our members will comply with applicable legal requirements.
 

17


Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.
 
Adverse publicity concerning any actual or claimed failure by us or our members to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing practices, the regulation of our network marketing program, the licensing of our products for sale in our target markets or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could have an adverse effect on our goodwill and could negatively affect our ability to attract, motivate and retain members, which would negatively impact our ability to generate revenue.  We cannot ensure that all members will comply with applicable legal requirements relating to the advertising, labeling, licensing or distribution of our products.
 
In addition, our members’ and consumers’ perception of the safety and quality of our products and ingredients, as well as similar products and ingredients distributed by other companies, can be significantly influenced by media attention, publicized scientific research or findings, widespread product liability claims and other publicity concerning our products or ingredients or similar products and ingredients distributed by other companies.  Adverse publicity, whether or not accurate or resulting from consumers’ use or misuse of our products, that associates consumption of our products or ingredients or any similar products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact our reputation or the market demand for our products.

We are subject to risks relating to product concentration and lack of revenue diversification.
 
Although we have in recent years expanded our line of products, we derive more than 10% of our total revenue from each of our Premium Noni Juice and Enhanced Essential Probiotics® products. Further, we currently source each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, we are unable to adequately source or deliver the products, or we are unable to offer the products for any reason without suitable replacements, our business, financial condition and results of operations could be materially and adversely affected. Our future success will also depend on our ability to reduce our dependence on these few products by developing and introducing new products and product or feature enhancements in a timely manner. Even if we are able to develop and commercially introduce new products and enhancements, they may not achieve market acceptance and the revenue generated from these new products and enhancements may not offset the costs, which could substantially impair our business, financial condition and results of operations.
 
We rely on a limited number of independent third parties to manufacture and supply our products.
 
All of our products are manufactured by a limited number of independent third parties.  There is no assurance that our current manufacturers will continue to reliably supply products to us at the level of quality we require.  If a key manufacturer suffers liquidity problems or experiences operational or other problems assisting with our products, our results could suffer.  In the event any of our third-party manufacturers become unable or unwilling to continue to provide the products in required volumes and quality levels at acceptable prices, we will be required to identify and obtain acceptable replacement manufacturing sources or replacement products.  There is no assurance that we will be able to obtain alternative manufacturing sources or products or be able to do so on a timely basis.  An extended interruption in the supply of certain of our products may result in a substantial loss of revenue.  In addition, any actual or perceived degradation of product quality as a result of our reliance on third party manufacturers may have an adverse effect on revenue or result in increased product returns.  
 
Growth may be impeded by the political and economic risks of entering and operating foreign markets.
 
Our ability to achieve future growth is dependent, in part, on our ability to continue our international expansion efforts.  However, there can be no assurance that we would be able to grow in our existing international markets, enter new international markets on a timely basis, or that new markets would be profitable.  We must overcome significant regulatory and legal barriers before we can begin marketing in any foreign market.
 

18


Also, it is difficult to assess the extent to which our products and sales techniques would be accepted or successful in any given country.  In addition to significant regulatory barriers, we may also encounter problems conducting operations in new markets with different cultures and legal systems from those elsewhere.  We may be required to reformulate certain of our products before commencing sales in a given country.  Once we have entered a market, we must adhere to the regulatory and legal requirements of that market.  No assurance can be given that we would be able to successfully reformulate our products in any of our current or potential international markets to meet local regulatory requirements or attract local customers.  The failure to do so could have a material adverse effect on our business, financial condition, and results of operations.  There can be no assurance that we would be able to obtain and retain necessary permits and approvals.
 
In many markets, other direct selling companies already have significant market penetration, the effect of which could be to desensitize the local member population to a new opportunity or to make it more difficult for us to recruit qualified members. There can be no assurance that, even if we are able to commence operations in foreign countries, there would be a sufficiently large population of potential members inclined to participate in a direct selling system offered by us.  We believe our future success could depend in part on our ability to seamlessly integrate our business methods, including member compensation plan, across all markets in which our products are sold.  There can be no assurance that we would be able to further develop and maintain a seamless compensation program.
 
We may be held responsible for certain taxes or assessments relating to the activities of our members, which could harm our financial condition and operating results.
 
Our members are subject to taxation, and in some instances, legislation or governmental agencies impose an obligation on us to collect the taxes, such as value added taxes, and to maintain appropriate records.  In addition, we are subject to the risk in some jurisdictions of being responsible for social security and similar taxes with respect to our members.
 
We may be unable to protect or use our intellectual property rights.
 
We rely on trade secret, copyright and trademark laws and confidentiality agreements with employees and third parties, all of which offer only limited protection of our confidential information and trademarks.  Moreover, the laws of some countries in which we market our products may afford little or no effective protection of our intellectual property rights.  The unauthorized copying, use or other misappropriation of our confidential information, trademarks and other intellectual property could enable third parties to benefit from such property without paying us for it.  This could have a material adverse effect on our business, operating results and financial condition.  If we resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome, expensive and result in inadequate remedies.  It is also possible that our use of our intellectual property rights could be found to infringe on prior rights of others and, in that event, we could be compelled to stop or modify the infringing use, which could be burdensome and expensive.
 
We do not have a comprehensive product liability insurance program and product liability claims could hurt our business.
 
Currently, we do not have a comprehensive product liability insurance program, although the insurance carried by our suppliers may cover certain product liability claims against us.  As a marketer of dietary supplements, cosmetics and other products that are ingested by consumers or applied to their bodies, we may become subjected to various product liability claims, including that:
 
our products contain contaminants or unsafe ingredients;

our products include inadequate instructions as to their uses; or

our products include inadequate warnings concerning side effects and interactions with other substances.
 
If our suppliers’ product liability insurance fails to cover product liability claims or other product liability claims, or any product liability claims exceeds the amount of coverage provided by such policies or if we are unsuccessful in any third party claim against the manufacturer or if we are unsuccessful in collecting any judgment that may be recovered by us against the manufacturer, we could be required to pay substantial monetary damages which could materially harm our business, financial condition and results of operations. As a result, we may become required to pay high premiums and accept high deductibles in order to secure adequate insurance coverage in the future.  Especially since we do not have direct product liability insurance, it is possible that product liability claims and the resulting adverse publicity could negatively affect our business.
 

19


Our internal controls and accounting methods may require modification.
 
We continue to review and develop controls and procedures sufficient to accurately report our financial performance on a timely basis.  If we do not develop and implement effective controls and procedures, we may not be able to report our financial performance on a timely basis and our business and stock price would be adversely affected.
  
If we fail to achieve and maintain an effective system of internal controls in the future, we may not be able to accurately report our financial results or prevent fraud.  As a result, investors may lose confidence in our financial reporting.
 
The Sarbanes-Oxley Act of 2002 requires that we report annually on the effectiveness of our internal control over financial reporting.  Among other things, we must perform systems and processes evaluation and testing.  We must also conduct an assessment of our internal controls to allow management to report on our assessment of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act.  We are required to provide management’s assessment of internal controls in conjunction with the filing of our Annual Report on Form 10-K.  As disclosed under “Item 9A. Controls and Procedures” of this report, our management has delivered its report concluding that our internal control over financial reporting was effective at December 31, 2016, and our independent registered public accounting firm has also delivered its attestation to the report.  In the future, our continued assessment, or the assessment by our independent registered public accounting firm, could reveal significant deficiencies or material weaknesses in our internal controls, which may need to be disclosed in future Annual Reports on Form 10-K.  We believe, at the current time, that we are taking appropriate steps to mitigate these risks.  However, disclosures of this type can cause investors to lose confidence in our financial reporting and may negatively affect the price of our common stock.  Moreover, effective internal controls are necessary to produce reliable financial reports and to prevent fraud.  Deficiencies in our internal controls over financial reporting may negatively impact our business and operations.  

We rely on and are subject to risks associated with our reliance upon information technology systems.
 
Our success is dependent on the accuracy, reliability, and proper use of information processing systems and management information technology.  Our information technology systems are designed and selected to facilitate order entry and customer billing, maintain member records, accurately track purchases and member compensation payments, manage accounting operations, generate reports, and provide customer service and technical support.  Any interruption in these systems could have a material adverse effect on our business, financial condition, and results of operations.
 
Although we believe that the members of our software development team have the qualifications, know-how and experience to perform the necessary software development and other information technology services, there can be no assurance that there will not be delays or interruptions in these services.  An interruption or delay in availability of these services could, if it lasted long enough, prevent us from accepting orders, cause members to leave our business, or otherwise materially adversely affect our business.
 
System failures and attacks could harm our business.
 
Because of our diverse geographic operations and our internationally applicable member compensation plans, our business is highly dependent on the efficient functioning of our information technology systems and operations, which are vulnerable to damage or interruption from fires, earthquakes, telecommunications failures, computer viruses and worms, hacking, denial of service attacks, software defects and other events.  They are also subject to break-ins, sabotage, acts of vandalism and similar misconduct, as well as human error.  Despite precautions implemented by our information technology staff, problems could result in interruptions in services and materially and adversely affect our business, financial condition and results of operations.
 
Moreover, hackers could attack our system seeking to retrieve personal or confidential information of ours or of third parties, such as credit card information used to purchase our products on-line.  Although we take steps to prevent such loss of information, there can be no assurance that our system will not be successfully hacked.  Laws in the United States and other jurisdictions where we do business require prompt notice of any such loss of information.  Failure to comply with those reporting obligations could result in material penalties.  In addition, if our system were hacked, we could incur material costs in investigating the incidents and could be liable for damages.  Any such damages may or may not be covered by insurance.

20



Terrorist attacks, cyber-attacks, acts of war, epidemics or other communicable diseases or any other natural disasters may seriously harm our business.
 
Terrorist attacks, cyber-attacks, or acts of war or natural disasters may cause damage or disruption to us, our employees, our facilities and our members and customers, which could impact our revenues, expenses and financial condition.  The potential for future terrorist attacks, the national and international responses to terrorist attacks, and other acts of war or hostility, such as challenges to Chinese sovereignty claims in the South China Sea or Chinese objection to the Taiwan independence movement and the resultant tension in the Taiwan Strait, could materially and adversely affect our business, results of operations, and financial condition in ways that we currently cannot predict.  Additionally, natural disasters less severe than the Indian Ocean tsunami that occurred in December 2004 may adversely affect our business, financial condition and results of operations.
 
Because our systems, software and data reside on third-party servers, our access could be temporarily or permanently interrupted.
 
Beginning in 2012, most of our systems, software and data reside in the “cloud” on third-party servers to which we have contractual access.  Cyber-attacks or hacking on these servers unrelated to us, or system or hardware failures experienced by the third party vendor, could result in disclosure of or damage to our systems, software and data.  Moreover, any delay or failure in payment of the third party vendors, disputes with such vendors, or business interruption or failure of the third party vendors could result in loss of or interruption in access to our systems, software or data.  It is possible that our systems, software and data could in the future be moved to servers of different third parties or to our own servers.  Any such move could result in temporary or permanent loss of access to our systems, software or data.  Any protracted loss of such access would materially and adversely affect our business, financial condition and results of operations.

We may experience substantial negative cash flows, which may have a significant adverse effect on our business and could threaten our solvency.
 
We experienced substantial negative cash flows during the years ended December 31, 2009 and 2008, primarily due to declines in our revenues greater than the decreases in expenditures we could manage.  If we again experience negative cash flows, any resulting decreasing cash balance could impair our ability to support our operations and, eventually, threaten our solvency, which would have a material adverse effect on our business, results of operations and financial condition, as well as our stock price.  Negative cash flows and the related adverse market perception associated therewith may have negatively affected, and may in the future negatively affect, our ability to attract new members and/or sell our products.  There can be no assurance that we will be successful in maintaining an adequate level of cash resources and we could be forced to act more aggressively in the area of expense reduction in order to conserve cash resources as we look for alternative solutions.
 
If we experience negative cash flows, we may need to seek additional debt or equity financing, which may not be available on acceptable terms or at all.  If available, it could have a highly dilutive effect on the holdings of existing stockholders.
 
Unless we are able to maintain revenues, control expenses and achieve positive cash flows, our ability to support our obligations could be impaired and our liquidity could be adversely affected and our solvency and our ability to repay our debts when they come due could be threatened.  We may need to seek additional debt or equity financing on acceptable terms in order to improve our liquidity.  However, we may not be able to obtain additional debt or equity financing on satisfactory terms, or at all, and any new financing could have a dilutive effect to our existing stockholders.
 
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall.
     
Our quarterly revenue and operating results are difficult to predict and may fluctuate significantly from quarter to quarter.  If our quarterly revenue or operating results fall below the expectations of investors or securities analysts, the price of our common stock could fall substantially.
 
Our common stock is particularly subject to volatility because of the industry in which we operate.
 
The market prices of securities of direct selling companies have been extremely volatile, and have experienced fluctuations that have often been unrelated or disproportionate to the operating performance of such companies.  These broad market fluctuations could adversely affect the market price of our common stock.
 

21


Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive.
 
The public market for our common stock has historically been very volatile. Notwithstanding the transition in trading of our common stock from the OTC Market to the NASDAQ Capital Market in February 2015, our stock continues to experience wide fluctuations in trading volumes and prices. There are a number of factors that may contribute to this volatility, including the following:

active participation of speculative traders in our stock (including short sellers);

market rumors regarding our business operations;

government scrutiny of our business;

adverse publicity related to our business or industry; and

fluctuations in our operating results.

This market volatility for our stock may make it more difficult for holders of our stock to sell shares when they want and at prices they find attractive. There can be no assurance that a larger or more liquid market will be developed or maintained for our common stock.
 
Future sales by us or our existing stockholders could depress the market price of our common stock.
 
If we or our existing stockholders sell a large number of shares of our common stock, the market price of our common stock could decline significantly.  Further, even the perception in the public market that we or our existing stockholders might sell shares of common stock could depress the market price of our common stock.
 
Item 1B. UNRESOLVED STAFF COMMENTS

None.

Item 2. PROPERTIES
 
We lease 4,900 square feet of office space in Rolling Hills Estates, California for our corporate headquarters with terms expiring in September 2025. In addition, we lease 2,400 and 1,600 square feet of retail space in Monterey Park, California and Vancouver, British Columbia, respectively, to help further develop the market for our products in North America. The Monterey Park and Vancouver locations have terms expiring in August 2020 and February 2021, respectively. We also maintain an office in Dallas, Texas.

Outside of North America, we lease 7,300 square feet of office space in Hong Kong with terms expiring in February 2018, nine branch offices throughout China, and additional office space in Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam and the Cayman Islands. We also lease a multi-purpose facility and factory in Zhongshan, China and 11 service stations throughout the city of Guangzhou, China that serve or will in the future serve the needs of our Chinese consumers. We contract with third parties for fulfillment and distribution operations in all of our international markets. Through a local service provider, we maintain marketing and member centers in Almaty, Kazakhstan and Moscow, Russia. We believe that our existing office space is in good condition, and is suitable and adequate for the conduct of our business.
 

22


Item 3. LEGAL PROCEEDINGS

Securities Class Action

In January 2016, two putative securities class action complaints were filed against us and our top executives in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. On March 29, 2016, the court consolidated these actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and (ii) Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. We filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of our motion to dismiss on August 22 2016. On December 5, 2016, the Court denied our motion to dismiss. On February 17, 2017, we filed an answer to the consolidated complaint. We believe that these claims are without merit and intend to vigorously defend against them.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of our officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed us and our assets. The Derivative Complaints allege, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. We believe that these claims are without merit and intend to vigorously defend against them.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.



23


Part II
 
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information
 
Our common stock is currently traded on the NASDAQ Capital Market (“Nasdaq”) under the symbol “NHTC.” Prior to February 17, 2015, our common stock was quoted under the trading symbol “NHTC” on the OTCQB tier of the OTC Market. The following table sets forth the range of the high and low bid quotations of our common stock as reported by Nasdaq and the OTC Markets Group, Inc. The bid quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
 
2016
 
2015
 
High
 
Low
 
High
 
Low
First quarter
$
36.19

 
$
17.75

 
$
18.29

 
$
10.49

Second quarter
38.25

 
26.24

 
44.18

 
17.78

Third quarter
34.30

 
25.89

 
43.33

 
21.91

Fourth quarter
29.95

 
21.44

 
53.72

 
32.96

 
On March 7, 2017, the closing price of our common stock as reported by Nasdaq was $27.95 per share.
 
Holders of Record
 
At March 7, 2017, there were approximately 125 record holders of our common stock (although we believe that the number of beneficial owners of our common stock is substantially greater).

Dividends
 
The following tables summarize all cash dividend activity during 2016 and 2015 (in thousands, except per share data), all of which dividend payments were made to holders of our common stock:
Declaration Date
 
Per Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 

Declaration Date
 
Per Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 

Additionally, on January 24, 2017, the Board of Directors declared a cash dividend of $0.09 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends were paid on March 3, 2017 to stockholders of record on February 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.



24


Stock Performance Graph

Set forth below is a line graph and table comparing the performance of our common stock to the S&P 500 Index and to a market-weighted index of publicly traded peers from the period from December 31, 2011 through December 31, 2016. The graph assumes $100 was invested in our common stock, the S&P 500 Index and the index of publicly traded peers on December 31, 2011 and that all dividends were reinvested. The publicly traded companies in the peer group consist of Nature's Sunshine Products, Nu Skin Enterprises Inc., USANA Health Sciences Inc., and Herbalife Ltd. The graph represents past performance and should not be considered to be an indication of future performance.

nhtc201610-_chartx10870.jpg
 Period
 
NHTC
 
S&P 500
 
Peer Group
December 31, 2011
 
$
100

 
$
100

 
$
100

December 31, 2012
 
155

 
116

 
74

December 31, 2013
 
492

 
154

 
224

December 31, 2014
 
1,766

 
175

 
135

December 31, 2015
 
5,194

 
177

 
167

December 31, 2016
 
3,944

 
198

 
161


 


25


Item 6. SELECTED FINANCIAL DATA

The following selected consolidated financial data, which have been derived from our audited consolidated financial statements, are not necessarily indicative of the results of future operations and should be read in conjunction with “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations”, and the consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K (in thousands, except per share data).
 
Year Ended December 31
 
2016
 
2015
 
2014
 
2013
 
2012
Consolidated Statements of Operations Data:
 
 
 
 
 
 
 
 
 
Net sales
$
287,728

 
$
264,860

 
$
124,590

 
$
52,527

 
$
37,514

Cost of sales
54,903

 
54,098

 
26,981

 
12,551

 
9,685

Gross profit
232,825

 
210,762

 
97,609

 
39,976

 
27,829

Operating expenses:
 
 
 
 
 
 
 
 
 
Commissions expense
125,050

 
126,598

 
56,997

 
24,053

 
15,724

Selling, general and administrative expenses
43,245

 
36,024

 
19,687

 
11,634

 
9,415

Depreciation and amortization
394

 
263

 
105

 
66

 
45

Total operating expenses
168,689

 
162,885

 
76,789

 
35,753

 
25,184

Income from operations
64,136

 
47,877

 
20,820

 
4,223

 
2,645

Other expense, net
(59
)
 
(84
)
 
(184
)
 
(32
)
 
(39
)
Income before income taxes
64,077

 
47,793

 
20,636

 
4,191

 
2,606

Income tax provision (benefit)
8,991

 
552

 
266

 
102

 
(24
)
Net income
55,086

 
47,241

 
20,370

 
4,089

 
2,630

Preferred stock dividends

 

 
(10
)
 
(15
)
 
(17
)
Net income available to common stockholders
$
55,086

 
$
47,241

 
$
20,360

 
$
4,074

 
$
2,613

Income per common share:
 
 
 
 
 
 
 
 
 
Basic
$
4.84

 
$
3.84

 
$
1.67

 
$
0.36

 
$
0.24

Diluted
$
4.83

 
$
3.82

 
$
1.61

 
$
0.36

 
$
0.23

Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
 
 
Basic
11,382

 
12,302

 
12,131

 
11,154

 
10,944

Diluted
11,407

 
12,372

 
12,600

 
11,331

 
11,234

Cash dividends declared per common share
$
0.61

 
$
0.14

 
$
0.03

 
$

 
$

 
 
 
 
 
 
 
 
 
 
Consolidated Balance Sheets Data:
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
$
125,921

 
$
104,914

 
$
44,816

 
$
14,550

 
$
4,207

Inventories, net
11,257

 
10,455

 
3,760

 
1,828

 
867

Working capital
84,090

 
56,199

 
25,253

 
3,598

 
(325
)
Long-term incentive
8,190

 
5,770

 
1,665

 

 

Total assets
148,051

 
124,152

 
52,540

 
19,827

 
8,219

Total stockholders’ equity
82,439

 
56,809

 
26,450

 
6,077

 
1,909

 
 
 
 
 
 
 
 
 
 
Consolidated Statements of Cash Flows Data:
 
 
 
 
 
 
 
 
 
Net cash provided by (used in):
 
 
 
 
 
 
 
 
 
Operating activities
$
53,174

 
$
81,326

 
$
30,613

 
$
10,686

 
$
2,214

Investing activities
(905
)
 
(3,738
)
 
(339
)
 
(292
)
 
397

Financing activities
(30,595
)
 
(17,471
)
 
(189
)
 
(52
)
 
(3
)
Repurchase of common stock
(23,704
)
 
(16,071
)
 
(4,661
)
 
(52
)
 
(3
)
Income taxes paid, net of refunds
8,791

 
707

 
60

 
71

 
34


26



Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview
 
We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; South Korea; Singapore; Malaysia; Japan; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 10 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.
 
As of December 31, 2016, we were conducting business through 118,960 active members, compared to 109,360 in 2015 and 54,360 in 2014. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia. We have also begun investing some resources in Central and South America.
 
We generate 98% of our net sales from subsidiaries located outside North America, with sales of our Hong Kong subsidiary representing 92% of net sales in the latest fiscal year. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see “Item 1A. Risk Factors,” and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...” and “Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.
 
China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. Increased sales in China that could be derived from obtaining a direct selling license may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers and branch offices. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recorded when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. We bill members for shipping charges and recognize the freight revenue in net sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.
 

27


Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay any commissions. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

through commissions paid on product purchases made by their down-line members; and

through retail markups on sales of products purchased by members at wholesale prices (in some markets, sales are for personal consumption only and income may not be earned through retail mark-ups on sales in that market).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for each of fiscal 2016, 2015 and 2014 represented 44%, 48% and 46%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into agreements for business or market development, which could result in additional compensation to specific members.
 
Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly. 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Sales by our foreign subsidiaries are transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar, see “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” and more specifically under the caption “Foreign Currency Exchange Risk” for further information. 


28


Results of Operations
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated:
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales
100.0
%
 
100.0
%
 
100.0
 %
Cost of sales
19.1

 
20.4

 
21.7

Gross profit
80.9

 
79.6

 
78.3

Operating expenses:
 
 
 
 
 
Commissions expense
43.5

 
47.8

 
45.7

Selling, general and administrative expenses
15.0

 
13.6

 
15.8

Depreciation and amortization
0.1

 
0.1

 
0.1

Total operating expenses
58.6

 
61.5

 
61.6

Income from operations
22.3

 
18.1

 
16.7

Other expense, net

 

 
(0.2
)
Income before income taxes
22.3

 
18.1

 
16.5

Income tax provision
3.1

 
0.2

 
0.2

Net income
19.2
%
 
17.9
%
 
16.3
 %
 
The following table sets forth revenue by market for the periods indicated (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
North America
$
5,909

 
2.0
%
 
$
5,992

 
2.3
%
 
$
2,812

 
2.3
%
Hong Kong1
263,482

 
91.6

 
245,737

 
92.8

 
111,028

 
89.1

China
9,086

 
3.2

 
4,425

 
1.7

 
1,538

 
1.2

Taiwan
6,213

 
2.2

 
5,965

 
2.3

 
4,628

 
3.7

South Korea
691

 
0.2

 
1,128

 
0.4

 
1,009

 
0.8

Japan
86

 

 
92

 

 
89

 
0.1

Singapore
169

 
0.1

 

 

 

 

Russia, Kazakhstan and Ukraine2
858

 
0.3

 
1,139

 
0.4

 
3,113

 
2.5

Europe
1,234

 
0.4

 
382

 
0.1

 
373

 
0.3

Total
$
287,728

 
100.0
%
 
$
264,860

 
100.0
%
 
$
124,590

 
100.0
%
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
2 We discontinued our Ukraine operations during the second quarter of 2015.

Financial Results of 2016 Compared to 2015

Net Sales
 
Net sales were $287.7 million for the year ended December 31, 2016 compared with $264.9 million a year ago, an increase of $22.8 million, or 9%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, increased $17.7 million, or 7%, over the prior year. Hong Kong experienced an increase of 7,800 active members, or 8%, during 2016, which contributed to the increase in product sales volume. We also launched new Wellness products during 2016, which contributed approximately $11.2 million to our top-line growth. However, we believe our net sales increase was adversely impacted by the following:

A primary factor was the special measures the Chinese government implemented in preparation of the G20 Summit in Hangzhou, one of our top markets, in which they relocated city residents, emptied entire districts, blocked urban traffic and shut down businesses in July, August and early September 2016.

29



Also, we did not offer a comparable incentive trip promotion in 2016 as the 2015 supplemental incentive trip promotion to the U.S., which proved to be appealing and contributed to increased sales in 2015.

Finally, the devaluation of the Chinese yuan, which depreciated 7% against the Hong Kong dollar during 2016, indirectly affected our financial results by increasing the product pricing in the currency of our Chinese members.
 
Outside of our Hong Kong business, net sales increased $5.1 million, or 27%, compared with the prior year, driven by a 105% increase in our China e-commerce business and a 223% increase in Europe, offset by the performance of South Korea, which decreased 39% and our Commonwealth of Independent States (“CIS”) market, which decreased 25%. The $4.7 million net sales increase in our China e-commerce business was primarily driven by increased sales in our Home product line, which was introduced during the fourth quarter of 2015. The $852,000 net sales increase in Europe was primarily driven by our Wellness product line.
 
As of December 31, 2016, deferred revenue was $4.9 million, which primarily consisted of $2.2 million in unshipped product orders, and $2.3 million and $430,000 pertaining to auto ship advances and unamortized enrollment package revenue, respectively.
 
Gross Profit
 
Gross profit was 80.9% of net sales for the year ended December 31, 2016 compared with 79.6% of net sales for the year ended December 31, 2015. The gross profit margin percentage increase is due to higher event and training revenue, higher product margins and lower logistics costs.
 
Commissions
 
Commissions were 43.5% of net sales for the year ended December 31, 2016 compared with 47.8% of net sales for the year ended December 31, 2015.  The decrease as a percentage of net sales resulted primarily from the reduction in our on-going cash and other incentive programs which cost 3.0% of net sales for the year ended December 31, 2016 compared with 6.4% of net sales for the year ended December 31, 2015.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $43.2 million for the year ended December 31, 2016 compared with $36.0 million for the year ended December 31, 2015. Selling, general and administrative expenses increased by $7.2 million, or 20%, mainly due to an increase in event costs, member training costs, professional fees, and an increase in credit card fees and assessments due to higher net sales, offset by a decrease in our employee-related expenses, as compared to the year ended December 31, 2015.
 
Income Taxes
 
An income tax provision of $9.0 million was recognized for the year ended December 31, 2016 compared with $552,000 for the year ended December 31, 2015. The increase is due to greater profitability of our international operations, as well as the repatriation of foreign earnings back to the U.S. during the year. As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, we then determined that a portion of our undistributed foreign earnings were no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. In addition, during the three months ended December 31, 2016, we released our remaining valuation allowance against U.S. deferred tax assets as it was determined that it is more likely than not that we will realize the tax benefits of our deferred assets in future periods. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate.


30


Financial Results of 2015 Compared to 2014

Net Sales

Net sales were $264.9 million for the year ended December 31, 2015 compared with $124.6 million a year ago, an increase of $140.3 million, or 113%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, increased $134.7 million, or 121%, over the prior year.  Hong Kong experienced an increase of 54,100 active members, or 116%, during 2015, which is comparable to the increase in net sales. The sales increase in Hong Kong was primarily due to a substantial increase in product sale volumes attributable to the increase in new active members and effectiveness of our leadership development, promotional programs, incentives, events, new products, training, commission plans and services. During 2015, our on-going member cash and incentive programs, including a supplemental incentive trip promotion to the U.S. offered during part of 2015, were more appealing to our members than those offered during the prior year and contributed to increased sales. Additionally, we hosted the largest event in our company’s history in Hong Kong during August 2015, and launched new Wellness products that resulted in additional sales of approximately $7.0 million.
 
Outside of our Hong Kong business, net sales increased $5.6 million, or 41%, compared with the prior year. Double or triple digit percentage sales increases occurred in North America, Taiwan, South Korea and the China e-commerce business. These increases were offset by the performance of our CIS market, which continued to be negatively impacted by the political unrest in the region, as well as the devaluation of the Russian ruble, and decreased $2.0 million, or 63%, compared with the prior year.
 
As of December 31, 2015, deferred revenue was $4.0 million, which primarily consisted of $1.8 million in unshipped product orders, and $1.6 million and $331,000 pertaining to auto ship advances and unamortized enrollment package revenue, respectively.
 
Gross Profit
 
Gross profit was 79.6% of net sales for the year ended December 31, 2015 compared with 78.3% of net sales for the year ended December 31, 2014. The gross profit margin percentage increase was primarily attributable to higher product margins, lower third party service provider fees in Russia and lower logistics costs in Hong Kong.
 
Commissions
 
Commissions were 47.8% of net sales for the year ended December 31, 2015 compared with 45.7% of net sales for the year ended December 31, 2014.  The increase as a percentage of net sales for the year ended December 31, 2015 primarily resulted from an increase in the cost of our on-going member cash and other incentive programs.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $36.0 million for the year ended December 31, 2015 compared with $19.7 million for the year ended December 31, 2014. Selling, general and administrative expenses increased by $16.3 million, or 83%, mainly due to an increase in employee-related costs and incentive program accruals, professional fees, director costs, and facility costs, as well as an increase in credit card fees and assessments due to higher net sales as compared to the year ended December 31, 2014.
 
Income Taxes
 
An income tax provision of $552,000 was recognized for the year ended December 31, 2015 compared with $266,000 for the year ended December 31, 2014. The increase was due to greater profitability of our international operations, as well as the repatriation of foreign earnings back to the U.S. during the year. As a result of capital return activities approved by the Board of Directors during the three months ended September 30, 2015, and anticipated future capital return activities intended to take full advantage of existing U.S. net operating losses, we determined that a portion of our undistributed foreign earnings were no longer deemed reinvested indefinitely by our non-U.S. subsidiaries beginning in the quarter ended September 30, 2015. As such, an accumulated deferred tax liability of $9.3 million was recorded against these undistributed earnings, which included the impact of utilization of foreign tax credits. However, because it was anticipated that these earnings would be offset by U.S. net operating losses that had previously been fully offset by a valuation allowance, we also released a similar amount of valuation allowance. Accordingly, there was no significant impact on the income tax provision for the year ended December 31, 2015.


31


During 2015, $18.4 million in foreign earnings were repatriated back into the U.S. which were offset by U.S. net operating losses. As of December 31, 2015 there was a remaining deferred tax liability of $2.8 million, which was offset by an equivalent amount of net operating loss deferred tax assets. This represented the remaining balance of the U.S. tax impact of undistributed foreign earnings that was planned to be repatriated to the U.S. as of December 31, 2015. All other undistributed foreign earnings were intended to be permanently reinvested in non-U.S. operations to fund and expand the non-U.S. subsidiaries as of December 31, 2015.

Liquidity and Capital Resources
 
At December 31, 2016, our cash and cash equivalents totaled $125.9 million. Total cash and cash equivalents increased by $21.0 million and $60.1 million during 2016 and 2015, respectively. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2016, we had $73.5 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $120.0 million held in bank accounts overseas, which included $6.8 million held in banks located in China subject to foreign currency controls.
 
At December 31, 2016, the ratio of current assets to current liabilities was 2.47 to 1.00 and we had $84.1 million of working capital. Working capital as of December 31, 2016 increased $27.9 million compared to our working capital as of December 31, 2015, primarily due to cash generated from operations.

Cash provided by operations during 2016 was $53.2 million compared to $81.3 million during 2015. The decrease in operating cash flows resulted primarily from the timing of increased commission-related payments, the increase of our members' utilization of our eWallet functionality and U.S. income tax payments resulting from the repatriation of overseas profits of $7.4 million, offset by a reduction in our inventory purchases and increased net income during 2016.

Cash flows used in investing activities totaled $905,000 during 2016. Software development costs of $666,800 were incurred during the year ended December 31, 2016 for our Oracle ERP upgrade and enhancement of our back office software platform. Cash flows used in investing activities totaled $3.7 million during the year ended December 31, 2015 and consisted primarily of our June 2015 funding of a bank deposit amount in the amount of CNY 20 million (USD $3.3 million at June 30, 2015) for our direct selling license application. Such deposit is required by Chinese laws to establish a consumer protection fund. In August 2015, cash deposits in the amount of $218,000 were received from certain South Korean credit card processing companies. Additionally, buildout costs of $608,000 were incurred during 2015 for new offices located in California, Hong Kong and Singapore, at the multi-purpose facility in Zhongshan, China and at the new Healthy Lifestyle Center in Monterey Park, California.

Cash flows used in financing activities during 2016 totaled $30.6 million. We used $23.7 million to repurchase shares of our common stock. On January 12, 2016, the Board of Directors authorized an increase to our stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that our earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, we may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require us to acquire a specific number of shares, and may be suspended from time to time or discontinued. During February 2016, pursuant to the stock repurchase program, we authorized our broker to proceed with the purchase of shares of our common stock in the open market. During the year ended December 31, 2016, the stock repurchase program resulted in our purchasing a total of 903,031 shares of our common stock for an aggregate purchase price of $23.7 million, plus transaction costs. As of December 31, 2016, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax. Cash flows used in financing activities during 2015 totaled $17.5 million, and consisted primarily of $16.1 million used to repurchase a total of 547,042 shares of our common stock and $1.7 million in cash dividends.


32


Other financing cash flows during 2016 included the following cash dividend payments (in thousands, except per share amounts) to holders of our common stock:
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 15, 2016
 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 15, 2016
 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 16, 2016
 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 10, 2016
 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 16, 2016
 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
 
 

Subsequent to December 31, 2016, on January 24, 2017, the Board of Directors declared a cash dividend of $0.09 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends were paid on March 3, 2017 to stockholders of record on February 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.
 
We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 
We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application. We have also begun to invest some resources in Central and South America.

Quarterly Results of Operations (Unaudited)

The following table sets forth unaudited quarterly operating results for each of the last eight fiscal quarters. The information for each of these quarters has been prepared on the same basis as the audited annual financial statements included elsewhere in this annual report and, in the opinion of management, includes all adjustments, which includes only normal recurring adjustments, necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements and related notes included in “Item 8. Financial Statements and Supplementary Data” of this annual report. These quarterly operating results are not necessarily indicative of our operating results for any future period.
 
2016
 
2015
 
4th
Quarter
 
3rd
Quarter
 
2nd
Quarter
 
1st
Quarter
 
4th
Quarter
 
3rd
Quarter
 
2nd
Quarter
 
1st
Quarter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(In Thousands, Except Per Share Data)
Net sales
$
62,312

 
$
70,679

 
$
80,391

 
$
74,346

 
$
73,656

 
$
80,779

 
$
69,716

 
$
40,709

Gross profit
50,375

 
57,052

 
65,332

 
60,066

 
58,583

 
64,778

 
55,622

 
31,779

Income from operations
20,014

 
15,208

 
14,927

 
13,987

 
13,893

 
14,803

 
12,263

 
6,918

Net income
19,048

 
12,557

 
12,201

 
11,280

 
13,699

 
14,531

 
12,273

 
6,738

Income per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
1.70

 
1.12

 
1.08

 
0.96

 
1.13

 
1.19

 
0.99

 
0.54

Diluted
1.70

 
1.12

 
1.07

 
0.95

 
1.13

 
1.18

 
0.98

 
0.54



33


Contractual Obligations

The following table summarizes our contractual obligations as of December 31, 2016 and the expected effect on our cash flow and liquidity in future periods (in thousands):
 
 
Total
 
2017
 
2018-2019
 
2020-2021
 
Thereafter
Operating leases
 
$
3,923

 
$
1,559

 
$
1,154

 
$
510

 
$
700

Purchase obligations
 
20,745

 
9,725

 
11,020

 

 

Long-term incentive
 
10,064

 
1,874

 
2,390

 
1,963

 
3,837

Other commitments
 
357

 
107

 
163

 
87

 

Total
 
$
35,089

 
$
13,265

 
$
14,727

 
$
2,560

 
$
4,537


We have entered into non-cancelable operating lease agreements for locations within the United States and for our international subsidiaries, with expirations through September 2025 totaling $3.9 million.
 
In May 2013, we entered into an exclusive distribution agreement with one of our suppliers to purchase their product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, we are required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2016, we were in compliance with the exclusivity provision.
 
In February 2016, we amended a supply agreement with one of our suppliers to maintain worldwide exclusivity in return for purchasing a minimum of $9.4 million of product annually on average over the next three years, plus certain raw material guarantees. If we do not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is three years commencing February 2016 and shall automatically renew for successive three year terms unless notice of termination is provided by either party.

In recognition of the achievement of specified performance goals, financial rewards are awarded under our 2014 Long-Term Incentive Plan with cash payments through December 2023. See Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for additional information.

We have evaluated our tax positions and have determined that there are no uncertain tax positions for the current year or years prior.
 
We have employment agreements with certain members of our management team that can be terminated by either the employee or us upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to sales returns, member commissions and income taxes.


34


Revenue Recognition.  Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $2.2 million and $1.8 million at December 31, 2016 and 2015, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal. At December 31, 2016 and 2015, enrollment package revenue totaling $430,000 and $331,000 was deferred, respectively. Although we have no immediate plans to significantly change the terms or conditions of enrollment packages, any changes in the future could result in additional revenue deferrals or could cause us to recognize the deferred revenue over a longer period of time. Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $2.3 million and $1.6 million at December 31, 2016 and 2015, respectively.
 
Allowance for Sales Returns. An allowance for sales returns is provided during the period the product is shipped.  The allowance is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 2% and 1% of sales for the years ended December 31, 2016 and 2015, respectively.  The allowance for sales returns was $1.6 million at December 31, 2016 and 2015.  No material changes in estimates have been recognized during the periods presented.
 
Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  These incentives may be both monetary and non-monetary in nature.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $13.6 million and $19.6 million at December 31, 2016 and 2015, respectively.
 
Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of December 31, 2016, we no longer have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.


35


Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of December 31, 2016, we recorded a deferred tax liability for earnings that we plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2016.

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have operations both internationally and within the United States, and we are exposed to market risks in the ordinary course of our business. These risks include primarily interest rate, foreign exchange and inflation risks.

Interest Rate Fluctuation Risk

Our cash and cash equivalents consist of cash, available-for-sale securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The primary objective of our investment in available-for-sale securities is to preserve principal while maximizing income without significantly increasing risk. Because our cash and cash equivalents have a relatively short maturity, our portfolio's fair value is relatively insensitive to interest rate changes. In future periods, we will continue to evaluate our investment policy relative to our overall objectives.

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and expenses denominated in currencies other than the U.S. dollar. Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar. Our foreign currency exchange rate exposure to South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Canadian dollar, and European euro represented approximately 7%, 6% and 10% of our revenue during the years ended December 31, 2016, 2015 and 2014, respectively. We have experienced and will continue to experience fluctuations in our net income as a result of transaction gains and losses related to translating certain balances denominated in currencies other than the U.S. dollar.

Our foreign currency exchange rate exposure may increase in the near future as we further develop opportunities in Southeast Asia, Canada, Central America, South America and Europe. Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar. We also experience indirect exchange rate exposure due to the recent devaluation of the Chinese yuan, which has depreciated 7% against the Hong Kong dollar and has eroded our Chinese members purchasing power. Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition. Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.



36


Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

NATURAL HEALTH TRENDS CORP.
 
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

37


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  
Board of Directors and Stockholders
Natural Health Trends Corp.
Rolling Hills Estates, California
 
We have audited the accompanying consolidated balance sheets of Natural Health Trends Corp. (the “Company”) as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016. We also have audited the Company’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Management's Annual Report on Internal Control over Financial Reporting”. Our responsibility is to express an opinion on these financial statements and an opinion on the Company’s internal control over financial reporting based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
 
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Natural Health Trends Corp. as of December 31, 2016 and 2015, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
 
 
/s/ Lane Gorman Trubitt, LLC
 
Dallas, Texas
March 10, 2017


38


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)
 
 
December 31,
 
2016
 
2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
125,921

 
$
104,914

Inventories, net
11,257

 
10,455

Other current assets
4,066

 
2,343

Total current assets
141,244

 
117,712

Property and equipment, net
1,388

 
894

Goodwill
1,764

 
1,764

Restricted cash
2,963

 
3,166

Other assets
692

 
616

Total assets
$
148,051

 
$
124,152

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
2,145

 
$
2,862

Income taxes payable
663

 
379

Accrued commissions
13,611

 
19,634

Other accrued expenses
14,989

 
16,703

Deferred revenue
4,948

 
4,011

Amounts held in eWallets
19,165

 
16,414

Other current liabilities
1,633

 
1,510

Total current liabilities
57,154

 
61,513

Deferred tax liability
268

 
60

Long-term incentive
8,190

 
5,770

Total liabilities
65,612

 
67,343

Commitments and contingencies

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and 2015

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2016 and 2015
13

 
13

Additional paid-in capital
86,574

 
85,963

Retained earnings (accumulated deficit)
38,548

 
(9,647
)
Accumulated other comprehensive loss
(807
)
 
(101
)
Treasury stock, at cost; 1,692,218 and 840,202 shares at December 31, 2016 and 2015, respectively
(41,889
)
 
(19,419
)
Total stockholders’ equity
82,439

 
56,809

Total liabilities and stockholders’ equity
$
148,051


$
124,152

 
See accompanying notes to consolidated financial statements.

39


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales
$
287,728

 
$
264,860

 
$
124,590

Cost of sales
54,903

 
54,098

 
26,981

Gross profit
232,825


210,762

 
97,609

Operating expenses:
 
 
 
 
 
Commissions expense
125,050

 
126,598

 
56,997

Selling, general and administrative expenses
43,245

 
36,024

 
19,687

Depreciation and amortization
394

 
263

 
105

Total operating expenses
168,689

 
162,885

 
76,789

Income from operations
64,136

 
47,877

 
20,820

Other expense, net
(59
)
 
(84
)
 
(184
)
Income before income taxes
64,077

 
47,793

 
20,636

Income tax provision
8,991

 
552

 
266

Net income
55,086


47,241

 
20,370

Preferred stock dividends

 

 
(10
)
Net income available to common stockholders
$
55,086

 
$
47,241

 
$
20,360

Income per common share:
 
 
 
 
 
Basic
$
4.84

 
$
3.84

 
$
1.67

Diluted
$
4.83

 
$
3.82

 
$
1.61

Weighted-average number of common shares outstanding:
 
 
 
 
 
Basic
11,382

 
12,302

 
12,131

Diluted
11,407

 
12,372

 
12,600

Cash dividends declared per common share
$
0.61

 
$
0.14

 
$
0.03

 
See accompanying notes to consolidated financial statements.


40


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In Thousands)
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net income
$
55,086

 
$
47,241

 
$
20,370

Other comprehensive income (loss), net of tax:
 
 
 
 
 
Foreign currency translation adjustments
(838
)
 
(79
)
 
143

Release of cumulative translation adjustment
132

 
(82
)
 

Net change in foreign currency translation adjustment
(706
)
 
(161
)
 
143

Unrealized losses on available-for-sale securities

 
(2
)
 

Comprehensive income
$
54,380

 
$
47,078

 
$
20,513

 
See accompanying notes to consolidated financial statements.


41


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In Thousands, Except Share Data)
 
Preferred Stock
 
Common Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
(Accumulated Deficit)
 
Accumulated
Other
Comprehensive
(Loss) Income
 
Treasury Stock
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
Total
BALANCE, December 31, 2013
123,693

 
$
111

 
11,359,769

 
$
11

 
$
80,690

 
$
(74,619
)
 
$
(81
)
 
(26,998
)
 
$
(35
)
 
$
6,077

Net income

 

 

 

 

 
20,370

 

 

 

 
20,370

Conversion of Series A preferred stock
(123,693
)
 
(111
)
 
123,693

 

 
111

 

 

 

 

 

Exercise of warrants

 

 
1,407,855

 
2

 
4,946

 

 

 

 

 
4,948

Repurchase of common stock

 

 

 

 

 

 

 
(382,564
)
 
(4,661
)
 
(4,661
)
Common stock issued

 

 

 

 
(46
)
 
(74
)
 

 
25,342

 
120

 

Dividends declared

 

 

 

 

 
(476
)
 

 

 

 
(476
)
Foreign currency translation adjustments

 

 

 

 

 

 
143

 

 

 
143

Stock-based compensation

 

 

 

 
49

 

 

 

 

 
49

BALANCE, December 31, 2014

 

 
12,891,317

 
13

 
85,750

 
(54,799
)
 
62

 
(384,220
)
 
(4,576
)
 
26,450

Net income

 

 

 

 

 
47,241

 

 

 

 
47,241

Exercise of warrants

 

 
88,097

 

 
309

 

 

 

 

 
309

Repurchase of common stock

 

 

 

 

 

 

 
(547,042
)
 
(16,071
)
 
(16,071
)
Common stock issued

 

 

 

 
(182
)
 
(380
)
 

 
91,060

 
1,228

 
666

Dividends declared

 

 

 

 

 
(1,709
)
 

 

 

 
(1,709
)
Elimination of CTA upon dissolution

 

 

 

 

 

 
(82
)
 

 

 
(82
)
Foreign currency translation adjustments

 

 

 

 

 

 
(79
)
 

 

 
(79
)
Unrealized loss on available-for-sale securities

 

 

 

 

 

 
(2
)
 

 

 
(2
)
Stock-based compensation

 

 

 

 
86

 

 

 

 

 
86

BALANCE, December 31, 2015

 

 
12,979,414

 
13

 
85,963

 
(9,647
)
 
(101
)
 
(840,202
)
 
(19,419
)
 
56,809

Net income

 

 

 

 

 
55,086

 

 

 

 
55,086

Repurchase of common stock

 

 

 

 

 

 

 
(903,031
)
 
(23,704
)
 
(23,704
)
Common stock issued

 

 

 

 
507

 

 

 
51,015

 
1,234

 
1,741

Dividends declared

 

 

 

 

 
(6,891
)
 

 

 

 
(6,891
)
Elimination of CTA upon dissolution

 

 

 

 

 

 
132

 

 

 
132

Foreign currency translation adjustments

 

 

 

 

 

 
(838
)
 

 

 
(838
)
Stock-based compensation

 

 

 

 
104

 

 

 

 

 
104

BALANCE, December 31, 2016

 
$

 
12,979,414

 
$
13

 
$
86,574

 
$
38,548

 
$
(807
)
 
(1,692,218
)
 
$
(41,889
)
 
$
82,439

 
See accompanying notes to consolidated financial statements. 

42


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
 
 
Net income
$
55,086

 
$
47,241

 
$
20,370

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
Depreciation and amortization
394

 
263

 
105

Stock-based compensation
104

 
86

 
49

Cumulative translation adjustment realized in net income
132

 
(82
)
 

Deferred income taxes
217

 
(15
)
 
(43
)
Changes in assets and liabilities:
 
 
 
 
 
Inventories, net
(851
)
 
(6,762
)
 
(2,029
)
Other current assets
(1,681
)
 
(1,025
)
 
(501
)
Other assets
(90
)
 
(267
)
 
(85
)
Accounts payable
(714
)
 
637

 
(822
)
Income taxes payable
303

 
(115
)
 
243

Accrued commissions
(6,031
)
 
10,840

 
5,077

Other accrued expenses
51

 
10,714

 
3,706

Deferred revenue
947

 
1,331

 
147

Amounts held in eWallets
2,752

 
14,350

 
2,065

Other current liabilities
135

 
25

 
666

Long-term incentive
2,420

 
4,105

 
1,665

Net cash provided by operating activities
53,174

 
81,326

 
30,613

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
 
 
Purchases of property and equipment
(905
)
 
(710
)
 
(339
)
Increase in restricted cash

 
(3,028
)
 

Net cash used in investing activities
(905
)
 
(3,738
)
 
(339
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
 
 
Proceeds from exercise of warrants

 
309

 
4,948

Repurchase of common stock
(23,704
)
 
(16,071
)
 
(4,661
)
Dividends paid
(6,891
)
 
(1,709
)
 
(476
)
Net cash used in financing activities
(30,595
)
 
(17,471
)
 
(189
)
Effect of exchange rates on cash and cash equivalents
(667
)
 
(19
)
 
181

Net increase in cash and cash equivalents
21,007


60,098

 
30,266

CASH AND CASH EQUIVALENTS, beginning of period
104,914

 
44,816

 
14,550

CASH AND CASH EQUIVALENTS, end of period
$
125,921

 
$
104,914

 
$
44,816

 
See accompanying notes to consolidated financial statements.


43


NATURAL HEALTH TRENDS CORP.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Nature of Operations
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; South Korea; Singapore; Malaysia; Japan; and Europe. The Company also operates in Russia and Kazakhstan through its engagement with a local service provider.

 In September 2015, the Company relocated its corporate headquarters from Dallas, Texas to Rolling Hills Estates, California.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
 
Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Reclassification
 
Certain accounts receivable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. No change in total current assets occurred. Additionally, deferred tax liability balances have been reclassified from current to long-term in the prior year consolidated financial statements to conform to the early adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes.

Cash and Cash Equivalents
 
As of December 31, 2016, cash and cash equivalents include $6.8 million held in banks located within China subject to foreign currency controls. The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.


44


Additionally, as of December 31, 2016, cash and cash equivalents include the Company's investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2016 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders' equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
 
Cash and cash equivalents at the end of each period were as follows (in thousands):
 
 
December 31,
 
2016
 
2015
Cash
$
52,453

 
$
47,431

Cash equivalents
73,468

 
57,483

Total cash and cash equivalents
$
125,921

 
$
104,914


 
The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 2.9 million at December 31, 2016) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
 
Inventories
 
Inventories consist primarily of finished goods and are stated at the lower of cost or market, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. At December 31, 2016 and 2015, the reserve for obsolescence totaled $82,000, and $29,000, respectively.
 
Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment and office software and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
 

45


Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
 
Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in eWallets
 
Commencing in October 2014, the Company requires commission payments of certain members in Hong Kong to be first deposited into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available funds and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As such, certain installments to be paid are reflected on the balance sheet as a non-current liability, and the current portion of the installments is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 5 for grant information of distributions settled in common stock.
 
Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $333,000, $204,000 and $202,000 was recognized during 2016, 2015 and 2014, respectively.
 

46


Revenue Recognition
 
Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
 
Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  These incentives may be both monetary and non-monetary in nature.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. From time to time the Company also enters into agreements for business or market development, which may result in additional compensation to specific members.

Operating Leases

The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.

Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
 

47


Income Per Share
 
Basic income per share for 2014 was computed via the “two-class” method by dividing net income allocated to common stockholders by the weighted-average number of common shares outstanding during the period. Net income available to common stockholders is allocated to both common stock and participating securities as if all of the income for the period had been distributed. The Company’s Series A convertible preferred stock was a participating security due to its participation rights related to dividends declared by the Company. If dividends were distributed to common stockholders, the Company was also required to pay dividends to the holders of the preferred stock in an amount equal to the greater of (1) the amount of dividends then accrued and not previously paid on such shares of preferred stock or (2) the amount payable if dividends were distributed to the common stockholders on an as-converted basis.
 
Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. For 2014, the dilutive effect of the Company’s Series A convertible preferred stock was calculated using the more dilutive of the “two-class” method and the “if-converted” method, which assumes that the preferred stock was converted into common stock at the beginning of each period presented.

 All shares of the Company’s Series A convertible preferred stock were converted into shares of common stock in December 2014. Warrants to purchase 88,097 shares of common stock were still outstanding at December 31, 2014. Such warrants were exercised during April 2015.

The following table illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
55,086

 
 

 
 

 
$
47,241

 
 

 
 

 
$
20,360

 
 

 
 

Less: undistributed earnings to participating securities

 
 

 
 

 

 
 

 
 

 
(127
)
 
 

 
 

Net income allocated to common stockholders
$
55,086


11,382

 
$
4.84

 
$
47,241

 
12,302

 
$
3.84

 
$
20,233

 
12,131

 
$
1.67

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 

 

 
21

 
 

 

 
421

 
 

Non-vested restricted stock

 
25

 
 

 

 
49

 
 

 

 
48

 
 

Plus: reallocation of undistributed earnings to participating securities

 
 

 
 

 

 
 

 
 

 
5

 
 

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income allocated to common stockholders plus assumed conversions
$
55,086

 
11,407

 
$
4.83

 
$
47,241

 
12,372

 
$
3.82

 
$
20,238

 
12,600

 
$
1.61


 
Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. For the year ended December 31, 2016, 345 shares of non-vested restricted stock were not included as their effect would have been anti-dilutive.


48


Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 10). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company believes that its e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of the Company's products by members in China. The Company also believes that its Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with the Company’s interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that the Company’s activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 
Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, Chinese nationals collaborating with short traders to damage the Company's business and activities by individual members that may violate laws notwithstanding the Company’s strict policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.
 
The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.
 
Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.


49


Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2016
 
December 31, 2015
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
43,490

 
$

 
$
43,490

 
$
35,222

 
$
2

 
$
35,224

Corporate debt securities
1,673

 
(2
)
 
1,671

 
5,029

 
(5
)
 
5,024

Financial institution instruments
28,307

 

 
28,307

 
17,235

 

 
17,235

Total available-for-sale investments
$
73,470

 
$
(2
)
 
$
73,468

 
$
57,486

 
$
(3
)
 
$
57,483


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.

Recently Issued and Adopted Accounting Pronouncements

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Under this guidance, entities are required to present deferred tax tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities are permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and will be applied prospectively.  Early adoption is permitted. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements.


50


In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
 
2.     BALANCE SHEET COMPONENTS
 
The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2016
 
2015
Property and equipment:
 
 
 
Office equipment
$
517

 
$
495

Office software
672

 
536

Machinery
28

 
24

Furniture and fixtures
241

 
222

Leasehold improvements
840

 
730

Construction in progress (including internal use software development costs)
157

 
10

Property and equipment, at cost
2,455

 
2,017

Accumulated depreciation and amortization
(1,067
)
 
(1,123
)
 
$
1,388

 
$
894

Other accrued expenses:
 
 
 
Sales returns
$
1,632

 
$
1,552

Employee-related expense
10,541

 
11,064

Warehousing, inventory-related and other
2,816

 
4,087

 
$
14,989

 
$
16,703

Deferred revenue:
 

 
 

Unshipped product
$
2,191

 
$
1,783

Auto ship advances
2,327

 
1,597

Enrollment package revenue
430

 
331

Market development fees

 
300

 
$
4,948

 
$
4,011



3.     COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was $1.8 million, $1.5 million and $777,000 during 2016, 2015 and 2014, respectively.
 

51


Future minimum lease obligations as of December 31, 2016 are as follows (in thousands):
2017
$
1,559

2018
752

2019
402

2020
314

2021
196

Thereafter
700

Total minimum lease obligations
$
3,923



Purchase Commitments

In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2016, the Company was in compliance with the exclusivity provision.
 
In February 2016, the Company amended a supply agreement with one of its suppliers to maintain worldwide exclusivity in return for purchasing a minimum of $9.4 million of product annually on average over the next three years, plus certain raw material guarantees. If the Company does not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is three years commencing February 2016 and shall automatically renew for successive three year terms unless notice of termination is provided by either party.

Employment Agreements
 
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.
 
Consumer Indemnity
 
As required by the Door-to-Door Sales Act in South Korea, the Company maintains insurance for consumer indemnity claims with a mutual aid cooperative by possessing a mutual aid contract with Mutual Aid Cooperative & Consumer (the “Cooperative”). The contract secures payment to members in the event that the Company is unable to provide refunds to members. Typically, requests for refunds are paid directly by the Company according to the Company’s normal Korean refund policy, which requires that refund requests be submitted within three months. Accordingly, the Company estimates and accrues a reserve for product returns based on this policy and its historical experience. Depending on the sales volume, the Company may be required to increase or decrease the amount of the contract. The maximum potential amount of future payments the Company could be required to make to address actual member claims under the contract is equivalent to three months of rolling sales. At December 31, 2016, non-current other assets include KRW 223 million (USD $185,000) underlying the contract, which can be utilized by the Cooperative to fund any outstanding member claims. The Company believes that the likelihood of utilizing these funds to provide for members claims is remote.


52


Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives. On March 29, 2016, the court consolidated these actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and (ii) Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of its motion to dismiss on August 22, 2016. On December 5, 2016, the Court denied the Company’s motion to dismiss. On February 17, 2017, the Company filed an answer to the consolidated complaint. The Company believes that these claims are without merit and intends to vigorously defend against them.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 8, 2017. The Company believes that these claims are without merit and intend to vigorously defend against them.

The consolidated class action and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.

4.     STOCKHOLDERS’ EQUITY
 
Authorized Shares
 
The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value. On May 4, 2007, the Board of Directors designated up to 1,761,900 shares of preferred stock as Series A preferred stock with the following rights and preferences:

Priority – the Series A preferred stock shall rank, in all respects, including the payment of dividends and upon liquidation, senior and prior to the common stock and other equity of the Company not expressly made senior or pari passu with the Series A preferred stock (collectively, “Junior Securities”).


53


Dividends –dividends at the rate per annum of $0.119 per share shall accrue from the date of issuance of any shares of Series A preferred stock, payable upon declaration by the Board of Directors. Accruing dividends shall be cumulative; provided, however, that except as set forth below for the liquidation preference, the Company shall be under no obligation to pay such dividends. No dividends shall be declared on Junior Securities (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Series A preferred stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series A preferred stock in an amount at least equal to the greater of (i) the amount of the aggregate accrued dividends on such share of Series A preferred stock and not previously paid and (ii) in the case of a dividend on common stock or any class or series of Junior Securities that is convertible into common stock, that dividend per share of Series A preferred stock as would equal the product of (1) the dividend payable on each share as if all shares of such class or series had been converted into common stock and (2) the number of shares of common stock issuable upon conversion of a share of Series A preferred stock.

Liquidation preference – in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, then, before any distribution or payment shall be made to the holders of any Junior Securities, the holders of the Series A preferred stock then outstanding shall be entitled to be paid in cash out of the assets of the Company available for distribution to its stockholders (on a pari passu basis with the holders of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock) an amount per share equal to the sum of the Series A Original Issue Price plus any dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon. If the assets of the Company are insufficient to pay the aggregate liquidation preference and the liquidation preference of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock, the holders of the Series A preferred stock and the holders of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock shall share ratably with one another in any such distribution or payment in proportion to the full amounts to which they would otherwise be respectively entitled before any distribution shall be made to the holders of the Junior Securities. The “Series A Original Issue Price” shall mean $1.70 per share, subject to adjustment.

Voting rights – the holders of shares of Series A preferred stock shall be entitled to vote with the holders of the common stock, and with the holders of any other series of preferred stock, voting together as a single class, upon all matters submitted to a vote of stockholders of the Company. Each holder of shares of Series A preferred stock shall be entitled to the number of votes equal to the product (rounded down to the nearest number of whole shares) of 0.729 times the largest number of shares of common stock into which all shares of Series A preferred stock held of record by such holder could then be converted.

 Conversion – each share of Series A preferred stock shall be convertible, subject to adjustment only in the event of stock splits, stock dividends, recapitalizations and similar events that would affect all of stockholders, at the option of the holder thereof, at any time and from time to time, into such number of fully paid and nonassessable shares of common stock as determined by dividing the Series A Original Issue Price by the Series A Conversion Price (as defined) in effect at the time of conversion. The “Series A Conversion Price” shall initially be equal to $1.70. Each share of Series A preferred stock shall automatically be converted into shares of common stock at the then effective conversion price immediately upon such date as the average closing price of the common stock over a consecutive, trailing 6-month period equals or exceeds $10.00 per share.

On December 3, 2014, the Company filed a Certificate of Elimination of the Series A Convertible Preferred Stock (the “Certificate”) with the Secretary of State of the State of Delaware. The Certificate, which was effective upon filing, canceled the Company’s Series A preferred stock. At the time of filing the Certificate, no shares of Series A preferred stock remained outstanding as a result of the automatic conversion of all outstanding shares into the Company’s common stock due to the fact that the average closing price of the Company’s common stock equaled or exceeded $10.00 per share over a consecutive, trailing 6-month period that ended November 18, 2014.
 

54


Common Stock Purchase Warrants
 
On October 19, 2007, the Company issued warrants to purchase 3,141,499 shares of common stock in connection with a convertible debentures financing. The warrants consisted of seven-year warrants to purchase 1,495,952 shares of common stock, one-year warrants to purchase 1,495,952 shares of common stock, and five-year warrants to purchase 149,595 shares of common stock. The term for each of the warrants began six months and one day after their respective issuance and each have an exercise price of $3.52 per share. The exercise price and the number of shares underlying the warrants are subject to adjustment for stock dividends and splits, combinations, and reclassifications, certain rights offerings and distributions to common stockholders, and mergers, consolidations, sales of all or substantially all assets, tender offers, exchange offers, reclassifications or compulsory share exchanges. In addition, subject to certain exceptions, the exercise price and number of shares underlying the warrants are subject to anti-dilution adjustments from time to time if the Company issues its common stock or equivalent securities at below the exercise price for the warrants. If, at any time after the earlier of October 19, 2008 and the completion of the then applicable holding period under Rule 144, there is no effective registration statement for the underlying shares of common stock that are then required to be registered, the warrants may be exercised by means of a cashless exercise. Such one-year warrants expired unexercised on April 21, 2009 and such five-year warrants expired unexercised on April 21, 2013. Seven-year warrants to purchase 1,407,855 shares of common stock were exercised during 2014 at exercise prices ranging from $3.5108 to $3.52 per share for total proceeds of $4.9 million. As a result of the cash dividends declared on each share of outstanding common stock and in accordance with the terms of the related warrant agreement, the exercise price per share for each warrant was adjusted from $3.52 per share to $3.5082 per share. In April 2015, the remaining warrants to purchase 88,097 shares of common stock were exercised at $3.5043 per share for total proceeds of $309,000.
 
Dividends
 
The following tables summarize the Company’s cash dividend activity during 2016, 2015 and 2014 (in thousands, except per share data):

Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 

 
 
Dividends Per Share
 
 
 
 
Declaration Date
 
Preferred
 
Common
 
Amount
 
Payment Date
November 4, 2014
 
$
0.032

 
$
0.010

 
$
128

 
December 3, 2014
July 29, 2014
 
0.027

 
0.010

 
127

 
August 27, 2014
May 6, 2014
 
0.020

 
0.005

 
62

 
June 4, 2014
March 7, 2014
 
0.815

 
0.005

 
159

 
April 8, 2014
Total
 
$
0.894

 
$
0.030

 
$
476

 
 

 
Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


55


Treasury Stock

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the year ended December 31, 2016, the Company purchased a total of 903,031 shares of its common stock for an aggregate purchase price of $23.7 million, plus transaction costs. As of December 31, 2016, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

On July 28, 2015, the Board of Directors approved a stock repurchase program of up to $15.0 million of the Company’s outstanding shares of common stock. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, are anticipated to be conducted through December 2016, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act.  For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases.  The repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. In connection therewith, the Company was advised that George K. Broady, a director of the Company and owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 8.

During August 2015, pursuant to the foregoing stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million. The open market repurchases were completed on August 4, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 162,442 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. During October 2015, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.6 million. The open market repurchases were completed on October 30, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 106,264 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs.

On May 4, 2015, the Board of Directors approved a separate, prior stock repurchase program of up to $5.0 million of the Company’s outstanding shares of common stock.  In connection therewith, the Company was advised by Mr. Broady that he would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest (see Note 8). As such, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, was completed on May 13, 2015, and resulted in the Company purchasing a total of 186,519 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. 

On January 22, 2015, the Company entered into a stock repurchase agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased (see Note 8). The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock is publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million.
 

56


On November 4, 2014, the Board of Directors approved a special stock repurchase program of up to $5.0 million of the Company’s outstanding shares of common stock (the “Repurchase Plan”). In connection therewith, the Company was advised that Mr. Broady desired to participate in the Repurchase Plan on a basis roughly proportional to his family’s ownership interest, with an estimate of generating approximately $1.5 million through the sale of a portion of the shares of the Company’s common stock held by him (see Note 8). After noting Mr. Broady’s participation interest, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.0 million in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The Repurchase Plan was completed on December 17, 2014. The Repurchase Plan, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 359,840 shares of its common stock for an aggregate purchase price of $4.5 million, plus transaction costs. 
 
On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase 100,000 shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing shares in December 2012. The latest 10b5-1 plan terminated in November 2014 and the Company, as Trustee, has not entered into a new 10b5-1 plan. See Note 5.

5.     STOCK-BASED COMPENSATION
 
Stock-based compensation expense totaled approximately $104,000, $86,000 and $49,000 for 2016, 2015 and 2014, respectively. No tax benefits were attributed to the stock-based compensation because a valuation allowance was maintained for substantially all net deferred tax assets. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted.

On April 8, 2016, the Company initially granted 51,015 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(12,759
)
 
34.13

Nonvested at December 31, 2016
38,256

 
34.13


On January 20, 2015, the Company’s Board of Directors granted 60,960 shares of restricted common stock to certain employees and its then-existing outside directors for the purpose of further aligning their interest with those of its stockholders and as to the employee shares, settling fiscal 2014 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances. On February 11, 2015, the Board of Directors granted an additional 6,116 shares of restricted common stock to its newly-elected outside directors subject to the same conditions.


57


The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2014

 
$

Granted
67,076

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2015
44,712

 
12.15

Granted

 

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2016
22,348

 
12.15


 
As of December 31, 2016, total unrecognized stock-based compensation expense related to non-vested restricted stock was $38,000, which is expected to be recognized over a weighted-average period of one year.

On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase 100,000 shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing in December 2012. The latest 10b5-1 plan terminated in November 2014, and the Company, as Trustee, did not enter into a new 10b5-1 plan. The employees received the stock as incentive compensation in quarterly increments over three years beginning March 15, 2013, provided that they were employees of the Company on the date of the distribution. Any common stock that was forfeited by an employee whose employment terminated was delivered to the Company and held as treasury stock.
 
Shares
 
Wtd. Avg. Grant-Date Fair Value
Nonvested at December 31, 2013
53,324

 
$
1.37

Vested
(25,342
)
 
1.37

Forfeited
(3,998
)
 
1.37

Nonvested at December 31, 2014
23,984

 
1.37

Vested
(23,984
)
 
1.37

Forfeited

 

Nonvested at December 31, 2015

 



6.     INCOME TAXES
 
The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Domestic
$
(3,106
)
 
$
(7,820
)
 
$
4,502

Foreign
67,183

 
55,613

 
16,134

Income before income taxes
$
64,077

 
$
47,793

 
$
20,636


 

58


The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Current:
 
 
 
 
 
Federal
$
7,151

 
$
12

 
$
104

State
(81
)
 
100

 
11

Foreign
1,648

 
456

 
194

Total current taxes
8,718

 
568

 
309

Deferred taxes
273

 
(16
)
 
(43
)
Income tax provision
$
8,991

 
$
552

 
$
266



A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Income tax at federal statutory rate
$
22,427

 
$
16,250

 
$
7,016

Effect of permanent differences
12,496

 
370

 
9

Change in valuation allowance
(3,877
)
 
2,017

 
(2,070
)
Foreign rate differential
(21,713
)
 
(18,099
)
 
(5,240
)
Other reconciling items
(342
)
 
14

 
551

Income tax provision
$
8,991

 
$
552

 
$
266


 
Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2016
 
2015
 
2014
Cayman Islands
%
 
$
58,169

 
$
50,993

 
$
16,267

Hong Kong
16.5
%
 
3,992

 
2,645

 
1,129

China
25.0
%
 
3,855

 
1,493

 
153




59


Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Deferred tax assets:
 
 
 
Net operating losses
$
235

 
$
3,197

Stock-based compensation
623

 

Accrued expenses
3,174

 
3,367

Tax credits

 
418

Other

 
32

Total deferred tax assets
4,032

 
7,014

Valuation allowance
(235
)
 
(4,112
)
Net deferred tax assets
3,797

 
2,902

Deferred tax liabilities:
 
 
 
Foreign earnings
(3,650
)
 
(2,789
)
Other
(415
)
 
(173
)
Total deferred tax liabilities
(4,065
)
 
(2,962
)
Net deferred tax liability
$
(268
)
 
$
(60
)


As of December 31, 2016, the Company has released its valuation allowance against its U.S. deferred tax assets. In addition to having a net deferred tax liability and no indefinite lived intangibles, the Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets in future periods or carryback years.

As of December 31, 2016, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall deferred tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. As of December 31, 2016, the Company has no U.S. federal net operating loss or credit carryforwards as any remaining attributes are expected to be fully utilized to offset tax in the current year.

At December 31, 2016, the Company has foreign net operating loss carryforwards of approximately $1.3 million in various jurisdictions with various expirations.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of December 31, 2016, the Company has recorded a deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2016.

The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.


60


7.     SUPPLEMENTAL CASH FLOW INFORMATION
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
 
 
 
 
 
Cash paid during the year for:
(In Thousands)
Income taxes, net of refunds
$
8,791

 
$
707

 
$
60

Interest
9

 

 
1

Non-cash financing activity:
 

 
 

 
 

Conversion of preferred stock

 

 
111

Issuance of treasury stock
1,741

 
666

 


  
8.     RELATED PARTY TRANSACTIONS
 
Product Royalties
 
On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Mr. Broady is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Further, the Company agreed to pay BHS $11,700 as royalties for the period it began selling the product in the fourth quarter of 2012 through 2014. The Company recognized royalties of $3,400, $7,000 and $6,400 during 2016, 2015 and 2014, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under this agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty and Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. This provision was effective retroactive to January 1, 2015.  The Company recognized royalties of $475,000, $555,000 and $144,000 during 2016, 2015 and 2014, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
 
Stock Repurchase Agreements
 
On October 28, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4066 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on November 2, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.4 million. See Note 4.

On July 31, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4085 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on August 6, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 4.


61


On May 7, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4286 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 4, 2015. The Company’s purchases from Mr. Broady concluded on May 13, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company's broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 4.

On January 22, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased. The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock was publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million. See Note 4.

On November 14, 2014, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady of one-half of the number of shares of common stock purchased by the Company’s broker in the open market under the Repurchase Plan approved by the Company’s Board of Directors on November 4, 2014. The Stock Repurchase Agreement with Mr. Broady required that the Company report to Mr. Broady on a weekly basis information regarding the broker’s open market purchases, and that the Company purchase from Mr. Broady on a weekly basis at a per share purchase price equal to the weighted average price per share paid by the Company’s broker to purchase shares in the open market. The Company’s purchases concluded on December 17, 2014, totaled 119,947 shares of its common stock and resulted in an aggregate purchase price of $1.5 million. See Note 4.
 
9.     EMPLOYEE BENEFIT PLANS
 
     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2016, 2015 and 2014, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $134,000, $115,000 and $60,000 for 2016, 2015 and 2014, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

10.    SEGMENT INFORMATION
 
The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform. Outside of the China e-commerce retail platform, the Company believes that all of its other operating segments have similar economic characteristics, except for its operations located within the Commonwealth of Independent States (“CIS”). In making this determination, the Company believes that its operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. The Company’s engagement of a third-party service provider in the CIS market results in a different economic structure than its other markets.

However, there is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the either Chinese or the CIS markets on a stand-alone basis, and neither market is material for the two years presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.
 

62


The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales from external customers:
 
 
 
 
 
United States
$
4,100

 
$
3,246

 
$
1,438

Canada
1,809

 
2,746

 
1,374

Hong Kong
263,482

 
245,737

 
111,028

China
9,086

 
4,425

 
1,538

Taiwan
6,213

 
5,965

 
4,628

South Korea
691

 
1,129

 
1,009

Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)1
858

 
1,139

 
3,113

Europe
1,234

 
382

 
373

Other foreign countries
255

 
91

 
89

Total net sales
$
287,728

 
$
264,860

 
$
124,590


1 The Company discontinued its Ukraine operations during the second quarter of 2015.
 
The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales by product and service:
 
 
 
 
 
Product sales
$
269,731

 
$
253,041

 
$
118,843

Enrollment package revenue, freight and other
25,616

 
17,623

 
7,927

Less: sales returns
(7,619
)
 
(5,804
)
 
(2,180
)
Total net sales
$
287,728

 
$
264,860

 
$
124,590


 
Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2016
 
2015
Long-lived assets:
 
 
 
United States
$
763

 
$
283

Hong Kong
140

 
204

China
199

 
252

Other foreign countries
286

 
155

Total long-lived assets
$
1,388

 
$
894


 
11.     SUBSEQUENT EVENTS

On January 24, 2017, the Board of Directors declared a cash dividend of $0.09 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends were paid on March 3, 2017 to stockholders of record on February 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of settling fiscal 2016 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.


63


Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.
 
Item 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures
 
Management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of December 31, 2016. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that, as of December 31, 2016, our disclosure controls and procedures were effective.
 
Management’s Annual Report on Internal Control over Financial Reporting
 
Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
 
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
 
 Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
Management evaluates the effectiveness of our internal control over financial reporting by using the criteria established in Internal Control – Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  Based on this criteria, management concluded that our internal control over financial reporting as of December 31, 2016 was effective.
 
Attestation Report of the Company's Independent Registered Public Accounting Firm

The effectiveness of our internal control over financial reporting as of December 31, 2016, has been audited by Lane Gorman Trubitt, LLC, an independent registered public accounting firm, as stated in their attestation report in “Item 8. Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.


64


Item 9B. OTHER INFORMATION

None.
 
Part III 
 
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2016.
 
Item 11. EXECUTIVE COMPENSATION

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2016.
 
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2016.
 
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2016.
 
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2016.
 
Part IV
 
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Documents filed as part of this Form 10-K:
 
1.
Financial Statements. See Index to Consolidated Financial Statements under “Item 8. Financial Statements and Supplementary Data” of this report.
2.
Financial Statement Schedules. Financial statement schedules have been omitted because they are not required, not applicable, or because the required information is shown in the financial statements or notes thereto.
3.
Exhibits. The exhibits listed on the accompanying Exhibit Index are filed as a part of, and are incorporated by reference into, this report. We will furnish any of the exhibits referenced in the accompanying Exhibit Index to a requesting shareholder upon payment of a fee equal to our reasonable expenses in furnishing such exhibit(s).

Item 16. FORM 10-K SUMMARY

None.


65


SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
  
 
NATURAL HEALTH TRENDS CORP.
 
 
 
Date: March 10, 2017
/s/ Chris T. Sharng
 
Chris T. Sharng
 
President
 
(Principal Executive Officer)
 
POWER OF ATTORNEY
 
KNOW ALL MEN BY THESE PRESENTS that each of Natural Health Trends Corp., a Delaware corporation, and the undersigned directors and officers of Natural Health Trends Corp., hereby constitutes and appoints Chris T. Sharng and Timothy S. Davidson, or any one of them, its, his or her true and lawful attorney-in-fact and agent, for it, him or her and in its, his or her name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this report, and to file each such amendment to the report, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorney-in-fact and agent full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as it, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
 
Title
 
Date
 
 
 
 
 
/s/ Chris T. Sharng
 
President and Director
 
March 10, 2017
Chris T. Sharng
 
(Principal Executive Officer)
 
 
 
 
 
 
 
/s/ Timothy S. Davidson
 
Senior Vice President and Chief Financial Officer
 
March 10, 2017
Timothy S. Davidson
 
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
/s/ Randall A. Mason
 
Chairman of the Board and Director
 
March 10, 2017
Randall A. Mason
 
 
 
 
 
 
 
 
 
/s/ George K. Broady
 
Director
 
March 10, 2017
George K. Broady
 
 
 
 
 
 
 
 
 
/s/ Kin Y. Chung
 
Director
 
March 10, 2017
Kin Y. Chung
 
 
 
 
 
 
 
 
 
/s/ Yiu T. Chan
 
Director
 
March 10, 2017
Yiu T. Chan
 
 
 
 

66


EXHIBIT INDEX
(Pursuant to Item 601 of Regulation S-K)
Exhibit
Number
 
 
Exhibit Description
3.1
 
Certificate of Incorporation of Natural Health Trends Corp. (incorporated by reference to Exhibit 3.01 to Current Report on Form 8-K filed on July 12, 2005).
3.3
 
By-Laws of Natural Health Trends Corp. (incorporated by reference to Exhibit 3.02 to Current Report on Form 8-K filed on July 12, 2005).
4.1
 
Specimen Certificate for shares of common stock, $.001 par value per share, of Natural Health Trends Corp. (incorporated by reference to Exhibit 4.01 to Annual Report on Form 10-K filed on May 8, 2006).
+10.1
 
Natural Health Trends Corp. 2016 Equity Incentive Plan (incorporated by reference to Appendix C to Definitive Proxy Statement filed on March 4, 2016).
+10.2
 
Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Annual Report on Form 10-K filed March 4, 2016).
+10.3
 
Natural Health Trends Corp. Annual Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Appendix A to Definitive Proxy Statement filed on March 4, 2016).
+10.4
 
Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Appendix B to Definitive Proxy Statement filed on March 4, 2016).
+10.5
 
First Amendment to the Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) (filed herewith).
+10.6
 
Employment Agreement (including form of Non-Competition and Proprietary Rights Assignment Agreement) for Chris T. Sharng, dated April 23, 2007 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2007).
+10.7
 
Employment Agreement (including form of Non-Competition and Proprietary Rights Assignment Agreement) for Timothy S. Davidson dated April 23, 2007 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on April 26, 2007).
+10.8
 
Form of Restricted Stock Notice of Grant and Award Agreement for shares of restricted stock granted on (1) January 20, 2015 to each of Chris T. Sharng, Timothy S. Davidson, Randall A. Mason and George K. Broady, and (2) February 11, 2015 to each of Christopher R. O’Brien and Kin Y. Chung (incorporated by reference to Exhibit 10.9 to Annual Report on Form 10-K filed on March 6, 2015).
+10.9
 
Form of Indemnification Agreement dated February 11, 2015, between Natural Health Trends Corp. and each of its directors (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on February 12, 2015).
10.10
 
Stock Repurchase Agreement dated January 22, 2015 by and between Natural Health Trends Corp. and George K. Broady (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed January 26, 2015).
10.11
 
Stock Repurchase Agreement dated May 7, 2015 by and between Natural Health Trends Corp. and George K. Broady (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed May 7, 2015).
10.12
 
Stock Repurchase Agreement dated July 31, 2015 by and between Natural Health Trends Corp. and George K. Broady (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed July 31, 2015).
10.13
 
Stock Repurchase Agreement dated October 28, 2015 by and between Natural Health Trends Corp. and George K. Broady (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed October 28, 2015).
14.1
 
Worldwide Code of Business Conduct, as revised on November 5, 2015 (incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed on February 12, 2015).
21.1
 
Subsidiaries of Natural Health Trends Corp. (filed herewith).
23.1
 
Consent of Lane Gorman Trubitt, LLC (filed herewith).
24.1
 
Power of Attorney (see signature page).
31.1
 
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
31.2
 
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
32.1
 
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
 
 
 
 
 
 



101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation
 
 
+ Management contract or compensatory plan

EX-10.5 2 q42016ex10-5.htm EXHIBIT 10.5 Exhibit


Exhibit 10.5
First Amendment to the
Natural Health Trends Corp. 2014 Long-Term Incentive Plan
(Restated as of January 1, 2016)
THIS AMENDMENT to the Natural Health Trends Corp. 2014 Long-Term Incentive Plan, Restated as of January 1, 2016 (the “Plan”), is hereby adopted by Natural Health Trends Corp., a Delaware corporation (the “Company”), to be effective as of January 1, 2016 (the “Effective Date”).
WITNESSETH
WHEREAS, the Company sponsors and administers the Plan for the benefit of eligible employees of the Company;
WHEREAS, the Plan provides that amounts payable to participants will be paid in a combination of cash and common stock of the Company in a total of seventy individual monthly installments concluding in December, 2023, provided the recipient remains continuously employed by the Company as of the date on which each installment payment is made;
WHEREAS, the Company currently distributes all common stock payable under the Plan in the form of awards from the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “Equity Plan”); and
WHEREAS, the Compensation Committee of the Board of Directors of the Company desires to amend the Plan to conform the Plan to the Company’s existing practices and ease administrative burdens by providing that Plan distributions that are made in the form of the Company’s common stock or other common stock rights will be made in a single, one-time award under the Equity Plan;
NOW, THEREFORE, Sections 5.2 and 5.3 of the Plan are restated in their entirety to provide as follows, effective as of the Effective Date:
5.2
Distribution of Incentive Payments. Following the conclusion of each Performance Period, the Committee, based, to the extent applicable, on the Company’s audited financial statements for the Company’s taxable year in which such Performance Period ends, will certify in writing the extent to which the applicable performance goals for such Performance Period have been satisfied. Thereafter, payments under an Individual Award Opportunity shall, except as provided in Section 5.3, be made in accordance with the following:
(a)
Form of Distributions. Distributions under this Section 5.2 may be made, in the sole discretion of the Administrator, in the form of cash or in the form of an award of a number of whole shares of Common Stock or other Common Stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan or other applicable plan of the Company.





(b)
Schedule of Cash Distributions.
(i)
Fifty percent (50%) of the payment under an Individual Award Opportunity for a Performance Period that is payable in cash shall be paid in thirty-five (35) equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the Performance Period to which the Individual Award Opportunity relates; and
(ii)
The remaining fifty percent (50%) of the payment earned under an Individual Award Opportunity for a Performance Period that is payable in cash shall be paid in thirty-five (35) equal consecutive monthly installments commencing in February, 2021 and ending in December, 2023.
(c)
Schedule of Common Stock Distributions.     The portion of the Participant’s Individual Award Opportunity for a Performance Period that is payable in Common Stock or other Common Stock rights shall be satisfied in a single distribution in February of the calendar year immediately following the conclusion of the Performance Period to which the Individual Award Opportunity relates, or as soon thereafter as is administratively practical. This distribution will take the form of an award under the Natural Health Trends Corp. 2016 Equity Incentive Plan, or other applicable plan of the Company, subject to the terms, including vesting, of the applicable plan and award agreement under which such award is made.
(d)
Special Rule Affecting Certain 2016 Distributions. Notwithstanding any provision of this Section to the contrary, all distributions to be made under Section 5.2 above in connection with the 2015 Performance Period to Participants who are “covered employees” within the meaning of Section 162(m) of the Code to which the Participant may become entitled shall be postponed, and distributions relating to these Individual Award Opportunities shall be conditioned on the receipt of the approval of the Company’s stockholders of the material terms of the Plan’s performance goals and other criteria under Article IV in accordance with Treasury Regulation Section 1.162-27(e)(4). Provided stockholder approval is obtained, the payments under Section 5.2 above that were postponed in accordance with the last sentence shall be paid to the affected Participant in a single lump-sum, without interest, as soon as administratively practicable following the conclusion of the 2016 annual meeting of the Company’s stockholders, but in no event later than April 30, 2016. All remaining payments under Section 5.2 to which the Participant may become entitled with respect to the 2015 Performance Period shall be paid as originally scheduled, subject to the applicable provisions of this Article V. In no event will any distribution under this Section 5.2 be delayed to such an extent that the amount would be treated as non-qualified deferred compensation under Section 409A of the Code.





5.3
Continuous Employment Requirement. Except as provided in this Section 5.3, to be eligible to receive a distribution under Section 5.2, a participant must remain in a continuous employment or other service provider relationship with the Company, Parent, or a Subsidiary through both the conclusion of the Performance Period to which an Individual Award Opportunity relates and through the date on which either each cash installment payment under Section 5.2(b)(i) or (ii) is made or the “grant date” (as defined in Section 2(s) of the Natural Health Trends Corp. 2016 Equity Incentive Plan or other applicable plan of the Company) on which the shares of Common Stock are distributed under Section 5.2(c). If the Participant separates from service for any reason other than on account of a Qualifying Termination Event (defined below), any Individual Award Opportunity granted to the Participant that remains undistributed shall be immediately and irrevocably forfeited in full.
(a)
In the event of the Participant’s separation from service with the Company, Parent, or a Subsidiary on account of death, upon Disability, involuntarily for a reason other than for Cause, voluntarily for Good Reason, due to Retirement, or upon a Change in Control Termination (each, a “Qualifying Termination Event”):
(i)
any Individual Award Opportunity granted to the Participant for the Performance Period during which he or she separates from service shall be immediately and irrevocably forfeited in full; and
(ii)
any Individual Award Opportunity applicable to any prior Performance Period, the performance goals for which were satisfied prior to the Participant’s Qualifying Termination Event but the proceeds of which remain undistributed, shall be paid to the Participant or, if applicable, the Participant’s Beneficiary(ies) in a single lump sum, net applicable withholding and other taxes, within 2-1/2 months following the Participant’s separation from service and as soon as administratively practicable after the Committee has certified in writing the extent to which the applicable performance goals for earning one or more Individual Award Opportunities have been satisfied.
(b)
Whether the Participant experienced a Qualifying Termination Event shall be determined by the Committee in its sole discretion, but in good faith. Whether a Participant has experienced a separation from service shall be interpreted by the Committee in accordance with Treasury Regulation 1.409A-1(h).
IN WITNESS WHEREOF, the undersigned has executed this Amendment this 14th day of November, 2016 to be effective as of the 1st day of January, 2016.
NATURAL HEALTH TRENDS CORP.

By:    /s/ Timothy S. Davidson        
Timothy S. Davidson

Title:    Chief Financial Officer



EX-21.1 3 q42016ex21-1.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
  
SUBSIDIARIES OF THE REGISTRANT
AS OF DECEMBER 31, 2016
 
NATURAL HEALTH TRENDS CORP.
A DELAWARE CORPORATION
 
Name
 
Jurisdiction
 
 
 
NHT Global, Inc.
 
United States (Delaware)
NHTC International, LLC
 
United States (Delaware)
NHT Global (Canada) Company 
 
Canada
NHTC Holding Company
 
Cayman Islands
NHTC Trading Company
 
Cayman Islands
NHT Global Taiwan Company
 
Cayman Islands
NHT Global CIS Company
 
Cayman Islands
NHT Global (China) Commodities Co., Ltd.
 
China
NHT Global (Zhongshan) Cosmetics Co., Ltd.
 
China
NHT Global Hong Kong Limited
 
Hong Kong
Natural Health Trends Japan, Inc.
 
Japan
NHTC Global Singapore Pte. Ltd.
 
Singapore
NHTC Wellness Products Malaysia Sdn. Bhd.
 
Malaysia
NHTK Ltd.
 
South Korea
NHT Global Europe S.R.L.
 
Italy
 
The names of omitted subsidiaries when considered in the aggregate as a single subsidiary do not constitute a significant subsidiary as of the end of the year covered by this report.



EX-23.1 4 q42016ex23-1.htm EXHIBIT 23.1 Exhibit


Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Natural Health Trends Corp.
Rolling Hills Estates, California

We consent to the incorporation by reference in Registration Statement on Form S-8 (333-210658) of our report dated March 10, 2017, with respect to the consolidated balance sheets of Natural Health Trends Corp. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and the effectiveness of internal control over financial reporting as of December 31, 2016, which appear in this Annual Report on Form 10-K for the year ended December 31, 2016.

/s/ Lane Gorman Trubitt, LLC

Dallas, Texas
March 10, 2017



EX-31.1 5 q42016ex31-1.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;
 
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: March 10, 2017
 
/s/ Chris T. Sharng
 
 
 
Chris T. Sharng
 
 
 
President
 
 
 
(Principal Executive Officer)
 


EX-31.2 6 q42016ex31-2.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;
 
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: March 10, 2017
 
/s/ Timothy S. Davidson
 
 
 
Timothy S. Davidson
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 


EX-32.1 7 q42016ex32-1.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Natural Health Trends Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
 
1.        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2.        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
Date: March 10, 2017
 
/s/ Chris T. Sharng
 
 
 
Chris T. Sharng
 
 
 
President
 
 
 
(Principal Executive Officer)
 
 
 
Date: March 10, 2017
 
/s/ Timothy S. Davidson
 
 
 
Timothy S. Davidson
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 
  
The foregoing certifications are not deemed filed with the United States Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 



EX-101.SCH 8 nhtc-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Balance Sheet Components - Components of Balance Sheet Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Employee Benefit Plans (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Income Taxes - Components of Benefit From Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Income Taxes - Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Income Taxes - Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2406407 - Disclosure - Income Taxes Income Taxes - Foreign Rate Differentials (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Basic and Diluted Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Summary of Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Related Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Segment Information - The Company's Net Sales by Product and Service (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Segment Information - Long Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Segment Information - Net Sales by Market (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Stock-Based Compensation - Common Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Stockholders' Equity - Dividend Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 nhtc-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 nhtc-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 nhtc-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental Cash Flow Elements [Abstract] Schedule of cash flow, supplemental disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Segment Reporting [Abstract] Net sales by product and service: Sales Revenue, Goods, Net [Abstract] Product sales Sales Revenue, Goods, Gross Enrollment package revenue, freight and other Shipping and Handling Revenue Less: sales returns Sales Returns, Goods Total net sales Sales Revenue, Goods, Net Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock [Member] Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Shares granted during period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Common stock, dividends, per share declared Common Stock, Dividends, Per Share, Declared CommonStockSpecialDividendsPerShareDeclared CommonStockSpecialDividendsPerShareDeclared Special dividends declared during the period for each share of common stock outstanding. Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Soothe Soothe [Member] Represents Soothe. ReStore [Member] ReStore [Member] Represents a product called ReStore™. Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Director Director [Member] Broady Health Sciences Broady Health Sciences [Member] Represents Broady Health Sciences. Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] George Broady George Broady Member Represents George Broady. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Royalty rate Royalty Rate Represents the royalty rate. Royalty expense Royalty Expense Termination notice, number of days Number Of Days Termination Notice Represents number of days termination notice. Treasury stock acquired rate Treasury Stock Acquired Rate Represents the treasury stock acquired rate times the number of shares purchased. Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Shares repurchased per trading day Stock Repurchase Program Number Of Shares Repurchased Per Day The number of shares acquired per day under a share repurchase program. Income Statement [Abstract] Net sales Cost of sales Cost of Goods Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses Selling, General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other expense, net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income Net Income (Loss) Attributable to Parent Preferred stock dividends Dividends, Preferred Stock Net income available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Income per common share: Earnings Per Share [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Common Stock, Dividends, Per Share, Cash Paid Common Stock, Dividends, Per Share, Cash Paid Balance Sheet Related Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Income Tax Disclosure [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] China CHINA Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Net operating loss carryforwards Operating Loss Carryforwards Foreign net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Accounting Policies [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software and Software Development Costs [Member] Software and Software Development Costs [Member] Furniture and Fixtures Furniture and Fixtures [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period [Member] Represents the Long-Term Incentive Plan (the “LTI Plan”), payments commencing in February of the calendar year immediately following the conclusion of the performance period. Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 [Member] Represents the Long-Term Incentive Plan (the “LTI Plan”), payments commencing in February 2021 and ending in December 2023. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Cash Cash Cash equivalents Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash and Cash Equivalents Inventory valuation reserves Inventory Valuation Reserves Property, and equipment useful life Property, Plant and Equipment, Useful Life Deferred tax liability recorded against undistributed foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Long-term incentive plan, percentage of award payable in cash nhtc_DeferredCompensationRewardPaymentPercentage Represents the percentage of deferred compensation award payable. Long-term incentive plan, number of installments nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments Represents the number of equal consecutive monthly installments of deferred compensation award payable. Loss on foreign exchange Foreign Currency Transaction Gain (Loss), Unrealized Number of securities called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Stock-based compensation Share-based Compensation Cumulative translation adjustment realized in net income Cumulative Translation Adjustment Realized In Net Income Represents cumulative translation adjustment realized in net income. Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories, net Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Amounts held in eWallets Increase (Decrease) in Customer Advances and Deposits Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Increase in restricted cash Increase (Decrease) in Restricted Cash Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of warrants Proceeds from Warrant Exercises Repurchase of common stock Payments for Repurchase of Common Stock Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Distributed Distributed [Member] Represents distributed. Restricted Stock Restricted Stock [Member] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] [Line Items] for Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Basic EPS: Earnings Per Share, Basic [Abstract] Net income available to common stockholders Less: undistributed earnings to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Net income allocated to common stockholders (in shares) Net income allocated to common stockholders (in dollars per share) Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Warrants to purchase common stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Non-vested restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Plus: reallocation of undistributed earnings to participating securities Plus: reallocation of undistributed earnings to participating securities Represents the reallocation of undistributed earnings during the period. Diluted EPS: Earnings Per Share, Diluted [Abstract] Net income allocated to common stockholders plus assumed conversions Net Income (Loss) Available to Common Stockholders, Diluted Net income allocated to common stockholders plus assumed conversions (in shares) Net income allocated to common stockholders plus assumed conversions (in dollars per share) Subsequent Events Subsequent Events [Text Block] Segment Information Segment Reporting Disclosure [Text Block] Compensation and Retirement Disclosure [Abstract] Maximum compensation percentage Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage Age requirement for 401 K contributions Age Requirement For 401K Contributions Represents age requirement for 401K contributions. Employer matching contribution, percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Employers matching contribution, immediate vesting percentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage Defined contribution plan, cost recognized Defined Contribution Plan, Cost Recognized Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Inventories, net Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Income taxes payable Accrued Income Taxes, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Other Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Amounts held in eWallets Other Deferred Credits, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Long-term incentive Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and 2015 Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2016 and 2015 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, at cost; 1,692,218 and 840,202 shares at December 31, 2016 and 2015, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Income Tax Foreign Rate Differential [Table] Income Tax Foreign Rate Differential [Table] Income Tax Foreign Rate Differential components CAYMAN ISLANDS CAYMAN ISLANDS Hong Kong HONG KONG China Income Tax Foreign Rate Differential [Line Items] Income Tax Foreign Rate Differential [Line Items] [Line Items] for Income Tax Foreign Rate Differential components Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign statutorytaxrate statutorytaxrate Statutory tax rate of foreign subsidiary. Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Treasury stock, shares Treasury Stock, Shares Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive 2016 Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based compensation expense Allocated Share-based Compensation Expense Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Tax benefit attributable to compensation expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Unrecognized stock-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized stock-based compensation expense, period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Number of shares authorized to be repurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased Incentive compensation period nhtc_ShareBasedCompensationIncentiveCompensationPeriod The period to which employees receive stock as incentive compensation. Schedule of Additional Balance Sheet Components Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Document And Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current taxes Current Income Tax Expense (Benefit) Deferred foreign taxes Deferred Foreign Income Tax Expense (Benefit) Income tax provision Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Preferred Stock Preferred Stock [Member] Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Treasury Stock Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Treasury stock, shares Conversion of Stock, Shares Converted Conversion of Stock, Shares Converted Conversion of Stock, Amount Converted Conversion of Stock, Amount Converted Conversion of Stock, Shares Issued Conversion of Stock, Shares Issued Conversion of Stock, Amount Issued Conversion of Stock, Amount Issued Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] BALANCE Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Exercise of warrants (in shares) Stock Issued During Period, Shares, Other Exercise of warrants Stock Issued During Period, Value, Other Repurchase of common stock (in shares) Repurchase of common stock Shares issued for stock-based compensation awards (in shares) Stock Issued During Period, Shares, Share-based Compensation, Gross Shares issued for stock-based compensation awards Stock Issued During Period, Value, Share-based Compensation, Gross Dividends declared Dividends Elimination of CTA upon dissolution Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Unrealized loss on available-for-sale securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition BALANCE Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Stockholders' Equity Note [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock Series A Preferred Stock [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Seven Year Warrants Seven Year Warrants [Member] Represents Seven Year Warrants. One Year Warrants One Year Warrants [Member] Represents One Year Warrants. Five Year Warrants Five Year Warrants [Member] Represents Five Year Warrants. George K. Broady George K. Broady [Member] George K. Broady, a director of the Company. Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Number of classes of stock Number Of Classes Of Stock Number Of Classes Of Stock Preferred stock, dividends per share, declared Preferred Stock, Dividends Per Share, Declared Share price Share Price Preferred stock, voting rights Preferred Stock, Number Of Votes Per Share Preferred Stock, Number Of Votes Per Share Term of warrant nhtc_TermOfWarrant Represents the term of the warrant. Warrants, exercise price Class of Warrant or Right, Exercise Price of Warrants or Rights Authorized amount of shares to be repurchased Stock Repurchase Program, Authorized Amount Treasury stock, purchase price Treasury Stock Value Acquired Cost Method Excluding Related Party Equity impact of the cost of shares that were repurchased during the period, excluding those repurchased from a related party. Recorded using the cost method. Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Preferred Stock, Dividends, Per Share, Cash Paid Preferred Stock, Dividends, Per Share, Cash Paid Dividends Per Share, Common (in dollars per share) Dividends Dividends, cash Dividends, Cash Payment Date Dividends Payable, Date to be Paid Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Tax credits Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Foreign earnings Other Deferred Tax Liabilities, Other Total deferred tax liabilities Deferred Tax Liabilities, Gross Total deferred tax liabilities Deferred Tax Liabilities, Net Loss Contingencies [Table] Loss Contingencies [Table] Guaranteed Insurance Contract, Type of Guarantee [Axis] Guaranteed Insurance Contract, Type of Guarantee [Axis] Guaranteed Insurance Contract, Type of Guarantee [Domain] Guaranteed Insurance Contract, Type of Guarantee [Domain] Korean Business Segment Korean Business Segment [Member] Represents Korean Business Segment. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Noncurrent Assets Other Noncurrent Assets [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Rent expense for operating leases Operating Leases, Rent Expense Minimum monthly purchase amount nhtc_PurchaseCommitmentMonthlyAmountMinimum Represents the monthly purchase minimum the Company is required to purchase until the termination date. Minimum annual purchase amount Purchase Commitment, Remaining Minimum Amount Committed Purchase commitment term nhtc_PurchaseCommitmentTerm Period of time that a purchase commitment agreement is in effect. Purchase commitment renewal term nhtc_PurchaseCommitmentRenewalTerm Period of time that a purchase commitment agreement is automatically renewed for after the original term ends unless notice of termination is given by either party to the agreement. Distributor claims reserve Distributor Claims Reserve Represents the funds which can be utilized to fund any outstanding distributor claims for product returns. Income Taxes Income Tax Disclosure [Text Block] 2016 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2017 Operating Leases, Future Minimum Payments, Due in Two Years 2018 Operating Leases, Future Minimum Payments, Due in Three Years 2019 Operating Leases, Future Minimum Payments, Due in Four Years 2020 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease obligations Operating Leases, Future Minimum Payments Due Conversion of Stock [Table] Conversion of Stock [Table] Conversion of Stock [Line Items] Conversion of Stock [Line Items] Cash paid during the year for: Supplemental Cash Flow Information [Abstract] Income taxes, net of refunds Income Taxes Paid, Net Interest Interest Paid Non-cash financing activity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Conversion of preferred stock Stock Issued Stock Issued Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reclassification, Policy [Policy Text Block] Reclassification, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Amounts Held in Distributor eWallets Amounts Held in Distributor eWallets [Policy Text Block] Represents the policy of amounts held in customer eWallets. Long-Term Incentive Compensation Related Costs, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Operating Leases Lease, Policy [Policy Text Block] Commissions Commissions, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Per Share Earnings Per Share, Policy [Policy Text Block] Certain Risks and Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Available-for-sale Securities Available-for-sale Securities [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] United States UNITED STATES Other foreign countries Other Foreign Countries [Member] Represents other foreign countries. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-lived assets Long-Lived Assets Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Nonvested Restricted Stock Shares Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Nonvested Share Activity Schedule of Nonvested Share Activity [Table Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Nonvested, Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Nonvested, Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested weighted average grant-date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Nonvested weighted average grant-date fair value (in dollars per share) Related Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Dividends Payable Schedule of Dividends Payable [Table Text Block] Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Unshipped product Unshipped Product [Member] Represents unshipped product. Auto ship advances Auto Ship Advances [Member] Represents Auto Ship advances. Enrollment package revenue Enrollment Package Revenue [Member] Represents enrollment package revenue. Market development fees Market Development Fees [Member] Represents market development fees deferred revenue. Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Property and equipment: Property, Plant and Equipment [Abstract] Office equipment Office equipment Represents other equipment. Office software Capitalized Computer Software, Gross Machinery Machinery and Equipment, Gross Furniture and fixtures Furniture and Fixtures, Gross Leasehold improvements Leasehold Improvements, Gross Construction in progress Construction in Progress, Gross Property and equipment, at cost Property, Plant and Equipment, Gross Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Other accrued expenses: Other accrued expenses: Represents other accrued expenses abstract. Sales returns Accrued Sales Returns Accrued Sales Returns Employee-related expense Accrued Employee Benefits, Current Warehousing, inventory-related and other Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Other accrued expenses Deferred revenue: Deferred Revenue [Abstract] Deferred revenue Deferred Revenue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Nonvested, balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, weighted average price at date of issuance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Nonvested, weighted average price at date of issuance (in dollars per share) Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Income Tax Foreign Rate Differential [Table Text Block] Income Tax Foreign Rate Differential [Table Text Block] [Table Text Block] for Income Tax Foreign Rate Differential components Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Location [Table] Entity Location [Table] Hong Kong Entity Location [Line Items] Entity Location [Line Items] Income tax at federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effect of permanent differences Effect of permanent differences Effect of permanent differences. Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Other reconciling items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Statement of Comprehensive Income [Abstract] Other comprehensive income, net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Release of cumulative translation adjustment Net change in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized losses on available-for-sale securities Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Employee Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Canada CANADA Taiwan TAIWAN, PROVINCE OF CHINA South Korea KOREA, REPUBLIC OF Commonwealth of Independent States (Russia, Kazakhstan and Ukraine) Russia and Kazakhstan and Ukraine [Member] Geographic locations of Russia and Kazakhstan and Ukraine. Europe [Member] Europe [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Municipal bonds and notes Municipal Bonds and Notes [Member] Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments. Corporate debt securities Corporate Debt Securities [Member] Financial institution instruments Financial Institution Instruments [Member] Information pertaining to financial institution instruments. Debt Instrument [Line Items] Debt Instrument [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains/Losses Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Fair Value Available-for-sale Securities EX-101.PRE 12 nhtc-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 nhtc201610-_chartx10870.jpg TOTALRETURNCHART begin 644 nhtc201610-_chartx10870.jpg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end XML 14 nhtc20161231_10k_htm.xml IDEA: XBRL DOCUMENT 0000912061 2016-01-01 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 2012-08-13 0000912061 2015-05-04 0000912061 2016-01-12 0000912061 2014-11-05 2014-12-17 0000912061 nhtc:SevenYearWarrantsMember 2015-04-30 0000912061 nhtc:SevenYearWarrantsMember us-gaap:MinimumMember 2014-12-31 0000912061 2015-07-28 0000912061 nhtc:SevenYearWarrantsMember us-gaap:MaximumMember 2014-12-31 0000912061 us-gaap:SeriesAPreferredStockMember 2016-12-31 0000912061 nhtc:SevenYearWarrantsMember 2014-01-01 2014-12-31 0000912061 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0000912061 2016-11-25 2016-11-25 0000912061 2016-05-20 2016-05-20 0000912061 2016-03-24 2016-03-24 0000912061 2016-08-26 2016-08-26 0000912061 nhtc:FiveYearWarrantsMember 2007-10-01 2007-10-19 0000912061 nhtc:OneYearWarrantsMember 2009-04-01 2009-04-21 0000912061 nhtc:OneYearWarrantsMember 2007-10-01 2007-10-19 0000912061 nhtc:SevenYearWarrantsMember 2007-10-01 2007-10-19 0000912061 nhtc:FiveYearWarrantsMember 2013-04-01 2013-04-21 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2013-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0000912061 us-gaap:RestrictedStockMember 2014-12-31 0000912061 us-gaap:RestrictedStockMember 2015-01-20 2015-01-20 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 us-gaap:PreferredStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-02-11 2015-02-11 0000912061 2016-01-01 2016-03-31 0000912061 2012-08-13 2012-08-13 0000912061 country:HK 2014-01-01 2014-12-31 0000912061 country:CN 2016-01-01 2016-12-31 0000912061 country:HK 2015-01-01 2015-12-31 0000912061 country:KY 2016-01-01 2016-12-31 0000912061 country:KY 2015-01-01 2015-12-31 0000912061 country:CN 2015-01-01 2015-12-31 0000912061 country:HK 2016-01-01 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000912061 country:KY 2014-01-01 2014-12-31 0000912061 country:CN 2014-01-01 2014-12-31 0000912061 nhtc:GeorgeBroadyMember 2015-02-19 2015-02-19 0000912061 nhtc:GeorgeBroadyMember 2015-10-28 2015-10-28 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:GeorgeBroadyMember us-gaap:DirectorMember 2014-11-14 2014-11-14 0000912061 2015-07-31 2015-07-31 0000912061 2015-05-07 2015-05-07 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 2013-02-01 2013-02-28 0000912061 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0000912061 nhtc:GeorgeBroadyMember 2015-07-31 2015-07-31 0000912061 nhtc:GeorgeBroadyMember 2015-05-07 2015-05-07 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2014-10-01 2014-12-31 0000912061 nhtc:GeorgeBroadyMember 2015-01-22 2015-01-22 0000912061 2015-10-28 2015-10-28 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2014-01-01 2014-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2014-01-01 2014-12-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-12-31 0000912061 us-gaap:PreferredStockMember 2014-12-31 0000912061 country:US 2015-12-31 0000912061 country:HK 2016-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-12-31 0000912061 country:CN 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2015-12-31 0000912061 country:US 2016-12-31 0000912061 country:HK 2015-12-31 0000912061 country:US 2016-01-01 2016-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2015-01-01 2015-12-31 0000912061 us-gaap:EuropeMember 2014-01-01 2014-12-31 0000912061 us-gaap:TreasuryStockMember 2013-12-31 0000912061 country:KR 2015-01-01 2015-12-31 0000912061 country:CA 2014-01-01 2014-12-31 0000912061 country:TW 2015-01-01 2015-12-31 0000912061 country:TW 2016-01-01 2016-12-31 0000912061 country:CA 2015-01-01 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2014-01-01 2014-12-31 0000912061 country:US 2014-01-01 2014-12-31 0000912061 nhtc:OtherForeignCountriesMember 2015-01-01 2015-12-31 0000912061 country:KR 2016-01-01 2016-12-31 0000912061 country:CA 2016-01-01 2016-12-31 0000912061 us-gaap:CommonStockMember 2015-12-31 0000912061 country:TW 2014-01-01 2014-12-31 0000912061 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000912061 nhtc:OtherForeignCountriesMember 2016-01-01 2016-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2016-01-01 2016-12-31 0000912061 country:US 2015-01-01 2015-12-31 0000912061 nhtc:RussiaAndKazakhstanAndUkraineMember 2014-01-01 2014-12-31 0000912061 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000912061 country:KR 2014-01-01 2014-12-31 0000912061 us-gaap:SubsequentEventMember 2017-01-24 2017-01-24 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:SubsequentEventMember 2017-01-24 2017-01-24 0000912061 us-gaap:CommonStockMember 2014-12-31 0000912061 2016-06-30 0000912061 us-gaap:PreferredStockMember 2013-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000912061 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000912061 us-gaap:PreferredStockMember 2014-01-01 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2015-12-31 0000912061 2017-02-24 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000912061 2013-12-31 0000912061 2014-12-31 0000912061 us-gaap:TreasuryStockMember 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000912061 us-gaap:RetainedEarningsMember 2014-12-31 0000912061 us-gaap:CommonStockMember 2013-12-31 0000912061 us-gaap:PreferredStockMember 2016-12-31 0000912061 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2015-12-31 0000912061 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000912061 us-gaap:CommonStockMember 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000912061 nhtc:DistributedMember 2014-01-01 2014-12-31 0000912061 2015-12-31 0000912061 nhtc:DistributedMember 2015-01-01 2015-12-31 0000912061 nhtc:DistributedMember 2016-01-01 2016-12-31 0000912061 country:CN 2016-12-31 0000912061 2015-06-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-12-31 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2015-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2015-12-31 0000912061 2015-01-01 2015-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember 2015-12-31 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000912061 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000912061 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2015-12-31 0000912061 nhtc:AutoShipAdvancesMember 2015-12-31 0000912061 nhtc:AutoShipAdvancesMember 2016-12-31 0000912061 nhtc:UnshippedProductMember 2015-12-31 0000912061 nhtc:UnshippedProductMember 2016-12-31 0000912061 2014-01-01 2014-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2016-12-31 0000912061 nhtc:MarketDevelopmentFeeMember 2015-12-31 0000912061 nhtc:EnrollmentPackageRevenueMember 2015-12-31 0000912061 nhtc:MarketDevelopmentFeeMember 2016-12-31 0000912061 us-gaap:OtherNoncurrentAssetsMember nhtc:KoreanBusinessSegmentMember 2016-12-31 0000912061 2015-05-29 2015-05-29 0000912061 2015-11-20 2015-11-20 0000912061 2015-08-28 2015-08-28 0000912061 2015-03-27 2015-03-27 0000912061 2014-08-27 2014-08-27 0000912061 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0000912061 2014-06-04 2014-06-04 0000912061 2014-12-03 2014-12-03 0000912061 2014-04-08 2014-04-08 0000912061 2015-10-30 2015-10-30 0000912061 us-gaap:MinimumMember us-gaap:SeriesAPreferredStockMember 2007-05-04 0000912061 2015-08-01 2015-08-03 0000912061 us-gaap:MaximumMember 2014-12-31 0000912061 2007-10-19 0000912061 us-gaap:SeriesAPreferredStockMember 2007-05-04 0000912061 2015-08-04 2015-08-04 0000912061 us-gaap:TreasuryStockMember 2014-12-31 0000912061 2015-04-01 2015-04-30 0000912061 us-gaap:MinimumMember 2014-12-31 0000912061 2015-05-04 2015-05-04 0000912061 2014-11-04 0000912061 nhtc:GeorgeKBroadyMember 2015-01-22 2015-01-22 0000912061 nhtc:FiveYearWarrantsMember 2007-10-19 0000912061 2015-05-13 2015-05-13 0000912061 nhtc:SevenYearWarrantsMember 2007-10-19 0000912061 nhtc:GeorgeKBroadyMember 2014-11-04 2014-11-04 0000912061 nhtc:SevenYearWarrantsMember 2015-04-01 2015-04-30 pure utreg:Rate nhtc:class shares iso4217:USD iso4217:USD shares nhtc:installment iso4217:KRW false --12-31 FY 2016 0000912061 Yes Accelerated Filer No No 35 35 0.5 0.5 2 P3Y P3Y P3Y P5Y P1Y P7Y P1Y P5Y P7Y 0.001 50000000 12979414 12979414 0 0.001 5000000 0.000 0.000 P7Y P5Y P5Y P3Y P3Y P3Y 840202 1692218 10-K 2016-12-31 NATURAL HEALTH TRENDS CORP. 202402875 11341890 125921000 104914000 11257000 10455000 4066000 2343000 141244000 117712000 1388000 894000 1764000 1764000 2963000 3166000 692000 616000 148051000 124152000 2145000 2862000 663000 379000 13611000 19634000 14989000 16703000 4948000 4011000 19165000 16414000 1633000 1510000 57154000 61513000 268000 60000 8190000 5770000 65612000 67343000 0 0 13000 13000 86574000 85963000 38548000 -9647000 -807000 -101000 41889000 19419000 82439000 56809000 148051000 124152000 287728000 264860000 124590000 54903000 54098000 26981000 232825000 210762000 97609000 125050000 126598000 56997000 43245000 36024000 19687000 394000 263000 105000 168689000 162885000 76789000 64136000 47877000 20820000 -59000 -84000 -184000 64077000 47793000 20636000 8991000 552000 266000 55086000 47241000 20370000 0 0 10000 55086000 47241000 20360000 4.84 3.84 1.67 4.83 3.82 1.61 11382000 12302000 12131000 11407000 12372000 12600000 0.61 0.14 0.03 55086000 47241000 20370000 -838000 -79000 143000 -132000 82000 0 -706000 -161000 143000 0 -2000 0 54380000 47078000 20513000 123693 111000 11359769 11000 80690000 -74619000 -81000 -26998 -35000 6077000 20370000 20370000 -123693 -111000 123693 111000 1407855 2000 4946000 4948000 382564 4661000 4661000 -46000 -74000 25342 120000 0 476000 476000 143000 143000 49000 49000 0 0 12891317 13000 85750000 -54799000 62000 -384220 -4576000 26450000 47241000 47241000 88097 309000 309000 547042 16071000 16071000 -182000 -380000 91060 1228000 666000 1709000 1709000 82000 82000 -79000 -79000 -2000 -2000 86000 86000 0 0 12979414 13000 85963000 -9647000 -101000 840202 -19419000 56809000 55086000 55086000 903031 23704000 23704000 507000 51015 1234000 1741000 6891000 6891000 -132000 -132000 -838000 -838000 104000 104000 0 0 12979414 13000 86574000 38548000 -807000 1692218 -41889000 82439000 55086000 47241000 20370000 394000 263000 105000 104000 86000 49000 -132000 82000 0 217000 -15000 -43000 851000 6762000 2029000 1681000 1025000 501000 90000 267000 85000 -714000 637000 -822000 303000 -115000 243000 -6031000 10840000 5077000 51000 10714000 3706000 947000 1331000 147000 2752000 14350000 2065000 135000 25000 666000 2420000 4105000 1665000 53174000 81326000 30613000 905000 710000 339000 0 3028000 0 -905000 -3738000 -339000 0 309000 4948000 23704000 16071000 4661000 6891000 1709000 476000 -30595000 -17471000 -189000 -667000 -19000 181000 21007000 60098000 30266000 104914000 44816000 14550000 125921000 104914000 44816000 Principles of Consolidation<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Use of Estimates<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected. Reclassification<div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">Certain accounts receivable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. No change in total current assets occurred. Additionally, deferred tax liability balances have been reclassified from current to long-term in the prior year consolidated financial statements to conform to the early adoption of ASU No. 2015-17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</span>. Cash and Cash Equivalents<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> held in banks located within China subject to foreign currency controls. The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Additionally, as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company's investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders' equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. 6800000 Cash and cash equivalents at the end of each period were as follows (in thousands):<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,914</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 52453000 47431000 73468000 57483000 125921000 104914000 Restricted Cash<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, the Company funded a bank deposit account in the amount of CNY </span><span style="font-family:inherit;font-size:10pt;"><span>20 million</span></span><span style="font-family:inherit;font-size:10pt;"> (USD </span><span style="font-family:inherit;font-size:10pt;"><span>2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely. 20000000 2900000 Inventories<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">Inventories consist primarily of finished goods and are stated at the lower of cost or market, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, the reserve for obsolescence totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$82,000</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$29,000</span></span>, respectively. 82000 29000 Property and Equipment<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years for office equipment and office software and </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value. Goodwill<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented. Income Taxes<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</span></div><br/> Amounts Held in eWallets<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Commencing in October 2014, the Company requires commission payments of certain members in Hong Kong to be first deposited into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available funds and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability. Long-Term Incentive<div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of any cash payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of the payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As such, certain installments to be paid are reflected on the balance sheet as a non-current liability, and the current portion of the installments is reflected in other accrued expenses.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 5 for grant information of distributions settled in common stock. Foreign Currency<div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income. 333000 204000 202000 Revenue Recognition<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.</span></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. Commissions<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and pays commissions on product sales generally two weeks following the end of the weekly sales period.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  These incentives may be both monetary and non-monetary in nature.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. From time to time the Company also enters into agreements for business or market development, which may result in additional compensation to specific members. Stock-Based Compensation<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award. Income Per Share<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic income per share for 2014 was computed via the “two-class” method by dividing net income allocated to common stockholders by the weighted-average number of common shares outstanding during the period. Net income available to common stockholders is allocated to both common stock and participating securities as if all of the income for the period had been distributed. The Company’s Series A convertible preferred stock was a participating security due to its participation rights related to dividends declared by the Company. If dividends were distributed to common stockholders, the Company was also required to pay dividends to the holders of the preferred stock in an amount equal to the greater of (1) the amount of dividends then accrued and not previously paid on such shares of preferred stock or (2) the amount payable if dividends were distributed to the common stockholders on an as-converted basis.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. For 2014, the dilutive effect of the Company’s Series A convertible preferred stock was calculated using the more dilutive of the “two-class” method and the “if-converted” method, which assumes that the preferred stock was converted into common stock at the beginning of each period presented. 88097 The following table illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="32" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income allocated to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plus: reallocation of undistributed earnings to participating securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income allocated to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,238</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 55086000 47241000 20360000 0 -127000 55086000 11382000 4.84 47241000 12302000 3.84 20233000 12131000 1.67 0 21000 421000 25000 49000 48000 0 5000 55086000 11407000 4.83 47241000 12372000 3.82 20238000 12600000 1.61 345 Certain Risks and Concentrations<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A substantial portion of the Company’s sales are generated in Hong Kong (see Note 10). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes that its e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of the Company's products by members in China. The Company also believes that its Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with the Company’s interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that the Company’s activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, Chinese nationals collaborating with short traders to damage the Company's business and activities by individual members that may violate laws notwithstanding the Company’s strict policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><span style="font-family:inherit;font-size:10pt;">The Company’s </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Premium Noni Juice</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Enhanced Essential Probiotics</span><span style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span>products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected. Fair Value of Financial Instruments<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items. Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,029</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,024</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 43490000 0 43490000 35222000 2000 35224000 1673000 -2000 1671000 5029000 -5000 5024000 28307000 0 28307000 17235000 0 17235000 73470000 -2000 73468000 57486000 -3000 57483000 Recently Issued and Adopted Accounting Pronouncements<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</span><span style="font-family:inherit;font-size:10pt;">. Under this guidance, entities are required to present deferred tax tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities are permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Inventory: Simplifying the Measurement of Inventory.</span><span style="font-family:inherit;font-size:10pt;"> Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and will be applied prospectively.  Early adoption is permitted. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span>, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. The components of certain balance sheet amounts are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>840</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (including internal use software development costs)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Market development fees</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 517000 495000 672000 536000 28000 24000 241000 222000 840000 730000 157000 10000 2455000 2017000 1067000 1123000 1388000 894000 1632000 1552000 10541000 11064000 2816000 4087000 14989000 16703000 2191000 1783000 2327000 1597000 430000 331000 0 300000 4948000 4011000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Leases</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$777,000</span></span><span style="font-family:inherit;font-size:10pt;"> during 2016, 2015 and 2014, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Commitments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$40,000</span></span><span style="font-family:inherit;font-size:10pt;"> of product per month until the termination date. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the exclusivity provision.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Company amended a supply agreement with one of its suppliers to maintain worldwide exclusivity in return for purchasing a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of product annually on average over the next three years, plus certain raw material guarantees. If the Company does not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years commencing February 2016 and shall automatically renew for successive </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> year terms unless notice of termination is provided by either party. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Agreements</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Consumer Indemnity</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As required by the Door-to-Door Sales Act in South Korea, the Company maintains insurance for consumer indemnity claims with a mutual aid cooperative by possessing a mutual aid contract with Mutual Aid Cooperative &amp; Consumer (the “Cooperative”). The contract secures payment to members in the event that the Company is unable to provide refunds to members. Typically, requests for refunds are paid directly by the Company according to the Company’s normal Korean refund policy, which requires that refund requests be submitted within three months. Accordingly, the Company estimates and accrues a reserve for product returns based on this policy and its historical experience. Depending on the sales volume, the Company may be required to increase or decrease the amount of the contract. The maximum potential amount of future payments the Company could be required to make to address actual member claims under the contract is equivalent to three months of rolling sales. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, non-current other assets include KRW </span><span style="font-family:inherit;font-size:10pt;"><span>223 million</span></span><span style="font-family:inherit;font-size:10pt;"> (USD </span><span style="font-family:inherit;font-size:10pt;"><span>$185,000</span></span><span style="font-family:inherit;font-size:10pt;">) underlying the contract, which can be utilized by the Cooperative to fund any outstanding member claims. The Company believes that the likelihood of utilizing these funds to provide for members claims is remote.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, two putative securities class action complaints were filed against the Company and its top executives. On March 29, 2016, the court consolidated these actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and (ii) Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of its motion to dismiss on August 22, 2016. On December 5, 2016, the Court denied the Company’s motion to dismiss. On February 17, 2017, the Company filed an answer to the consolidated complaint. The Company believes that these claims are without merit and intends to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Li v. Natural Health Trends Corp</span><span style="font-family:inherit;font-size:10pt;">. A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 8, 2017. The Company believes that these claims are without merit and intend to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated class action and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Claims</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor. 1800000 1500000 777000 Future minimum lease obligations as of <span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>314</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1559000 752000 402000 314000 196000 700000 3923000 40000 9400000 223000000 185000 STOCKHOLDERS’ EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Authorized Shares</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> classes of capital stock consisting of up to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>5,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> par value, and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> par value. On May 4, 2007, the Board of Directors designated up to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>1,761,900</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock as Series A preferred stock with the following rights and preferences:</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Priority</span><span style="font-family:inherit;font-size:10pt;"> – the Series A preferred stock shall rank, in all respects, including the payment of dividends and upon liquidation, senior and prior to the common stock and other equity of the Company not expressly made senior or pari passu with the Series A preferred stock (collectively, “Junior Securities”).</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span><span style="font-family:inherit;font-size:10pt;"> –dividends at the rate per annum of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.119</span></span><span style="font-family:inherit;font-size:10pt;"> per share shall accrue from the date of issuance of any shares of Series A preferred stock, payable upon declaration by the Board of Directors. Accruing dividends shall be cumulative; provided, however, that except as set forth below for the liquidation preference, the Company shall be under no obligation to pay such dividends. No dividends shall be declared on Junior Securities (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Series A preferred stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series A preferred stock in an amount at least equal to the greater of (i) the amount of the aggregate accrued dividends on such share of Series A preferred stock and not previously paid and (ii) in the case of a dividend on common stock or any class or series of Junior Securities that is convertible into common stock, that dividend per share of Series A preferred stock as would equal the product of (1) the dividend payable on each share as if all shares of such class or series had been converted into common stock and (2) the number of shares of common stock issuable upon conversion of a share of Series A preferred stock.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidation preference</span><span style="font-family:inherit;font-size:10pt;"> – in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, then, before any distribution or payment shall be made to the holders of any Junior Securities, the holders of the Series A preferred stock then outstanding shall be entitled to be paid in cash out of the assets of the Company available for distribution to its stockholders (on a pari passu basis with the holders of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock) an amount per share equal to the sum of the Series A Original Issue Price plus any dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon. If the assets of the Company are insufficient to pay the aggregate liquidation preference and the liquidation preference of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock, the holders of the Series A preferred stock and the holders of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock shall share ratably with one another in any such distribution or payment in proportion to the full amounts to which they would otherwise be respectively entitled before any distribution shall be made to the holders of the Junior Securities. The “Series A Original Issue Price” shall mean </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$1.70</span></span><span style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Voting rights</span><span style="font-family:inherit;font-size:10pt;"> – the holders of shares of Series A preferred stock shall be entitled to vote with the holders of the common stock, and with the holders of any other series of preferred stock, voting together as a single class, upon all matters submitted to a vote of stockholders of the Company. Each holder of shares of Series A preferred stock shall be entitled to the number of votes equal to the product (rounded down to the nearest number of whole shares) of </span><span style="font-family:inherit;font-size:10pt;"><span>0.729</span></span><span style="font-family:inherit;font-size:10pt;"> times the largest number of shares of common stock into which all shares of Series A preferred stock held of record by such holder could then be converted.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion</span><span style="font-family:inherit;font-size:10pt;"> – each share of Series A preferred stock shall be convertible, subject to adjustment only in the event of stock splits, stock dividends, recapitalizations and similar events that would affect all of stockholders, at the option of the holder thereof, at any time and from time to time, into such number of fully paid and nonassessable shares of common stock as determined by dividing the Series A Original Issue Price by the Series A Conversion Price (as defined) in effect at the time of conversion. The “Series A Conversion Price” shall initially be equal to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$1.70</span></span><span style="font-family:inherit;font-size:10pt;">. Each share of Series A preferred stock shall automatically be converted into shares of common stock at the then effective conversion price immediately upon such date as the average closing price of the common stock over a consecutive, trailing </span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;">-month period equals or exceeds </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$10.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 3, 2014, the Company filed a Certificate of Elimination of the Series A Convertible Preferred Stock (the “Certificate”) with the Secretary of State of the State of Delaware. The Certificate, which was effective upon filing, canceled the Company’s Series A preferred stock. At the time of filing the Certificate, no shares of Series A preferred stock remained outstanding as a result of the automatic conversion of all outstanding shares into the Company’s common stock due to the fact that the average closing price of the Company’s common stock equaled or exceeded </span><span style="font-family:inherit;font-size:10pt;">$10.00</span><span style="font-family:inherit;font-size:10pt;"> per share over a consecutive, trailing </span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;">-month period that ended November 18, 2014.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Purchase Warrants</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 19, 2007, the Company issued warrants to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>3,141,499</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in connection with a convertible debentures financing. The warrants consisted of </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year warrants to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>1,495,952</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year warrants to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>1,495,952</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, and </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year warrants to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>149,595</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. The term for each of the warrants began six months and one day after their respective issuance and each have an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.52</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The exercise price and the number of shares underlying the warrants are subject to adjustment for stock dividends and splits, combinations, and reclassifications, certain rights offerings and distributions to common stockholders, and mergers, consolidations, sales of all or substantially all assets, tender offers, exchange offers, reclassifications or compulsory share exchanges. In addition, subject to certain exceptions, the exercise price and number of shares underlying the warrants are subject to anti-dilution adjustments from time to time if the Company issues its common stock or equivalent securities at below the exercise price for the warrants. If, at any time after the earlier of October 19, 2008 and the completion of the then applicable holding period under Rule 144, there is no effective registration statement for the underlying shares of common stock that are then required to be registered, the warrants may be exercised by means of a cashless exercise. Such </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year warrants expired unexercised on April 21, 2009 and such </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year warrants expired unexercised on April 21, 2013. </span><span style="font-family:inherit;font-size:10pt;">Seven</span><span style="font-family:inherit;font-size:10pt;">-year warrants to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>1,407,855</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were exercised during 2014 at exercise prices ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5108</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$3.52</span></span><span style="font-family:inherit;font-size:10pt;"> per share for total proceeds of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the cash dividends declared on each share of outstanding common stock and in accordance with the terms of the related warrant agreement, the exercise price per share for each warrant was adjusted from </span><span style="font-family:inherit;font-size:10pt;"><span>$3.52</span></span><span style="font-family:inherit;font-size:10pt;"> per share to </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5082</span></span><span style="font-family:inherit;font-size:10pt;"> per share. In April 2015, the remaining warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>88,097</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were exercised at </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5043</span></span><span style="font-family:inherit;font-size:10pt;"> per share for total proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$309,000</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the Company’s cash dividend activity during 2016, 2015 and 2014 (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 19, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 26, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 21, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 20, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 24, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,891</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 20, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 28, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>489</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 28, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 4, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 29, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 27, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 4, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.010</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">December 3, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 29, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 27, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 6, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">June 4, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 7, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.815</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">April 8, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.894</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.030</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Treasury Stock</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, the Company purchased a total of </span><span style="font-family:inherit;font-size:10pt;"><span>903,031</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 28, 2015, the Board of Directors approved a stock repurchase program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s outstanding shares of common stock. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, are anticipated to be conducted through December 2016, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act.  For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases.  The repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. In connection therewith, the Company was advised that George K. Broady, a director of the Company and owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 8. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During August 2015, pursuant to the foregoing stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The open market repurchases were completed on August 4, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>162,442</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. During October 2015, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The open market repurchases were completed on October 30, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>106,264</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 4, 2015, the Board of Directors approved a separate, prior stock repurchase program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s outstanding shares of common stock.  In connection therewith, the Company was advised by Mr. Broady that he would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest (see Note 8). As such, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, was completed on May 13, 2015, and resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>186,519</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 22, 2015, the Company entered into a stock repurchase agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of </span><span style="font-family:inherit;font-size:10pt;"><span>91,817</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock, which would be purchased at the rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares each trading day following the date of the agreement until all of such shares were purchased (see Note 8). The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock is publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 4, 2014, the Board of Directors approved a special stock repurchase program of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s outstanding shares of common stock (the “Repurchase Plan”). In connection therewith, the Company was advised that Mr. Broady desired to participate in the Repurchase Plan on a basis roughly proportional to his family’s ownership interest, with an estimate of generating approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> through the sale of a portion of the shares of the Company’s common stock held by him (see Note 8). After noting Mr. Broady’s participation interest, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The Repurchase Plan was completed on December 17, 2014. The Repurchase Plan, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of </span><span style="font-family:inherit;font-size:10pt;"><span>359,840</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>100,000</span></span> shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing shares in December 2012. The latest 10b5-1 plan terminated in November 2014 and the Company, as Trustee, has not entered into a new 10b5-1 plan. Se 5000000 0.001 50000000 0.001 1761900 0.119 1.70 0.729 1.70 10.00 3141499 1495952 1495952 149595 3.52 1407855 3.5108 3.52 4900000 3.52 3.5082 88097 3.5043 309000 The following tables summarize the Company’s cash dividend activity during 2016, 2015 and 2014 (in thousands, except per share data):<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 23, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 25, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 19, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 26, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 21, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 20, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 24, 2016</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,891</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 20, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 28, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>489</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 28, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 4, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 29, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 27, 2015</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 4, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.010</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">December 3, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 29, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 27, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 6, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.020</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">June 4, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 7, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.815</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">April 8, 2014</span></span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.894</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.030</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.35 3941000 2016-11-25 0.08 901000 2016-11-25 0.07 787000 2016-08-26 0.06 686000 2016-05-20 0.05 576000 2016-03-24 0.61 6891000 0.05 598000 2015-11-20 0.04 489000 2015-08-28 0.03 372000 2015-05-29 0.02 250000 2015-03-27 0.14 1709000 0.032 0.010 128000 2014-12-03 0.027 0.010 127000 2014-08-27 0.020 0.005 62000 2014-06-04 0.815 0.005 159000 2014-04-08 0.894 0.030 476000 15000000.0 70000000.0 903031 23700000 32000000.0 70000000.0 15000000.0 3500000 162442 5000000.0 3600000 106264 5000000.0 5000000.0 3500000 186519 5000000.0 91817 5000 1100000 5000000.0 1500000 3000000.0 359840 4500000 100000 STOCK-BASED COMPENSATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$104,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$86,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$49,000</span></span><span style="font-family:inherit;font-size:10pt;"> for 2016, 2015 and 2014, respectively. </span><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;"> tax benefits were attributed to the stock-based compensation because a valuation allowance was maintained for substantially all net deferred tax assets. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense for the three months ended March 31, 2016.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 8, 2016, the Company initially granted </span><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 20, 2015, the Company’s Board of Directors granted </span><span style="font-family:inherit;font-size:10pt;"><span>60,960</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and its then-existing outside directors for the purpose of further aligning their interest with those of its stockholders and as to the employee shares, settling fiscal 2014 performance incentives. The shares vest on a quarterly basis over the next </span><span style="font-family:inherit;font-size:10pt;">three years</span><span style="font-family:inherit;font-size:10pt;"> and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances. On February 11, 2015, the Board of Directors granted an additional </span><span style="font-family:inherit;font-size:10pt;"><span>6,116</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to its newly-elected outside directors subject to the same conditions.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s other restricted stock activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested restricted stock was </span><span style="font-family:inherit;font-size:10pt;"><span>$38,000</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>100,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing in December 2012. The latest 10b5-1 plan terminated in November 2014, and the Company, as Trustee, did not enter into a new 10b5-1 plan. The employees received the stock as incentive compensation in quarterly increments over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years beginning March 15, 2013, provided that they were employees of the Company on the date of the distribution. Any common stock that was forfeited by an employee whose employment terminated was delivered to the Company and held as treasury stock.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Grant-Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2013</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,342</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 104000 86000 49000 64000 2500000 51015 0 0 51015 34.13 12759 34.13 38256 34.13 60960 6116 The following table summarizes the Company’s other restricted stock activity:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,076</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,712</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested restricted stock was </span><span style="font-family:inherit;font-size:10pt;"><span>$38,000</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span>. 0 0 67076 12.15 22364 12.15 44712 12.15 0 0 22364 12.15 22348 12.15 38000 P1Y 100000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Grant-Date Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2013</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,342</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 53324 1.37 25342 1.37 3998 1.37 23984 1.37 23984 1.37 0 0 0 0 INCOME TAXES<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of income before income taxes consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,077</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the income tax provision consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax at federal statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,713</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,099</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,240</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory Tax Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cayman Islands</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,267</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,493</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,014</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,902</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,650</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(415</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2016, the Company has released its valuation allowance against its U.S. deferred tax assets. In addition to having a net deferred tax liability and no indefinite lived intangibles, the Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets in future periods or carryback years.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2016, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall deferred tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. As of December 31, 2016, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> U.S. federal net operating loss or credit carryforwards as any remaining attributes are expected to be fully utilized to offset tax in the current year.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At December 31, 2016, the Company has foreign net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in various jurisdictions with various expirations.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of December 31, 2016, the Company has recorded a deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2016.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries. The components of income before income taxes consist of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,077</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,793</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -3106000 -7820000 4502000 67183000 55613000 16134000 64077000 47793000 20636000 The components of the income tax provision consist of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 7151000 12000 104000 -81000 100000 11000 1648000 456000 194000 8718000 568000 309000 273000 -16000 -43000 8991000 552000 266000 A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax at federal statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,713</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18,099</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,240</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(342</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>552</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 22427000 16250000 7016000 12496000 370000 9000 -3877000 2017000 -2070000 -21713000 -18099000 -5240000 -342000 14000 551000 8991000 552000 266000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory Tax Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cayman Islands</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,267</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,645</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,855</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,493</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 58169000 50993000 16267000 0.165 3992000 2645000 1129000 0.250 3855000 1493000 153000 Deferred income taxes consist of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,014</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,902</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,650</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(415</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> 235000 3197000 623000 0 3174000 3367000 0 418000 0 32000 4032000 7014000 235000 4112000 3797000 2902000 3650000 2789000 415000 173000 4065000 2962000 268000 60000 0 1300000 19800000 SUPPLEMENTAL CASH FLOW INFORMATION<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid during the year for:</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In Thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes, net of refunds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash financing activity:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conversion of preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> SUPPLEMENTAL CASH FLOW INFORMATION<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid during the year for:</span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In Thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes, net of refunds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash financing activity:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conversion of preferred stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>666</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 8791000 707000 60000 9000 0 1000 0 0 111000 1741000 666000 0 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Royalties</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Soothe</span><span style="font-family:inherit;font-size:10pt;">™. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Mr. Broady is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Further, the Company agreed to pay BHS </span><span style="font-family:inherit;font-size:10pt;"><span>$11,700</span></span><span style="font-family:inherit;font-size:10pt;"> as royalties for the period it began selling the product in the fourth quarter of 2012 through 2014. The Company recognized royalties of </span><span style="font-family:inherit;font-size:10pt;"><span>$3,400</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6,400</span></span><span style="font-family:inherit;font-size:10pt;"> during 2016, 2015 and 2014, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">’ notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor™.</span><span style="font-family:inherit;font-size:10pt;">  Under this agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty and Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. This provision was effective retroactive to January 1, 2015.  The Company recognized royalties of </span><span style="font-family:inherit;font-size:10pt;"><span>$475,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$555,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$144,000</span></span><span style="font-family:inherit;font-size:10pt;"> during 2016, 2015 and 2014, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>120</span></span><span style="font-family:inherit;font-size:10pt;"> days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchase</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Agreements</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 28, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>0.4066</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on November 2, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 4.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 31, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>0.4085</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on August 6, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 4.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 7, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>0.4286</span></span><span style="font-family:inherit;font-size:10pt;"> times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 4, 2015. The Company’s purchases from Mr. Broady concluded on May 13, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company's broker in its open-market purchases, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 4.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 22, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of </span><span style="font-family:inherit;font-size:10pt;"><span>91,817</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock, which would be purchased at the rate of </span><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares each trading day following the date of the agreement until all of such shares were purchased. The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock was publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. See Note 4.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On November 14, 2014, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady of one-half of the number of shares of common stock purchased by the Company’s broker in the open market under the Repurchase Plan approved by the Company’s Board of Directors on November 4, 2014. The Stock Repurchase Agreement with Mr. Broady required that the Company report to Mr. Broady on a weekly basis information regarding the broker’s open market purchases, and that the Company purchase from Mr. Broady on a weekly basis at a per share purchase price equal to the weighted average price per share paid by the Company’s broker to purchase shares in the open market. The Company’s purchases concluded on December 17, 2014, totaled </span><span style="font-family:inherit;font-size:10pt;"><span>119,947</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock and resulted in an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$1.5 million</span></span>. See Note 4. 0.025 11700 3400 7000 6400 P120DT0H 0.025 475000 555000 144000 P120DT0H 0.4066 1400000 0.4085 1500000 0.4286 1500000 91817 5000 1100000 119947 1500000 EMPLOYEE BENEFIT PLANS<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">      The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span><span style="font-family:inherit;font-size:10pt;"> of their compensation, subject to limitations established by the Internal Revenue Service. Employees age </span><span style="font-family:inherit;font-size:10pt;"><span>21</span></span><span style="font-family:inherit;font-size:10pt;"> and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2016, 2015 and 2014, the Company matched employee deferral contributions up to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>4.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of salary, which vested </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$134,000</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$115,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$60,000</span></span> for 2016, 2015 and 2014, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature. 0.90 P21Y0M0D 0.045 1 134000 115000 60000 SEGMENT INFORMATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform. Outside of the China e-commerce retail platform, the Company believes that all of its other operating segments have similar economic characteristics, except for its operations located within the Commonwealth of Independent States (“CIS”). In making this determination, the Company believes that its operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. The Company’s engagement of a third-party service provider in the CIS market results in a different economic structure than its other markets. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">However, there is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the either Chinese or the CIS markets on a stand-alone basis, and neither market is material for the two years presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by geographic area are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales from external customers:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263,482</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,965</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,009</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,234</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Company</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">discontinued its Ukraine operations during the second quarter of 2015.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by product and service are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales by product and service:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,843</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s long-lived assets by geographic area are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The Company’s net sales by geographic area are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales from external customers:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263,482</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,965</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,009</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,234</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 4100000 3246000 1438000 1809000 2746000 1374000 263482000 245737000 111028000 9086000 4425000 1538000 6213000 5965000 4628000 691000 1129000 1009000 858000 1139000 3113000 1234000 382000 373000 255000 91000 89000 287728000 264860000 124590000 The Company’s net sales by product and service are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales by product and service:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,843</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 269731000 253041000 118843000 25616000 17623000 7927000 7619000 5804000 2180000 287728000 264860000 124590000 The Company’s long-lived assets by geographic area are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 763000 283000 140000 204000 199000 252000 286000 155000 1388000 894000 SUBSEQUENT EVENTS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.09</span></span><span style="font-family:inherit;font-size:10pt;"> and a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.35</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends were paid on </span><span style="font-family:inherit;font-size:10pt;">March 3, 2017</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">February 21, 2017</span><span style="font-family:inherit;font-size:10pt;">. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On January 24, 2017, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of settling fiscal 2016 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances. 0.09 0.35 56260 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2016
Feb. 24, 2017
Jun. 30, 2016
Document And Entity Information      
Entity Registrant Name NATURAL HEALTH TRENDS CORP.    
Entity Central Index Key 0000912061    
Current Fiscal Year End Date --12-31    
Entity Filer Category Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Common Stock, Shares Outstanding (in shares)   11,341,890  
Entity Public Float     $ 202,402,875
Document Type 10-K    
Document Period End Date Dec. 31, 2016    
Document Fiscal Year Focus 2016    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 125,921 $ 104,914
Inventories, net 11,257 10,455
Other current assets 4,066 2,343
Total current assets 141,244 117,712
Property and equipment, net 1,388 894
Goodwill 1,764 1,764
Restricted cash 2,963 3,166
Other assets 692 616
Total assets 148,051 124,152
Current liabilities:    
Accounts payable 2,145 2,862
Income taxes payable 663 379
Accrued commissions 13,611 19,634
Other accrued expenses 14,989 16,703
Deferred revenue 4,948 4,011
Amounts held in eWallets 19,165 16,414
Other current liabilities 1,633 1,510
Total current liabilities 57,154 61,513
Deferred Tax Liabilities, Net, Noncurrent 268 60
Long-term incentive 8,190 5,770
Total liabilities 65,612 67,343
Commitments and Contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and 2015 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2016 and 2015 13 13
Additional paid-in capital 86,574 85,963
Retained earnings (accumulated deficit) 38,548 (9,647)
Accumulated other comprehensive (loss) income (807) (101)
Treasury stock, at cost; 1,692,218 and 840,202 shares at December 31, 2016 and 2015, respectively (41,889) (19,419)
Total stockholders’ equity 82,439 56,809
Total liabilities and stockholders’ equity $ 148,051 $ 124,152
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0.000 0.000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 12,979,414 12,979,414
Treasury stock, shares 1,692,218 840,202
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Income Statement [Abstract]      
Net sales $ 287,728 $ 264,860 $ 124,590
Cost of sales 54,903 54,098 26,981
Gross profit 232,825 210,762 97,609
Operating expenses:      
Commissions expense 125,050 126,598 56,997
Selling, general and administrative expenses 43,245 36,024 19,687
Depreciation and amortization 394 263 105
Total operating expenses 168,689 162,885 76,789
Income from operations 64,136 47,877 20,820
Other expense, net (59) (84) (184)
Income before income taxes 64,077 47,793 20,636
Income tax provision 8,991 552 266
Net income 55,086 47,241 20,370
Preferred stock dividends 0 0 (10)
Net income available to common stockholders $ 55,086 $ 47,241 $ 20,360
Income per common share:      
Basic (in dollars per share) $ 4.84 $ 3.84 $ 1.67
Diluted (in dollars per share) $ 4.83 $ 3.82 $ 1.61
Weighted-average number of common shares outstanding:      
Basic (in shares) 11,382 12,302 12,131
Diluted (in shares) 11,407 12,372 12,600
Common Stock, Dividends, Per Share, Cash Paid $ 0.61 $ 0.14 $ 0.030
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Statement of Comprehensive Income [Abstract]      
Net income $ 55,086 $ 47,241 $ 20,370
Other comprehensive income, net of tax:      
Foreign currency translation adjustments (838) (79) 143
Release of cumulative translation adjustment 132 (82) 0
Net change in foreign currency translation adjustment (706) (161) 143
Unrealized losses on available-for-sale securities 0 (2) 0
Comprehensive income $ 54,380 $ 47,078 $ 20,513
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive (Loss) Income
Treasury Stock
Treasury stock, shares             26,998
Common stock, shares issued     11,359,769        
Preferred stock, shares outstanding   123,693          
Conversion of Stock, Shares Converted   (123,693)          
Conversion of Stock, Amount Converted $ 111 $ (111)          
Conversion of Stock, Shares Issued     123,693        
Conversion of Stock, Amount Issued       $ 111      
BALANCE at Dec. 31, 2013 6,077 111 $ 11 80,690 $ (74,619) $ (81) $ (35)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 20,370       20,370    
Exercise of warrants (in shares)     1,407,855        
Exercise of warrants $ 4,948   $ 2 4,946      
Repurchase of common stock (in shares) (1,407,855)           (382,564)
Repurchase of common stock $ (4,661)           $ (4,661)
Shares issued for stock-based compensation awards (in shares)             25,342
Shares issued for stock-based compensation awards 0     (46) (74)   $ 120
Dividends declared (476)       (476)    
Elimination of CTA upon dissolution 0            
Foreign currency translation adjustments 143         143  
Unrealized loss on available-for-sale securities 0            
Stock-based compensation 49     49      
BALANCE at Dec. 31, 2014 26,450 $ 0 $ 13 85,750 (54,799) 62 $ (4,576)
Treasury stock, shares             384,220
Common stock, shares issued     12,891,317        
Preferred stock, shares outstanding   0          
Conversion of Stock, Amount Converted 0            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 47,241       47,241    
Exercise of warrants (in shares)     88,097        
Exercise of warrants 309     309      
Repurchase of common stock (in shares)             (547,042)
Repurchase of common stock (16,071)           $ (16,071)
Shares issued for stock-based compensation awards (in shares)             91,060
Shares issued for stock-based compensation awards 666     (182) (380)   $ 1,228
Dividends declared (1,709)       (1,709)    
Elimination of CTA upon dissolution (82)         (82)  
Foreign currency translation adjustments (79)         (79)  
Unrealized loss on available-for-sale securities (2)         (2)  
Stock-based compensation 86     86      
BALANCE at Dec. 31, 2015 $ 56,809 $ 0 $ 13 85,963 (9,647) (101) $ (19,419)
Treasury stock, shares (840,202)           (840,202)
Common stock, shares issued 12,979,414   12,979,414        
Preferred stock, shares outstanding   0          
Conversion of Stock, Amount Converted $ 0            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income $ 55,086       55,086    
Repurchase of common stock (in shares) (903,031)           (903,031)
Repurchase of common stock $ (23,704)           $ (23,704)
Shares issued for stock-based compensation awards (in shares)             51,015
Shares issued for stock-based compensation awards 1,741     507     $ 1,234
Dividends declared (6,891)       (6,891)    
Elimination of CTA upon dissolution 132         132  
Foreign currency translation adjustments (838)         (838)  
Unrealized loss on available-for-sale securities 0            
Stock-based compensation 104     104      
BALANCE at Dec. 31, 2016 $ 82,439 $ 0 $ 13 $ 86,574 $ 38,548 $ (807) $ (41,889)
Treasury stock, shares (1,692,218)           (1,692,218)
Common stock, shares issued 12,979,414   12,979,414        
Preferred stock, shares outstanding   0          
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income $ 55,086 $ 47,241 $ 20,370
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 394 263 105
Stock-based compensation 104 86 49
Cumulative translation adjustment realized in net income 132 (82) 0
Deferred Income Tax Expense (Benefit) 217 (15) (43)
Changes in assets and liabilities:      
Inventories, net (851) (6,762) (2,029)
Other current assets (1,681) (1,025) (501)
Other assets (90) (267) (85)
Accounts payable (714) 637 (822)
Income taxes payable 303 (115) 243
Accrued commissions (6,031) 10,840 5,077
Other accrued expenses 51 10,714 3,706
Deferred revenue 947 1,331 147
Amounts held in eWallets 2,752 14,350 2,065
Other current liabilities 135 25 666
Long-term incentive 2,420 4,105 1,665
Net cash provided by operating activities 53,174 81,326 30,613
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchases of property and equipment (905) (710) (339)
Increase in restricted cash 0 (3,028) 0
Net cash used in investing activities (905) (3,738) (339)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from exercise of warrants 0 309 4,948
Repurchase of common stock (23,704) (16,071) (4,661)
Dividends paid (6,891) (1,709) (476)
Net cash used in financing activities (30,595) (17,471) (189)
Effect of exchange rates on cash and cash equivalents (667) (19) 181
Net increase in cash and cash equivalents 21,007 60,098 30,266
CASH AND CASH EQUIVALENTS, beginning of period 104,914 44,816 14,550
CASH AND CASH EQUIVALENTS, end of period $ 125,921 $ 104,914 $ 44,816
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was $1.8 million, $1.5 million and $777,000 during 2016, 2015 and 2014, respectively.
 
Future minimum lease obligations as of December 31, 2016 are as follows (in thousands):
2017
$
1,559

2018
752

2019
402

2020
314

2021
196

Thereafter
700

Total minimum lease obligations
$
3,923



Purchase Commitments

In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2016, the Company was in compliance with the exclusivity provision.
 
In February 2016, the Company amended a supply agreement with one of its suppliers to maintain worldwide exclusivity in return for purchasing a minimum of $9.4 million of product annually on average over the next three years, plus certain raw material guarantees. If the Company does not purchase the minimum product as required, then a Cure Payment, as defined, will be due to the supplier. The term of the agreement is three years commencing February 2016 and shall automatically renew for successive three year terms unless notice of termination is provided by either party.

Employment Agreements
 
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.
 
Consumer Indemnity
 
As required by the Door-to-Door Sales Act in South Korea, the Company maintains insurance for consumer indemnity claims with a mutual aid cooperative by possessing a mutual aid contract with Mutual Aid Cooperative & Consumer (the “Cooperative”). The contract secures payment to members in the event that the Company is unable to provide refunds to members. Typically, requests for refunds are paid directly by the Company according to the Company’s normal Korean refund policy, which requires that refund requests be submitted within three months. Accordingly, the Company estimates and accrues a reserve for product returns based on this policy and its historical experience. Depending on the sales volume, the Company may be required to increase or decrease the amount of the contract. The maximum potential amount of future payments the Company could be required to make to address actual member claims under the contract is equivalent to three months of rolling sales. At December 31, 2016, non-current other assets include KRW 223 million (USD $185,000) underlying the contract, which can be utilized by the Cooperative to fund any outstanding member claims. The Company believes that the likelihood of utilizing these funds to provide for members claims is remote.

Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives. On March 29, 2016, the court consolidated these actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and (ii) Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of its motion to dismiss on August 22, 2016. On December 5, 2016, the Court denied the Company’s motion to dismiss. On February 17, 2017, the Company filed an answer to the consolidated complaint. The Company believes that these claims are without merit and intends to vigorously defend against them.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 8, 2017. The Company believes that these claims are without merit and intend to vigorously defend against them.

The consolidated class action and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2016
Stockholders' Equity Note [Abstract]  
Stockholders' Equity STOCKHOLDERS’ EQUITY
 
Authorized Shares
 
The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value. On May 4, 2007, the Board of Directors designated up to 1,761,900 shares of preferred stock as Series A preferred stock with the following rights and preferences:

Priority – the Series A preferred stock shall rank, in all respects, including the payment of dividends and upon liquidation, senior and prior to the common stock and other equity of the Company not expressly made senior or pari passu with the Series A preferred stock (collectively, “Junior Securities”).

Dividends –dividends at the rate per annum of $0.119 per share shall accrue from the date of issuance of any shares of Series A preferred stock, payable upon declaration by the Board of Directors. Accruing dividends shall be cumulative; provided, however, that except as set forth below for the liquidation preference, the Company shall be under no obligation to pay such dividends. No dividends shall be declared on Junior Securities (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Series A preferred stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series A preferred stock in an amount at least equal to the greater of (i) the amount of the aggregate accrued dividends on such share of Series A preferred stock and not previously paid and (ii) in the case of a dividend on common stock or any class or series of Junior Securities that is convertible into common stock, that dividend per share of Series A preferred stock as would equal the product of (1) the dividend payable on each share as if all shares of such class or series had been converted into common stock and (2) the number of shares of common stock issuable upon conversion of a share of Series A preferred stock.

Liquidation preference – in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, then, before any distribution or payment shall be made to the holders of any Junior Securities, the holders of the Series A preferred stock then outstanding shall be entitled to be paid in cash out of the assets of the Company available for distribution to its stockholders (on a pari passu basis with the holders of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock) an amount per share equal to the sum of the Series A Original Issue Price plus any dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon. If the assets of the Company are insufficient to pay the aggregate liquidation preference and the liquidation preference of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock, the holders of the Series A preferred stock and the holders of any series of preferred stock ranking on liquidation on a parity with the Series A preferred stock shall share ratably with one another in any such distribution or payment in proportion to the full amounts to which they would otherwise be respectively entitled before any distribution shall be made to the holders of the Junior Securities. The “Series A Original Issue Price” shall mean $1.70 per share, subject to adjustment.

Voting rights – the holders of shares of Series A preferred stock shall be entitled to vote with the holders of the common stock, and with the holders of any other series of preferred stock, voting together as a single class, upon all matters submitted to a vote of stockholders of the Company. Each holder of shares of Series A preferred stock shall be entitled to the number of votes equal to the product (rounded down to the nearest number of whole shares) of 0.729 times the largest number of shares of common stock into which all shares of Series A preferred stock held of record by such holder could then be converted.

 Conversion – each share of Series A preferred stock shall be convertible, subject to adjustment only in the event of stock splits, stock dividends, recapitalizations and similar events that would affect all of stockholders, at the option of the holder thereof, at any time and from time to time, into such number of fully paid and nonassessable shares of common stock as determined by dividing the Series A Original Issue Price by the Series A Conversion Price (as defined) in effect at the time of conversion. The “Series A Conversion Price” shall initially be equal to $1.70. Each share of Series A preferred stock shall automatically be converted into shares of common stock at the then effective conversion price immediately upon such date as the average closing price of the common stock over a consecutive, trailing 6-month period equals or exceeds $10.00 per share.

On December 3, 2014, the Company filed a Certificate of Elimination of the Series A Convertible Preferred Stock (the “Certificate”) with the Secretary of State of the State of Delaware. The Certificate, which was effective upon filing, canceled the Company’s Series A preferred stock. At the time of filing the Certificate, no shares of Series A preferred stock remained outstanding as a result of the automatic conversion of all outstanding shares into the Company’s common stock due to the fact that the average closing price of the Company’s common stock equaled or exceeded $10.00 per share over a consecutive, trailing 6-month period that ended November 18, 2014.
 
Common Stock Purchase Warrants
 
On October 19, 2007, the Company issued warrants to purchase 3,141,499 shares of common stock in connection with a convertible debentures financing. The warrants consisted of seven-year warrants to purchase 1,495,952 shares of common stock, one-year warrants to purchase 1,495,952 shares of common stock, and five-year warrants to purchase 149,595 shares of common stock. The term for each of the warrants began six months and one day after their respective issuance and each have an exercise price of $3.52 per share. The exercise price and the number of shares underlying the warrants are subject to adjustment for stock dividends and splits, combinations, and reclassifications, certain rights offerings and distributions to common stockholders, and mergers, consolidations, sales of all or substantially all assets, tender offers, exchange offers, reclassifications or compulsory share exchanges. In addition, subject to certain exceptions, the exercise price and number of shares underlying the warrants are subject to anti-dilution adjustments from time to time if the Company issues its common stock or equivalent securities at below the exercise price for the warrants. If, at any time after the earlier of October 19, 2008 and the completion of the then applicable holding period under Rule 144, there is no effective registration statement for the underlying shares of common stock that are then required to be registered, the warrants may be exercised by means of a cashless exercise. Such one-year warrants expired unexercised on April 21, 2009 and such five-year warrants expired unexercised on April 21, 2013. Seven-year warrants to purchase 1,407,855 shares of common stock were exercised during 2014 at exercise prices ranging from $3.5108 to $3.52 per share for total proceeds of $4.9 million. As a result of the cash dividends declared on each share of outstanding common stock and in accordance with the terms of the related warrant agreement, the exercise price per share for each warrant was adjusted from $3.52 per share to $3.5082 per share. In April 2015, the remaining warrants to purchase 88,097 shares of common stock were exercised at $3.5043 per share for total proceeds of $309,000.
 
Dividends
 
The following tables summarize the Company’s cash dividend activity during 2016, 2015 and 2014 (in thousands, except per share data):

Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 

 
 
Dividends Per Share
 
 
 
 
Declaration Date
 
Preferred
 
Common
 
Amount
 
Payment Date
November 4, 2014
 
$
0.032

 
$
0.010

 
$
128

 
December 3, 2014
July 29, 2014
 
0.027

 
0.010

 
127

 
August 27, 2014
May 6, 2014
 
0.020

 
0.005

 
62

 
June 4, 2014
March 7, 2014
 
0.815

 
0.005

 
159

 
April 8, 2014
Total
 
$
0.894

 
$
0.030

 
$
476

 
 

 
Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Treasury Stock

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the year ended December 31, 2016, the Company purchased a total of 903,031 shares of its common stock for an aggregate purchase price of $23.7 million, plus transaction costs. As of December 31, 2016, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

On July 28, 2015, the Board of Directors approved a stock repurchase program of up to $15.0 million of the Company’s outstanding shares of common stock. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, are anticipated to be conducted through December 2016, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act.  For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases.  The repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. In connection therewith, the Company was advised that George K. Broady, a director of the Company and owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest. See Note 8.

During August 2015, pursuant to the foregoing stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million. The open market repurchases were completed on August 4, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 162,442 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. During October 2015, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.6 million. The open market repurchases were completed on October 30, 2015. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 106,264 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs.

On May 4, 2015, the Board of Directors approved a separate, prior stock repurchase program of up to $5.0 million of the Company’s outstanding shares of common stock.  In connection therewith, the Company was advised by Mr. Broady that he would participate in the stock repurchase program on a basis roughly proportional to his family’s ownership interest (see Note 8). As such, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.5 million in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The stock repurchase program, which included both open market purchases and the purchase of shares from Mr. Broady, was completed on May 13, 2015, and resulted in the Company purchasing a total of 186,519 shares of its common stock for an aggregate purchase price of $5.0 million, plus transaction costs. 

On January 22, 2015, the Company entered into a stock repurchase agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased (see Note 8). The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock is publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million.
 
On November 4, 2014, the Board of Directors approved a special stock repurchase program of up to $5.0 million of the Company’s outstanding shares of common stock (the “Repurchase Plan”). In connection therewith, the Company was advised that Mr. Broady desired to participate in the Repurchase Plan on a basis roughly proportional to his family’s ownership interest, with an estimate of generating approximately $1.5 million through the sale of a portion of the shares of the Company’s common stock held by him (see Note 8). After noting Mr. Broady’s participation interest, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $3.0 million in accordance with Rules 10b5-1 and 10b-18 under the Exchange Act. The Repurchase Plan was completed on December 17, 2014. The Repurchase Plan, which included both open market purchases and the purchase of shares from Mr. Broady, resulted in the Company purchasing a total of 359,840 shares of its common stock for an aggregate purchase price of $4.5 million, plus transaction costs. 
 
On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase 100,000 shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing shares in December 2012. The latest 10b5-1 plan terminated in November 2014 and the Company, as Trustee, has not entered into a new 10b5-1 plan. Se
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation STOCK-BASED COMPENSATION
 
Stock-based compensation expense totaled approximately $104,000, $86,000 and $49,000 for 2016, 2015 and 2014, respectively. No tax benefits were attributed to the stock-based compensation because a valuation allowance was maintained for substantially all net deferred tax assets. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted.

On April 8, 2016, the Company initially granted 51,015 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(12,759
)
 
34.13

Nonvested at December 31, 2016
38,256

 
34.13


On January 20, 2015, the Company’s Board of Directors granted 60,960 shares of restricted common stock to certain employees and its then-existing outside directors for the purpose of further aligning their interest with those of its stockholders and as to the employee shares, settling fiscal 2014 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances. On February 11, 2015, the Board of Directors granted an additional 6,116 shares of restricted common stock to its newly-elected outside directors subject to the same conditions.

The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2014

 
$

Granted
67,076

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2015
44,712

 
12.15

Granted

 

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2016
22,348

 
12.15


 
As of December 31, 2016, total unrecognized stock-based compensation expense related to non-vested restricted stock was $38,000, which is expected to be recognized over a weighted-average period of one year.

On August 13, 2012, the Board of Directors authorized the Company, acting as trustee for certain of its non-officer, overseas employees, to execute a Rule 10b5-1 plan to purchase 100,000 shares of its common stock in accordance with guidelines specified under Rule 10b5-1 of the Exchange Act and the Company’s policies regarding stock transactions.  Pursuant to this authority, the Company, as Trustee, entered into a 10b5-1 plan and began purchasing in December 2012. The latest 10b5-1 plan terminated in November 2014, and the Company, as Trustee, did not enter into a new 10b5-1 plan. The employees received the stock as incentive compensation in quarterly increments over three years beginning March 15, 2013, provided that they were employees of the Company on the date of the distribution. Any common stock that was forfeited by an employee whose employment terminated was delivered to the Company and held as treasury stock.
 
Shares
 
Wtd. Avg. Grant-Date Fair Value
Nonvested at December 31, 2013
53,324

 
$
1.37

Vested
(25,342
)
 
1.37

Forfeited
(3,998
)
 
1.37

Nonvested at December 31, 2014
23,984

 
1.37

Vested
(23,984
)
 
1.37

Forfeited

 

Nonvested at December 31, 2015

 

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes
12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
 
The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Domestic
$
(3,106
)
 
$
(7,820
)
 
$
4,502

Foreign
67,183

 
55,613

 
16,134

Income before income taxes
$
64,077

 
$
47,793

 
$
20,636


 
The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Current:
 
 
 
 
 
Federal
$
7,151

 
$
12

 
$
104

State
(81
)
 
100

 
11

Foreign
1,648

 
456

 
194

Total current taxes
8,718

 
568

 
309

Deferred taxes
273

 
(16
)
 
(43
)
Income tax provision
$
8,991

 
$
552

 
$
266



A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Income tax at federal statutory rate
$
22,427

 
$
16,250

 
$
7,016

Effect of permanent differences
12,496

 
370

 
9

Change in valuation allowance
(3,877
)
 
2,017

 
(2,070
)
Foreign rate differential
(21,713
)
 
(18,099
)
 
(5,240
)
Other reconciling items
(342
)
 
14

 
551

Income tax provision
$
8,991

 
$
552

 
$
266


 
Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2016
 
2015
 
2014
Cayman Islands
%
 
$
58,169

 
$
50,993

 
$
16,267

Hong Kong
16.5
%
 
3,992

 
2,645

 
1,129

China
25.0
%
 
3,855

 
1,493

 
153



Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Deferred tax assets:
 
 
 
Net operating losses
$
235

 
$
3,197

Stock-based compensation
623

 

Accrued expenses
3,174

 
3,367

Tax credits

 
418

Other

 
32

Total deferred tax assets
4,032

 
7,014

Valuation allowance
(235
)
 
(4,112
)
Net deferred tax assets
3,797

 
2,902

Deferred tax liabilities:
 
 
 
Foreign earnings
(3,650
)
 
(2,789
)
Other
(415
)
 
(173
)
Total deferred tax liabilities
(4,065
)
 
(2,962
)
Net deferred tax liability
$
(268
)
 
$
(60
)


As of December 31, 2016, the Company has released its valuation allowance against its U.S. deferred tax assets. In addition to having a net deferred tax liability and no indefinite lived intangibles, the Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets in future periods or carryback years.

As of December 31, 2016, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall deferred tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision. As of December 31, 2016, the Company has no U.S. federal net operating loss or credit carryforwards as any remaining attributes are expected to be fully utilized to offset tax in the current year.

At December 31, 2016, the Company has foreign net operating loss carryforwards of approximately $1.3 million in various jurisdictions with various expirations.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of December 31, 2016, the Company has recorded a deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2016.

The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information
12 Months Ended
Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information SUPPLEMENTAL CASH FLOW INFORMATION
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
 
 
 
 
 
Cash paid during the year for:
(In Thousands)
Income taxes, net of refunds
$
8,791

 
$
707

 
$
60

Interest
9

 

 
1

Non-cash financing activity:
 

 
 

 
 

Conversion of preferred stock

 

 
111

Issuance of treasury stock
1,741

 
666

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions
12 Months Ended
Dec. 31, 2016
Related Party Transactions [Abstract]  
Related Party Transactions RELATED PARTY TRANSACTIONS
 
Product Royalties
 
On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Mr. Broady is owner of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Further, the Company agreed to pay BHS $11,700 as royalties for the period it began selling the product in the fourth quarter of 2012 through 2014. The Company recognized royalties of $3,400, $7,000 and $6,400 during 2016, 2015 and 2014, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under this agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty and Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. This provision was effective retroactive to January 1, 2015.  The Company recognized royalties of $475,000, $555,000 and $144,000 during 2016, 2015 and 2014, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
 
Stock Repurchase Agreements
 
On October 28, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4066 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on November 2, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.4 million. See Note 4.

On July 31, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4085 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on July 28, 2015. The Company’s purchases from Mr. Broady concluded on August 6, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 4.

On May 7, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase of common stock from Mr. Broady in off-the-market, private transactions at a rate equal to 0.4286 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 4, 2015. The Company’s purchases from Mr. Broady concluded on May 13, 2015, were completed at a per share purchase price equal to the weighted average price per share paid by the Company's broker in its open-market purchases, and resulted in an aggregate purchase price of $1.5 million. See Note 4.

On January 22, 2015, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady in off-the-market, private transactions of a total of 91,817 shares of the Company’s common stock, which would be purchased at the rate of 5,000 shares each trading day following the date of the agreement until all of such shares were purchased. The shares were purchased at a per share price equal to the closing price per share of the Company’s common stock on the preceding trading day, as reported on the primary market in which the Company’s common stock was publicly traded. The Company’s purchases concluded on February 19, 2015, and resulted in an aggregate purchase price of $1.1 million. See Note 4.

On November 14, 2014, the Company entered into a Stock Repurchase Agreement with Mr. Broady that provided for the Company’s purchase from Mr. Broady of one-half of the number of shares of common stock purchased by the Company’s broker in the open market under the Repurchase Plan approved by the Company’s Board of Directors on November 4, 2014. The Stock Repurchase Agreement with Mr. Broady required that the Company report to Mr. Broady on a weekly basis information regarding the broker’s open market purchases, and that the Company purchase from Mr. Broady on a weekly basis at a per share purchase price equal to the weighted average price per share paid by the Company’s broker to purchase shares in the open market. The Company’s purchases concluded on December 17, 2014, totaled 119,947 shares of its common stock and resulted in an aggregate purchase price of $1.5 million. See Note 4.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Employee Benefit Plans
12 Months Ended
Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]  
Employee Benefit Plans EMPLOYEE BENEFIT PLANS
 
     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2016, 2015 and 2014, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $134,000, $115,000 and $60,000 for 2016, 2015 and 2014, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information
12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
 
The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform. Outside of the China e-commerce retail platform, the Company believes that all of its other operating segments have similar economic characteristics, except for its operations located within the Commonwealth of Independent States (“CIS”). In making this determination, the Company believes that its operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. The Company’s engagement of a third-party service provider in the CIS market results in a different economic structure than its other markets.

However, there is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the either Chinese or the CIS markets on a stand-alone basis, and neither market is material for the two years presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.
 
The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales from external customers:
 
 
 
 
 
United States
$
4,100

 
$
3,246

 
$
1,438

Canada
1,809

 
2,746

 
1,374

Hong Kong
263,482

 
245,737

 
111,028

China
9,086

 
4,425

 
1,538

Taiwan
6,213

 
5,965

 
4,628

South Korea
691

 
1,129

 
1,009

Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)1
858

 
1,139

 
3,113

Europe
1,234

 
382

 
373

Other foreign countries
255

 
91

 
89

Total net sales
$
287,728

 
$
264,860

 
$
124,590


1 The Company discontinued its Ukraine operations during the second quarter of 2015.
 
The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales by product and service:
 
 
 
 
 
Product sales
$
269,731

 
$
253,041

 
$
118,843

Enrollment package revenue, freight and other
25,616

 
17,623

 
7,927

Less: sales returns
(7,619
)
 
(5,804
)
 
(2,180
)
Total net sales
$
287,728

 
$
264,860

 
$
124,590


 
Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2016
 
2015
Long-lived assets:
 
 
 
United States
$
763

 
$
283

Hong Kong
140

 
204

China
199

 
252

Other foreign countries
286

 
155

Total long-lived assets
$
1,388

 
$
894

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2016
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS

On January 24, 2017, the Board of Directors declared a cash dividend of $0.09 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends were paid on March 3, 2017 to stockholders of record on February 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of settling fiscal 2016 performance incentives. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Nature of Operations and Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2016
Accounting Policies [Abstract]  
Principles of Consolidation Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
Reclassification, Policy [Policy Text Block] Reclassification
 
Certain accounts receivable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. No change in total current assets occurred. Additionally, deferred tax liability balances have been reclassified from current to long-term in the prior year consolidated financial statements to conform to the early adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes.
Cash and Cash Equivalents Cash and Cash Equivalents
 
As of December 31, 2016, cash and cash equivalents include $6.8 million held in banks located within China subject to foreign currency controls. The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

Additionally, as of December 31, 2016, cash and cash equivalents include the Company's investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2016 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders' equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
Restricted Cash Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 2.9 million at December 31, 2016) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
Inventories Inventories
 
Inventories consist primarily of finished goods and are stated at the lower of cost or market, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. At December 31, 2016 and 2015, the reserve for obsolescence totaled $82,000, and $29,000, respectively.
Property and Equipment Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment and office software and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
Goodwill Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
Income Taxes Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in Distributor eWallets Amounts Held in eWallets
 
Commencing in October 2014, the Company requires commission payments of certain members in Hong Kong to be first deposited into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available funds and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.
Long-Term Incentive Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As such, certain installments to be paid are reflected on the balance sheet as a non-current liability, and the current portion of the installments is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 5 for grant information of distributions settled in common stock.
Foreign Currency Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
Revenue Recognition Revenue Recognition
 
Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
Operating Leases  
Commissions Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  These incentives may be both monetary and non-monetary in nature.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. From time to time the Company also enters into agreements for business or market development, which may result in additional compensation to specific members.
Stock-Based Compensation Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
Income Per Share Income Per Share
 
Basic income per share for 2014 was computed via the “two-class” method by dividing net income allocated to common stockholders by the weighted-average number of common shares outstanding during the period. Net income available to common stockholders is allocated to both common stock and participating securities as if all of the income for the period had been distributed. The Company’s Series A convertible preferred stock was a participating security due to its participation rights related to dividends declared by the Company. If dividends were distributed to common stockholders, the Company was also required to pay dividends to the holders of the preferred stock in an amount equal to the greater of (1) the amount of dividends then accrued and not previously paid on such shares of preferred stock or (2) the amount payable if dividends were distributed to the common stockholders on an as-converted basis.
 
Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. For 2014, the dilutive effect of the Company’s Series A convertible preferred stock was calculated using the more dilutive of the “two-class” method and the “if-converted” method, which assumes that the preferred stock was converted into common stock at the beginning of each period presented.
Certain Risks and Concentrations Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 10). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company believes that its e-commerce direct selling model in Hong Kong does not violate any applicable laws in China, even though it is used for the internet purchase of the Company's products by members in China. The Company also believes that its Chinese entity, including its e-commerce retail platform, is operating in compliance with applicable Chinese laws. However, there can be no assurance that the Chinese authorities will agree with the Company’s interpretations of applicable laws and regulations or that China will not adopt new laws or regulations. Should the Chinese government determine that the Company’s activities violate China’s direct selling or anti-multilevel marketing legislation, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 
Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling or anti-multi-level marketing legislation, subjective interpretations of laws and regulations, Chinese nationals collaborating with short traders to damage the Company's business and activities by individual members that may violate laws notwithstanding the Company’s strict policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.
 
The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.
Fair Value of Financial Instruments Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company’s cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.
Recently Issued and Adopted Accounting Pronouncements Recently Issued and Adopted Accounting Pronouncements

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Under this guidance, entities are required to present deferred tax tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities are permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and will be applied prospectively.  Early adoption is permitted. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Nature of Operations and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2016
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents Cash and cash equivalents at the end of each period were as follows (in thousands):
 
 
December 31,
 
2016
 
2015
Cash
$
52,453

 
$
47,431

Cash equivalents
73,468

 
57,483

Total cash and cash equivalents
$
125,921

 
$
104,914

Schedule of Earnings Per Share, Basic and Diluted The following table illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
55,086

 
 

 
 

 
$
47,241

 
 

 
 

 
$
20,360

 
 

 
 

Less: undistributed earnings to participating securities

 
 

 
 

 

 
 

 
 

 
(127
)
 
 

 
 

Net income allocated to common stockholders
$
55,086


11,382

 
$
4.84

 
$
47,241

 
12,302

 
$
3.84

 
$
20,233

 
12,131

 
$
1.67

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 

 

 
21

 
 

 

 
421

 
 

Non-vested restricted stock

 
25

 
 

 

 
49

 
 

 

 
48

 
 

Plus: reallocation of undistributed earnings to participating securities

 
 

 
 

 

 
 

 
 

 
5

 
 

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income allocated to common stockholders plus assumed conversions
$
55,086

 
11,407

 
$
4.83

 
$
47,241

 
12,372

 
$
3.82

 
$
20,238

 
12,600

 
$
1.61

Available-for-sale Securities Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2016
 
December 31, 2015
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
43,490

 
$

 
$
43,490

 
$
35,222

 
$
2

 
$
35,224

Corporate debt securities
1,673

 
(2
)
 
1,671

 
5,029

 
(5
)
 
5,024

Financial institution instruments
28,307

 

 
28,307

 
17,235

 

 
17,235

Total available-for-sale investments
$
73,470

 
$
(2
)
 
$
73,468

 
$
57,486

 
$
(3
)
 
$
57,483

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]  
Schedule of Additional Balance Sheet Components The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2016
 
2015
Property and equipment:
 
 
 
Office equipment
$
517

 
$
495

Office software
672

 
536

Machinery
28

 
24

Furniture and fixtures
241

 
222

Leasehold improvements
840

 
730

Construction in progress (including internal use software development costs)
157

 
10

Property and equipment, at cost
2,455

 
2,017

Accumulated depreciation and amortization
(1,067
)
 
(1,123
)
 
$
1,388

 
$
894

Other accrued expenses:
 
 
 
Sales returns
$
1,632

 
$
1,552

Employee-related expense
10,541

 
11,064

Warehousing, inventory-related and other
2,816

 
4,087

 
$
14,989

 
$
16,703

Deferred revenue:
 

 
 

Unshipped product
$
2,191

 
$
1,783

Auto ship advances
2,327

 
1,597

Enrollment package revenue
430

 
331

Market development fees

 
300

 
$
4,948

 
$
4,011

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases Future minimum lease obligations as of December 31, 2016 are as follows (in thousands):
2017
$
1,559

2018
752

2019
402

2020
314

2021
196

Thereafter
700

Total minimum lease obligations
$
3,923

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2016
Stockholders' Equity Note [Abstract]  
Schedule of Dividends Payable The following tables summarize the Company’s cash dividend activity during 2016, 2015 and 2014 (in thousands, except per share data):

Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 23, 2016 (special)
 
$
0.35

 
$
3,941

 
November 25, 2016
October 23, 2016
 
0.08

 
901

 
November 25, 2016
July 19, 2016
 
0.07

 
787

 
August 26, 2016
April 21, 2016
 
0.06

 
686

 
May 20, 2016
March 1, 2016
 
0.05

 
576

 
March 24, 2016
Total
 
$
0.61

 
$
6,891

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2015
 
$
0.05

 
$
598

 
November 20, 2015
July 28, 2015
 
0.04

 
489

 
August 28, 2015
May 4, 2015
 
0.03

 
372

 
May 29, 2015
February 27, 2015
 
0.02

 
250

 
March 27, 2015
Total
 
$
0.14

 
$
1,709

 
 

 
 
Dividends Per Share
 
 
 
 
Declaration Date
 
Preferred
 
Common
 
Amount
 
Payment Date
November 4, 2014
 
$
0.032

 
$
0.010

 
$
128

 
December 3, 2014
July 29, 2014
 
0.027

 
0.010

 
127

 
August 27, 2014
May 6, 2014
 
0.020

 
0.005

 
62

 
June 4, 2014
March 7, 2014
 
0.815

 
0.005

 
159

 
April 8, 2014
Total
 
$
0.894

 
$
0.030

 
$
476

 
 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Nonvested Restricted Stock Shares Activity The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2014

 
$

Granted
67,076

 
12.15

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2015
44,712

 
12.15

Granted

 

Vested
(22,364
)
 
12.15

Nonvested at December 31, 2016
22,348

 
12.15


 
As of December 31, 2016, total unrecognized stock-based compensation expense related to non-vested restricted stock was $38,000, which is expected to be recognized over a weighted-average period of one year.
Schedule of Nonvested Share Activity
 
Shares
 
Wtd. Avg. Grant-Date Fair Value
Nonvested at December 31, 2013
53,324

 
$
1.37

Vested
(25,342
)
 
1.37

Forfeited
(3,998
)
 
1.37

Nonvested at December 31, 2014
23,984

 
1.37

Vested
(23,984
)
 
1.37

Forfeited

 

Nonvested at December 31, 2015

 

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Domestic
$
(3,106
)
 
$
(7,820
)
 
$
4,502

Foreign
67,183

 
55,613

 
16,134

Income before income taxes
$
64,077

 
$
47,793

 
$
20,636

Schedule of Components of Income Tax Expense (Benefit) The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Current:
 
 
 
 
 
Federal
$
7,151

 
$
12

 
$
104

State
(81
)
 
100

 
11

Foreign
1,648

 
456

 
194

Total current taxes
8,718

 
568

 
309

Deferred taxes
273

 
(16
)
 
(43
)
Income tax provision
$
8,991

 
$
552

 
$
266

Schedule of Effective Income Tax Rate Reconciliation A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Income tax at federal statutory rate
$
22,427

 
$
16,250

 
$
7,016

Effect of permanent differences
12,496

 
370

 
9

Change in valuation allowance
(3,877
)
 
2,017

 
(2,070
)
Foreign rate differential
(21,713
)
 
(18,099
)
 
(5,240
)
Other reconciling items
(342
)
 
14

 
551

Income tax provision
$
8,991

 
$
552

 
$
266

Income Tax Foreign Rate Differential [Table Text Block]
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2016
 
2015
 
2014
Cayman Islands
%
 
$
58,169

 
$
50,993

 
$
16,267

Hong Kong
16.5
%
 
3,992

 
2,645

 
1,129

China
25.0
%
 
3,855

 
1,493

 
153

Schedule of Deferred Tax Assets and Liabilities Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Deferred tax assets:
 
 
 
Net operating losses
$
235

 
$
3,197

Stock-based compensation
623

 

Accrued expenses
3,174

 
3,367

Tax credits

 
418

Other

 
32

Total deferred tax assets
4,032

 
7,014

Valuation allowance
(235
)
 
(4,112
)
Net deferred tax assets
3,797

 
2,902

Deferred tax liabilities:
 
 
 
Foreign earnings
(3,650
)
 
(2,789
)
Other
(415
)
 
(173
)
Total deferred tax liabilities
(4,065
)
 
(2,962
)
Net deferred tax liability
$
(268
)
 
$
(60
)
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information (Tables)
12 Months Ended
Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]  
Schedule of cash flow, supplemental disclosures SUPPLEMENTAL CASH FLOW INFORMATION
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
 
 
 
 
 
Cash paid during the year for:
(In Thousands)
Income taxes, net of refunds
$
8,791

 
$
707

 
$
60

Interest
9

 

 
1

Non-cash financing activity:
 

 
 

 
 

Conversion of preferred stock

 

 
111

Issuance of treasury stock
1,741

 
666

 

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales from external customers:
 
 
 
 
 
United States
$
4,100

 
$
3,246

 
$
1,438

Canada
1,809

 
2,746

 
1,374

Hong Kong
263,482

 
245,737

 
111,028

China
9,086

 
4,425

 
1,538

Taiwan
6,213

 
5,965

 
4,628

South Korea
691

 
1,129

 
1,009

Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)1
858

 
1,139

 
3,113

Europe
1,234

 
382

 
373

Other foreign countries
255

 
91

 
89

Total net sales
$
287,728

 
$
264,860

 
$
124,590

Schedule of Segment Reporting Information, by Segment The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Net sales by product and service:
 
 
 
 
 
Product sales
$
269,731

 
$
253,041

 
$
118,843

Enrollment package revenue, freight and other
25,616

 
17,623

 
7,927

Less: sales returns
(7,619
)
 
(5,804
)
 
(2,180
)
Total net sales
$
287,728

 
$
264,860

 
$
124,590

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2016
 
2015
Long-lived assets:
 
 
 
United States
$
763

 
$
283

Hong Kong
140

 
204

China
199

 
252

Other foreign countries
286

 
155

Total long-lived assets
$
1,388

 
$
894

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)
12 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
installment
Dec. 31, 2014
USD ($)
shares
Jun. 30, 2015
USD ($)
Dec. 31, 2013
USD ($)
Oct. 19, 2007
shares
Property, Plant and Equipment [Line Items]            
Cash $ 52,453,000 $ 47,431,000        
Cash equivalents 73,468,000 57,483,000        
Cash and cash equivalents 125,921,000 104,914,000 $ 44,816,000   $ 14,550,000  
Restricted cash 2,900,000     $ 20,000,000    
Inventory valuation reserves 82,000 29,000        
Deferred tax liability recorded against undistributed foreign earnings 3,650,000 2,789,000        
Loss on foreign exchange $ (333,000) $ (204,000) $ (202,000)      
Number of securities called by warrants | shares     88,097     3,141,499
Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period            
Property, Plant and Equipment [Line Items]            
Long-term incentive plan, percentage of award payable in cash   50.00%        
Long-term incentive plan, number of installments | installment   35        
Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023            
Property, Plant and Equipment [Line Items]            
Long-term incentive plan, percentage of award payable in cash   50.00%        
Long-term incentive plan, number of installments | installment   35        
Software and Software Development Costs [Member] | Minimum            
Property, Plant and Equipment [Line Items]            
Property, and equipment useful life 3 years          
Software and Software Development Costs [Member] | Maximum            
Property, Plant and Equipment [Line Items]            
Property, and equipment useful life 5 years          
Furniture and Fixtures | Minimum            
Property, Plant and Equipment [Line Items]            
Property, and equipment useful life 5 years          
Furniture and Fixtures | Maximum            
Property, Plant and Equipment [Line Items]            
Property, and equipment useful life 7 years          
China            
Property, Plant and Equipment [Line Items]            
Cash and cash equivalents $ 6,800,000          
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Nature of Operations and Summary of Significant Accounting Policies - Basic and Diluted Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   345    
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount $ 19,800      
Basic EPS:        
Net income available to common stockholders   $ 55,086 $ 47,241 $ 20,360
Less: undistributed earnings to participating securities     $ 0 $ 127
Net income allocated to common stockholders (in shares)   11,382,000 12,302,000 12,131,000
Net income allocated to common stockholders (in dollars per share)   $ 4.84 $ 3.84 $ 1.67
Effect of dilutive securities:        
Warrants to purchase common stock (in shares)   0 21,000 421,000
Non-vested restricted stock (in shares)   25,000 49,000 48,000
Plus: reallocation of undistributed earnings to participating securities     $ 0 $ 5
Diluted EPS:        
Net income allocated to common stockholders plus assumed conversions   $ 55,086 $ 47,241 $ 20,238
Net income allocated to common stockholders plus assumed conversions (in shares)   11,407,000 12,372,000 12,600,000
Net income allocated to common stockholders plus assumed conversions (in dollars per share)   $ 4.83 $ 3.82 $ 1.61
Distributed        
Basic EPS:        
Net income available to common stockholders   $ 55,086 $ 47,241 $ 20,233
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Nature of Operations and Summary of Significant Accounting Policies - Summary of Available-for-sale Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Debt Instrument [Line Items]    
Adjusted Cost $ 73,470 $ 57,486
Gross Unrealized Gains/Losses (2) (3)
Fair Value 73,468 57,483
Municipal bonds and notes    
Debt Instrument [Line Items]    
Adjusted Cost 43,490 35,222
Gross Unrealized Gains/Losses 0 2
Fair Value 43,490 35,224
Corporate debt securities    
Debt Instrument [Line Items]    
Adjusted Cost 1,673 5,029
Gross Unrealized Gains/Losses (2) (5)
Fair Value 1,671 5,024
Financial institution instruments    
Debt Instrument [Line Items]    
Adjusted Cost 28,307 17,235
Gross Unrealized Gains/Losses 0 0
Fair Value $ 28,307 $ 17,235
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Components - Components of Balance Sheet Accounts (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Property and equipment:    
Office equipment $ 517 $ 495
Office software 672 536
Machinery 28 24
Furniture and fixtures 241 222
Leasehold improvements 840 730
Construction in progress 157 10
Property and equipment, at cost 2,455 2,017
Accumulated depreciation and amortization (1,067) (1,123)
Property and equipment, net 1,388 894
Other accrued expenses:    
Sales returns 1,632 1,552
Employee-related expense 10,541 11,064
Warehousing, inventory-related and other 2,816 4,087
Other accrued expenses 14,989 16,703
Deferred revenue:    
Deferred revenue 4,948 4,011
Unshipped product    
Deferred revenue:    
Deferred revenue 2,191 1,783
Auto ship advances    
Deferred revenue:    
Deferred revenue 2,327 1,597
Enrollment package revenue    
Deferred revenue:    
Deferred revenue 430 331
Market development fees    
Deferred revenue:    
Deferred revenue $ 0 $ 300
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies - Narrative (Details)
₩ in Millions
12 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2016
KRW (₩)
Loss Contingencies [Line Items]        
Rent expense for operating leases $ 1,800,000 $ 1,500,000 $ 777,000  
Minimum monthly purchase amount 40,000      
Minimum annual purchase amount $ 9,400,000      
Purchase commitment term 3 years      
Purchase commitment renewal term 3 years      
Korean Business Segment | Other Noncurrent Assets        
Loss Contingencies [Line Items]        
Distributor claims reserve $ 185,000     ₩ 223
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies - Future Minimum Lease Obligations (Details)
$ in Thousands
Dec. 31, 2016
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2016 $ 1,559
2017 752
2018 402
2019 314
2020 196
Thereafter 700
Total minimum lease obligations $ 3,923
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity - Narrative (Details)
1 Months Ended 12 Months Ended
Oct. 30, 2015
USD ($)
shares
Oct. 28, 2015
USD ($)
Aug. 04, 2015
USD ($)
shares
Aug. 03, 2015
USD ($)
Jul. 31, 2015
USD ($)
May 13, 2015
USD ($)
shares
May 07, 2015
USD ($)
May 04, 2015
USD ($)
Jan. 22, 2015
USD ($)
shares
Nov. 04, 2014
USD ($)
shares
Apr. 30, 2015
USD ($)
$ / shares
shares
Dec. 17, 2014
USD ($)
shares
Apr. 21, 2013
Apr. 21, 2009
Oct. 19, 2007
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
class
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Jan. 12, 2016
USD ($)
Jul. 28, 2015
USD ($)
Aug. 13, 2012
shares
May 04, 2007
$ / shares
Class of Stock [Line Items]                                            
Number of classes of stock | class                               2            
Preferred stock, shares authorized | shares                               5,000,000 5,000,000          
Preferred stock, par value (in dollars per share)                               $ 0.001 $ 0.001          
Common stock, shares authorized | shares                               50,000,000 50,000,000          
Common stock, par value (in dollars per share)                               $ 0.001 $ 0.001          
Preferred stock, dividends per share, declared                               0.119            
Share price                               1.70            
Preferred stock, voting rights                               $ 0.729            
Number of securities called by warrants | shares                             3,141,499     88,097        
Warrants, exercise price                             $ 3.52              
Proceeds from exercise of warrants | $                               $ 0 $ 309,000 $ 4,948,000        
Authorized amount of shares to be repurchased | $               $ 5,000,000.0   $ 5,000,000.0                 $ 70,000,000.0 $ 15,000,000.0    
Treasury stock, purchase price | $ $ 3,600,000     $ 3,500,000       $ 3,500,000       $ 3,000,000.0                    
Repurchase of common stock (in shares) | shares 106,264   162,442     186,519         88,097 359,840       903,031   1,407,855        
Repurchase of common stock | $ $ 5,000,000.0 $ 1,400,000 $ 5,000,000.0   $ 1,500,000 $ 5,000,000.0 $ 1,500,000         $ 4,500,000       $ 23,704,000 $ 16,071,000 $ 4,661,000        
Remaining authorized repurchase amount | $                               $ 32,000,000.0            
Number of shares authorized to be repurchased | shares                                         100,000  
George K. Broady                                            
Class of Stock [Line Items]                                            
Repurchase of common stock (in shares) | shares                 91,817 1,500,000                        
Repurchase of common stock | $                 $ 1,100,000                          
Shares repurchased per trading day | shares                 5,000                          
Seven Year Warrants                                            
Class of Stock [Line Items]                                            
Term of warrant                             7 years     7 years        
Warrants, exercise price                     $ 3.5043                      
Proceeds from exercise of warrants | $                     $ 309,000             $ 4,900,000        
Authorized amount of shares to be repurchased | $                             $ 1,495,952              
One Year Warrants                                            
Class of Stock [Line Items]                                            
Term of warrant                           1 year 1 year              
Five Year Warrants                                            
Class of Stock [Line Items]                                            
Term of warrant                         5 years   5 years              
Authorized amount of shares to be repurchased | $                             $ 149,595              
Minimum                                            
Class of Stock [Line Items]                                            
Warrants, exercise price                                   $ 3.5108        
Minimum | Seven Year Warrants                                            
Class of Stock [Line Items]                                            
Warrants, exercise price                                   3.5082        
Maximum                                            
Class of Stock [Line Items]                                            
Warrants, exercise price                                   3.52        
Maximum | Seven Year Warrants                                            
Class of Stock [Line Items]                                            
Warrants, exercise price                                   $ 3.52        
Series A Preferred Stock                                            
Class of Stock [Line Items]                                            
Preferred stock, shares outstanding | shares                               1,761,900            
Share price                                           $ 1.70
Series A Preferred Stock | Minimum                                            
Class of Stock [Line Items]                                            
Share price                                           $ 10.00
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity - Dividend Activity (Details) - USD ($)
12 Months Ended
Nov. 25, 2016
Aug. 26, 2016
May 20, 2016
Mar. 24, 2016
Nov. 20, 2015
Aug. 28, 2015
May 29, 2015
Mar. 27, 2015
Dec. 03, 2014
Aug. 27, 2014
Jun. 04, 2014
Apr. 08, 2014
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Stockholders' Equity Note [Abstract]                              
Preferred Stock, Dividends, Per Share, Cash Paid                 $ 0.032 $ 0.027 $ 0.020 $ 0.815     $ 0.894
Dividends Per Share, Common (in dollars per share) $ 0.08 $ 0.07 $ 0.06 $ 0.05 $ 0.05 $ 0.04 $ 0.03 $ 0.02 $ 0.010 $ 0.010 $ 0.005 $ 0.005 $ 0.61 $ 0.14 $ 0.030
Dividends $ 901,000                       $ 6,891,000 $ 1,709,000 $ 476,000
CommonStockSpecialDividendsPerShareDeclared $ 0.35                            
Dividends, cash $ 3,941,000 $ 787,000 $ 686,000 $ 576,000 $ 598,000 $ 489,000 $ 372,000 $ 250,000 $ 128,000 $ 127,000 $ 62,000 $ 159,000 $ 6,891,000 $ 1,709,000 $ 476,000
Payment Date Nov. 25, 2016 Aug. 26, 2016 May 20, 2016 Mar. 24, 2016 Nov. 20, 2015 Aug. 28, 2015 May 29, 2015 Mar. 27, 2015 Dec. 03, 2014 Aug. 27, 2014 Jun. 04, 2014 Apr. 08, 2014      
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Apr. 08, 2016
Feb. 11, 2015
Jan. 20, 2015
Aug. 13, 2012
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Apr. 07, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Award vesting period           3 years      
Share-based compensation expense           $ 104,000 $ 86,000 $ 49,000  
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost         $ 64,000        
Tax benefit attributable to compensation expense           $ 0      
Number of shares authorized to be repurchased       100,000          
Incentive compensation period       3 years          
Restricted Stock                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Award vesting period     3 years            
Shares granted during period 51,015 6,116 60,960     0 67,076    
Unrecognized stock-based compensation expense           $ 38,000      
Unrecognized stock-based compensation expense, period for recognition           1 year      
Restricted Stock | Equity Incentive 2016 Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Shares granted during period           51,015      
Common Stock [Member] | Equity Incentive 2016 Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                 2,500,000
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation - Restricted Stock Activity (Details) - $ / shares
12 Months Ended
Apr. 08, 2016
Feb. 11, 2015
Jan. 20, 2015
Dec. 31, 2016
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period       3 years  
Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]          
Nonvested, balance (in shares)       44,712 0
Granted (in shares) 51,015 6,116 60,960 0 67,076
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     3 years    
Vested (in shares)       (22,364) (22,364)
Nonvested, balance (in shares)       22,348 44,712
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]          
Nonvested, weighted average price at date of issuance (in dollars per share)       $ 12.15 $ 0
Granted (in dollars per share)       0 12.15
Vested (in dollars per share)       12.15 12.15
Nonvested, weighted average price at date of issuance (in dollars per share)       $ 12.15 $ 12.15
Equity Incentive 2016 Plan [Member] | Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]          
Nonvested, balance (in shares)       0  
Granted (in shares)       51,015  
Vested (in shares)       (12,759)  
Nonvested, balance (in shares)       38,256 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]          
Nonvested, weighted average price at date of issuance (in dollars per share)       $ 0  
Granted (in dollars per share)       34.13  
Vested (in dollars per share)       34.13  
Nonvested, weighted average price at date of issuance (in dollars per share)       $ 34.13 $ 0
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation - Common Stock Unit Activity (Details) - $ / shares
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]    
Nonvested, Balance (in shares) 23,984 53,324
Vested (in shares) (23,984) (25,342)
Forfeited (in shares) 0 (3,998)
Nonvested, Balance (in shares) 0 23,984
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested weighted average grant-date fair value (in dollars per share) $ 1.37 $ 1.37
Vested (in dollars per share) 1.37 1.37
Forfeited (in dollars per share) 0 1.37
Nonvested weighted average grant-date fair value (in dollars per share) $ 0 $ 1.37
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2016
Dec. 31, 2016
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards   $ 0.0
Foreign net operating loss carryforwards   $ 1.3
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount $ 19.8  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes - Components of Income Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Income Tax Disclosure [Abstract]      
Domestic $ (3,106) $ (7,820) $ 4,502
Foreign 67,183 55,613 16,134
Income before income taxes $ 64,077 $ 47,793 $ 20,636
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes - Components of Benefit From Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Current:      
Federal $ 7,151 $ 12 $ 104
State (81) 100 11
Foreign 1,648 456 194
Total current taxes 8,718 568 309
Deferred foreign taxes 273 (16) (43)
Income tax provision $ 8,991 $ 552 $ 266
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes - Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Entity Location [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 67,183 $ 55,613 $ 16,134
Income tax at federal statutory rate 22,427 16,250 7,016
Effect of permanent differences 12,496 370 9
Change in valuation allowance (3,877) 2,017 (2,070)
Foreign rate differential (21,713) (18,099) (5,240)
Other reconciling items (342) 14 551
Income tax provision 8,991 552 266
CAYMAN ISLANDS      
Entity Location [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 58,169 50,993 16,267
statutorytaxrate 0.00%    
Hong Kong      
Entity Location [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 3,992 2,645 1,129
statutorytaxrate 16.50%    
China      
Entity Location [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 3,855 $ 1,493 $ 153
statutorytaxrate 25.00%    
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes - Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Deferred tax assets:    
Net operating losses $ 235 $ 3,197
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost 623 0
Accrued expenses 3,174 3,367
Tax credits 0 418
Other 0 32
Total deferred tax assets 4,032 7,014
Valuation allowance (235) (4,112)
Deferred tax assets, net 3,797 2,902
Deferred tax liabilities:    
Foreign earnings (3,650) (2,789)
Other (415) (173)
Total deferred tax liabilities (4,065) (2,962)
Total deferred tax liabilities $ (268) $ (60)
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes Income Taxes - Foreign Rate Differentials (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 67,183 $ 55,613 $ 16,134
CAYMAN ISLANDS      
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 58,169 50,993 16,267
statutorytaxrate 0.00%    
Hong Kong      
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 3,992 2,645 1,129
statutorytaxrate 16.50%    
China      
Income Tax Foreign Rate Differential [Line Items]      
Income (Loss) from Continuing Operations before Income Taxes, Foreign $ 3,855 $ 1,493 $ 153
statutorytaxrate 25.00%    
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash paid during the year for:      
Income taxes, net of refunds $ 8,791 $ 707 $ 60
Interest 9 0 1
Non-cash financing activity:      
Conversion of preferred stock 0 0 111
Stock Issued $ 1,741 $ 666 $ 0
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 30, 2015
USD ($)
shares
Oct. 28, 2015
USD ($)
Aug. 04, 2015
USD ($)
shares
Jul. 31, 2015
USD ($)
May 13, 2015
USD ($)
shares
May 07, 2015
USD ($)
Apr. 29, 2015
Feb. 19, 2015
USD ($)
Jan. 22, 2015
shares
Nov. 14, 2014
USD ($)
shares
Apr. 30, 2015
shares
Dec. 17, 2014
USD ($)
shares
Feb. 28, 2013
Dec. 31, 2014
USD ($)
Dec. 31, 2016
USD ($)
shares
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
shares
Related Party Transaction [Line Items]                                  
Royalty rate                         2.50%        
Termination notice, number of days                             120 days    
Repurchase of common stock $ 5,000,000.0 $ 1,400,000 $ 5,000,000.0 $ 1,500,000 $ 5,000,000.0 $ 1,500,000           $ 4,500,000     $ 23,704,000 $ 16,071,000 $ 4,661,000
Repurchase of common stock (in shares) | shares 106,264   162,442   186,519           88,097 359,840     903,031   1,407,855
George Broady                                  
Related Party Transaction [Line Items]                                  
Treasury stock acquired rate   0.4066   0.4085   0.4286                      
Repurchase of common stock               $ 1,100,000                  
Repurchase of common stock (in shares) | shares                 91,817                
Shares repurchased per trading day | shares                 5,000                
Director | George Broady                                  
Related Party Transaction [Line Items]                                  
Repurchase of common stock                   $ 1,500,000              
Repurchase of common stock (in shares) | shares                   119,947              
Soothe | Broady Health Sciences                                  
Related Party Transaction [Line Items]                                  
Royalty rate             2.50%                    
Royalty expense                           $ 11,700 $ 3,400 7,000 $ 6,400
Termination notice, number of days                             120 days    
ReStore [Member] | Broady Health Sciences                                  
Related Party Transaction [Line Items]                                  
Royalty expense                             $ 475,000 $ 555,000 $ 144,000
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
Employee Benefit Plans (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]      
Maximum compensation percentage 90.00%    
Age requirement for 401 K contributions 21 years    
Employer matching contribution, percent of employees' gross pay 4.50%    
Employers matching contribution, immediate vesting percentage 100.00%    
Defined contribution plan, cost recognized $ 134,000 $ 115,000 $ 60,000
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information - Net Sales by Market (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Segment Reporting Information [Line Items]      
Net sales $ 287,728 $ 264,860 $ 124,590
United States      
Segment Reporting Information [Line Items]      
Net sales 4,100 3,246 1,438
Canada      
Segment Reporting Information [Line Items]      
Net sales 1,809 2,746 1,374
Hong Kong      
Segment Reporting Information [Line Items]      
Net sales 263,482 245,737 111,028
China      
Segment Reporting Information [Line Items]      
Net sales 9,086 4,425 1,538
Taiwan      
Segment Reporting Information [Line Items]      
Net sales 6,213 5,965 4,628
South Korea      
Segment Reporting Information [Line Items]      
Net sales 691 1,129 1,009
Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)      
Segment Reporting Information [Line Items]      
Net sales 858 1,139 3,113
Europe [Member]      
Segment Reporting Information [Line Items]      
Net sales 1,234 382 373
Other foreign countries      
Segment Reporting Information [Line Items]      
Net sales $ 255 $ 91 $ 89
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information - The Company's Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Net sales by product and service:      
Product sales $ 269,731 $ 253,041 $ 118,843
Enrollment package revenue, freight and other 25,616 17,623 7,927
Less: sales returns (7,619) (5,804) (2,180)
Total net sales $ 287,728 $ 264,860 $ 124,590
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information - Long Lived Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]    
Long-lived assets $ 1,388 $ 894
United States    
Segment Reporting Information [Line Items]    
Long-lived assets 763 283
Hong Kong    
Segment Reporting Information [Line Items]    
Long-lived assets 140 204
China    
Segment Reporting Information [Line Items]    
Long-lived assets 199 252
Other foreign countries    
Segment Reporting Information [Line Items]    
Long-lived assets $ 286 $ 155
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events (Details) - $ / shares
Jan. 24, 2017
Nov. 25, 2016
Subsequent Event [Line Items]    
CommonStockSpecialDividendsPerShareDeclared   $ 0.35
Subsequent Event    
Subsequent Event [Line Items]    
Common stock, dividends, per share declared $ 0.09  
CommonStockSpecialDividendsPerShareDeclared $ 0.35  
Restricted Stock [Member] | Subsequent Event    
Subsequent Event [Line Items]    
Shares granted during period 56,260  
EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�@(J,^ MF,"0B37VZ/BC@8V/2.*/D*T/R0CL1 +&F3A^,HX3Q; 06($R C 9*32:(Z M3.HPC<.D&+F9A34""]/6D9*)#=D+3, M3T>.TLD_N.E0=(R*BV*:-!^%4IQFL,LYZ'(.) U-7(8P\@$8*0""!!5 , M[]OX]MJ@F:V/;JA.#QJ7)RF*Z0;N4>/$XY30274 %$*XF'$:/$P>$+ZA/B!H M9NL@^+Q B2>!\W1& CXQ$/F/$L$[& %;V"\1]4N44SHMD8]"Q-M $(K._9GP MH8'26RH$@>C$3C2ZQ&HNCZY!4,%.G!MM[X+1ZM"$/&!["4[6U[8Y<9?CNTS7 MV7QC\E@V*G@6VERQ[B(\"*&Y\3&^,[DXF69JF%3\H.TP,V/9=13=1(NV[Y:B MH65;_0502P,$% @ 5'5J2K+CX\U% @ %P< !D !X;"]W;W)K&ULA57M;ILP%'T5Q /4?$,K@M0DFC9IDZ).VWX[Y":@ M&LQL)W1O/]L00HS;_HGMRSG']UP[UWE/V2NO (3SUI"6K]Q*B.X)(5Y6T&#^ M0#MHY9N[UX#+_6I$BJ BKS#)_@)XE>W8W*%)I5#W4#+:]HZ#(XK]]E_VF8* MKP&_:^CY;.XH)WM*7]7BVV'E>BHA(% *I8#E<($-$**$9!I_1TUWVE(1Y_.K M^A?M77K98PX;2O[4!U&MW,QU#G#$9R)>:/\51C^QZXSFO\,%B(2K3.0>)25< M_SKEF0O:C"HRE0:_#6/=ZK$?OJ17FIT0C(1@(OC)AX1P)(0W0O0A(1H)D4% M@Q5=FRT6N,@9[1TVG&Z'U27RGR)9_5(%=;'U-UD>+J.7(O;]'%V4T(A9#YA@ MAKDAD%2?M@AL6ZR#!3VXWV"S1(3>/62[A*21/8G0ZC/4_/#.9V 7B*P"D1:( M[@1"HU #)M&85F.R]-&HYF8)2KW4<+O$))X]V=B:;&Q)-C*2'3#Q;(]'(],E MPCR5)>*=FY%8TTPLAQ+;!5*K0&KQF1@^T\]<;#Y%;)<(WW_':69--+,D:ASZ M.EL>D6Y"5K.0K-2T('(6:IG+.AEX] M+ 3MQF<(36]A\1]02P,$% @ 5'5J2NAA*;D.! J1, !D !X;"]W M;W)K&ULE9CM??D0CI%6CDY^Q("??5>KU:YDIONB_%5MI*PGO_-L M6\V\35WOSGV_>M[(/*G.BIW<-M^LBS)/ZN:V?/&K72F356>49SXE1/AYDFZ] M^;1[MBCGT^*USM*M7)23ZC7/D_+/A&G3$CU3NJZ/K21O*4U'\:F_N5C./ MM".2F7RN6XFD^7B3ES++6J5F'/\I4>_@LS4\OA[4K[O@FV">DDI>%MG/=%5O M9E[D359RG;QF];+8WTH54.!-5/0/\DUF#=Z.I/'Q7&15]W_R_%K51:Y4FJ'D MR>_^,]UVG_O^&QXK,]R *@-Z,*#A20.F#-B[ 9PTX,J NWH(E$'@ZD$H _%N M($X:A,H@?#<@)PTB91 =#("?-(B50>P: Y A<\1U4'!(-KA.+0SI!NKL94@X M,&0#1U']KE11ST3/TB&$\'C.7"!.0 M,7.%,3!F/F,,&S/7&,/'S W&!&/FUF0"T.*Z0QBJQ?4%8[2X[C&&CID'C-%B M?T3B$MIX_L%TM/GYBN@P;7X6F([&?,-T-%]+DZ'B/7:_6:"'54KQ54H[!38: MB< 5&*[ .@4^4@BU><.8"/?"<2\<4=!6U )A&,&]!+B7P% /;\7/2,Z9MM[ M(=V?5K"A&" 2\2S M$"-NE%.!YU08.661UA\N>B8X'A(15&BIOT(P03G7U*X1+!)& WPPL2@BL58Z MCR;%@CCB^NR;6$P885JS7")#XR2,CAKX:$I#?$I#I- 5XAPA>#,C';>9.0:,R@7'=C9W9 MCB'P\?K_HJ#1\H$(0HLKRUX"%'$5ZJZHX2JP!V791@Z7* 2ES M_71QBT*6XP6UU"0U:S+0CVU?*5:3H;$3(ACCQC:HJ.-,A>8>B&@);ELYU-(# MJ-D#S-,3!MF.3]1VFC0[0, L*:>6VJ;,?=E02VU3["BH'\(5-#I?A(%Y7D&X M(#"Y)<(!YV:9^T<_(=N76(])^9)NJ\E343>_1[N?C.NBJ&6C2IP MD\EUW5Z&S779OSSJ;^IBIUZ,^8>W<_._4$L#!!0 ( %1U:DI..&PO=V]R:W-H965TGR!7R!^]P&Y@X+.UHRHY4OJB-M]/N>NIA(! )90"EK<; M[( 0)233^#MJNI.E(L[7;^I?=>VREB/FL*/D3W,2=>YN7.<$9WPEXHD.WV"L M)W:=L?@?< ,BX2H3Z5%1PO75J:Y0WI!U5$5H%("T1WC=HL&F7#?+&;Q%:3>"T0+3I1VC ?5))831*+ MP.*-E#9,:#=)K2:I12!:F-@PL=UD8S796 22A8G!)!K3F1'&621K/3UP*[Z,G&G8I>.Z$^XEET&IZ/@3J]BW@IAZJ9@>\R9B+_ MQ.S2=-PY4B%G@S[!9TH%R"2]!_F)U/(G,&T(G(5:IG+-S"@T&T'[<&ULE5?;CN(X$/V5*!\P297M7%J U T:[4J[4FM&L_NY- .NRC2\D-@Y=5)UX)2IVZ]9[+XNJF?O[MCT\!$&S MWNLR:[Z8@Z[LDZVIRZRURWH7-(=:9YL^J"P"#,,H*+.\\A>S?N^Y7LS,L2WR M2C_77G,LRZS^[TD7YC3WP?_8^);O]FVW$2QFAVRGO^OVQ^&YMJO@S++)2UTU MN:F\6F_G_B,\K$0?T"/^R?6IN;CWNE)>C'GM%G]NYG[89:0+O6X[BLQ>WO12 M%T7'9//X.9+ZYW=V@9?W'^Q?^^)M,2]9HY>F^#??M/NYG_C>1F^S8]%^,Z<_ M]%B0\KVQ^K_TFRXLO,O$OF-MBJ;_]-;'IC7ER&)3*;/WX9I7_?4T/(GC,8P/ MP#$ SP$0_39 C 'B5X#\;8 < Z03$ RE]-JLLC9;S&IS\NKAZSUDW:\('J15 M?]UM]F+WSZP\C=U]6R@9SX*WCFC$/ T8O,# &1%8]O,KD'O%$Y)PO'[!DB)$ M> U944@L^20$6Z?HX\55G0E/(%D"V1/(RP0B1Z>R#1!U4:B$T%%C24$"I<.T MHB"08B+=A$TWH8*I"<53EB"]73 (>4>>LV8JXJ3<+4T8Q!84Q$X[C$E+E@ MHHL R5FF8H*"[1*/@'4CN4(YW/:0W*)>2:B,$X2I'42J-B'(4):.IWQSR?09IGU$*)RAXVR/< MKASRMD?\7+D1$ 0$((AQ%"8"IJOG^@K2_*#5QT"!O=XSO$(ZW.](SG@J7 M4$U02%#-+L+;=1.\V04]XXEN(^;JOZUR MFM>2 ;EN7C&8Q'5I<#'CE+K>]?-CXZW-L6J[4>%B]SRC/F(W(SG[3W9V'2;- M7S3#X/MW5N_RJO%>3&LGL'Y.VAK3:IMB^,5^I7L[:Y\7A=ZVW6UL[^MAX!P6 MK3F,PW1PGN@7_P-02P,$% @ 5'5J2L8:M;98 @ _@8 !D !X;"]W M;W)K&UL?55AK]H@%/TK3;_O42B%:K3)4[-LR9:8 MMVS[C!6U>6WI /7MWP]H[5/*WA>!VW,.YU[PLK@*^:I.G.OHK:E;M8Q/6G=S M %1YX@U33Z+CK?ER$+)AVBSE$:A.*LJT4:2 M'Y;Q,YQOJ,4[P*^*7]7=/+*9[(1XM8NO^V6<6$.\YJ6V"LP,%[[F=6V%C(T_ M@V8\;FF)]_.;^F>7N\EEQQ1?B_IWM=>G99S'T9X?V+G6+^+ZA0_Y9'$T)/^- M7WAMX-:)V:,4M7*_47E66C2#BK'2L+=^K%HW7@?]&RU,0 ,!C01(/B2D R%] M)^ /"7@@8(\ ^E1<;39,LV(AQ362_>EVS%XB.,>F^J4-NF*[;Z8\RD0O19:1 M!;A8H0&SZC'H#@-'!##JXQ8HM,4*3>CH<8/U%)$FCY#-%$)QV$0:S#-U_/0A M3QH6P$$![ 3P@T#N%:K'$(=I^TS)C*;02S< R]($>[#-% 9AGN,T[#H+NLX" MKF>>ZQZ3/=@AT+L$ZRD*4H)2S_,416?H/W4F0<=DZIAXEV%%)KM\H@1Z>:T# MJ"Q/L.>4XJ\&[0.P C._0)LIC"(<#;S78.[ M+M!P>70=5D6E.+?:_IGNHF,3?T:VBWCQE6GN?2]^E^E?AN],'JM613NA38]R MG>0@A.;&9?)DJGHRC]&XJ/E!VRDU<]FWY'ZA13>\-F!\\HI_4$L#!!0 ( M %1U:DJCZ"]02@( X( 9 >&PO=V]R:W-H965TX.+^ M*8+O]WSOZ0]:=%R\R))2%;S6K)';L%2J?01 GDI:$_G 6]KH.Q MLU_5697;, N#,[V0&U//O/M,!T,X# ;W7^F=,@TW2O0S3IQ)^QN<;E+Q>F#1 M4FKRVH]58\>NO[/!0YF_ T%:"R R3\+XJ$@GA6 7IFU^I$HLBL$[P+1OZV6 MF(\"/L8ZS)-9M-G9>]JMU*OW'4Y1 >Z&:, \]1@TPQ<11R,$: &C"N15 M@6Q]/%619'Z"V$L06X+DG8UX9J/'I!;36 R,LVSFQ 5E>>)7DGB5)*Z2)/<3 M8"\!7I]%ZB5(5V318_#$YF:.V;L8E,5^(1NOD(TC),D7"#(O0;8^BMQ+D*^( M(G=LPB2:1>%B4+3P5<#(WV>1(P5EZ0+%0JO"]7% ?Y]!M"*0 ?0ND3R?=[P+ M0A@MB/'W+/0T+<8+%/YF@\E_1.)O-XC71(*=;6'Z]H9(7!!T_(#)QFQ.RF]$ M7*M&!D>N]!YO=^(+YXIJPNA!$Y;Z&ULE53MCILP$'P5Q /$?!E(!$A-JJJ56BFZJNUOARP!G<'4 M=L+U[6L;#A'BMM<_L;V>G9U9XLT&QI]%#2"=EY9V(G=K*?L=0J*LH25BPWKH MU$W%>$ND.O(+$CT'L<#E7NOO-W!]_3"0;Q MO8%!+/:.MG)B[%D?/IUSU].*@$(I-051RPT.0*EF4CI^3J3N7%,G+O>O[!^, M>67F1 0<&/W1G&6=NZGKG*$B5RJ?V/ 1)D/8=2;WG^$&5,&U$E6C9%287Z>\ M"LG:B45):EM[542:Y7DW]W<)__1S=1:);5X^8/,K95@ M^_9NJF%C?0#>H],(KU_ ",(+JS@.8F]5"2U>G1Z#7PB_-)UP3DRJ!VR>6<68 M!$7I;119K2;O?*!02;U-U)Z/XV<\2-9/HQ7-\[WX#5!+ P04 " !4=6I* M@-3-P@Y< #=;@$ % 'AL+W-H87)E9%-T&UL[;UK<]M6EBCZ M>C_^5%5U\&F=Y=5__.&^KC>OOOFF6MPGZ[CJ M%9LDAR>KHES'-?RSO/NFVI1)O*SNDZ1>9]\,^OW)-^LXS?\0;//T/[?):;'- MZ__XPWC:_\.?_U2E?_Y3_>>S8K%=)WD=G.3+X#ROT_HIN,AYS+3(@^/@Q^NS MX.C%RS]]4__Y3]_@1_QA- C>%7E]7\%7RV39?'R6+'K!, J#03^:-!^^26Y[ MP6!$#Z?-AW_9YO!EW__EGN4V7YI%E2!J?PW5U1MN8Y62P2> Y/E_QFUX)E M/1^235'6:7X77-=QO:V:K_^2M'Z2$7XJ,D">N)05M5Z[+#H^_#G)LN./>?&8 M!]=)7!4Y+/6BJK;=:RW6:\"\Z[I8? R#Z_NX3*K@_;:NZCA?XM*/TCRHZ.<6 M5LH05]O;+%T$;[(BKCM1Z.9ITSJ+J'_\0^<'5TF9%LO. M,[V?7T/EV7AS-9\YZ:H ::[W[DJ@;B6@$BX M*%S/!@'JG?*[HE@^IEG6_/U# A0G72!$<5?^E>Y:H?^9@F26QK=IEM8 B18X M@2@@H:^"3?P4WV:MX[[(%\4Z">KX4]+Y#HQ1;G'M3#X! M.ZK:Y.,L626PY&50)G!VV_9$:U[K?9(M$<&2G^,L\VS+>F4W M\:?@K7DO#"X3..O+(I=!FA^^+?*[XSHIU[#>!3Q/'UJ[XD7LF!R)7%HC5E6$ M9' %D2PG^:+],O+_5]4F7B3_\0=@\%52/B1_^'/0')((YGV1+8$Z_^__9S:( MIM\2[M9/+0RY*M7>*Z:R+_J]?C\"9"@#N'K;Y-M@'/;[??R?D-H@WM;W]:2S0(Y]-Y M.(I&S34]9PTGRV6*$@2 B8MXD\(IMB]V#2(58GQ0^W!A H.,J*JGJ)&%6T)90;$.NJ+?!> M@1%L;5%4-6P^G,P'X2":T<9FHWXXZ \TE'8!((0+66V2!6)OUI(K&'^K3HS: MB^\TS^'?[^) 1UG*+DN"B_K][[X3&0!(XED66Q2702P F3=TZX=8 +60]] M&X-W7Y+FK M<[_>NS3OZ_YU-9'3?S#.">M3JO"8WF]0@D468TD;:DI+Y B?(8*,.IB>P8]N M3 #R'U0@@'CV4!%>>1]^5\(%#C9EL4K;<@GO$ BC8I-M&<@P6O52"[=!DH8Q MP@#81(+J!]ZQ>+E.<])N\";O8,- :^ JT"6@[]:H"/S=JS;Q;2Y:B^Z Z:HL MUNKM3CE!QO#*4#+.;0**7"(DD,63;M$%(?V05I[5X_'YR6CCO@7+]"%=)AY, M,D,$\4.<9B@A!75!TI"Z%4+7.E:X80)/;R,FM\[[=5R!AG+8W3U+LRU>F\/> M_CE)[^[A]>/X 8[D+@GR+;$ 0%Q[197-L'HT+!> M%P8D^E\!QWT&O3AU&*< _% ]Q6$0WI&Z"<-[#]]F-"&TQA$!,UNP? -8G=[E M(I,NG@(T1529W,7EW[85"X)M22,#RIK0P;'L@!/Z/_9A\.(^!HD2H;$Z; 7- M07[,@;1GR!X"E$X097)S(8YAU&,DA4&5P,!=8FX+5L\X:5ND_6-P3J+#P2=- M5*R;!-#8NU!VAXB("'M\D0/V[A81S[6(:(M_9P>(B(QJ+OB.WI*(>+%;1/2N MO4O2L$B YUB ?B"!U2>AK3'\K/:)#9Z/6,5[YD &M MC]5.TY7G_39B;;8E7&LA"A8WVC5R]UI2#]\!A(SF].@NT&_E["I 7P)X]TT*!ISZ9H MUQU[.!#A6G)IQWLM!;7CO9:9<1??1%[[)BL>#[?JG9Y?O^Y^O@S8?W M[X+W5^#ROGV4Q2))X/*3>I$<0!T-O=AX!,K6RE=L'=BY M\O/5*EF08)=\$G$*G2U$-A:'6JU%F] @/OA#@MO)Y5E ?YS_GQ\O?CIY>WYY MH#V(M3!S M;U@XCN_*1$@M;VM MTF4:LW\!!T"U-57&B?J^++9W]\%ULJG9JC;H#\:]X -2'-%OZ7R+/$?#&N ( MC=%8,BP-]O@BZLV"=0H:/;P6XC_'^I^XPA?3Z91,GDM@1/ ITGKF#,J$-W)- M>+W@S;;&8T%[P'J[%O@4MUEZ)QN(B29X;(+P58SPRX@Y'!'8A".\?$5>6N 3 M43@>S_$?LV Z'N ?\V#4QS\&?1AKA']$032?X'D"LJ\ M,$4=L#FA.YEO0B& MX7PP#!3E"FP,!"G[7?Q$LEI(AZD0Q4&2.,<+FFU)3EZB.22]W3)34/@A9Y$3 M"<&SK[:;39:"0(?,2$M(^ 2HYG(+UUX=^%^VV1-#ZO$^7=RCV:Q A_,BSN ! M:%3)(Z)5OJ5_;_,L <$"'00HF\ 2YW"*\1..FP+>P6RX#_4<%XGZVTPHF!)*!6[?7'6L P_9>C-AG^":Y+;?H/V9,ML>+T66)%GL^DZ=# M#TU#Z[$HL^4C$']G?N)F<"5(_U60(GKOP&K>&^F;9P%,GR=)B&Q)*>"_M/(\ M^43HD23!4Q*70"TV,&VP %Z+ZRGC1U@<@!=MSW>P:V!725(!'%;.QI<%4(.\ MJ,TQXE.U.+T2<^0$-U@/.O034$.?V"\95^1WR/$%=$8">P"ZD2A44T#K$:4E MSU7!"S& 3BM[/Z0E),P=G8-CN_X] ,9W"UC*WRX6< %(.M,CTJR5NANPY71! M9VJC8%HY$E*2D@Z\B4%^Z07G@&O%$\=^&)+?XASF+8LQ$!*ILUD3:E<*H=9Q M#B=+7]1)O(8EHW,%Z,EM8E]ALQ["WM*>I\PLX!O6$E&[*+*:IB MOY:3:,0CO.,')RE*4^;[_QVO-]^:[1[A6A%G!OUOK=?HE^C;EXP_>F!24=F! MSQA2:-1VSI@PI,%!MKFR:,N% ^BNMB@YFU%Z&"##ESLDX(.8SS*6>A?%!I2T M@>&"CE<#$9"CT71]L2A*\@<+(9('L-L)JE6*28-%M OSV06$M#IBE M'^&W>Z1YL'>>3M8$)ZHOG[J/B'WJ.@N,2?);%RBF76OS5'": 3R0\N'>0OO44@'"288S$-+O@-\*FNBKMHBQ=OEB4%JBC>; G6P):T4U,%E<$5+ M25/P.$ XIT5EB JGH+4A=;U(0;O"%M\E#*@06 MR L0Z.KC4_#V[15RFD5Q3%-A/&R59 1LXIS;$L,CT?2!\.E9:U% <7>C(8=W M^P3$^TQ#0%-KW]LR$9TXHC-"B0^Y0&P$\6I%O!FD+,#"BM39>R/L+Y$:T&5X M3 F:+W-[M2!EPD/KS#J,@82!"3D^R3.@#G> ME&2S.2W*32\,3N]+0/2;'CD T-F-8]^D@/?W3\$UH@+<#Q89](_B MPY, :QW:$5@2P,\,^49)$&*U['RT0K M"L _*3J3)ENG%2C*1&8J8\0MD[M8&"J2%/A7AL**B+*WH/CD2**-+QY%@5-@ MBG$H]!*_+;=L.0+*Q\MXR14'2\XQ[^ M90OJHL9L(A8 .%0KT5!?9E9"F0[1RO%:4UT"UX6P KA)L. M L6KX/^#K08/ZF('/38E$9?Z"NMS;8IG*5O-9;6*H:@\ ?W86?FKX(H$34*#C*M&(G2REJ @-,L<0@@814B UGA*0F5V@7T)&3 M?0DC(WO&8X)&,M#T8J!C6]:&:M*[08Q/EFG29 :*%P!25=N8E:88-IUNMLK# M"5"X$R-/R5<4_V&1O2;=5(8E'"=^4G>.2*-(_TH[12ZW@,:?!'D2EXB'2U1]%W17&8 4_!*S]=K8 MVVB!%AU>D+)M'F V]#K1=H?06O!5W^%/3CN 3* ML,#W6-,'I(5;BD O$HHN4L-@&@!X$W5%M$T81&8F/VB7OJMO5T\O#C<="@V M[(WCJ'HJR(G@MBN;047<'/).< D:\@[7Y/7-^],?OG__]NS\P[6RSZ)O].87 MD/M4-+2*/K*//+7#IE?X.?M1(KR.>P M)Q^#Z64[$:(1S]/^4'3SIX"R+?LB:;XN@/R3IT?3V652I7=LT.5U1N%T$H7S M7>M$ZG:-ABX@/ZUGVHK-;D5"" Q,97S@M]%"!I(:R3"3;X,K)%QXAG0PT;>B MR'5,P%Z(,LX_AA2,@?]@?VAEO MT7+7.2R(TETXK)F1SI5ER*63?,)+76']7A3-36BQ '(AHZF"MBUP9.N[80JW4S"M"BLBUF;V-W:F$DFW'*+1VFVP N[3:S MV&^U\R@,[HM'%-1$4DH^+9(-N=% V$*F!$ ' EX\:@9E88"%F:Y6IJ=D8T9> M6#YLLMS!):NV(/CI50*K*GQK5M%LHJRZ)QD<%>)FBG/K8RMJNQ'XIR":=KWQ M4GND83="+8V5I /OR,UH&SMY]:NTK- /: M6<5PARN37:A"5SI7,A><(L8-U'C?@+K*G029&UD2#H.FJ[99/+Z[0U$793=) M4W0ABL>U?R5XV\E)6R8/*6^3W![: "52Q$(B+-VMN[)K23>%63I"C^>$C]J( M0+B;HK62XF93/N1&%H*@N)[0W-V=.P+IE"0 2>22'%U("PCAJ495%!,'21/ M@$$ ;*,T>$<0;>[N/D:G0I*KG2@_9XND'@UX8I.PT('S1'DT&5DXT<#Q_OT; M*OG6>_$U_VDY2^'L'G0B/'I&<_-/AXU8$:CX'K _0GM@K0HU5ZLX-1=1J S[ M]T.5"D,Q G8T"[$/YF6:G!![D1MA76_\MH54X=<@ C GRM9UQG+0K7@!560; M"KYJD^RJ:7!'DU*#]-?9'XI5J']9@AT01 QXL+@F:WZ:=S;V;*Y4GC@XWL9\DN+*)F[YE"E:KMN0?8]B#XIAIA1=#H*.H!EI#SR$6O6+&0* MP %4F\!*!G1$JI./*0T[G4U<\_M;+2\?@W.;#G8;Q:\6^*4W*M&)5 '(*K\60"G^*< M3Y/XH18Q_#2!8T.HQ =?)I*_MUFFPS\PO(3,4_#D29B \221Z]>$%)IKWD6/ M]A$A_&>+"+&.*Z+LSBLB8JU,L\8@@1=1;]HW5R]$___?2!U M)]B[Y0@K,LPF2U$A;F2\8DB/V"HD"5A2]L5.1*.(#,I40DP^N*@&&H5*HRPV MM64^%! QGUG12XCL>&IL$B)],N5D$/QO*#9VA*\Y221?EL"=%SD96RH2(#J. MF:+)V'#+(1VT;V4-V,V511'5+UDGR"\6=,&T3Z[IH1CDAFG:6"K@[@"A; =1FW?(#C&]Z@T!(UVC*1MD M@$RB'YD_DAD1Q=RQ$6$EH28GY/2FZ927#,XW+L ;7;SL,)6;>XVD-3O%^@80CAHU&6ID''5@;:R23N@%\ M9DAEG+$E@44I]M:5\6DZ#LZS),.L.(D:M493_B4R8^N#X#O)L8]#X/9-D7L[Q(^)"R-V-LPZCE5 MT$QFQ,\JD110^_VB+NB;N6W:->9J2KO4F:=VKL PC$91.)K/N]ED*XDE=NP0 MR^06^ /%G^HT*L94/:'8OA/BGN@WS8-CB@3W+@F7,P[GXT''DD*2A;]H '9# M/.P>930/Q_-QQQA6_#QJKLIO7MO;O@6-"%Y//ZE(1[(5YV@U1;=)S1PQ+2U! MVQA2*4N/9#! 5$YJD;0WC:@OACW8HT7D<$F-UY06TQ*'&K&0>M%DZ_5*%CIM MMV$X5V(%@.=62*4X=HT^4744V>"1UPE( M>25-JMQC/#Y'U"JB45(>%] -X:#$!$FYA1N2Y"S;KF@@G=2G?F@M/BBXX,,V MJXKR2:G[\EE%,26QU 5PA#.U9;8]\S)K_TE]]BG!!H^7J1B9K#H2;TIM,>:69B(@IMMD*^9QEH* MNDELYDM"2(PY+ N2^A KB'HS(66#/,S+.JQ=ZP35* M4!YJ1ZF(Z)[+S6 F[)2B!_ISOIPX@H_4'3!$-,3PXOW4&OC-;-Q%*#F.V,QA M.SHF3"C4H.1HHXZLUU]#>EL#5E M##)+>JQAKCT;7K8%CI9U&@TPE$S@9KQQ8E,C9$*@9L*"O+??W1DM17V(TAU? MZ61IX&(#0^#3GSGAVC6]TOA=F'IU*UGW:DQ;KYJZ%R_YGU M^(7[Y" MU4!['[&>*Y4E4F(7O2@5123-CE]29&LPE #3(\JQBC,LI=#O#<>;FQ6DPG4UU;.I$'CA7E]Z;!)/91')FY5<)]C;O MC(/Q5/TL=9@GDJ:+FYA$\)]).)M'7PHD*69!H_;Q/^/YS-IL7QYS@NU,_@6O MCH+1;*XWJQ[H. 9^:1@,IP/>Z5Q^-2&H4_/> *#:5[M5OYO= L9@D(''P0T'OD]8X8 L,!_S?JXY2#64L]%4C,Y5^X^*E\$ W,Z4_E M.>Y]8KW;Q_\'.$\&' 4]TN_AWJ?ZS1D#!MZ,QG/!(=$\+,#,YFK9N-P18,R5 MB:,@]9ESB0[Q4JNL5-'#0.A##=CB\"<0MKLR7HO_&T21$LY7'/@VZC*ECL:]ON9(2*>G?>L'+!BP MT44Z6)Y$34#+$IQ98TRIR:?:E\BG5ZL+D:J:$L=%?GQ/@>](:97MV3+4>U@9 M2?8HM7YC)EB(Q#?CB>M=ZR]D91O3H:"@LOB(^^K1V#RHF(11&#^>7\8]H>1M:*6NK.B< S+CVE! M1*G;@V%O:M7I()\M%1W2R7.4N-)=..'%<&!=?@&,2Q$ZD:F;T+! RE2,'SYVE?^IT%EN,J7KDYN#!5B5';NTRG&20=591C>Y50N/NS>G(R)=>MF! M.AY;8,LZ\YO357*)UNDBW<1F&@QPW?*T4C]$HX4DGOP/.?[:Y/B?C1!?. 94 M,DC@YMME5.+E RE6M.MFAB%'T?&=:@5FH%GQ,>?E$M@I8G#\[XK2[;\PH7CV M*)> <5@1Y>Y+BX$-'(!#N)T]61$'[*7"=(Q5#-?9NKRXT.H^W>A<"30R)!RK M/=-D7XFW1%F:7 L#$.X*3F3Y)^5?S%"4+MSF)4.KQA/CK?UQ:5$O4KO%$"8V M&H:-J#^[A1#E(I(4^65P6W 9*CV712?%ZN8! N'YN])@(UM53-I$@_]R$0S- M@*/)(!R-!E_*@&W>T,U_!8.TXJF9TS\U.DP^&QW41J51TK\&0O0GX6 R^FT0 MPDY[.%!023:HYR>A!/X?(+A\);GEV=SB]LDZ!N8=:'/^W:AY<%1I:OZ2A&$T M0?\+7$!#CSTR&$HJE1)5\%J(5&6*G;B"U>]Q Q^IG(5%&!#IHZ'">I83GW5) M9Y-P',U_LTNJZY4,0@_5=HO\[4B[E3I+C4NARXGI3,0& NF!&H -."'U&+XY MYO,AJO! JC9ASAQC,X9A;-H^@RDU<$R?,SXVR<%(3 M]MYF)H085K)(.'++;#?DDGB2NZ_?!(6U?%+7":L"JD#7/70#T0"S@S.JB[]$ M^?UF!ZY4DBJ[Y+E-_NZ\Z];MNRQ1+[($ ;@43>OQ0>R+W1"_&=MRHIVL$N-7 MH/V9=+3/4X2LBXA:H*IUV>9LC7F_&D,+52R]-H3@]KGO"A<[1L!_HB?@8 ,S@[$:8,SAU-[^Z=ER M_VNSY2:>M-BF-M%(29:1][M_#CEZ.)Z'LU'_2UGTR,+9G2Q:5$^1*@:'^%BL M383DL^7@O[I$A[84731E0'#Y6*1!2D"$%$=7);J>9T*)2X4RX $L;",2FIO< MZ 3.D?97[G]-O.MT1^5^J\)UL7+>!'1@Z^@I%WD@!Z'T KA2!?7VI)X?OSZY M/L>*V.^NSB^O3VXNWE\&73T%=%%I.OIDV:(Z_1%)!6'P J0V_(LJ1X_8[XY M/J!J]&5![91NN=R])X4N3Q.,F%;'?9AJ2^53'ALTWS;M K]%#2K5-AD6V5##KECM QOLVM[-Z%)$&HT))I MV#X+UW6JOM/B";ZYJ[H'@5(*.%RHIII,JFTQ@UZS!0SN+P$48,&5NS$.UC\. MGX0>@%&TTJ C#,%].]5:GE2;$V->URT_E9RJHON0@&%8V;;&0$']L^JW0R]O M8[ME2KJ\G,-"'/R<->3 M?)Y80G9@Y1+[)A3N0;?!B_T7]^YB#4<]:)A\!,/<00RTW0\ M#U[*SSL'GP3#63@83^1=VT+2]UA(=L3+:&2?],/YI'\ LGL16]=\O4^ E'Q2 MY6Q /\0ZM:90UZ]S 6)-[C054[XYS]T8?96[T2[O__Q+DI9?YU:\MPT,T1YC MMCIP5Y*8A!%@U4&G3X)X\I@]L>PCV3ON.5L@8 UWG9B:3I]WCYGE==[FKW=S M1SMN[F0:]J>3(!KTX/ZJFSL8A,/)"&XN_[R'+(Q&X30:R+MJ7#6/^N_G##U! M\^AP-)-W=W3I(!UQFV.V*ERYORM8[I(>5-DN6=BP'K,9R!@JRDGT93=#)-N)QRVL/0.!Y4<-&31-+K%37" M.<2(;5ON[<0H('M4G[^9CD)E:9D1L5LP-JP;]=O*:3AB-^V@).8,]EX:'=^. M+2&5C^Z2W=V[UR;%1.>.B0Z_B8'M_41-R7>2LV$P'H;# <5=]X930Q+'0.0& M2!+QUS=Z7T?#<#Z?J=_W4/@!O#P;-0;FWUH#-VGS@6*?_+>C]?/-CL;5V&'P MH YJ%Y>G[]^=!S Y1?Q)@IL/1-)P-^O3G"-3!0:":' ,;C69PP.-P N<, MFE@T'*G^BK[EO@C0T#&=4H1Y.)T/X0^0="?#B6?;N*'4TP+\JV_ZE#M.O +A MBVN?O@A@7^.(PO;Q__HC2=4^FD6(5\ 'HD@#(0HGP*Q'(,5'*GJ9^@1+3:$!]ZR8AYG_@"9*52;=T!$$$% 4\DV6Z M4M4H,8!V- ?U:]H/YL&I[HWD,V["?9@!YKX,!B&VR#N"_TSQ3B@TH)6HL:D/ MR]$@@H/',SV*,.\*E<*C<3@8X6?O10R6$T1N6B=K@),0Q1&<='0X,NRX=(J_ M>LY,9Z(M,.:S%$>Z5?J5+$>N;7C5N5\L@9FP3G);/'PN ESK92+]_("S-.]K M_ 1'"5I %NN2ET"H_QT!,@NCR1S_ #68R LBQ&0:?(^UE'_ _XLFO3&\BUQF M &#.9>\#@;H+\7'F/"(>>9 U\9#[%#J)U)>3$3_"K^=CN#_AP /A"W(.LNT-@ < 9%B MM%2_# ="SSP&>V %F.*$]VQ$DW_,."IK"E03@'QN( MQ&ZSJZ^9CM.&^S@9XTV"FSB=S?65.AI%-&TTQ9OG6;XU+"ZN/QGS(/.)=Y7J M]2=DA(/)C#GB!&?N4,U<>^0]A2]D'+N/X/81%U45&I__V+ON^3TD5OXY.;?C M!W86MEPJ9LU<18=JFZ_0,HKUV1Y8Q,<\7$S);+B(\SA[HLPI+)E4@+ OV?8Z ML4!N *7SF[H[1O9%TPG%*%,7)*(I.A.S_I+ 92 M)3E)/R[+I]L8!&.2S3LS,MHGX7=<-;L5*!KG/04K7(3;-*F^9_ZQK>'^MBW3 M:IDN3,]:%.$+ZC+01-)"]5_Q.MHDH0#>WBY8@*48'T[ =_H ME;OKQ4O7##P9VK$2RGOE02OMV#(=C5O)\JIZN;1--7VQC2>OLTZSRL@FKD=I MDJ)$XUNF%8^5+B/'WSFI"Z@F87%":LCR(I#?YEIS9H^SRR3P7 %E,F#\U.P% M>S' W*G2_ Q=Y(:&RFI$.&9WB':O/8C8,4Q*&WL1S:WFSB(D,0TW,-KKK TI M?@=W9PH^";[!LFBX-L(DOI:''8S JF<,6P="GE;WXJ/? T..(TNIHH0X!#K7 M0^L6JJ2JU2RHD2"G3=N 6QZ8_H=#2C!6(ODXZO2;:W5/B:B/RM,A_80XB.YA MRZ7EQ <@A0S2VMQ0^_RE@#R9;+B7N&:H"IVX%PZUHR$JB-9UW'M:%U*^QM1,\2^:J8RXI=UI[#JPVJ2EDF^8R.UG3S4:K" M,T@T,T0*4^S 158[9*NM_C:24598R*+*#,<+*0&/8JT:H"4AP%JSK('5]MN" MDAAGVZ<,*H5.^J6" S0X3H+=15P;MV8D5>9O/QWIZ+S>:X4(8:=FXM(PRRE6 MOGB#57=.I7DFI7IFD:_*(J,^PB%3L?BB94A1E$P M 86ZP^RG@L*NL%%U<&/9W ]_<\W)S?A97URBJ=S M'5Q)&=4/Q9/T:GG?:$.Y.YR>OWLR#;6ER\Z"_$(D-4@4KL3L7"^HJ2T MV]YI#Q,4;Y)/@-U8,1&W9F[T0MGNCR1XY_7WUSILQVU !81LBW7ZMB7K$%;4 MK.P0Z3.,?ET4$@TTF@V^;;;DH<)KTL6+&_3*UR*:86-NV(0KE@RL %>4+RJ% M-K#8^3-;EZ68G>XRWI M!E;3>C+>H?\,1['!= 0/J4B<]>/R91BH9(5TC=(1%K^AKF@<2Y)E+EP>BS); M/J9+(.5OV%6_;P,O(BR4TJ?X>XUTVO//CKVT;IU%/V)%LI&M[_257V'(__,J_HA MN0:M0-]4=5F0;?ZKWQ9)#FA4-;Q-$$8@2*AB"A(Y0;*_W26MMX]*X_2T_[6( M%AB(+I# 9_X#P^ =ME83&.1].FF3?X,!B%C/O\;VQUU0Q0O!^Q:1T"TU"P ' MBKA0K;%UX0D[$77OM1U-QRIT>3P>FZN+!?SZ_W*7U[V[05&&NP(;!7_RXHON M.M= LA(4-%HXU6'=4AT=I*![K"_-JVLF#7UNGATI_*1^Z RS?F_4!ZG,5(%O M%=(TN6JZJ[N[3,EVX7*W?]OF5KU;$RC@J\MB0E Z1O;81YHU7/9EF35!Y62= MF8 )=;R-'/%F=IZ;_^&DZ:D('5T=N9FO1Z+]7A"2S7:3Y,?-5)C/28@;60EQ MNE+$R%2@&4;_E=%Z-OYOBM82 S;YKXG4XVZDQK3MZ7]AE![,_K4HM54[XHL0 MVDW'_VW1^8^_!R(_*Y__U\/F_\GG5Q/_=TCA1P7EGRJ'OW$I3'\')Z'_=[\5 M'(-]?!]G*W6B>ULH/8-4XU,[.=JH7/;DH\X8L?K)-PPE# 6[*W8[1USIG$UO1^=QM>;_C04B6Y_6#5F: MQ_RLF]?*NP]ULG,$EW$^FNZ*K_\"SM4TLY^KJ.G7'']">-FRX#O9X#C[AZ1. M.3[\L+C>\W=7;]__O#Z_/']S<1--X> ^I6MN6SEG_Q='WMB! M9$Y["S+W2X<,VW+%Y))N*=C/IPSE;S+JH#X&Z"$)'Z]A)E,,3;)%C89C[R[WH3 MC.CF#76I@BBR['T3?ZF&Y(ZNU"Z_I[SR@0@U+G>'I_/\.W1S.JY->_EHZ]5V MWDJN!).E/*D?BU*R+3BT@6\5UHN+U]2Z8QWGZ!>B,Q423_9G%C.E_8#FS?>8 M^Y.H%Q^Y5TDM:V"TK[9KS']4WA#,Z3A&NI>4"S*_QB#WP2'4"!R0+\30K$0R MBEGM_L!%*1T+QO$'+$R2KE!3KUD=S%$QO"NVH^OT=%AML<;F78 S /JDQ'"0 M1>5L6U0/"3H*LF+!*2C C$V]$[BNC^QDQ&P^P#4JM@H'+#1+>1%/+[07D2[- M.OZH_7TJ1$CH5?<^K1796Z,,3]F9K"S7Q20L+U855$"R0L>Q1>5DJU1ZW!88 M3L OU$\;D:*VP+3H8/4P-&&!'20+?GF=@+JZA!M0D_Q.!02RTG.?ELOC#;FF5:ZJ2)8:&@!\4YX2V:YE011G4H$K?(Q3I2J42!.778=!N) M=8? G0Z65EGC'4^T) (UQ4YCC.@HBNAA"1>*&OF*O&A(/9BEAC@Y&RP]&$VKX,1K. M@E/ KF4,_YCUY\$@G,*C*!Q.1U9RP& R#$>S03 8C!S JF9S"9 WQ_@B&,RFX12V@(DEHW V MX?8EHW \[\.T-BNURV!SZ#HOSV8 5I!0A?1BV8@#Z+"X.7BER2ZY:IE:?6W< M\D_S2H?=:.A,YH 9&+,T& _#_HBRQ*)9.!O!$>0E+(?$2A5[RL* 22 M2F95?1E@UMP$=2',VIB&\\$T> N;(83@X/%UOD*]+)&##P$"?"L'.GA2%2-K@0X9_ MAUQ)#="B:+X#QQ#=8\Y-D,#SYQ.4CI-^VQRZ33"F$TI%G WM1*%1'[X?R=V/ MYD SQH/N&P64(1JK5D/MW2 1&L[P8&;S43NN[[8"_1T1YYQZ,>]]86>HW^OK M\__S(\K YS_!_U\[EEJVGDR#SHQ[W3 M;G3C0LF^WY.N^EX;C=;LVU M%IJ*D](#S_058K,E:B%D4B='N"P:4;#1TEQ:==MV/6E$-0UZOWV5*A-PI/YZV1S= M]W8W5ET!&0==6GIOGMI-.1NO!I_6V:L*"&#R'W^@2U\^)'_8]7W0G.M'UB// MI1IGZS8TGQ-!V91,G.2()%14DD4E5,+7>\- 86.6R/'F5+)N@:I-LO0;5V"B M$Q!! /S*O.@DWY!F^#'1=455F1O0^3;2 I7$-\Y29:%>K.0<,,\^"J8@^*F= MNZ:T@J53PI 9\IV*1?=]5[?\#*;'*AJ6?9!3D_G6)SR.7]+9AA;CUQ]QT& K M$/I#HQ%KR CY%/Q5_GN#)7I>@R[YL1TQV_B6VE?'3*A;T \K\ M.FX?TSHZPNCW[<9)E:@Y"^:8&AI_^3Y)'8JQ9D:\Y/)W=!>N?X1M4H6_\3'2 MNM>\Q.#Z/@$AY=0]*0J2EYUYZRA0J#DB%?UQKIO5'O[BCNHY"_4-_9%8WTC! MU^#%Q$KL(5T4X'8;YQ];9@T6$=QZ42P?$/07DDA=9,WT09ZILA+6EA:^5M3; MG(_1K6QCOR\&".3=XOKMWEK,+GGZ7??O1 :M:Z8H0PUHHK@/LHO&3U43)3MR M' Z"J^NU-LDSM/YE]3JB>=I;#^I;-&XAI%F=ZEJ(2N MD46G*M+12?."JY618>@16PAK3UJH.D>LZ1CWHF&=&^$@US6NSB [[@Y6@Q^E0NPY1##F>],@V-=>% MJ/ J[WF,)D%J?=F./< C)QD6[ZLZ<04?1?\D*0WED*9YR"8IKZ*-?I18/^M"ARPLS[- MGD2T8@?075$LK7)YM8J:1=B"@L8Z/I:6IFYA8B+?5HX_YS@%=L]_89(7VT2; M#H>'-'FL-*+EM=(NBUM@6DFU2')IK\Y$5;V"0GZM+Q"_7"<,6Q)+E[BP1T#2 M.J&0$;]JZEB:R8UN3PNCW:J^?+9D%]_B?DC22M:JT#!Y[[1=5VG,)DN7I#(T MJ.N.?**RD):M6I0I^5*O4.6_H1?3GX>LG$SC0/6))@"TH:@Y;J[0Y%1*I#K2C@TNZT!]P/=IX/R)NMQ>3RYR54 M;O46X^0T,K4Z])6M&#(S-5_V.LK!B""EDB#8D&Z*#=TF]2,*Z4S[E(A=:I\F M"2A8%(,B)W8H?E@.+Y9JCJT0EH2K?X@TZ.ZGHU!,F:CJ#%V 4.CKZ-2B ML%:LO/)*'-A:%S!MWC5+G:4CH$#*V$"02M=00G 3 3*D7%6M$9S;L%'PSAV@ M3$V$!$YGE:ZPV +ZXF'%=&[I?<$4A9/&-()M-S"VPCR\+$6V;4/7(5Z2&TW. M22 !G&%EE71U:L$Z4*&5ZOIZ@:DJ:%W@7K,TG:I"H&,.5>BFJ<71D67/@K"I MGE"X80NN$8TN"=Y8Y)^KO>#.DZ5;RWP4^+YM-4IX>W/A]DEH M\"'-\NUZV9*_&]N5:>WG**B0J^.NB#,1(M#/+D(S1GPD2^E^V]0R<2ZUJ+!Q M)<02SQ8(L<[+WC$-,7Z2&E,4HE _'9,0Q+&-B ]8K!=_(1V;*K;"G6:?&X<+ M)EP?(+7\ !3=M#U75A%K;I"]_FQT.^A)< ME^3+=F'>P=!2XA6I=89E+D@^%\:=E:H(SA=>+(T@,Z(9CV@)5LE1A%F+3R94 M13UJ=,)R9B4]3,V$MBW"M[A1MJYUR54EN%.QK1UTH9L?M2ZR"E[\8)CZ00-[ MOFOXC-5MI)@Y1>L:84'WZ6:3"%:E(&+!65 YG9I+MZGH (Y3P_+.S@SH9N G MS,&PS;C30$,%N%FYIE8LN7!:S(Q8L4) G:YX(23#I]5'_)F*5!';\CG I,+P MD\XFB$N@_25/I?)@VJ_)RJTJX^R'(TJOV%&!2"?D[DWO?>\UUB8&F+'S"AAC M3XB?PSN-U4+,FY6^D" *V394)4ZA>5"!DAO-X+%1A;FU[4U(5.4D=7(Z=L ^ M;"J[+%NPTJT]?70$44H4D_ER++E'$=J-==XYLVW.A\8[5>H8&'%3,852J=PJ M"(L$$]%+50([N6TPO@ K2-5;JM[).U!A!\V=Q*;F&U6/5T$'KKC2\'31719= M0-L;FC-I08O%-\KPUV7.J3PUL/&B)($4J4))=4EZ.\,M3 \?7!40*ZXY(X%. M]?%V$ZRH!'QJG1'KJVV^R5JQ*+[FD!QE_S')%-&N?$NKU&TS5W5!98B0]N)U MH]#^"NWK-#F;RW #CPD(4K78MX);-%=((*IR,W)$!WF8MAL0;',VD? 96@45 M;:,G1>"A9I!95XD5=#B1E,HZ-.B*;H27YO;QG_)4554L4NT4(9)F[ _VIVP0 M7*G/*9Z!*5\IK%07?.@^&]F,=.$HS;?D0].KPHCP!^W %"JHWW56)HX/L=7J MLY4>26NT>=9HI'M(#&MJ<9'W.@B/C#&^E *I.G.8'&J][X2)J6-!N8+HI7K) M*"W<<%%0BG9Q5Q: ]K=%OJV"!U VUBC)8_P/Y85(J@F3(G'4!N<8PM$1\.!P M,.S<>2=E$RR)TB08>::U&TM45:*;Q"DA"B^T&XNKYWZ\1XLEEB.A? ^7!BFJ M8\.%^*Y(8:0^8146^P6.Y+68JGVW"X).U1 4)=ZEIGP;#_! ,JY0Q9+@T$;= MCZPJ9!4BD1&$$EZ)SI\!/L4!_FQ-5$U))7M1'2\6]2.*DRP-/XTQE";+\+_6 MT/:>!1Z?/4?/BY-82(-V1\AI^O(8W%2=Y]3.4?;5;F$=.1#;2&6Z-S!T%>[@ M9$201:%/J)BJ'!=JQ)+TPA4Z;TC)M)8D13^( */+L$9IFFOFYL?Z!Z1W%(IS M$*^CHH,^DL@"L)Y;2)@&&XK6^(,##>4%6K.+\""BT=7[LLMB>@4WE#H]'#1Z M\Z, )DH7RIQ@,LRD(^5(MU\E"\%#&@>6Z@I7ZYCY)0= M2J.C-7"AC!UVN)8*"!,+5ZL-C:%#ZBN)^K(Z'UL!*^H&7UI3Z_K''5.GE;L\ MPJE6 IN;NF6Y2-$0OE(Y&8(I.&^CWM9]O.1(#\OLXI-IS$UC3(392BRN2B MMBNLJNA%.U';4YP0CO9HX,RBK0/[@,6&BC862N7*ZEA.G>V8J4=447%2'T"Y M8PIV6A!Q$MI_F'RR9Q! /ZL#;-,:T*4&)5:]5QCDB2-M+*(<+*:L.H]G42NQ@*O4N4'.;!R.3>DOH7]6 M^=[EECUH5JL 1"G)+=2;0QFDT0JLF1BI%\[^<6]>(AV!BW,\LCE"*V5 7S,# M<+4.UFU=T)-P1JT)>9^* R7VF!SFA,?8+!#:3 %\%B(MBX1O'E!T9')D1;# M3'$X"D(AZ9B4B0! 9K<=Y?0IWDV.F]PJ!M"@4W^TP.Y!G89V@Y>KO;WFR5I- MC-W-MS)$4SL]DO1SH#:I%2%MMFV'(;5R^A8Q]@='AQZ&P90T@"EW(%]:3D?V M5Q(V&_FX234)=-17R)1L:1P#7WK*A>17Q.3(V$N3X$D2/:+6V +E27A0\H M+JUOZ=09-10J[T*)XYTX(;'&J!![KHCO7H0:JFKCJ)9EH-,4E4+"L M3LG%(^)U?-<,VM562-9\]4ZQA4).DBMWF&=")EVEGO3%H/7!I<09M?[EE0@I MW--8@X%,WJ>W*>LIY+S7U>$,K_G7 MI8,^9?RJ3-;I=HV5[-/@+]M4@N/.\WL\>/A#V3]1FKQ-L5(L^KNBZ>C;EN)F M-=Z$F4TDP07F'%#CY":$6Q!I#,S(#3) M.DH!-A8UXPD.[7XXP0J7_T#+OTT6\59+56DI1,S$YO=\&]%%L(I<>:OM;MFT M6#-?94]8H1D/EG-;L2\U<2X/HR\)Z]Q"47524CS9\89T <6/2-XL %J4%;#$ MG"."X3=;G%J^\]M0=E8:#J7I#@..5#5&CQ)5AQ[@ZT3Q.1Q(OJ=G498 M%GF!T5P^)/R\05"1L?L%2[\1@ZW6E]?(22B8AG,Q5161-R?7KW5L3,J3>S_[ MD?N[J.].KG_4GTE6T^0XFG&+0EU,0[?AP$2*9H)"R"Q(YP:J*V2<"\ND6I3I M+;NTFOA7E*V?[+._;;BO=N3>D/_#[C9)81VJI?%QL3JV EN 55B_L"=)K1RN MUF.NV$-E X([=" @&'61XE<"6QV;:"J+4R1S6J'8U6RP'*_0!F>JA8U5ZJRE MU" ?2]>Z*9RN+X,IZ?:PK%LV4M722@PBVGIJ9[%1>1ELW1U+?#\UH+8B1L4T MH@5K8+]QMT"]-[6.M'5.=+8P')!6(ZM)JYL<]^>A:]4_EB)X]H^O@@L[!!S6 MK$N>D=%>O ,J/=JZ#8*Q%9J4(=^.CR&'%/6$R>U4+GW12A*,=?\VJ:"2<)82)EB9J&$^Z.;7OP.>3@[&4VDP M]!P\U9F#N@4:-1S"1E8:LHR-(ONF56-SA+P2;'$8:MI=)O9BYR 4UW>+]GEL MC)QTH%(G_.$^F.>1),I!%+K]K;SQ:;7.3VB%SCN-(_AQ 8K9G9*MR?POO@L\ MH8RW0L359$C0':# ; JMB08Z[@-A(7 0\X;EK[ RM>E*WB?91C+G,'G35 ;Q MG 0:E CWZIHZ.Z!V5NLF!D2;0PQ?HM %_%T'57-'#8/T(#%P-B69XV2#^ 6M M5^5HDA.2M1AZ^)\82Z9^<'V2O\8=FGWY';)S[/XIKI$MQHQW7J//R9T.G+8K MBGN%; ],=1BBY3AC1=7-EF@D973VS26_A!:;J2R8E:WJ7$=I,&+S4QS03:MPSZWMZ]_)PI#]D"7UPM_ _-& MN6Y:+4D3I!F2LL.N^>:OB%L4F*,SUY1EC:O"JO*U6+@7^1D(,"6KC4;9I[1" M; I7Y# P]=6N>6']L',X'5"BM/PKG4;O\E068 M)F,"JY_[.8#J_NG[UK, E./$Q M%3:D$Q]01;M!/QQ.^E*.KB/'RW'*-J*9FFTWCZ+!-'CI+&M?*)=>5H2%TP:X MNMYL9!89#<)A'W\>\L^PY,%PB#]'5)XOZDVFP;F0G!6?,M);L\I7P<\4S2V. M=.6;=6*VFAM1_P5T5G^.!MRA5(HM6P8;=XC!V'QBNIN.9L$5(.HK8F;*0+XC ML^XY4!^K^])&BGW0W\":N)Q!LI0(,HX9M8]E1%U;X5B&[K%,Y5@&ZEAF^/.$ M2G+"L42MM#V%HL=PY8XI",=4(#G@9;?Z2,.V^FN1S.8OX^!D^;)=Y_Q"V)!4]P-K>R%8DDOF"DA*3L: MT@-F4DT<:JA6*BVVFW6['ZC6OF>6/K^C'J/%W4P1I:9ZI]?@XVT+LT(4/U7 MN)N5)P;:SZN1Z:^[\2IXWRQ6 2"-Z-;/Q^JA+EHQ@8L_'DY 2,/*^9CC-9@% MB"+>@A4!D@M$Q8ZZ%;-1'\ZU3[4"J;ZTE,NA;D\HI1\UQ&"$*KJ!]'J6Z -T4D@U(/ ;,ZW=L-]3%15 $ NX<8A7)DT-KC "7"_L3Y'-'6.Z7$="J^BFU M0YMN+=#4G'JO^,UD.*#_CL<#;;D]5O&VJMY"U _'2'%QUA'RL@3/F2Q 6MG2 M'UEU9\-9A%6,^S,\1Q"EY[,Y_C$)I_VAL2I(X!S62FTFN0'M""/JVQV%4R#^ M)UNL4@(O88@)%VL +@ <'S8PG^[(TP*JU ^&P*[?<:$N^\ P/4M3AR'Q#ECJ M:$;_[4+)._8>?VNS2G_A@?..Q$;.1L.]R7WR-#K&4( M-AG:%L:NNFE[;BV5,V6$F)-]+)@"9L ?\V#4'U"34!AKQ(G T7R"RAIP$-(? ML84SD]7N96&I[/F@12>O+9'@CZHXV"&@/-/!RU?LT#W((^T1XS%M&14O-/9Z MM4:G^JSJ"K^CH^RALOL9Q;'SO3Y#SHAR-E?N%G&;,T*U#X5>THU8AW*N1U(F M%TD!U<4E2(\BRQHH6GW[VWZO/POF?=^[9!*2_E7TXC28PG66CHJ#B3R0QL.1 M>6\23&83T:+E5_8\6>^,@6NJGZ5L[40P"#L&S FN9 MSVPSJ3QV.D[BJR.0FN=ZL^J!U<4/7QH&*(?23J7/E^7(F)KWX/:,^VJWZG>S MVVC$9*X_MY%:ZUQM"&@OAL#!!X%F+RN& -%\^&_$1;MG%IF0UQ@2<_D7+GXJ M'Z!^I0 BS95H[Q/KW3[^/\!Y,N"J>2/]'NY]JM^<,6#@S0BH#>/03)X:P"!# MXV43:0:,\5(/7QY2%P6Y+*2PA^U'9^>F*+LG3,,^0"X: M] #F/_$01P-@GA.L\\X_[QQ\'(Q&X30:R+MJW*8F^#E#3["MXW TDW>[*ZER M@(!3>X9@*=[@A:]-D)4[E._0G3'EY\5P)I7H3+IHNT:5G;,=MQ/ 1,TKJ <> M641WL2\#%Z%B?K3S<[$VXM"I'!/66 K<3N /09 &$8J(3V\X-0["Q\?K.&FV'"!+RP6V" M%74#\WD8G,%?V'Z(.+N4]]BO.Z7.>$[U-BM JG;(R6?VEM +1&4TC/H3T@>. MIN%LT*<_1^$8N(^J3 *D( )9>HQ=(88HC4?#46/[SG*!!X,')!=M 6WT3;*D4!10 M^,-H3 K(@,W*'),5',TB1&&@%E&D(0OJ%%"QT1CH[%QQ,%T6FV Y Q(Z"\:3 M&2@:\V85K $:0*C+0%'\)\IWEV%66PR4_VPT 9V!$+M-!J2#0#8 MUESZM@Q&^-E[$3E,%!Z0V#7 24CZ") G^FS\LC!)K8\PZLQ>WU^)YNXHJ-_! MT[J.[EJ?BL;@YN4%P3?.05;*$ LT@_AWW,HLC"9H>QCW87-#.2RLESNX9C'M]>CP;XX,1#!*-VVJLK9E:41,@T^A0A[3<9\[(4UGE@>).SI,"S-\ MK!&MR+$#VF<>-)5RCQ/E/U=-U;1C/#BI[7QS73]--SRZ?0J^,^V93LHD]DD, M3:WK?_K%_7?J%[<+_]H]72T,#A$]Y(UGH]7_M(O[&NWB=IMW3^,Y1VKR.>NUT?R.M=':;[YEVT.;_:=@7>--NQXY_VB[HFE MO#_U3Z6<@2$5K#6-4-@/]=>WF/9]@8)ZR[7KZU'2#)?J:K7Q9&D<(F=W2YZN M,&+*,MYA<$#=B!59-<2E=D'BBA(\]7N?.!NSA6BZ:)+=E":F"F"W6(Y'@F?^ M$?CAVE6\.-3&\-.=!7M/5<%>HLX75L'>-TX=MM-6P=XKJV#O%5G^O&N37EBZ MLABMS2T^1[DG=M'>A>?(QV@M__?#IS#5J)QZN/\(=MRA[ZV82657,+XK3?CA=:&>P'&^406K %&0 M\P$[?X%_WRC>V3ZS=]SPBN2GYM-W6'>OJ]W3LP,_0Q84R+%&&1$8\:Z"0&X> M"_XQ>,<1YKM(]PE 3,<$6OVNSC])_-B*PX:=H%'?&MF_UQS^4 ,?ABEO8B#= M>@XE&ZFYNF8PT9XM4O&949LM1'Q&O"!*5XPW;:_>,X=98E&*LC(N^=:(NZ,Z MFV_O#_+1R7SQ1E2:>?P@=,9(MC:,1,MGQ7$4IMAFF!$_NECE4%&6; M^/N"*=O'XH^I/&S+.DZRA7J'ADJV8.*/C&S)"[:EH\45.N(D/?S@H$#)3F5, M148V7V@%2K; TXJ3;.VATR3DD:M\$9//BXKTF@'0 S"<1-\B7KSC_I<>>M16 M^P_1]7>:&'[X\#/5WL#)6V^2TNJN?A<1Q.!-'6Q"7?>,5\4;N:FB/E7;%2TI MQ%[I2[TNR:M[WKZRQ0X^#DHD/^2],LF31ZQ0ZWF?[,5Y\%I53U(VU7^(Y>G2 MY.BR':Z3*6(OB2Q.U[HUYG,1J1$\2V0H>&^%F!K\VDUE3>1JZ\GN(-:#@E_*;..A-%8'8@>,GV[M>T!\=,!J_.=PYVE^VV=Z;AX%_T?" "?'% M_G3O6(W%MY84YSWTQN^?[[)XT*#8;?X[V92M(S"ZJ?\;(B;1]-#1)?RT90"Q M'O;G.\V)SUE7PXY*V?+/^?!90&A0W7W?T %&@YV&7L*[0S!=$&^P ^-&##ZS MK!:Q(2T>I6Y2M'81>F.D))!RO3[6S_[!/[5E&J<*=ZCL'5*:%(7B+HOFJ:66 M/.>[UI2FN+=66$)=.KU%R,A:0RGL>P=^*(C'<7V3+DT8H]Z3*0;!0=38$U@I.(T38EDSP W)=4">%)[T4R5L_<]7WQ([(JZ M73I]Y['L^-P[F6KU9IVXV9+:M.=+RY#>0AD?9/RK_2XI2I '?^@%K\LB7K;T M PD[M8?:<+<;;F\ -Z]KZ&LJ8$QF=H4CK<.1'DB" 2VZ"!=TY_>1-^CV#?+A MG=]U&&"5G/&/X("U=QAEY>?#QM#M%,R5(^)T*'6Q.TUT'X-_CFX[=(>,HS(5 M=."R3]OU,F>58>(E[2JOQ$?453J)U_ZKLDC\4PJ7]T\Y\S^T\SK\4T[]#XD_ MBHS5,,329):%N2R7-X%:,X.=HM*QKSE32K\)<--59!UNR-N%SBMD)+UVH]K_^[=]V(5O'8T&WSJ>, MV-Z0&,I=E+UK5H@ M>Y?[+,FE^;%Q5#M3^0'9S/CJD&[N),%)$CS]8_WXG%2D+_HX5(E%JZ*T^\'O MVQUP=&'6!D@4@T3-G94;NT/]$*7(^+H_8Z@OQL,P,+BADO,T;CR# +4@XQ59 MNE7%K[ 1#3Y3LN)]K1NGOM](_5*=^>39^E\_ M&URV.^&L F^_^3T*+_#$M MU@)5:8@=KC>5*KCC%94;UOW&[P+]GR6Y+SB1Y#[:2M#,K^NNR&&-I1(% YTH MJ)(\EY+DF:HDS\,D+1NL^]^V('R VWO_-0=BL)>0=M]%A[Y@[,?O),RVMB0ZLPI3];[5V+4=;.4F2CY_ MG^?RM"N#9A7TR[Q$B[4L5.H8.LBUBE155TDIDQL+ENT]T9QYD:]&[DQ]; M9[DK_;'KRK2R'EN7V)_GV)K\Y)=W)Y?!Q?7;D\NSZ^93O4_8OV^GWIA;'9#? M,C].>N/VZY@^V/ZU@5,:$;_T/GL2_O93L1T7PV0PAO2W?G"NE!.'5:'75N@ M?-#)T7QJ9#.=T*=F2D:A%Q?\U]^3$-B2C_9CI0>L(5+UG>_9Z85=:-X5/K\[ MK7 G,C4PJS--]W/0Z[#TWQTT[) 4QNUYO8*S-*]IZ_<Y_A=8DQOF6!]WG\.[RP'7 M;7=P3_$49[6? 0Y\=/[&:B668W.MQ$["6,9/;7?5H._]79QP?@^A*]!T&+<^)(#%(']8^N)A MX^KV,4J21+73D"DJ*+#%,F>=QF/E;6O: B79IOGZW,O?3^Z<[A-D=AOUH^ ' M;K^,YDV?5C&(_/D7LBML-5MCU.6=,XS.!:)BL0* ZH^@6:&6L(E;9S7RX9Z: MH^J:)%6)3;:IN0,J4=\+%N!M<%N6SL"2:T3E+(U%LX5>GNSQ8\ISO59YKA)I M^'S:OS/#=^<%=S(NVRP%T[+;(@AF5K=OCTZK]AM3ORBKNG74G%+=97/MR 8] M[$BL--@_5NX!75F)R->2[_S\T]J;V]S\P$EU;BM/S\AM;G[L26OV"V$ZE?DP M&&(.7>"D)3\?3*W\X+88=6QE2/S'$8]')OT]?:D\P?(8%LP&!T@AMBG^/S/S^;D^@XS-6" MXH<48P7FC/(\@JE2V3O/RRM-J^8^7-TW[ MA75<0N T/L81#'IOH??WHE>^OUG8.!OBW3W%MVDWI'L[I'_^>-YP'+7GCP?2 MWR"\>@ ;-SS8]S2W'V=3_GH7VSI<([SO[T>W!:TA'!AAKZS689@(7A=M!SJ# MSHP8!C-$(WB+*!E+8J(2Q A=.'/;&":""@F4?ELTF17.GYP[<#/S(I4ZC' A M;6Z7P?V.R^4-QW)F FE%6 ;.L,PS)!26/([/;&+K?$W%RC'HT6F":<2+8)V M%]8!]J&3C(6,L:S2!'!I&H84)P9'DFEJGDIDGG$J)9@>Q 1-!4>681E1#K3L M!%/Z8+XR7Y,U[7D"W!KSE_@0&(KE4.^Z'-;_FBT&;U7-::_*=@_2!1F9"?6A MT-OA=FY*!]]+G)"YG<^3"D"KHRRCB_>43#G#;C,[$P8')AR&:)D'I$*2)ZUG M2F6B#5A",,-2D.4">14T.3A^RV:RL]X5I'6%G!N"!4$5[BIB2.L>,Q+7D$OYB[ %WKR^K&4,LK--:7 MVC5]'1OC!!54W9LM6F<$Z_$G Q[TJE6C2B*"]?@SCDG![*W&JV_.PU]02P,$ M% @ 5'5J2I@.REO1 P 8R \ !X;"]W;W)K8F]O:RYX;6S%F5MO MVR 4@/\*\LNZARXQIE>UE=;+I$A5%RW5WJE]TJ#:X(*3;O]^V&G6XRPYVLM) MGF)C@C^!.1\<+MZW@J=-V8!C_KI M,ADFL=X 5>P:7?TNB<[]_S"YZ=3D<.OR>06V64)Y*'5CG TS4X=$6%W!9;*J M(K[:0MS9QC2_Q<@NFXIU$]&]>E1<)FF\;G03_[,PP3R5D A_;N(#/RK2%IP/ M\B;>N](4\>V%N-:EMCF(2=0QP3D\?YZ4H<9@CPA($^X(:O*-$LP M'2-0A&Z,?0:;&\!S^Y1 /.5%;$?T9>;* GSX).Y>YS%$(K(S@NQL!V2'USI MT4T.L.&?H#VDHO:0EV]D!>-2_>F.9DB9A5LED7M=E-Q-TVTMTMVL"'P2A?I,S">-#-W,-J M.;!\W@7ER;RJ-%X?I)0Q4F9ED)CI*<:DK)$R:Z.W"NS"L[.=Y@[B4K\E^<"D M%)(R.X04L#C RVM*)9)9)9LD_-Z3X3.&I-PBN=VRQRQ@HRD)JAWFT-E["%+R/T^F]'&-2%E+, M%NIAKC%_<[WS!5S#;*'-:<#WJ%GB MW):B+*2X+;1AOQ:[,;YMHLM>=EI1%E+,%MJ,^3B#+H3V!IVRD&*VT&;,>V>? MQ7UT)L:D+*2X3V[6,ZU_/TN\1U>4@51GH,'J'+Z(G[B%XB$V'V)YKLM\[$7[ MLSPQ4$=M,F\Z+\N;6/;=WCO=G9RW;:P._:_^ %!+ P04 " !4=6I*G.$P M>-0! ('@ &@ 'AL+U]R96QS+W=OZ_=IO0ELNW MRVX3\Z((AUWX:+JW5,684SA=Y*I? MT/_DV,;_K&_6Z^TR/C;+]WVL\R\5WPN*\'N0C@Y.-!3@^:C0?- MZ$'S\: Y/>AZ/.B:'G0S'G1##[H=#[JE!\D4R#CE)R&L^5H+X%KX7@L 6_AB M"R!;^&8+0%OX:@M@6_AN"X!;^'(+H%OX=@O 6_AZ*]!;^7HKT%LO\*R-'K;Y M>BO06_EZ*]!;^7HKT%OY>BO06_EZ*]!;^7HKT%OY>BO06_EZ&]#;^'H;T-OX M>AO0VRYP5H(.2_AZ&]#;^'H;T-OX>AO0V_AZ&]#;^'H;T-OX>AO0V_AZ.]#; M^7H[T-OY>CO0V_EZ.]#;+W#6C0Z[^7H[T-OY>CO0V_EZ.]#;^7H[T-OY>CO0 MV_EZSP9ZIZKLXNHE=]MZD\Y=\F/XGS4#N%,^[N+Y,TY3_]P_4#KW6V(X?9[] M[^(T]2LB_'CQ^_ )4$L#!!0 ( %1U:DIBCXVUQ $ /\= 3 6T-O M;G1E;G1?5'EP97-=+GAM;,W9RV[",! %T%]!V5;$^%'Z$+!INVV1VA]PDX%$ M)+%E&PI_7R= I2(J40'2W1"2<69N@G4VC#XVEGQO75>-'R=%"/:1,9\55&N? M&DM-K,R,JW6(IV[.K,X6>DY,# 9#EIDF4!/ZH>V13$;/--/+*O2>MM?;UN-$ M6UN5F0ZE:=BJR0^:]G<-4T=5M\87I?4W<4'2>UG'+CY>&R>QZA-VPH3#&]OS M>-_;BIPK<_I7-#.;E1GE)EO6\9;46T:?:A5== MQ\9L7;%?"]+KY0B;BHX'Z"J7G!SBMJ!CH[K"]I.?-7"_&S+CJ&]=K+I0'GF\ M&&D:JYZU"R_YB-1NG9SRDX;'UM?[8;^,6W3?C[WPGZ)GW>&\MWZY' (DAP3) MH4!RW(+D&(+DN /)<0^2XP$D!Q^@!$$1E:.0RE%,Y2BH&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 M Q0 ( %1U:DH9:'U[FP( *$) 8 " ?<( !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ 5'5J2OYQ+OXS @ ) < !@ ( !'1 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J M2G>#_1>=!@ 3"4 !@ ( !EAD 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ 5'5J2CZ:F0VU 0 T@, !@ M ( !A2< 'AL+W=O&UL4$L! A0#% @ 5'5J2A9: *2S 0 MT@, !D ( !72L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J2H+]T4VR 0 T@, !D M ( !'C$ 'AL+W=O;0! #2 P &0 @ $',P >&PO=V]R:W-H M965T&UL4$L! M A0#% @ 5'5J2IMX)1R[ @ 5@L !D ( !W38 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J M2LV 2:2X 0 T@, !D ( !R#T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J2B&^P(CM 0 9@4 M !D ( !H4, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J2I4L>U_$ P D!$ !D M ( !NDD 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 5'5J2H)6"WYM P P0\ !D ( !-E0 'AL+W=O M&PO=V]R:W-H965T!_0$ +\% 9 " 75: M !X;"]W;W)K&UL4$L! A0#% @ 5'5J2O\Q M&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J2EQ:#O1$ P $@\ !D M ( !\VD 'AL+W=O&PO M=V]R:W-H965T[@$ M /0$ 9 " 1AP !X;"]W;W)K&UL4$L! A0#% @ 5'5J2I7MW3LW @ 1 8 !D ( ! M/7( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 5'5J2N &PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J2NAA*;D. M! J1, !D ( !+8, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5'5J2L8:M;98 @ _@8 !D M ( !C(T 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 5'5J2H#4S<(.7 W6X! !0 ( !U90 M 'AL+W-H87)E9%-T&UL4$L! A0#% @ 5'5J2A<]T1R+ @ M1@\ T ( !%?$ 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ 5'5J2ISA,'C4 0 "!X !H M ( !R?< 'AL+U]R96QS+W=O<&5S72YX;6Q02P4& #H .@#(#P ROL end XML 65 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 189 282 1 false 46 0 false 8 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2103100 - Disclosure - Commitments and Contingencies Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 8 false false R9.htm 2104100 - Disclosure - Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity Stockholders' Equity Notes 9 false false R10.htm 2105100 - Disclosure - Stock-Based Compensation Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 2106100 - Disclosure - Income Taxes Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 2107100 - Disclosure - Supplemental Cash Flow Information Sheet http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 12 false false R13.htm 2108100 - Disclosure - Related Party Transactions Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 2109100 - Disclosure - Employee Benefit Plans Sheet http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 14 false false R15.htm 2110100 - Disclosure - Segment Information Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformation Segment Information Notes 15 false false R16.htm 2111100 - Disclosure - Subsequent Events Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 2201201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Nature of Operations and Summary of Significant Accounting Policies (Policies) Policies 17 false false R18.htm 2301302 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables Nature of Operations and Summary of Significant Accounting Policies (Tables) Tables 18 false false R19.htm 2302301 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables 19 false false R20.htm 2303301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies 20 false false R21.htm 2304301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockholdersEquity 21 false false R22.htm 2305301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockBasedCompensation 22 false false R23.htm 2306301 - Disclosure - Income Taxes (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.naturalhealthtrendscorp.com/role/IncomeTaxes 23 false false R24.htm 2307301 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformation 24 false false R25.htm 2310301 - Disclosure - Segment Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.naturalhealthtrendscorp.com/role/SegmentInformation 25 false false R26.htm 2401403 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 2401404 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Basic and Diluted Income Per Share (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails Nature of Operations and Summary of Significant Accounting Policies - Basic and Diluted Income Per Share (Details) Details 27 false false R28.htm 2401405 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Summary of Available-for-sale Investments (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails Nature of Operations and Summary of Significant Accounting Policies - Summary of Available-for-sale Investments (Details) Details 28 false false R29.htm 2402402 - Disclosure - Balance Sheet Components - Components of Balance Sheet Accounts (Details) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails Balance Sheet Components - Components of Balance Sheet Accounts (Details) Details 29 false false R30.htm 2403402 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 30 false false R31.htm 2403403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Obligations (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails Commitments and Contingencies - Future Minimum Lease Obligations (Details) Details 31 false false R32.htm 2404402 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 32 false false R33.htm 2404403 - Disclosure - Stockholders' Equity - Dividend Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails Stockholders' Equity - Dividend Activity (Details) Details 33 false false R34.htm 2405402 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 34 false false R35.htm 2405403 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails Stock-Based Compensation - Restricted Stock Activity (Details) Details 35 false false R36.htm 2405404 - Disclosure - Stock-Based Compensation - Common Stock Unit Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails Stock-Based Compensation - Common Stock Unit Activity (Details) Details 36 false false R37.htm 2406402 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 37 false false R38.htm 2406403 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails Income Taxes - Components of Income Before Income Taxes (Details) Details 38 false false R39.htm 2406404 - Disclosure - Income Taxes - Components of Benefit From Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails Income Taxes - Components of Benefit From Income Taxes (Details) Details 39 false false R40.htm 2406405 - Disclosure - Income Taxes - Income Tax Reconciliation (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails Income Taxes - Income Tax Reconciliation (Details) Details 40 false false R41.htm 2406406 - Disclosure - Income Taxes - Deferred Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails Income Taxes - Deferred Income Taxes (Details) Details 41 false false R42.htm 2406407 - Disclosure - Income Taxes Income Taxes - Foreign Rate Differentials (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails Income Taxes Income Taxes - Foreign Rate Differentials (Details) Details 42 false false R43.htm 2407402 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationTables 43 false false R44.htm 2408401 - Disclosure - Related Party Transactions - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions - Narrative (Details) Details 44 false false R45.htm 2409401 - Disclosure - Employee Benefit Plans (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual Employee Benefit Plans (Details Textual) Details http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans 45 false false R46.htm 2410402 - Disclosure - Segment Information - Net Sales by Market (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails Segment Information - Net Sales by Market (Details) Details 46 false false R47.htm 2410403 - Disclosure - Segment Information - The Company's Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails Segment Information - The Company's Net Sales by Product and Service (Details) Details 47 false false R48.htm 2410404 - Disclosure - Segment Information - Long Lived Assets (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails Segment Information - Long Lived Assets (Details) Details 48 false false R49.htm 2411401 - Disclosure - Subsequent Events (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.naturalhealthtrendscorp.com/role/SubsequentEvents 49 false false All Reports Book All Reports nhtc20161231_10k.htm nhtc-20161231.xsd nhtc-20161231_cal.xml nhtc-20161231_def.xml nhtc-20161231_lab.xml nhtc-20161231_pre.xml true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20161231_10k.htm": { "axisCustom": 0, "axisStandard": 18, "contextCount": 189, "dts": { "calculationLink": { "local": [ "nhtc-20161231_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20161231_def.xml" ] }, "inline": { "local": [ "nhtc20161231_10k.htm" ] }, "labelLink": { "local": [ "nhtc-20161231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20161231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml" ] }, "schema": { "local": [ "nhtc-20161231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 446, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 17, "http://www.naturalhealthtrendscorp.com/20161231": 14, "http://xbrl.sec.gov/dei/2014-01-31": 9, "total": 40 }, "keyCustom": 27, "keyStandard": 255, "memberCustom": 21, "memberStandard": 24, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Stock-Based Compensation", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Income Taxes", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Supplemental Cash Flow Information", "role": "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Related Party Transactions", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Employee Benefit Plans", "role": "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Segment Information", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Subsequent Events", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Income Taxes (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Supplemental Cash Flow Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Segment Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Basic and Diluted Income Per Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Basic and Diluted Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Summary of Available-for-sale Investments (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Summary of Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "nhtc:OfficeEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Balance Sheet Components - Components of Balance Sheet Accounts (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "shortName": "Balance Sheet Components - Components of Balance Sheet Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "nhtc:OfficeEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Obligations (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails", "shortName": "Commitments and Contingencies - Future Minimum Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Stockholders' Equity - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "3", "lang": null, "name": "us-gaap:PreferredStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "D2014Q4Dec03-Dec03", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Stockholders' Equity - Dividend Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails", "shortName": "Stockholders' Equity - Dividend Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "D2014Q4Dec03-Dec03", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2014Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Stock-Based Compensation - Common Stock Unit Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails", "shortName": "Stock-Based Compensation - Common Stock Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2013Q4", "decimals": "0", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Income Taxes - Components of Income Before Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "shortName": "Income Taxes - Components of Income Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Income Taxes - Components of Benefit From Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails", "shortName": "Income Taxes - Components of Benefit From Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Operations", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - Income Taxes - Income Tax Reconciliation (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "shortName": "Income Taxes - Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406406 - Disclosure - Income Taxes - Deferred Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails", "shortName": "Income Taxes - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406407 - Disclosure - Income Taxes Income Taxes - Foreign Rate Differentials (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "shortName": "Income Taxes Income Taxes - Foreign Rate Differentials (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Supplemental Cash Flow Information (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails", "shortName": "Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2013Q1Feb1-Feb28", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Related Party Transactions - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "shortName": "Related Party Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2013Q1Feb1-Feb28", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409401 - Disclosure - Employee Benefit Plans (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual", "shortName": "Employee Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Segment Information - Net Sales by Market (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails", "shortName": "Segment Information - Net Sales by Market (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Segment Information - The Company's Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails", "shortName": "Segment Information - The Company's Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Segment Information - Long Lived Assets (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "shortName": "Segment Information - Long Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "D2016Q4SD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockSpecialDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - Subsequent Events (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2017Q1jan24-jan24_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Commitments and Contingencies", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China", "verboseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong", "verboseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_KY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CAYMAN ISLANDS", "terseLabel": "CAYMAN ISLANDS" } } }, "localname": "KY", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TAIWAN, PROVINCE OF CHINA", "terseLabel": "Taiwan" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityLocationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Location [Line Items]", "terseLabel": "Entity Location [Line Items]" } } }, "localname": "EntityLocationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "stringItemType" }, "dei_EntityLocationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Entity location table associates entities with primary and other locations. The domain members may be countries, states, provinces and groupings of these and other geographic codes.", "label": "Entity Location [Table]", "terseLabel": "Entity Location [Table]" } } }, "localname": "EntityLocationTable", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "stringItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AgeRequirementFor401KContributions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents age requirement for 401K contributions.", "label": "Age Requirement For 401K Contributions", "terseLabel": "Age requirement for 401 K contributions" } } }, "localname": "AgeRequirementFor401KContributions", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "durationItemType" }, "nhtc_AmountsHeldnDistributorEWalletsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the policy of amounts held in customer eWallets.", "label": "Amounts Held in Distributor eWallets [Policy Text Block]", "terseLabel": "Amounts Held in Distributor eWallets" } } }, "localname": "AmountsHeldnDistributorEWalletsPolicyTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Auto Ship advances.", "label": "Auto Ship Advances [Member]", "terseLabel": "Auto ship advances" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "terseLabel": "Broady Health Sciences" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special dividends declared during the period for each share of common stock outstanding.", "label": "CommonStockSpecialDividendsPerShareDeclared", "terseLabel": "CommonStockSpecialDividendsPerShareDeclared" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents cumulative translation adjustment realized in net income.", "label": "Cumulative Translation Adjustment Realized In Net Income", "negatedLabel": "Cumulative translation adjustment realized in net income" } } }, "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of equal consecutive monthly installments of deferred compensation award payable.", "label": "nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments", "terseLabel": "Long-term incentive plan, number of installments" } } }, "localname": "DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_DeferredCompensationRewardPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of deferred compensation award payable.", "label": "nhtc_DeferredCompensationRewardPaymentPercentage", "terseLabel": "Long-term incentive plan, percentage of award payable in cash" } } }, "localname": "DeferredCompensationRewardPaymentPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_DistributedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents distributed.", "label": "Distributed [Member]", "terseLabel": "Distributed" } } }, "localname": "DistributedMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "nhtc_DistributorClaimsReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the funds which can be utilized to fund any outstanding distributor claims for product returns.", "label": "Distributor Claims Reserve", "terseLabel": "Distributor claims reserve" } } }, "localname": "DistributorClaimsReserve", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Document And Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "xbrltype": "stringItemType" }, "nhtc_EnrollmentPackageRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents enrollment package revenue.", "label": "Enrollment Package Revenue [Member]", "terseLabel": "Enrollment package revenue" } } }, "localname": "EnrollmentPackageRevenueMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "terseLabel": "Equity Incentive 2016 Plan [Member]", "verboseLabel": "Restricted Stock [Member]" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nhtc_FinancialInstitutionInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to financial institution instruments.", "label": "Financial Institution Instruments [Member]", "terseLabel": "Financial institution instruments" } } }, "localname": "FinancialInstitutionInstrumentsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_FiveYearWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Five Year Warrants.", "label": "Five Year Warrants [Member]", "terseLabel": "Five Year Warrants" } } }, "localname": "FiveYearWarrantsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_GeorgeBroadyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents George Broady.", "label": "George Broady Member", "terseLabel": "George Broady" } } }, "localname": "GeorgeBroadyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_GeorgeKBroadyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "George K. Broady, a director of the Company.", "label": "George K. Broady [Member]", "terseLabel": "George K. Broady" } } }, "localname": "GeorgeKBroadyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_IncomeTaxForeignRateDifferentialLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Line Items]", "terseLabel": "Income Tax Foreign Rate Differential [Line Items]" } } }, "localname": "IncomeTaxForeignRateDifferentialLineItems", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "stringItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Table]", "terseLabel": "Income Tax Foreign Rate Differential [Table]" } } }, "localname": "IncomeTaxForeignRateDifferentialTable", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "stringItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Table Text Block]", "terseLabel": "Income Tax Foreign Rate Differential [Table Text Block]" } } }, "localname": "IncomeTaxForeignRateDifferentialTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "nhtc_IncomeTaxReconciliationEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effect of permanent differences.", "label": "Effect of permanent differences", "terseLabel": "Effect of permanent differences" } } }, "localname": "IncomeTaxReconciliationEffectOfPermanentDifferences", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_KoreanBusinessSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Korean Business Segment.", "label": "Korean Business Segment [Member]", "terseLabel": "Korean Business Segment" } } }, "localname": "KoreanBusinessSegmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Long-Term Incentive Plan (the \u201cLTI Plan\u201d), payments commencing in February 2021 and ending in December 2023.", "label": "Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 [Member]", "terseLabel": "Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023" } } }, "localname": "LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Long-Term Incentive Plan (the \u201cLTI Plan\u201d), payments commencing in February of the calendar year immediately following the conclusion of the performance period.", "label": "Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period [Member]", "terseLabel": "Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period" } } }, "localname": "LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_MarketDevelopmentFeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents market development fees deferred revenue.", "label": "Market Development Fees [Member]", "terseLabel": "Market development fees" } } }, "localname": "MarketDevelopmentFeeMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "nhtc_MunicipalBondsAndNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds and Notes [Member]", "terseLabel": "Municipal bonds and notes" } } }, "localname": "MunicipalBondsAndNotesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfClassesOfStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Classes Of Stock", "label": "Number Of Classes Of Stock", "terseLabel": "Number of classes of stock" } } }, "localname": "NumberOfClassesOfStock", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Termination notice, number of days" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_OfficeEquipment": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents other equipment.", "label": "Office equipment", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipment", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_OneYearWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents One Year Warrants.", "label": "One Year Warrants [Member]", "terseLabel": "One Year Warrants" } } }, "localname": "OneYearWarrantsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_OtherAccruedExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents other accrued expenses abstract.", "label": "Other accrued expenses:", "terseLabel": "Other accrued expenses:" } } }, "localname": "OtherAccruedExpensesAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents other foreign countries.", "label": "Other Foreign Countries [Member]", "terseLabel": "Other foreign countries" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "nhtc_PlusreallocationOfUndistributedEarningsToParticipatingSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the reallocation of undistributed earnings during the period.", "label": "Plus: reallocation of undistributed earnings to participating securities", "terseLabel": "Plus: reallocation of undistributed earnings to participating securities" } } }, "localname": "PlusreallocationOfUndistributedEarningsToParticipatingSecurities", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_PreferredStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred Stock, Number Of Votes Per Share", "label": "Preferred Stock, Number Of Votes Per Share", "terseLabel": "Preferred stock, voting rights" } } }, "localname": "PreferredStockNumberOfVotesPerShare", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "nhtc_PurchaseCommitmentMonthlyAmountMinimum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monthly purchase minimum the Company is required to purchase until the termination date.", "label": "nhtc_PurchaseCommitmentMonthlyAmountMinimum", "terseLabel": "Minimum monthly purchase amount" } } }, "localname": "PurchaseCommitmentMonthlyAmountMinimum", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_PurchaseCommitmentRenewalTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time that a purchase commitment agreement is automatically renewed for after the original term ends unless notice of termination is given by either party to the agreement.", "label": "nhtc_PurchaseCommitmentRenewalTerm", "terseLabel": "Purchase commitment renewal term" } } }, "localname": "PurchaseCommitmentRenewalTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_PurchaseCommitmentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time that a purchase commitment agreement is in effect.", "label": "nhtc_PurchaseCommitmentTerm", "terseLabel": "Purchase commitment term" } } }, "localname": "PurchaseCommitmentTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStore [Member]" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the royalty rate.", "label": "Royalty Rate", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "nhtc_RussiaAndKazakhstanAndUkraineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographic locations of Russia and Kazakhstan and Ukraine.", "label": "Russia and Kazakhstan and Ukraine [Member]", "terseLabel": "Commonwealth of Independent States (Russia, Kazakhstan and Ukraine)" } } }, "localname": "RussiaAndKazakhstanAndUkraineMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]", "terseLabel": "Schedule of Additional Balance Sheet Components" } } }, "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "nhtc_ScheduleofEarningsPerShareBasicandDilutedbyCommonClassIncludingTwoClassMethodLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "ScheduleofEarningsPerShareBasicandDilutedbyCommonClassIncludingTwoClassMethodLineItems", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "nhtc_ScheduleofEarningsPerShareBasicandDilutedbyCommonClassIncludingTwoClassMethodTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleofEarningsPerShareBasicandDilutedbyCommonClassIncludingTwoClassMethodTable", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "nhtc_SevenYearWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Seven Year Warrants.", "label": "Seven Year Warrants [Member]", "terseLabel": "Seven Year Warrants" } } }, "localname": "SevenYearWarrantsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_ShareBasedCompensationIncentiveCompensationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The period to which employees receive stock as incentive compensation.", "label": "nhtc_ShareBasedCompensationIncentiveCompensationPeriod", "terseLabel": "Incentive compensation period" } } }, "localname": "ShareBasedCompensationIncentiveCompensationPeriod", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_SootheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Soothe.", "label": "Soothe [Member]", "terseLabel": "Soothe" } } }, "localname": "SootheMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_Statutorytaxrate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statutory tax rate of foreign subsidiary.", "label": "statutorytaxrate", "terseLabel": "statutorytaxrate" } } }, "localname": "Statutorytaxrate", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "percentItemType" }, "nhtc_StockRepurchaseProgramNumberOfSharesRepurchasedPerDay": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares acquired per day under a share repurchase program.", "label": "Stock Repurchase Program Number Of Shares Repurchased Per Day", "terseLabel": "Shares repurchased per trading day" } } }, "localname": "StockRepurchaseProgramNumberOfSharesRepurchasedPerDay", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "nhtc_TermOfWarrant": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the term of the warrant.", "label": "nhtc_TermOfWarrant", "terseLabel": "Term of warrant" } } }, "localname": "TermOfWarrant", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_TreasuryStockAcquiredRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the treasury stock acquired rate times the number of shares purchased.", "label": "Treasury Stock Acquired Rate", "terseLabel": "Treasury stock acquired rate" } } }, "localname": "TreasuryStockAcquiredRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "nhtc_TreasuryStockValueAcquiredCostMethodExcludingRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of shares that were repurchased during the period, excluding those repurchased from a related party. Recorded using the cost method.", "label": "Treasury Stock Value Acquired Cost Method Excluding Related Party", "terseLabel": "Treasury stock, purchase price" } } }, "localname": "TreasuryStockValueAcquiredCostMethodExcludingRelatedParty", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents unshipped product.", "label": "Unshipped Product [Member]", "terseLabel": "Unshipped product" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20161231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r8", "r35", "r37", "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r43", "r336", "r355" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r58", "r187" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r78", "r79", "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r77", "r80", "r289" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r50" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r234", "r236", "r254", "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words \"stock-based compensation\".", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r236", "r248", "r253" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r0", "r7", "r13", "r139" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r335", "r354" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r31", "r32", "r73" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r168", "r169", "r172" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "terseLabel": "Gross Unrealized Gains/Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r62" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Adjusted Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r170", "r171", "r173", "r174", "r175", "r345", "r346" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r237", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r293", "r294" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r372" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Office software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r3", "r55" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r4", "r29", "r55", "r105" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r98", "r305" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r3", "r4", "r40", "r106", "r112", "r165" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r40", "r106", "r112", "r165", "r334" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r55" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash financing activity:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r108", "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r127", "r216", "r217", "r235" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r119" ], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants, exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of securities called by warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommissionsPolicy": { "auth_ref": [ "r112", "r332", "r333" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.", "label": "Commissions, Policy [Policy Text Block]", "terseLabel": "Commissions" } } }, "localname": "CommissionsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r66", "r190", "r340", "r360" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r66", "r189", "r193", "r199", "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividends Per Share, Common (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, dividends, per share declared" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2016 and 2015" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Compensation and Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r111", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Long-Term Incentive" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r6", "r18", "r19", "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income, net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r298", "r299", "r300", "r349", "r350", "r366" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Certain Risks and Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r27", "r129", "r285", "r344", "r351" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet Statement [Table]", "terseLabel": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r112", "r288", "r291", "r292" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r186" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r108", "r109", "r110" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Conversion of Stock, Amount Converted", "verboseLabel": "Conversion of preferred stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r108", "r109", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Conversion of Stock, Amount Issued" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Conversion of Stock [Line Items]", "terseLabel": "Conversion of Stock [Line Items]" } } }, "localname": "ConversionOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r108", "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r108", "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion of Stock, Shares Issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockTable": { "auth_ref": [ "r108", "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock [Table]", "terseLabel": "Conversion of Stock [Table]" } } }, "localname": "ConversionOfStockTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r90" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CounterpartyNameAxis": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r9", "r118", "r279", "r283" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r124", "r282" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r9", "r118", "r279", "r283" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r9", "r118", "r279", "r283" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r65", "r122", "r205", "r208", "r209", "r210", "r312", "r313", "r314", "r348" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r227", "r228" ], "lang": { "en-US": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage", "terseLabel": "Maximum compensation percentage" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r227", "r228" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r11", "r118", "r281", "r283" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred foreign taxes" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r11", "r103", "r118", "r281", "r283" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r12", "r45", "r46", "r270", "r337", "r353" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r223", "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Revenue [Abstract]", "terseLabel": "Deferred revenue:" } } }, "localname": "DeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r36", "r219", "r220", "r221", "r222", "r223", "r224" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r36", "r218" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r36", "r218", "r219", "r220", "r221", "r222", "r223" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r10", "r271" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r272" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r257", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r258", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r2", "r275", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r257", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r257", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r273" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r263", "r274" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r262", "r263", "r264" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r258", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r258", "r277", "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "negatedLabel": "Foreign earnings", "terseLabel": "Deferred tax liability recorded against undistributed foreign earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the cost recognized during the period for defined contribution plans.", "label": "Defined Contribution Plan, Cost Recognized", "terseLabel": "Defined contribution plan, cost recognized" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of employees' gross pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Employers matching contribution, immediate vesting percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r103", "r185" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r103" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r216", "r237", "r250", "r251", "r252", "r256" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Date the declared dividend will be paid, in CCYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Payment Date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r211", "r347" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends declared", "terseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r211", "r347" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Dividends, cash" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r211", "r347" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r86", "r134", "r140", "r142", "r343", "r362" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income allocated to common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic EPS:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r86", "r134", "r343", "r362" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income allocated to common stockholders plus assumed conversions (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted EPS:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r112", "r139", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r305" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "terseLabel": "Tax benefit attributable to compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r112", "r296", "r297" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r104", "r302", "r303", "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Loss on foreign exchange" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r112", "r304", "r311" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r186" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r181", "r182", "r183" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r112", "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis": { "auth_ref": [ "r352", "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by guarantee for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders.", "label": "Guaranteed Insurance Contract, Type of Guarantee [Axis]", "terseLabel": "Guaranteed Insurance Contract, Type of Guarantee [Axis]" } } }, "localname": "GuaranteedInsuranceContractTypeOfGuaranteeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeDomain": { "auth_ref": [ "r352", "r365" ], "lang": { "en-US": { "role": { "documentation": "Guarantee for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders.", "label": "Guaranteed Insurance Contract, Type of Guarantee [Domain]", "terseLabel": "Guaranteed Insurance Contract, Type of Guarantee [Domain]" } } }, "localname": "GuaranteedInsuranceContractTypeOfGuaranteeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r123" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r84", "r331", "r341", "r363" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r123" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "verboseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r124", "r267", "r274", "r276", "r282" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r15", "r124", "r280" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfBenefitFromIncomeTaxesDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r112", "r260", "r261", "r268", "r269", "r284", "r370" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r259", "r265", "r266" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r116", "r265", "r266" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r117", "r265", "r266" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r265", "r266" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Other reconciling items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r265", "r266" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).", "label": "Increase (Decrease) in Customer Advances and Deposits", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRestrictedCash": { "auth_ref": [ "r16", "r94", "r96" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.", "label": "Increase (Decrease) in Restricted Cash", "negatedLabel": "Increase in restricted cash" } } }, "localname": "IncreaseDecreaseInRestrictedCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r1", "r23", "r24", "r135", "r138" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Warrants to purchase common stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r136", "r140" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Non-vested restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r99", "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for interest during the period.", "label": "Interest Paid", "terseLabel": "Interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r70", "r177" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r39", "r71", "r112", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r70", "r130", "r177", "r180" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory valuation reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r295", "r367", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r295", "r367", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesSummaryOfAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense for operating leases" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasePolicyTextBlock": { "auth_ref": [ "r112", "r316", "r319", "r320", "r364" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.", "label": "Lease, Policy [Policy Text Block]", "terseLabel": "Operating Leases" } } }, "localname": "LeasePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r33", "r186" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r61" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r54", "r339", "r358" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r64" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r33", "r186" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r98", "r101" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r98", "r101" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r98", "r100", "r104" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r18", "r19", "r85", "r104", "r140", "r342", "r361" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r132" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income available to common stockholders", "verboseLabel": "Net income available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r132", "r133" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "verboseLabel": "Net income allocated to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r162" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Nonvested Restricted Stock Shares Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease obligations" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2016" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2018" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2017" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r315", "r317" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r35", "r37", "r38", "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "totalLabel": "Other accrued expenses", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r72" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r75", "r78", "r306", "r307", "r310", "r311" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r74", "r308" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Net change in foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r78", "r81", "r82", "r309" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "negatedLabel": "Elimination of CTA upon dissolution", "negatedTerseLabel": "Release of cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r76", "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized losses on available-for-sale securities", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCreditsCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.", "label": "Other Deferred Credits, Current", "verboseLabel": "Amounts held in eWallets" } } }, "localname": "OtherDeferredCreditsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r34", "r35", "r63" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r14", "r97" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r14", "r97" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r16", "r95" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r231", "r232", "r233" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r237", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Preferred Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Preferred stock, dividends per share, declared" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r48" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and 2015" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassification, Policy [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductOrServiceAxis": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Information by products and services or groups of similar products and services.", "label": "Products and Services [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductsAndServicesDomain": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property and equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r58", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r57", "r186" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r41", "r42", "r188", "r359" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsComponentsOfBalanceSheetAccountsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r56", "r112", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r41", "r186" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r44", "r338", "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Minimum annual purchase amount" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r17", "r21", "r22", "r321", "r322", "r323" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r324", "r326", "r327", "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r120", "r324", "r326", "r327", "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r4", "r55" ], "lang": { "en-US": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r51", "r211", "r357" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r92" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesReturnsGoods": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": 1.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate refunds recognized during an accounting period due to goods returned by customers (other than under warranty provisions). Returns are a deduction from gross revenue in arriving at net revenue.", "label": "Sales Returns, Goods", "negatedTerseLabel": "Less: sales returns" } } }, "localname": "SalesReturnsGoods", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsGross": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": 3.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Gross", "terseLabel": "Product sales" } } }, "localname": "SalesRevenueGoodsGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNet": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Net", "terseLabel": "Net sales", "totalLabel": "Total net sales" } } }, "localname": "SalesRevenueGoodsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sales Revenue, Goods, Net [Abstract]", "terseLabel": "Net sales by product and service:" } } }, "localname": "SalesRevenueGoodsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of cash flow, supplemental disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]", "terseLabel": "Schedule of Dividends Payable" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Share Activity" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r58", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r120", "r324", "r326", "r327", "r328", "r329" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r88", "r161" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r149", "r150", "r151", "r154", "r184" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r154", "r184" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r237", "r250" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r67", "r121", "r200", "r201", "r202", "r205", "r206", "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r28", "r163", "r371" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r146", "r147", "r148", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r92", "r176" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted during period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, balance (in shares)", "periodStartLabel": "Nonvested, balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, weighted average price at date of issuance (in dollars per share)", "periodStartLabel": "Nonvested, weighted average price at date of issuance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r235", "r240" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r112", "r237", "r242" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested, Balance (in shares)", "periodStartLabel": "Nonvested, Balance (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested weighted average grant-date fair value (in dollars per share)", "periodStartLabel": "Nonvested weighted average grant-date fair value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationCommonStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShippingAndHandlingRevenue": { "auth_ref": [ "r87", "r226" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails": { "order": 2.0, "parentTag": "us-gaap_SalesRevenueGoodsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fees charged to customers for the delivery, generally by postal or freight service providers, of product or goods purchased.", "label": "Shipping and Handling Revenue", "terseLabel": "Enrollment package revenue, freight and other" } } }, "localname": "ShippingAndHandlingRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationCompanysNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r47", "r48", "r49", "r204" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r69", "r204" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r28", "r163", "r371" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLivedAssetsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r108", "r109", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Stock Issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "terseLabel": "Shares issued for stock-based compensation awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Gross", "terseLabel": "Shares issued for stock-based compensation awards" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized amount of shares to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r49", "r52", "r53", "r166" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r286", "r287", "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r20", "r49", "r52", "r53", "r114", "r115", "r167", "r203", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r214" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid during the year for:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r68", "r213" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r68", "r213" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedTerseLabel": "Treasury stock, shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r49", "r204", "r211" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r68", "r213", "r215" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,692,218 and 840,202 shares at December 31, 2016 and 2015, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r204", "r211", "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r137" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedTerseLabel": "Less: undistributed earnings to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r143", "r144", "r145" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r133", "r138" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Net income allocated to common stockholders plus assumed conversions (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r25", "r131", "r138" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Net income allocated to common stockholders (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesBasicAndDilutedIncomePerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Glossary": "Antidilution", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505113" }, "r1": { "Glossary": "Call Option", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506649" }, "r10": { "Glossary": "Deferred Tax Asset", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510090" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586" }, "r11": { "Glossary": "Deferred Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=63044130" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Glossary": "Deferred Tax Liability", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510232" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m)(1)(i)(B)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r13": { "Glossary": "Diluted Earnings Per Share", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510752" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1757-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r14": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599" }, "r15": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599" }, "r16": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r17": { "Glossary": "Management", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517382" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r18": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308" }, "r19": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r2": { "Glossary": "Carryforwards", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506874" }, "r20": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644" }, "r21": { "Glossary": "Principal Owners", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521851" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r22": { "Glossary": "Related Parties", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=16382449" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.B.Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68075638&loc=d3e60635-111653" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65897934&loc=d3e2410-114920" }, "r23": { "Glossary": "Treasury Stock Method", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6527216" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39675-114964" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=66904339&loc=d3e4534-113899" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r24": { "Glossary": "Warrant", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528364" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r25": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11149-113907" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65896087&loc=d3e11178-113907" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32123-109318" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04(c)(Schedule I))", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=d3e5283-111683" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4568447-111683" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4568740-111683" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=65897068&loc=SL4590271-111686" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611" }, "r3": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453394&loc=d3e39740-112701" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=6456037&loc=d3e48589-112741" }, "r321": { "Glossary": "Affiliate", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6504562" }, "r322": { "Glossary": "Control", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6508935" }, "r323": { "Glossary": "Immediate Family", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6515043" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41256-110953" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41261-110953" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-06)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=68064133&loc=d3e61044-112788" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=68064133&loc=d3e61082-112788" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.7-05(c)(Schedule II))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6588021&loc=d3e7104-158389" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=65670824&loc=d3e14754-158437" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r373": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r4": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Glossary": "Common Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508022" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Glossary": "Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831223" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Glossary": "Contingent Stock Agreement", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508534" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r8": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r9": { "Glossary": "Current Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509736" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" } }, "version": "2.0" } ZIP 71 0000912061-17-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-17-000012-xbrl.zip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�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

;,H+!,M &:6B0%]$"&_\ :8,Y3A='O34=W,D>>7:U.A2$?:+JY[9IK$!'_ MO'$&A3$024O"\4V]-N$"$8N:*6>&E3B\P!]P6T\K+<>BT,=G\LI@NJS],=!D4OZ#8O2GG>Z*0#_;)1#A>F?1A M4\6.,F E-)PP 3AR# 7=>U#N(EVRH.P'H13WWZ#NET&U+^)QN;U,'5S>>_ME MGG 7=##G!%-422C#'PT1"@@G',:)DM&=3Q#Z0*G-"O?C:3X=C?-)5(3&\T4D M::L3'5CJC3IGD'N#*56&.!?.*2*$9ZN2MX KJ%K%U?7F#M+7FN\#J@2+_^G- M?"NAZK:LYM%B%Y-H[-D&&HZ0(6<0=I S)1BU0=YC 2L4P:4HNM,-ZF3H^EK9 M#TCGE8_1:'&[F,22Q#]5CTR\M=%7%]=E57S,O[:3GN;C9RRL3Z.L#HJSBNZ] M$EJ+F:1$.FE8N[SY/3HZ)Y.MWB \J^2U$J?,0H],6%\,>TJQU!IBZBV6!FIE M;;LHC]Y.J70R-+ZT\:2SC[XOETHHE]!Z^>9WWXT.H$[-C;DTL[(>Z M9M!8+C -&K*)JA-VQ*_\)J6/(4"'[A7]$+P-?-_%%GW_Z#>-"\8<,5ZFF0B M0*(XL<0R*+15-31,R597KH[-]=VQ=V?MF/X0&ZIE_UU57BU&\[?5AZ*Z&X\: M9+M]UCQ3B#$@L B7$&1$.%4D1S42V.-$\<,MLTWTPO+G#INGHI;&@3?.].4^&4;<4DC"@I3$"H]@N+#6Y!$CT6!S,9S&K):>MN/H,JN^3.*4@D"8EKHD$< M+-W3=)",6:@-HPA(+A2)OOE4;+60=EDADY7J2:%N]89E8F$Z>.P^;YP9C2#3 MP!GO-'9>:^3@YJA2>+C5^_I@VAZY. FN;T .AJ9W#9/]R=ENQU4Q"IPX^(#^ MN&$6]D:CI"?4.,L9!0ZMTX,$0H(ZT\[;NR_UX!1&/'6Y/ 6&-JJ;KLK\ZOX? M2]/JA]&XF(X.N;SL[I%%#T*I)+3(>8.$(YAM[A61BD$I=1UPK5L\DKBW+*;S MHOH2:7Z3WQZRCKW4//.<$J[CZPAEPHMES.3F.A%TV#1O1P-6USI +.(-SNF&8V102Q-=-PET-MQ"H='$U.1KCO1@U;C3F/GL MQ.X7KS^=V Q-ZQNHM)RN)OQ4!&"*U5&W7SUXWC(+$V(R1L(RK#%BL93"YE@U MG@_+$M<#ZF67\+2RSY7W03NY?Q\.N)W6N6V3S #BB$7(4>D,I4KP=1G-,"%J M<*MT DF4[TY>44^$(\4>O)J<^QICUO<]G3]N&)!@B%+I+?<$Z2"OE)":$,4& MYH;9XNG3C>5/.QZ.=ZW%OIXQQ;(W&VB%HC$/4 MAR1P_(R[F>%=@E0&ZY^K(I\MJCN/\S+T>]J]*]%N+E?[=MA=W;(G(,@ MW/+C7%E,@Z8]D)N#A+A6;XJ]Y8GKAYM=@9-@]WTTU656PWJ^T6OYEV)^4^[+ MJM&D>RQ/8SWP!$HGK$!<0^HWA@AH$M4[.?=.W0-4J>5CF:1_5D^[J5@\[A44 M32((!Q(IQV%,R,^DJTF$PK?*K=);GK@TTG 20JW<#^)7MW>#=U7YN-;/\=$"N#2 M>'5_6+E#OIHN,_G/'Y@O>_64?O[9F/HJG][/WA3SZ P_T_=K;X>ML\-^[^F^ M)QASS[\>WQ57:C8KSIHC93VW(& Q3"DFMM].LH$[=Y/N67S]DT#KH+2J94H& MRHA@"&$@&"4'K>M]NW3OH4'?KW_9W*&[\6@9]Y:9<#MS'."P60"MI)/.AOLW MX"*L[C0FB;WNW-VR=Z=+=U^8#=6A^\,\G"/Q0S\5<;/_Y9,#[U8[^V18 M AH?]12'.N"@)486QXP2&K, ?R)39,O'JQY8_U3,.@(N@9J]IO?A1 \^/.SL MD^F8:L1(Q3T@.-!FD$(<.&@I 8@A?7G97#I@Y5/A2(7>Q4F/45YJC!P0' 6" MA,8ZW$ $XYAS[?W@,K>DE(WCL&G,^EDQ^LOG\N['9/L MUP\O<'?[RRQ,D0*J5;@Z4BHY%MA8H!%7!)#P_T0IWAI>L#I O#P1@5Z9]8^? M]S#K'S]GD@@0B\Q8BPV5GFH6C3]2A)W&"M[.:-K;8T;WS#H:@5Z99=[L899Y MD\68:H*)%(11&H1+2 2$EH03BY'BK2Q8O;U7=,^LHQ%H8Z%Z.[\IJCK[\/+# M^Q(7'>J2*>U%F)V6GGLJ"%'*^7AH4VX@ ;+5F=;;HT1W+.L8EP2JS)MR.EHF MFYZO#"1[-)BG33-EA%!<&NZ9IH$D$6A"Q%AJO/.*MGI'[/O$Z^>"?2(TYS(: M;JUVO^35[\7\&[>.:4495]HJ''022S@#2 ,;#CR,*!3F4!3 MVH=HR#H ( $ MT91A=V,*4Z-J6!2#%V,=:\S>#JQCQV'VY[".(8@@%>%6SJP!<=.4SM284$5; MO3 -T#K6F/6-K6/' 7=Q]@U.F#0D+$$2(VGGJ]:XSXYAE5,:9QD"'FTP04B$TAP[3!P=6*X?L,]BZVC+K: 3.:ICT)@B5Q\(: M&RAD&DF]H=);ULHP>09;5UMF'8W 60V32FJAPW4#&,.1T%H9NSD#O-/#*M'< MP\HZ%H%>F?7QMSW,^OA;1BTB6BBK!(8,8N/Y]L!60>#:,*LWK]CNF74T KTR MZ^?W>YCU\_N,82$!QT1QS94*MRU@W6:JB+72$WMS6NV>64Q5F?B@;T^&N&02(8K7I MS>&T.Q;VA$^"FYY;Q+*#!W-M/&R6.8.@8 J%0]JY(&""*@@<-DYK!!QLM4Y[ MJQW<'9,[P&( CW3,"(V\"^=T.+\E09CIC03:\(\VS.NMB&_'*[0[7%+88.(C MS?OBKI@NBI_*\BJZ6^\SO[S0/-/&2!L4:R)YN)Y*0@63-5%.RF&5$^K7WG\Z M/.=ZL$N8DGT9+*%C',3#\M9G_'3X\VTY7?[NU_ 1-9J/[\;S^Z3A!2].; AY MXI?!*\]FIF+QWL]+^Z6^WS995[17L5)YH\?5DP M <604/I@0O7>GUX/43C;1>(1#[*G?2.C&$)MPKXF&8#0&N4U6$/(!&UW?^WZ MF3:AH.Q^Q$V*\^"?=F/M\/E]A**<1N*;/N^^U"^3X>X93D5AA,=4$:, U6ML MPJ'9+G- NB?>5(*QZ^&W TA37 ,?S_+@8]^+[3,A';5$4N1-K! O"62J)BO: MGX;_Z'L:MYY>%#L$Z9N1@<$^]@Z ]!D8"WJX.L?N#M>H?M'@^E_!+83<(>F!UVPG":7S_?%;%Z-1_/BJIGJ M]&+[H#$0K*$-&!N,F>;4"5A;/<+/4[E%-C3.GY6QS]++A]^LE3IY]*_3D PH1@<+B'W>'4X13SWV&' M" =>0(Y(30C@;+C6E';LV,'3D\"X8.X.33\X!U-/=YY8W?I?34=AHQG?%;%! MG,-^]XF]G3+FM,?*&\R(C/\$GMIQXWAOW@L[;]O"EXK[AQ7R;:O,4FL8\EP2 M8#16PGIF:A(HD)H,@OFP,BNUPK_LCOPAV.3VWO__&6[LX^GG=T4U+J_@ M'B'H\C.9 !Y RV XYI!FA"$(T!I$";VZ, M+CWXTYP,]Q4/89,G9XNIE,@_7 M1&DV0 9C;(WTF@)A-(&2>U$O66E0NV3;_85H%ST#O@:%1,BBJ2_-BW M=;;7H;N'SV46, R@9Q0 @\.E76N[ =4)GJ@2X_!E= #@#UFB'Z?/5XOY35F- M_[VW6D7GW\JT=("SL"E(HC"4D@>]N8838=)JO^TO$/<"9;DCY%.XKMU^F93W M1;&N/O RQ1_SK[J8!J[/?6#/<2I -Q_(.-'*8".YQ X;S!WB9@,<]*V"K_H+ M1SZ?R)X%[B%ON+4-=C:O%DO#WC*4[>--/GW[)0XQ^RD,,9^]FJZT\#[VX2.G MD!%%-<$P FX=IT$"[&:3P!*TRC#77S3W!6[/_3)D*+OVFW)Z%RZ8Q>JN.?M8 MSO/)4\WJ33G_GV+^OAB5GZ<'U)#>OIEAJ P0%%*.B$.8!P5O<^]E2/DV\MY? MZ/O ]_8$'+AD 5^M:%]6ZQ_%=ONL:FDGDC%L&4,>X^@4'1,H0PLVC/"ZU=;? M7X* ;W I=,&6%.I0@]ILVVO'QU(7#RJU[=-Q3ADWH\YPA94 2-"8U0%(NME& M8OGU-M+;7X:$,RHN"5%NX_OQ,C0;/X:'/]RI-;<;*%/8(^Z8IY0K"V*2%UH' M@X3+P[6T!C M0>DM6\!Q. \U6T ;]W2)"2<$2N"UI)SP6(BWIIQ0\VWG FC,]GWNZ<.'?L]F=N!<<'<'9H/W3F8.DCW=(.Y M0! R)CAFW$%)3;U)">M,*S-D*O?TQH W=T\_#H[!AN53 #A2C'IFH(+80&IP MK?,PYUOY;5Q,6'[;<_<4"(?P&'@!4U].)KZL8J>SN.*\-)&,,6Q]T*N1 M9K1 CV9LT( MI21-5/(QW9M$:SOAD-GR;:R/U2/A>9?&:@Z9AU!9;[1 $AAKG X'; T_YN@; M614]BV;Z%=2*>Q>]>(;GX8FXE8@BSJ%1$D&)-9$U^%ISTF;I#"_@Z5M9.BZ8 90Q314.US^Z>891-/SNVPC0NI#5T2_S+GKE;!CT6S'^?!,] M;>^**O]<+$],F\\+GX^K?^:313&8>_TQ,\V,I)QR $6L*&AHV/=8_7ZB'%*) M'H_^<_'OEV]_DB4X\'67<1:C3QR26A!D2=2P]>9&*I+E_1W,H=>/Q ]PY1[) M^8M>KH_ODL-]V#[#G$-D 75 M:4N)9XY"8;FW0GN)X:%XG]Y#II8+X'XY]R."H)[VRJ006& -A$ VAOX)%M-J MKLCDU";*N+TWK.E$_NR.5#H1C*'&'FVJ[CT$KFF5TJ=],HFD#5 P113W!AF* M$*\Q89@G$I"VWM'M6;RKYNB) "50;A_.\* CZ//&F5-,/2U%V!4ZWP#;A^:].PANI[^Y!J6]F*EW8,-8B(V4TB(#,8/. M"[$]Y,)=;M@139V=V6T!2<7/HPHO4!B$W%)HK$0"LP#'5LR=]V2PIW(++NRI MP- .AHODZ- .W+2,3,[ 7P*:C4II/&R7(4\UI@8BX)VP&FNIV(8,"5KYX20I MI=$8_Z>E-$X@/P476Q5$ 9A0A"EW.@;!BB#9#-5D$.Y;Z;Z]O4]UPL43R$]W ME_DM6A.G\[?5^VBC/J#^[.R3$1[N B(H#N%6 ( V3((-><*;5FX#Z>I^=J8. M=070N?C?]%+[4J^,8,(>^T 4[6DP2P74J]WK2NSEG7 M!29M&.?'=T=P[N76F=?2>VJUT0)XZBPPVVEJ@UN5@>S-):1SUG4"2I*D#9-8 M+.E=7LWO/X:9SO+1T@-$WS_\S2&S8N-!,JP415!1SH2A A =J*\!L!:TJF_&7CZ6;SL<-=NPC1\JX M0-&R@*56P *H <;;:PD5=K#'^HFTBM8N3+[?.2-!O M.&16&D^1<)(+O;$:*NN'Q+6.UWA75DH3&HK!K M@"R<:1AQ&W89Q#'V%FJ]N3@Q,+!B]GV*1$<(I7@B+6]OR^FQ6\.>7ADECB*D M*".,*.A43%>[O?2J5J76>DLRU*T0= =+6LZWV!$:],ZX"4>?Q!I:2+R'#@FY MW0>IEVTDH;?BZKU)0D?PG$E3>+N8S^9YT'VGGX]4%1[TS+S43#*!)!*(*F(% M$9L',\_;):;LK?1X_[I">VB22T$=*3RKQ=86HTGX5W/%<><(&2=2$F7BF4B5 MDX93N#&\.>Q::9"]%>CN4RJZ@BA5$HQWU7AT, O%LE'F*712A0./&HJ#A%M/ MMP1 V^I)I[?*TQT'#;=%HN&1[M+ M-Q\Y$YH'W8;1N!BPQY0;*C8A\C'HKK=3'#7;O&H M4>85\MIR *5"@"!"E+*;^RSC[6JS7(+U[Q08SK4%N*]%-1K/5F?2YI<;"=N7 MI+O5>!G6PFD!%$'(*\%B_JZ-TP- O)TCP(78"%,@EN0V4(Z*XFKF USKZ=9$ M[*U1O*=;9BE B'/IO-7$*"/8 Z56Z'9N/A=C)^P,F!3:?B3Z??%E48UN\BBV MY>:_%&%&5^[K:+*(IHN'GE,[M86V V8. M04PLH\0P:;!FAI!-D"CA[?('PH%;#Y-"EL)AY"$I:XOXFI9]SB&[>V6*(V@U M8($"6.P885!N M''2Y:.F[,\ MCOG X,:/"P*(6LG&)=@\4\!UMKWF,1E;(?]8ZN(!44=O-PW'S83'G&K&E>6< M8AUQ(IZ2WEDL8ME.&:=HG9(-,QG\3#LCLT4OE4[*O:,-M;87-)V/3J MW22?OLEOBX/!-WU\+J-*;@ZHR].,PFS&=T5L$.>P/_)L;Z?,2X^0#U!Y@X65'$AD MZTD';6-80>KG95O9$Z@I=JHG:L1AS6E'CPPSX9V5(KK=2&>I]E[4RBA4.E$U MNO/I4-W@$TT]7A@U9:[EJT>(&ISSWT80/RE&(WSR3'\/G:( M+%SSB$">0HT8$A)8X?1&T+$;5D+6SGC>,TR)7AX77[ZLWA[RBEU6M\M=,=%;X-XYG+.::ZRZ7$4U^9B2KCL[95)Y*Q1 &AEE*'=0,37A[85/3'2V#$6 M3C9!C8(\P()J@IB7PTW:V &/#I?V;(?.-\#VP5FWAL#M,QBV]FI-_IF0154T. M.'3I#"" &# 34C$&8F ]&NOSMQ_B;3_FL^.__^O]02P,$ M% @ 5'5J2ABL[$NOO D'\) !4 !N:'1C+3(P,38Q,C,Q7VQA8BYX M;6SLO6N3VSBV)?I]?@5OGQMGJB/2520 $F3W.3,!D$"UHUVVQ\[NFA,5-Q2R MQ,S4M%+,)B67\_SZ ?B2\B$) &*GKG]J)(S9>ZU%XB%C0U@X]_^^[?[M?N=EQ6)WGV^V7EKF\VV^]'Y?;>^\7Y=Y]0_OIBSNO5^+\A^KK_,W;YJ_Y-4? MUJO-/_XD__%E7N7>MVKUIVIQE]_/WQ6+^;:V?;?=/OSIIY]^__WW'[]]*=<_ M%N7M3\#WX4_]WSKZ#?FG-]W7WL@?O0G &QC\^*U:_L$3'FZJVK:"D>[KWUY\ M_W=8?SM(DN2G^K?]5ZO5:U\4CPU^^I^_O/M<^_EFM:FV\\TB_\-_^R^>U]!1 M%NO\4W[CR7__[=/;H^B2G^0W?MKDMY+OCWFY*I:?M_-R^V[^)5\+&/73[LK\ MYO5'K,ORR1,D0XED*(@D0_]RYL';QX?\W_]0K>X?UH*>GP;@-P"\?0G6%;J: MA/BZZ;VT7\\I&6,3[:V6__X'\6FV MJ][?6EAM>R(6 &T4_Y>EMU/WDC?_+&#]H1^%]T:'O.>K%PPWI# MXEI&'T79OKE/7C!2+KRB7.:EB(JZOS0O%V=:J_W&3XM"#/4/VS=/&DY&1RY= M*AR^I0U?PKW7N'K9&47,L]RM\P\WG>%#,-FJ6JR+:B=>X>OYEW5^+;HY%;3\ M8Y8DR(&TE.=MX7M%3?>0O;=&X'\RJL.^_1R#_YH#QZW711UA55E MN%/^4-1;L7,OQ\=TCB+8! D$<(8X32&<1+Z&0$C^ER4=$1:^RPXMRMYFO\^I3_C7?[/*?BV)9B;E^ M;S+)8H92R$G$ H )QAQGG4D_A9E6*#/$D.-X14#Q*HG/^_+H/93%O/- MTJOR\NMJD?]),T(9Q*FB'(U%IZ8DU2RVN*Z\&MF5)_F]F#2=(.J4/-G@=R(2 M9<65YS)ECQ]CJ?JY+*IJYJ=)%#- .&=1Q@!%/ *=,1%@@$$BI6;"L3Q];!6I MEJB!4J3(F:$(V:?+AOS4J"ZL.C4&';W1HW*B2J/IQ#F-,>%$65WN5@\/,M[: M+/\BAG[QS=O6]"PAD(<\#4!"H9\%B / .H,H"XB6PIB;<:PR;"/^YKJ>4#S, M%_^8W^9>V76DFS)?W=XU,5&QO!(SEB*$>CLL2>+9 MB[50U0%=PXA2[SFWW'NV)[W+J^I/[12M;. 9Q4$Z[&F%0+89&Q3]U&#:Z.C?,1CP%S$Q$5<_ROQSG&3 S)]G^@4]7J_M\GM3)^4&#//X%@ERU+FYO+I<TC3*)D](1 M0Q<4TC*:?"BKR>Y+E?]S)^8+[.N3Y7B011A%# ,@9FEQ&!, :!()X4(0XB3$ MRAM4#)_OC*0SXETE\%NO-AB8H47PVY3KXW.PB@. MQ3#/,,*,Q2CS(0.=*3_-]#(,)@9<;PAYUG':/0;'.XU%ZHS4QCYKPY3F+&%C MJ$P-05UA]#BFV3U+'_??^3A_E#^K M@>W1;98?Q0OV?GZ?9\7]?+69A81B I(TABF@V(\Y0J2#"L,LT5L'N0! URLH M_]RMMH]>TQ%_:S#IAC@7:3?5-9:)-YF>7NJUEJ-5&?N,GES/N6 #3D/!+TO! MBS6DB[?'N?%D<[==S)J>\E80O-FNON;R999&?\GOO^3EC"<< "Y&*I[".$NP MGX"L,XA8!F=?\_)+<6Y\VI:KA3PO_'E;+/[A_=8@4]1X M&UR>5NJ12332VQZ8)Y%Y$MH%>%RV!\#K'C<5/I^ LL"KZF FW:R'J "T ]1Y MQU\99BRR==G!PJ8CA?4W:5BZL9MVP"CF+$MBG(9QPK*0!EVLA;+ 3P>HD**%D15H MD.:HDF:D-P[X&KK4>FXV.H;,')UEV:%QDO*BZ\-I:3%BQ%!6WJTV^=MM?E_- M (X#$$"2IIF8M,51X,=!KV(AB0C6U8=*/!HY'8N*%PJ-ZH ML#>&YO3LJ,N./J&35!X#-TZ+CRDOUM9WCZT<=#FH:EO6N<;J@SS.=7TWWWQX MD(^H?A:/V%9O-TTENED$PS3FON^3)"5QE,4H"SOX'$2AU37?L4"[UD?I1.7= M2E#YTEON2GGNZZ'&9GDY>+1FMK1$/,46UI1OB?^-++.Z] Z=] Z\E&4D#K_7 M>MJL-5]Y?<:^]]:KW?6VPE^O=5@>6Y8N>ZN-]_'TJW.9M6E+33EDO7KLMVDB M8]?D:-%=U[Y,NZF.K0+T?;&I5WBSU=?5,M\L*V&PAISEB[7XUW(&$PY1'/N$ MT)@G?@@9PIWID$.M]1,K!AV/:0U&KY(@K[QE!_-*#FM>)9%ZRQ:JWA!GAVVU MX6ETHO6&EI;CSPW'V9YC@;$93\1/SY'L9#!0(>Z$D%OE?1HB;->EPN%[JK'1 MY\#NYX=\L9)5_(Z:AR&* 0\#"B(0)WX6,]IK+V1*"SG6C8XB@DI0-;:R6&7] MM!!>E' 3,9PTUQJ;B"[%N=F6HA;B?ICOQ_9N,BOBLG9"Z]T4I9?/%W=M%"!+ M_A[$"EZQV\I+(^1E'#\.W)"D0>*Q[4DNVF$"FY6 M;A^OQ32@FB_J*4%_7#-@,<8D]N.(^H &1$P,6(11RA,>$7)6&JW9<2>)+32O MQN8=@KO8.>1S;)T("JT1/8V T)X[A:,7TK3\_3$ ]/');^K3C52>;H0!(AAE M*(N"F&:DPQ*11.ODH1L$KG._!\76C_?7*YDA?/IKLQ/1;AI),=E[\?;1S-RZ M:AK'5? UV#V53'7:6M/08,<^'JU_[XY15;5N2\1^*#\W%:OKO9T$1)$?PY@$ M!*1QC$&"06<*<@AUQ-C(@&.M;3%5=7W%%E=EM,';C#XUF73.G)X*&I'F1.%> M(^:$@ WB<1KZ-,R%PN)[9:0N%=DLNS>FW;0) <[" .$8)BB+.0@"%'?V4)IH M%=\VMW(9G3':SCV 2BVY<!^F?'T=J&RWUG^IZ]EACT@_Y0_BM_7FH0;9T.SZH7_'TN=&'$P@/VZ&NQC: M^AK:]BG_+-CI#/@XXEF:00P#$N+$1TG0&_ Q5;I#TN"QCM6M!6/2JS7I41 Z M=\SH)O7'(D5#Z]R1,UCLYOT%78OY>ITOO1;KO_Y+C&+PYZ$J^,3S8S)H1L\$ M=- 0>#'XU;"SUO*,LH&D4 C_!,4$T8U'8 XA(P'4FH!;-.E?2)_EI M@XR738J'+:PZ9G?($NLELF+J-!FLK0[@>AHS6!>.*:ZW#N;.1/W:R71*01!1 MGZ6"$LAAQH:H@V:K,%X*T-D@+8IJ2A*,P91F.0I^!).N,B)FLTFS2\-&. ME:-#HZ<5NO2HZ81#9O0TH@-RH4(&3WDX(0V&A$U#%DS!%U9>&HW$$BV+^?+Q M+_E\O;W[O%CEPKNJM0:2.$A($F2 \13$#,&H7RR4()2S3 -L.!:(!IG70/,Z M;!HYEB'T*62A1F).3T!>)\TD0S6$/8UTU4@L#LY=O4[LT)35<>^/Y:\L\#6! M9)8-+PJ[;Y'N0=/=1FC:@XP'907GYCX '"),0YC0,(IY3&' ^R$@AGJ7#1L9 M<*S(AY@\" T@+.R^'E9T6[_KR MA<(.CF%(A&4>A0PRQ/W.;(:AUH'.P<9&78<\0#B@P.EP@O57*9US.V3-4IO6 M,7=9O%.H@&J-Z:F$@[;<4=M'86HV'NE:H!HI7"BPZ&T5U:%$(\UPQHJDK+1F?')*ALV?6$2F# M(SEYD*(\>'$&;Y'=.WHLBC/A8@+AFQ'L8N [H!FP-1;8-UE7,Q<:&H$P3'B& M.0)4S)]#A/K:'Y%F>*;WZ)&D+F_@:$9=FBPIQECN"#)3/G:&&S>ATQ,63@5* M9G1-)"PR!/\\"!K"@5+(\WXGIXK33U0O"^VJT4^BS#,4@HI M T&:,A!FF/0)-H82I8MN+)AQK!4'@+Q-C>C*V]2 9:V7I8"L$1\,)%0A?!J/ M2SU9:7!Y'VX\B&P.CL2>OI/>]L5K.S0T.\G%L6#-#H$3 M"-\L.5)8?[DTY/RZS.?5KGRL2RV2Q3]WJS)?UO$D8X%/$BYM10GDG'(_Z==* M$%,JM3'0A&L9;X&UE4/G+33=V>X "A7$>QSV](2[)ZZYEKQ#I3LS'D"?.UO:Q7S'^7JF)8/)W<".F[!B<+J"Z=K M*UVG>%XA6F]F;X=@W,<5,$*L2=2!Q8Y7T: MZ02[+A4.W],!6M?<>];9G@44Q0C["2 ,!S#@?I3T=8F#F#-CB=.T_N\ M;-LR!ZCKN\&R*;2(3BF]B[>,67K@^K7)?I\5D'U$] UOMQ&R[,W;^W#VO4@6 MKI)^#B[49\+>L82!VZ:80#+!L8/%:*^U7F#^=B,BT?RS>,'K_??]92$9S'@0 M()(D@(J1UJ<\(G&:IB#$"$5)IA@]FC[>G7HVB+P>TL6NQ#E"S8F <2B9TP@6 M!WM1V'W%-*^[F:]EY_R:;W;YST6QK-[G6S%G%@_DF"4D)%F,,Y9&6686*$]UC$'/3Z!O#7'A^[\AP/M1/J%?;#S>UD<_% M>CF+?(A!BF-$XM!'+ @XY)V5E&&E/;6FSW;<%^IDJ8SJ3O8'.RRIC;$N"=(; M6SMN:BR>!#/VX?,G3)S0"E/.IB$3QNA?G#8?PH*J./Q<%E4E@MR;U79&$85^ MRE&8Q"#AXD.,^T$Y0B"=;8OM?*TF##K/U1*%'H+RBU]#D?,V@45/$[3(4=,# M5[SH:4%#RK__PD)?S[6ISV^YIW=]# MB?V0$4!1P!"E 8'8)W%G+T! :R^ZN17'84(/K-N87OU)3Q@&\*]8Z4!>;GA^EYX2F#*=T&@ICP8_"]LMF,$V7EU&OJJJ^!'>SY'E>S0#C2<1Q MB#'+"*F.V/0IKF@(A%YA[S)^\2WP,9D59:O*U^.WMS_E&2-Q:V"++^]5F)>5M MN_J:=T=Z,"<9]2%D,(5!1D#,?=P9!PG*M)3'CDG7R\,-RBOOML%9]ZKY$Z1] M<*2I4)8H5Q2L\=G6U*^.Z)\/B'X*\C)' -68.Z5O=JF?B-Q9=NJY^KG@3+FB MO-P8OUC5R^7B\SJ7'R2&^Z+EX7WSY?Q@FN&1.:FF8)Q#A@,(DQ Q!T=F*(L$YR6__ICE/,6+ MM-; K-9YT@RS65;Y&IK%NG#J2B=EITL1CV,CY=!XOF/M:/=UPQ)BI M>K2T_2 !'3\8XE9"]I2HB(@!@1.3$1,/C@F),1O*4K*]R\OWQ:9X:K&;XD4Q MCB+&@RR%?AK%"8]Y;Q2P5.M@U4!3KE?;)+HN)+GR-KGF*OQ0(A5U9CP.-26G MIN\06:\]+;BQY>4R [%$Q$E2\X\UR>;'.GM,Y=:R(6?:;$1AG?"]H<^ M'*#Y35'FS?>NY]_RBGW;EG-!\FHS+Q_K4J "M*!N*SA)PK[4^+U5\Z>M]$!/+"_:E&I*^[VTHIY, M/XD'FVAZ[YJW]ZUKXO;[M7M7WE-WO,Z?2QQZ<-(P)T:%*;P.TQA2)L'$JPH.90-*.F33?Y'(G'0[]B(,@A11G. TRCFBWDRY,$ZJUL&%JPW&D_;8? M-N1VUZ^K2GL)PY@\'>EWRYN1; M(73[0^Z%%-7)8?82;L\IISN:45&^ %Z\J MUE!65-7F?;X]R"002 *$8)3@"-,XRVB"NDTL$0E"HA/LZCW9<7@J#YDU0:F> MGFC2HZ8B[IC1TPY)RM.PCVRWY>K+;CO_LA8R7,C;,O+-R%'<$W9.J(<9B]/0 M#$/LA8WW2'//Q>KK:IEOEM5'T<1Y6>;+^H#Y+,X 9!P0P&'JIS&+0])-Y*G/ M83+;Y+?RY@W%C1:&5I3Z1M+TC4- REVDQ],64UIV0#5W5IBRJ+B9PB5]9OLG M.D17WI["SR?5:C$#&60H8("*^1=(>192WDD?#5*.C,,6"[9'"VR\>0=6 MCMR')>!:O ,B'QMM8! ;C4S_X.CIL $:P-XAXBNOQGS!<.H\H:H!E\6FF89B M.O/N5-!FG455A67SGN1UD.IZ;S6HBYV@/,;."?T:3.@T MA&JX&X7E%VV8]#0REV1IB#%,"(U0C#A"/NERZ10DB=:Y;3,+CD6G!E$7XUT6 MZ_6\K&K]J85'LRZO(8%FJF.?NZ&2S58I\I8O(AMIP+#,M#"="HTRCF=2X8'"X MV+2H+BLW+0@-P=$EMMO.-K $^<+YFK74&!%8C-XRET*L^!=GBOO*:_;T'T",L]AH MTU1=ZUZJA(+66555[4YZ2*,\3RME?]C+31.PD@0D-$P0QS$C,:$TYWJ0=(Y"LU/QO,A\7I--?0$=W"Z3EM#AWJF)J"46U0O;]TN^^_TU;4R< MSJN[C_/5XM&'0LF(?[)F1OW>\CV\]" M)59/@M4MD6^#;S7]')UJ/=&TP[*C.OOGF3LAD%:)GX8JVG7I19E^ZWRIZA^= MBW=RD7^^R_/MIWPM=^>^-NU/0VF/0$:#-!8!+8> QR'F&:))C +5FRPL67/7 M)UN 7HW0:R%.(K&F1MV)3FF9^VET2]M.%4[?5_W09+655U[) K?-L1(^!(T)#'#(?90E J8]A!".*?!YGB.'@W$699D91' DIBD!*DB!D,$H8 MY7[&":%9@K+(80FN YQU*OP)TH,.>['^JD7DF;'4?H-,H_#7>*&MIS.51$]1OE.U)1 M ^=,9-240^W"#*\H-V$@ @&B),",^,S'40I1+/Z;)A1 IIHU&&+"76\]J#$P M@>#F!$J$-9J?1Y:QX !0#H(1XO(NY(5=-K<;D M54^Q!E'JMN;IZUR=4"Y;+$]#O:QYL0CX@'!")-H1K GYI$C4.= MGCCIL.;FYIQCI)Q0H>%$3D-_+/CQ_$H<2\RH7PEV^]Q:5MS/5YL9@Q#(%)(? M!$D<^92C-.[M :AW_Z"QE5$UI\&DJSKF#"JJSBCD#5&=<[PYNK'K""VG=&

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�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

DP[CS/ IO7,%3T6W_3C73'*@D_4;T[+<&C8YX8IHROA'-QZ.JCU]8*=Q M'D]NO+O1(5):435]*&SP7--2/LU\#2.+/^AM-*VCZX1H4=+7K'"DY=.1=5JR MTPG_A0:B9QZ8M6DOP?B.O\<3IEJ$=YD8;>U)+T>L!4!>8#DO8(H&<#(&&NP9SHYC/#+D.^L]+O,Q$#>A._]/SY9H_PKJA! 1TXAK4> MQF;!)Z)A4F3"/YX6F3C25OMM]&U:A:$7CZHT-<^-L]:C^M",3"E'5O:LD"J3 MN9V22)[V>YV9).:1WN7+D\+UF:5=((SBAM']L(R^&.>CU"SL]#6F07@5K'MQ M\ZW9'\RM<5[(X!Y,Y\0A4VN_2CXTV[\LOA[#,FN)& ^^)UDZ,#Z81S?RX\%U M5'@ER]C>FR3K?3!;C3 CQNTVB4B9S@9,_H1PBUW<$@J]Y.H*Z!A>-24(Z/>X M2(@(,SZHD53Q?'YD;1<_V,(4JY_2.R#9HJ""9A(Z614L#2R1UH]*JM7.. PUMH'^<\+LX,:L^87L3+C@EI+R(AM')F7HPH;H] M$Q)3D/B@?'P2HFDT4IBMJ#]M /BSI5VE&E;0@O:C'UDR-S&J"WG=/ _(;R8A MT-/ A&E EPY-[<=E3)&9W,DBZ,[TIMJ-CF08IGF<[T">J.T_;$K:PZ:;.&RZ M6'%<2^]U3"A]&XSZ[8PG;FK)W'M ;0A\O\O2!7KJ>C MU)I,9-29*"\WA$!E,UI#.LZ!D^?O/SYO*;T,HHOI>XGASC0Z4W-5VSUU@M3? MZ[T::,=0?Z8LJ[&5X)6%7.B"-E]>-9XD_1U&VYU\?X2*+\RQU)/XSCI+0:8_ M'/1=TAO=P$>8CDOMG\[T'D,_&N;QQ\F'.4R]FU:FG]:DQ=H>?*IP?=&&+?[\ M\^2FA]?PTY=6>VJU2]O7UB.S^:!>+!#)1JH;;R ^:ZGJQA@_5=Y8C[2DT7(< M>/A#VSE)S_H3,O\T6^*XU$4:&/D?H$A:RB1"GT8T4]QY9"H.;\'I:Z_W"R:B M.0K0:L'C$_'XX,LRT/M4M_Q@%IJW"_W6"UVV8C2HN29>APK8RMS]R=KO.\+V M3Z;*O/%=QZ6-4WDJ/ZY%0&\T._^"WB=7]YM&T;-C3@LGP\3=1GAL<.J,%&;!](."4)$V-S& MGJ= ;7)(@*7G!Z#9S+DVM; OO9J_I&DO!PU@<;DI0QQZFZ/R:D9]! *LZ$S[#+V%S&K"5Y G\3GD [A"U, =GRA)8GM#QACB>(ZA@C MHD&H,'41E\3W0D2IHY"B2DH7^P3;*_($]B8\ 7<8%?O $P[#R>1'@Z@7+3 F MR6L:DUN"3[^_EAZO:W(T@$^!W ;Q M^>3:;ZTPWUO7QX%#5N#JP!)A&/NN[6#I>]QS'(&(CR3V0PJ8E6I5T_O%:G8C MD"4=IU$UNX5L"]DM@6PMHS!QI,]"Q?R 2!>%ON]2:;1@C[O857-IW#>E!3@8A=WUDFP.%+*TDJD.%T'(F(>I M[7'A4AD0Z8.0#:C'I2/FDG%MS,G:!&19!X;70K:%[/Y!EE%D]4'.35E]^+W!F!H=PBF^V"+MEZ?O<"96XD[9DL$ MJBAE "R.P\!E@6">PQUL2Y>%JXJ[%VNHC>",=UR[20VUQ5F+LS5PAA&NPMJ] M@'")B.-Z-@EL'(B 8:-7!@ X$GJOI5C&^C7-XM;% M^@A*:24.D?1%2'2Z=$?[6+'K$"&X#$G ;+#X.0*%!>.<:A&]J((Y?ZDKM"R;D*5YM28!M!+.Y@TH:>MYC= M1\PZM>-<**2ZEBFEGN>&#D6^[QI=6+F^I[Q58\]?K LWA%FTY\=%WL['VD1@ MP1*IV<_&>9Y$'>O7Z#_1MQN=RMDD;_[M6Q8E@_C]&E5DQL-G9NR9/*'.< 24 M!0V/AT_0T$'8S[7P)!:X4BJ)@U#7!/:Q:_L>9Y00[J.0R+F*8DUKYJ9J=4$H M]R3BV+&9 M].Q0!6+5<]A+*]NO"$)0Q6F38KV%80O#M6!8J_''.:7*Q[JN)O(=&?JAXQO] M.70IPFI56;BT_OR*,*0=O!];IX?A:5;C+!W&K?D[#]]:B!&QI6]3RAWLA$*% M G%/F[^^ $$J7D&5G=Q1+%:#$I/0_3[1V3JO#A6]3LWA+#V. +\VI\RW;4]P MRK7PM6U?VO@GQ/34' JZ+DEM6=U-Q:%[FO6:_F=0%,Z@XH MX0AN>\P%9L<9\URE)"$VH!>4:LAF 5ULK3P^ M*+&[Q^"MN:T<%_'0103[2G$;!<(.'>J30#)'^4AN/-;X%<#;;,15B]T6NV^) M75X+V>!!&- 0V900&1 ?!\0SFC.%_WAJU:S<+W,Y;Q:[HM$HCFW%[F'XH2_2 M4=2OBKVNO8 4%K"7CG5IU'6 _7:FU2JIPA=.P4(JV0$>YU19C+ER&"622"4" MCGSB(I4@0/W1IZ-BN2Y@K$:$\\,,0";R6%=E$" -A'>X>.,,R%N)?1A'T M>]60PCHH)::*UVO#F0N$W,=Y&H_%?W+RUXI/%5WW[QP2,VJ2KS=N; MV/+36WC1_5;TIY?D)7G$/2L9Y9.C$U8ZC#-#,;G5&V? H*P1=#V/X>Z>]>]Q ME(WB3)_*T%K'T9M2QV-B["5=,-\3ID#N@^OC0<'[8#V\^_+B!;S1ZZ?=;^\,X]9?S^-^ M;/C>!ZPD08IC718$%$SJ8GUP2S&%/1YP$GQ 54ITJ1B7#K:%H\L *>$YQ FE M:[MAX(5(%6S;4(@ MN#LR!WGR./N>=&,KRN#?' 1 'U2@W/HI&0 YIN,<[LG??YQP_7*Z7\"L'EVX M.K]<96KQK "84880T%>=X/3W>J\&>IG[,TH"1H5*8/BZU8W[_?+J_WN'WIGO M,-KNY/LC5'J1W,+,GL1WUEEZ&\VICG=);W0#'V$Z2ID'XJP?#?/XX^3#'&;> M33V14W<[)N^>=E06;=CBSS^_FQ._9?M/7UKMJ=4N;5];>Q5"L=3&#<;/EG=_ MS6V;+F TSIH8^1]QE%D*0-^S@KAK=CXLBCO['C.S7D'W3:WW"R:B.0K08O_ MMV0/9J%YN]!OO=!E*T:#6GX3MU$J8 >[BWNR0*'_N!;]O-'D_&NZQS[E=_7;UGUO]?9^$O5+\OY9,?]4HGD;-N+?<*=J=_1YN5QO4 1:=YVQM5C?/JR+ M:F_7I2%W71_YV&><$R5\SPXH]1'W0YLND8CQ*:PW%X[":0>Q%NLMUENLOQSK M-JJ2L2'/#FU?A;9R A\1#^1[@!3(=>QPX:O%U3F>PGISD1Q8= 1K,\?LC*]' M#;*TW]<[TM80AA)=QU96$$S'NLK,MJ9Q_:3Z#$A[S'T>GJ3:B_< DC;/!(>=S^6D1')U*.'*A0N9*6]F8<9?:+@I\3&1($!.AXSUE M29HI-I;D)C54$(GX-0^%SU/N-K@UWA^F_ZF%JH:J6T'5]I@0@KG"EC:G1 H_ M8'Z(L">)PI@^E?S[6:@VIK[RCD"-)A]MH=I"=:>@ZN *JM0!]=8.&,/*5DSY MW$6.47(I9@#;IS(M/0O5QG1;TL%BDX M@G%LC5(KO\]'\:VF]'RDLYR,\HZ5C*PDMY+;H:'*KLFQ +1LLIV4:2K,H_$P MRJ)1W+^W=,J4?IK'\P?X)_,\'N7'@^,!C#OIC:/^ MPQS%WGWQ\?[9;"N<. [8L\"%/8?[W)>@.3HAEB)P22!=7LNVXH!"20*7(' M"EN;/J--H-"N_GY+^=\&R0@ ;PKKM D4=L(IZ]J5G>][S$&4@26I*&>^E('P MF$#8X4X AOY."0/2Y\'TO46RKJ4M[_\[?S)N)H[;TX MB'D ^F#+"[:,%]1"Y67H814&H8VHPW&(I1LBVW,\)&T_L,E<",P2O("_/B\@ M8B]XP6&8#)_ 9+!^A3_MH;)Y:+K5WJDDRG9L$00H8*8LL>TS5TB7.@'GPIF+ MMVU<3'_ZM8D=5M;H[NK6;9ZV9MUA0A705%40=QU;NI[ 'O4#CH24RL'29PSK M7;10K0+5ETG11J!*FCWLLG50W2L;W+])!M&:L-QE]-$*?5C8H?(Y]I@BW.=, MAM2C(0I=WV$D$'/'/1L7E/Y)$X+2;?)4Z-;*PT,2>[N,+TZJ(#X_Q$+:(0D= MS(DKA.NA$%'D4X<$@4TW+MT:P1?A9!_P=1@VHBG*KE=31SQ9W4G(TX9/:NZE MFNI40!:"*-_S&9*.R^&*2UT7N\K5A:("BCU^! M 6#.#YH![)5U6QSGGHL&WI9#1UNY ;7T2+>?9V%<'=)62$J&'.1A!VQ[GWK* M1Y2H0'@J=*D]=X1H.:6E"8;3H>)5SV9OK6ZQ!RI$RT/VCH?0ZMPT< H6*H4] MEWJ<"%\B@6T7,408"CVYH@>C 1XBW,WEE]HF#K+4$W1-(.G8RG60/A-EJY $A#H*UXZNN4Z(PS!TN/(] M[J%0!@P@'Q"F1.@$H?_LT;6%[/GBT^ M\[5,1]89!WGWZA2TA>=E^L/V$="RC=6?EM'7,2UTNC MK&>E5U:09+"2:99K2=*/,FWV6-THO[',$=!X8.Y:N;5":O[7DV+3X9S%'-<* MYL.SD< YZ#L16RH#TW]94]+[J^M0M,EEY>NM!?]/+EA2F/H^Z-E>MNZ07MFIF#E\#46>EX ME(^ D!A/K+.Q]UJ[7/K+H8'AE'2T^]8N0-?HJQ[4W GNB9S,JD%=+=OTCYH ME;D>#?"G-%NOAV%\F=58*%ZSET?6U^C>%'B![NF$"%?CT1AFLII8/?MZ-?*Y MY;A+^GWK,K:BD>'#.GE"%AO8P)VC1TZGSW/JH^T2;8^IWR\Z\+Y")QM0:\AZ M:@U=40LHA;DUD>.=F?75+"15Y!V2L_CU.1O?' M.MW(6/^8&^_\Q4TT.!WJ5^2_Z/'GQP-@LDGZ.%L_#Z; _([ S]%FL M&<8V!L 665[TI%MZUC4W[\;9*$I 0MT.^^E]'.?39###<3;4:6/@G7D\&NEZ M%-95HN>P>,,PSLPTPEI:R61!\R-+I_ HNP/?1YK71M:_ 52C..O?6Y=1GD!' MOY>=&<" BR&,;K(X+CX6>6B,6@1L.Q]?_@LF1/<6&KR*$\/,38*/V-)IH48E M;T[@E7%VFPRB"<,NR[?K1^LP+N;"*%Q7B9ZH).N.;[48[L::?<][(1IAZ/8F MT^!,?G[8Q?GCS0L,O@9ZJ$]AS<@;\_$8.DRT#VI<#SNVK[K4:7\,""ADAZ8]0\](2\=6_22@5E HL!> M_I0[5&^5(L_&+N(\I*[G*QOK\S&N(F'@K;2]99*L -'ZFJD.:AM;T>P\/K/8 M"^EQQBG-R(.4,!_,+VL3@/EZ5_3B$A1%>,6Q3F3E'EG^)WGRBSJWCD\L>1)8 MP?&Y_.5,J2_:4V+]?GSQR9*^?_K;R874/YR>3+X>G_QB'@B/3^2)?RP_ZT?] MSZ?GOYVIY=&YG[Z+DW1D1<-AO\@&UI#VV8RG\Q%*6.3ZM%VI"%'4]SGGOM0) MDL(P"!V%7$GG\\-47X]._55 )1XOOK_$F&4]4G M'6?6, /%#'[K6_&/N#O6"AIJI>_6EWXX77KKITA[-:%I: /4 MN;,QR#],HP^8_Q2_G[2A?G1OM-UBR>[HO4[QMHY';))VJ?2&%(X&>PU'P^ER M(]5J;#%9>CI3"VPR??OH)AK!R MK1,]=!E9-DA7W7,;3U(T]G?%NG$]TWBP> MIMDH+Q\?P>+IQ(Z@MH.F?)O A4K7K\^>3AQ9.&OB7J?H79[KC_GX]C;*8%P] MT^_B]?!%$U?9Y"BYC;7&#U9?7E.AZOP;;5C4Z7K"*#(\M8UMKR@0G, M)TB"!PMOPAI]U!2FAQL7D]?9,D!TEH6^\6Q.>9#@'TRR;8; MYSIL(*A]'WDAD3M/\L8%_*8 ;@'40@SI%\W[O#LUEEQ53]<2 M(T\'@[BO62ET6OO?+9W2-AT8:S?*@4L8#U+%4 L)UT^BRZ2?C.YU,X_-0R$_ M-#,M4AV7JD=U:SX)/"Y<6D CQ0R7?BTC34'.@#@T'3":U#6H-QFP_'M])1X: M\=,U)TUTD^4\3019(7AB+8>UGVR8@@4V$8$U5J?Y],?M UAC.5VM^0X^EH*5 MB2(,K Q:>DF \LL<5K-Q=ZQH=84I$X38+PH,U*'4F_>M#4N';>G2-(PG'A@2 MGF[&353#01UKO1B>ZQO5JLP,;K2Q*-%>V2R^ZAL?J];U )%YX?8NB!GD.2 F M*7XHU?LB]OK)K&:3L*[7]\:T=+VC=/V<=##D/$N763PU9K02/(BU0-0[=UK2 MZ%V T5*B80TA4+-A-"*@-W$R')42\\ 7Z6< :3TAIM!5%:9Q:-BPU+3['@P MH6.#&S"."\G1L<9Z,S&K2Y-985) "8#6[UDWD=9-@?A!:=.(+330PJ*.'T7R MT3I8>,.8WS>U7$W&A<[O>9.S6OZ"7#0@A-UEC=D8,'NK4$ZFM")66]# M'99V!%6+I3W _XJ[4TZG=V4K-XG^9=;AJ/=^BR">B1/JP40S:;X),@H/@ZBR>16T.P3*8LVQ@@ M$[T_S>IJOVY8#QUZJ]6M+0L*VD9BK)G<$]]S_KCO6?.,Y6G2^$XGEF47FM8L MI3+A"S?FBBZOXJN^_2/ !0A!;Q(]\+I,(N0%P?AG8^E?9\:1&6;1;7R79M^L MGW3FJ/=KN-T 7./"/B_C' "]HX)FS[7G O@Q3,!I=AT-Z@J&OOD"6'[O#JBU MYJW]R<@I]+-_>GYJ/N*?WY=1_P]\FY/YG'$ S#HI7[A?%)GUO%)>'KV M15X]B5W)D$Z!QGR")E",QPV(.<,N,KJF2 M78\,YRL()NOX^'AE(;*21'_E3 ..YP@?V1XGBG$BA/0IP9Y"*O $LGWV]N&V M&!U9P?&9\B].S\X[EOIOY?]VY2@]5_XDI!#&:_5 +%M&1F^-UK>C MEM@4S$A1Y2,?TQ C#MJ"Z],@(-S#U"\I+S)WR M$IL\Y87)D2:5W\Z.+_ZP3G\_ 0G]Z?@K2&L+A/6%/#ZQ/'6B0'3K4US%=2/! MO\@3^8LY"6:^GJG/(,T#Z_SBU/_UT^GG .P!, 4NX/9F5EDT0 M?'$F0;#[YF*G//Y9J/5@Z <*Q'Z@5M7:YQ:'-\+C6G0?++K?3HD7#@I#*6$2 M,!=*>;:BS GA.\.AM(/M5.+9D?7U[/C$/_X*4KTZPVV%2A5BL5: <\*A]SS;8ZH='E 0X$5MD/'PQZF'1.@@SPTQI51)W[&W0"7BVJOQZ=@[OCA_D+GB_ +4(6/GG/N? M5/#;Y]W.&[ )CABDW7%Y=,NPJR@W!]RGP133V(F7'JQZ@QC?-B+^^73"CP5N MOVDPO"&,GCY;8L3Q1W.H4C<#[WHL &B-] 'G<6R"X7YHX>SK.,U^TBMB0Q^+ M-"J.=S87DU2$'2R,G&\I^-EE)+M.P=9Y]R;NZ00-:Y!R.'\FP\HG[RTB:4Q$ M7VHBDWO3$'Q00N]-+(T^-C#1?#OF6Y74R 3B! M+W@1O+N(+,_B4=I2_WK43W>*^M6/F^0R68MGFW#;\C567T>:]B;GDG2&C,''\O3]67WS MUDI>R;S_E[]_??DBS_YH8Z1>%".U03K:HGA) MWEB\)+)](4/;DP&'_S'E4J0<9#-&6>C8H=/&2VZ!^^;\^)<3>;%>+L(M._TZ M+(TK5+'I[F/"RFME>"JUW7_5S7KUF\7>70?N$U6MD&=MXK+HP0YGDM"B83+!?<\3+CG2.EZB&#G!3$G MKQ3'<_J[.M-1]_+BXO3L1+W .SS?P8--@/#KR>GOEOS\V?JB3BSO#^OBDSI7 MUM9F!E:F(H^$P3;0[ MZX&@-16Z3SJY@=Y1&L2EK^NVH[U/T$)B]D]U9F== M\]B\ 09U->[K]"EI-HCO80%@4KM%LLKHVF3HU^F7DY%^_';R>)$_>>ZMNHY= MQQKVHV[Q\GP41[V.298Y*/+51GU=(57[8K3GK2R 1WH6\/T3OB] M2>!?5JBHGH8F!KW"P6>Y&UL]^O-MW* M/>5R6Z_6:)$.NS<-:RJRS0U*[Z)Y3+^M5M!C<4V%Z8J;JH1ZE\VX_W)=+_3I MY:A/EOFQYCC7V]9$7=0 MC0P:^IYD(X" ;C:]>N.T'3OJ7'] Y@^%\FHWZ[U8:RU M=FD?LNNG'5P[N'9PN[-A^#H,M\&3K'_)__+0IW-H2_Z6@VMP):=;)<82G115 MV[+QMHNY;!F#K'M3#/*9G?R]4H-:+K3S@WOIWMX^C'FO%W1--6G71]D.KAU< M.[AMY"S[98 ]LH%^:,N^)WK[>3Q(TLSZ!V@\UJQ!YM\D\57M@'NI%FW95+3K MW-IG3YUG;)G4/@RN9J-5S$@SJ%K%M-9DV\/![14S.LPE; ?7#FX+!W>()ML9 MB$P=#2J/K"]1JPKMJA[OWT2)*09:1GEZ:93UV@VTW5_8 S306I;4#JX=W-8- M;J]XS&$N83NX=G!;.+A#M+M^B=/L.K9^/;*\+(UZ]X>VYGNBGK?6U4XOWP%: M5RWC:0?7#F[K!K=7/.8PE[ =7#NX+1S<(5I7OR8#ZX\CR[\9MP$]K[CZ^RISW]A$:U=PFU;P *VTEO.T MXVO'MZWC>ZY*PE95$K4;JR2*F>_;E NLE,G8.[ZPCD\"]=_K%(_81.=^JN<6-Q61;83U/)_%U^-^40[^_,.O M[Y?O]WPO:W?/\)BM397MND<",5LX?--5)MUGTEL_?[K#'EE5>,M:/&U)N"MR-\*XKR;)4/-LK?5$#.W M-*%#T2.\999UN]FRQ.!\W?,K4Q%$ZQC'@UH)IP5EF:R?DNG=NG3)O07:9@PW M=$U!F1($Q>S1(]!AX$=_G&4Z]]!L5?#B'O'A5U.?R!0L^9NN](V)]F(@_GYK MZ_PV"!^ZIQ2VU_#Q[C]\CNX6%3![(5)(BY1GIIRU@F87!W<^C+M@Z0VLNL2Y M,N7/HBPV".JFM[>I?FO:_=:Q_NL(@J/8UT#J[BWTR#:6"F7Y& P MAK<]!C:,ZFC[$MU;PF#-/@"L_1^,6K3MXN">@P=!V+;4O\>Z,"+H>R!D=$+L MKWUHXGGDR.$07I/\L'S]+8BODD%2/)NE/^ZM\Q$\98I)UM RW9%B9D/J4$!# M]I2N]AHTFN<7CM9\E"5=#8%S+8LL>:?S[\CK+"[HVU2T-9EY5L;2Q$6@:>5) M 6359(^!DG58*&I-HAT^+<([LKN2_6KI/@E95/Q MD&P%U )HL3VEOH.%%M NLSZGT*&+&"3'QB'FM1!; #&^IU2XUQ +DRP?61)( MN&?(N*SOW3CRK IT!5*@/_%=,KHY$' \C+C9%_K9:W"HVV$_O3>XJ(PA+33Z M8]T5[)28?22=N13DPS!+XI&F_3/=Y=R2N:YZ/_NZ]\8G M:*JN%5,Y+;W6,07LP0R#U_2+:X0:3YSS$H^?]FB]R+]>;\\NVCL0C#X6/;P/ M9-QBM F,/E)Y8UV$3KTA+3@7@E/L*?WN-3B?]#">I"-=G DN_9)%96VFAU[' MVB8I3H)P#:LXZMZ8B-W9HJ:=Q[#M.%&Q@TSB>-"+;P?%5KF6T!4G*,3L'. ZUF4\ MNHL!4<^9JQIM$U@F(.%[Y;F_?*-:=-597Q M'/JF\K6D9XT7#:UE(?A0D"XO])X!GE5A;MJ_PQ%Z>FY>%*W2XFUW\*8#KYSM MA%JM:P>"LA>%M[0HVQV4F6!BBK<39S.=.Q"DO2@$ID7:[B#M%&RNRSBSB-A. ML#WLWR'@K3U:L).#^SW-^KV[I!<#/'K&B>J-\V00YQHO@]ZX.^KHS? W5X$-P":!<'=SZ^S)->$F5)O/@HV\&%JY 7 M'FUNM;"M(6Q@_[EFU$#3GZ-!;/V2FK*Z%]D8V#E(A<^?_4,DZ%;/V7L$=0.;#6A8L]0-LZ %8N[(+2O>X#UH*IM$'S'Z*WAMC&/-> M\3 !, MM6<6=W!PSV J3 81?(1/+:;>!E.DE5.[.+@93.6+!%41.+L_V4_$1GD'P3FFS'NM-CW0IIT7+4=G#KIK]^6:;IVFC: MA-'S Z[=/4- ;6[C5\EMO#/ +;[JVS\F(WAQUT1:F%_AXD(\BO:L;I-VQB<;X8-3J9/)[;_)[+P7D#M*1%0V'<93!'>;&8YTT M..H:"R"(1A$H_, :+N-N-,YC$T__W][99VL478-*G\66WF8&I:AG:95\^@[- M=XH;)^WMMWKS%-;._4_;0(Y[C;5764Q#RQ?1CW20WMZ#D0SR/3>%"KHW\6UT MF,3MR\][N?XM<9?$[4?];EF1XS I/%#A7A)!2^$EA4_R.QTJ@7^6WE[20$O@ M)8%_CB[C?GZ8Q/WU3.WE^K?$71+WURS6T6_/*BA/N">?]+C MV_Y?_S]02P$"% ,4 " !4=6I*#Q2[$O(. #NG $0 M@ $ ;FAT8RTR,#$V,3(S,2YX&UL M4$L! A0#% @ 5'5J2M#[J#C,00 -!0# !4 ( !N"\ M &YH=&,M,C Q-C$R,S%?9&5F+GAM;%!+ 0(4 Q0 ( %1U:DH8K.Q+K[P M )!_"0 5 " ;=Q !N:'1C+3(P,38Q,C,Q7VQA8BYX;6Q0 M2P$"% ,4 " !4=6I*5)HY!/!O !E=P4 %0 @ &9+@$ M;FAT8RTR,#$V,3(S,5]P&UL4$L! A0#% @ 5'5J2@V&